{"numRecords":"1392","DataElementQueryResults":[{"publicId":"2006877","version":"3","preferredName":"Assessment Result Type","preferredDefinition":"the result of the assessment(s) of patient's disease sites","longName":"ASSESS_RESULT_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C9AB5C45-BD36-0149-E040-BB89AD433808","latestVersionIndicator":"Yes","beginDate":"2003-04-11","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-14","modifiedBy":"SOKKERL","dateModified":"2018-10-25","changeNote":"ISO 11179 compliance. Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2006898","version":"1.1","preferredName":"Specimen Shipping Company Identifier Number","preferredDefinition":"the identifier number for the specimen used by the courier.","longName":"3029840v1.0:2018646v1.1","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B415377A-3B12-5556-E040-BB89AD437482","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"ZHANGWE","dateModified":"2021-07-02","changeNote":"ISO 11179 compliance. Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2181554","version":"2","preferredName":"Platelet Transfusion Administered Type","preferredDefinition":"the description of a type of transfusion administered to a patient.","longName":"TRNSF_ADM_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C9ABC5D4-8413-9A1F-E040-BB89AD4320CD","latestVersionIndicator":"Yes","beginDate":"2004-02-26","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2181816","version":"2","preferredName":"Diagnosis Method Type","preferredDefinition":"The basis by which a diagnosis is made.","longName":"DX_METH_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"Brain CDE Disease Committee","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C99B3FF5-5C93-CE3B-E040-BB89AD433965","latestVersionIndicator":"Yes","beginDate":"2004-03-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-13","modifiedBy":"SOKKERL","dateModified":"2017-09-11","changeNote":"9/13/12-updated max length on value domain #2181814. Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2182038","version":"2","preferredName":"Gross Tumor Present Indicator","preferredDefinition":"the indicator relating to whether there was gross evidence of tumor.","longName":"GROSS_TUM_PRES_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"Brain CDE Disease Committee","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CBDCA312-92D4-56AD-E040-BB89AD434EF1","latestVersionIndicator":"Yes","beginDate":"2004-03-19","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-12","modifiedBy":"TSESU","dateModified":"2017-03-07","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2190553","version":"1.1","preferredName":"Specimen Shipping Specimen Shipping Type","preferredDefinition":"information related to The act or business of transporting a tissue specimen._the type of shipment method for a specimen.","longName":"2190549v1.0:2190550v2.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4137FA7-8600-DAB1-E040-BB89AD433775","latestVersionIndicator":"Yes","beginDate":"2004-11-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2190879","version":"1.1","preferredName":"Blood Collection Tube Type","preferredDefinition":"the type of blood collection tube.","longName":"2190877v1.0:2190878v2.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B413FC2F-5072-36D1-E040-BB89AD435235","latestVersionIndicator":"Yes","beginDate":"2004-11-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"KNABLEJ","dateModified":"2019-09-13","changeNote":"9/13/19 jk removed designation to MCL.  ---Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2191326","version":"1.1","preferredName":"GOG Specimen Identifier Code","preferredDefinition":"information related to the GOG specimen ID._the specimen ID code.","longName":"2191324v1.0:2191325v1.1","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B4122C4C-89FF-17E5-E040-BB89AD430A5B","latestVersionIndicator":"Yes","beginDate":"2004-11-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2200444","version":"2","preferredName":"Gynecologic Site Involvement Status","preferredDefinition":"indicates the status of gynecologic site involvement.","longName":"GYN_SITE_INVOLVEMENT_GYN_SITE_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"035A2F36-B17A-8ED7-E050-BB89AD430D23","latestVersionIndicator":"Yes","beginDate":"2005-03-03","endDate":"2011-11-08","createdBy":"REBOYJ","dateCreated":"2014-09-18","modifiedBy":"REBOYJ","dateModified":"2014-10-15","changeNote":"Original version was retired, versioned to obtain needed CDE.-JR 9/18/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"2760870","version":"1.1","preferredName":"Laboratory Procedure Tumor Marker Biomarker Outcome Upper Limit of Normal Value","preferredDefinition":"information relating to the outcome of a laboratory procedure that involves testing for a biomarker (measurable and quantifiable biological parameters which serve as indices for health-related and physiology-related assessments, such as disease risk)._a numeric value for the highest normal result in a referenced range of results for a test to detect a biomarker.","longName":"2760865v1.0:2760871v1.1","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B7342531-0BF7-6B38-E040-BB89AD433093","latestVersionIndicator":"Yes","beginDate":"2008-06-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-23","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3296080","version":"1","preferredName":"Patient Quality of Life Radiation Therapy Oncology Group Vendor Consent Patient Consent Ind-2","preferredDefinition":"the yes/no indicator whether a person who receives medical attention, care, or treatment, has given permission for questions concerning Quality of Life using the Radiation Therapy Oncology Group's (RTOG), a multi-institutional cooperative organization comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, quality of life data capture system.","longName":"PT_QOL_RTOG_VEN_PT_CON_Y_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFBC8352-1948-DC9A-E040-BB89AD435BAE","latestVersionIndicator":"Yes","beginDate":"2011-10-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-10-20","modifiedBy":"TAYLORT","dateModified":"2020-11-04","changeNote":"11/4/2020 TL transferred ownership from CTEP to NRG/BC. Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3303074","version":"1","preferredName":"Person Prior Chemotherapy Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"Person; a human being._Earlier in time or order._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3303073v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1640086-5851-FB58-E040-BB89AD434A33","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-10","modifiedBy":"REBOYJ","dateModified":"2014-10-10","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3303086","version":"1","preferredName":"Person Recurrent Disease Disease Progression Therapeutic Procedure Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"Person; a human being._the return of a sign, symptom, or disease after a remission._Cancer that continues to grow or spread._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._To take, accept, or got something offered._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to a patient's/participant's therapy.","longName":"3303080v1.0:2018279v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B165988B-7FF6-C9E0-E040-BB89AD4352FB","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-10","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3303131","version":"1","preferredName":"Patient Oral Medication Administration Fasting Ability Ind-2","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._As pertains to a medication: ingest, inhale, instill, or inject._A drug or medicine that treats or prevents or alleviates the symptoms of disease._A systemic evaluation of the body and it's functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment._Abstaining from food._Oral; of, or relating to, or affecting, or for use in the mouth._A drug or medicine that treats or prevents or alleviates the symptoms of disease._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._Abstaining from food._The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment ._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3303130v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B167C047-B1A6-2CFD-E040-BB89AD43068A","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-10","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3303142","version":"1","preferredName":"Anti-ulcer Agent Prior Plan Therapeutic Procedure Administered Ind-2","preferredDefinition":"Yes/no indicator of whether anti-ulcer agents (proton pump inhibitors) were administered.","longName":"3303141v1.0:2018279v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B169109F-E479-4019-E040-BB89AD436A3A","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-10","modifiedBy":"TSESU","dateModified":"2023-05-24","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"5/24/23_revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3303146","version":"1","preferredName":"Anti-ulcer Agent Negation Prior Plan Therapeutic Procedure Use Ind-2","preferredDefinition":"Natural or synthetic Anti-ulcer Agents relieve and reduce the symptoms of ulcers in the stomach and upper small intestine, systemically and locally, by reducing gastric secretion (proton pump inhibitors), neutralizing hyperacidity (alkalinizing agents), or improving healing and protecting the mucosa (sucralfate). Recurrent gastric and duodenal ulcers caused by Helicobacter pylori infections are treated with antibiotic therapy._An operation in which a term denies or inverts the meaning of another term or construction._Earlier in time or order._Planned; devised, contrived, or formed in design._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._A manner, or usual, or accepted practice of using something._the yes/no indicator related to a patient's/participant's therapy.","longName":"3303145v1.0:2018279v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B168EFE4-E67A-4359-E040-BB89AD4363FD","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-10","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3304302","version":"1","preferredName":"Person Prior Therapy Adverse Event Clinical Trial Eligibility Criteria Eligibility Ind-2","preferredDefinition":"Person; a human being._An indicator that a person has been previously treated for the same condition or with the same therapy._Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3304301v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1CD0B9E-3DFB-AAAB-E040-BB89AD431783","latestVersionIndicator":"Yes","beginDate":"2011-11-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-15","modifiedBy":"JUAREZED","dateModified":"2017-05-03","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3304687","version":"1","preferredName":"Person Sleep Disorder Clinical Trial Eligibility Criteria Eligibility Ind-2","preferredDefinition":"Person; a human being._A change from the patient's baseline sleeping pattern, either an increase or a decrease in the number of hours slept. This can also refer to alterations in the stages of sleep._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3304686v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-93BE-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-16","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3304694","version":"1","preferredName":"Alcohol Consumption Restriction Clinical Trial Eligibility Criteria Eligibility Ind-2","preferredDefinition":"consumption of liquids containing ethanol; includes the behavior of drinking the alcohol._Anything that limits; a limitation._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3304693v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-93E4-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-16","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3310378","version":"1","preferredName":"Laboratory Procedure Aspartate Aminotransferase Measurement Assessment Date","preferredDefinition":"information related assessment by medical procedure that involves testing a sample to measure the aspartate aminotransferase._the date on which an observation was made or an event occurred.","longName":"2829896v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D1E2DE-82F9-92F2-E040-BB89AD4368AF","latestVersionIndicator":"Yes","beginDate":"2011-11-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-28","modifiedBy":"UMLLDR","dateModified":"2016-10-25","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3310497","version":"1","preferredName":"Laboratory Procedure Prothrombin Time Performed Date","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation. It is used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage and vitamin K status. Factors measured are fibrinogen, prothrombin, and factors V, VII, and X._Performed; carried out._the date on which an observation was made or an event occurred.","longName":"3310477v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D1E2DE-833F-92F2-E040-BB89AD4368AF","latestVersionIndicator":"Yes","beginDate":"2011-11-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-28","modifiedBy":"MORENOC","dateModified":"2016-10-20","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3310503","version":"1","preferredName":"Laboratory Procedure Partial prothrombin time Performed Date","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Definition not available._Performed; carried out._the date on which an observation was made or an event occurred.","longName":"3310502v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D1E2DE-839A-92F2-E040-BB89AD4368AF","latestVersionIndicator":"Yes","beginDate":"2011-11-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3310543","version":"1","preferredName":"Laboratory Procedure Other Performed Date","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Different than the one(s) previously specified or mentioned._Be specific about something; define clearly._Performed; carried out._the date on which an observation was made or an event occurred.","longName":"3310535v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D1E2DE-83E8-92F2-E040-BB89AD4368AF","latestVersionIndicator":"Yes","beginDate":"2011-11-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3314544","version":"1","preferredName":"Optimum Residual Disease or Disorder Description Type","preferredDefinition":"Residual disease type.","longName":"3314529v1.0:3314542v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2E5A138-D4C0-09FA-E040-BB89AD436EE7","latestVersionIndicator":"Yes","beginDate":"2011-11-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-29","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt_ Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3314602","version":"1","preferredName":"Primary Malignant Neoplasm Chemotherapy Ind-3","preferredDefinition":"the yes/no/unknown indicator related to chemotherapy provided for a malignant neoplasm.","longName":"3314599v1.0:2018278v2.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2E5A138-D512-09FA-E040-BB89AD436EE7","latestVersionIndicator":"Yes","beginDate":"2011-11-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-29","modifiedBy":"SARAHB","dateModified":"2016-08-17","changeNote":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3314673","version":"1","preferredName":"Staging Surgical Procedure Performed Ind-2","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._Performed; carried out._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3314661v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2E76512-5C5B-9B83-E040-BB89AD4327AD","latestVersionIndicator":"Yes","beginDate":"2011-11-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-29","modifiedBy":"VUJANOVA","dateModified":"2020-01-07","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3316619","version":"1","preferredName":"Prior Surgical Procedure Generation Ovarian Malignant Neoplasm Ind-2","preferredDefinition":"Earlier in time or order._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._The act of bringing into being._Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004_the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3316618v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F58459-88E7-7B9B-E040-BB89AD43181B","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-30","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3316714","version":"1.1","preferredName":"Person Disease-Free Survival Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Person; a human being._Period after successful treatment in which there is no appearance of the symptoms or effects of the disease._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"2236731v1.0:3316711v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F26328D4-E226-7A9B-E040-BB89AD437946","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"RODGERSC","dateModified":"2021-06-28","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3316735","version":"1","preferredName":"Neoadjuvant Therapy Chemotherapy Surgical Procedure Administered Ind-2","preferredDefinition":"Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._The act of having given something (e.g., a medication or test)._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3316734v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F8C91A-CB39-74AA-E040-BB89AD433818","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-30","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3316779","version":"1","preferredName":"Person Rheumatoid Arthritis Inflammatory Disorder Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated._An infectious or non infectious disorder characterized by signs and symptoms derived from focal or extensive tissue infiltration by acute (e.g., polymorphonuclear) or chronic (e.g., lymphocytic-plasmacytic) inflammatory cells. Representative examples of infectious disorders include viral infections, bacterial infections, and parasitic infections. Representative examples of non-infectious inflammatory disorders include inflammatory bowel disease and inflammatory polyps._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3316748v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F8C91A-CB7E-74AA-E040-BB89AD433818","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-30","modifiedBy":"MORENOC","dateModified":"2017-10-17","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3316870","version":"1","preferredName":"GOG Specimen Bank Previous Specimen Identifier","preferredDefinition":"information related to the GOG specimen bank ID._Occurring prior to something else._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._the yes/no indicator related to protocol administration.","longName":"3316850v1.0:2018304v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2F9AA24-761C-BB79-E040-BB89AD43455E","latestVersionIndicator":"Yes","beginDate":"2011-11-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-30","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321042","version":"1","preferredName":"Disease or Disorder Atypical Glandular Cell Diagnosis Ind-2","preferredDefinition":"A term used to describe abnormal cells that come from inside the cervix or from the lining of the uterus. These abnormal cells are found in a small number of Pap smears (a procedure used to detect cervical cancer) and may be a sign of more serious lesions or cancer. The term used to be atypical glandular cells of uncertain significance (AGUS)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A term used to describe abnormal cells that come from inside the cervix or from the lining of the uterus. These abnormal cells are found in a small number of Pap smears (a procedure used to detect cervical cancer) and may be a sign of more serious lesions or cancer. The term used to be atypical glandular cells of uncertain significance (AGUS)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._the yes/no indicator related to a patient's diagnosis.","longName":"3321040v1.0:2404918v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35A9198-AF44-CBB0-E040-BB89AD435648","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321072","version":"1","preferredName":"Person Atypical Glandular Cell Diagnosis Delay Intervention or Procedure Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"Person; a human being._A term used to describe abnormal cells that come from inside the cervix or from the lining of the uterus. These abnormal cells are found in a small number of Pap smears (a procedure used to detect cervical cancer) and may be a sign of more serious lesions or cancer. The term used to be atypical glandular cells of uncertain significance (AGUS)._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Delay; time during which some action is awaited; inactivity resulting in something being put off until a later time._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population.  This is a general term that encompasses the medical, social, behavioral, and environmnetal acts that can have preventive, therapeutic, or palliative effects._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3321048v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35AFCC9-7A8E-0C79-E040-BB89AD432086","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321248","version":"1","preferredName":"Specimen Cervical Collection Ind-2","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Relating to a neck, or cervix, in any sense._The act of gathering things together; having been brought together in one place._the yes/no question related to specimen characteristics.","longName":"2241613v1.0:3321245v1.0_SPEC_I","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35D2A2C-E9C6-2A51-E040-BB89AD4362AF","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replace VD Specimen Characteristics Ind-2 2018362v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321254","version":"1","preferredName":"Specimen Cervical Occurrence Collection Ind-2","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Relating to a neck, or cervix, in any sense._Occurrence; an instance of something happening._The act of gathering things together; having been brought together in one place._the yes/no question related to specimen characteristics.","longName":"2177198v1.0:3321251v1.0_SPEC_I","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35D2A2C-EA0B-2A51-E040-BB89AD4362AF","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replace VD Specimen Characteristics Ind-2 2018362v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321259","version":"1","preferredName":"Gynecologic Disease or Disorder Histologic Assessment Ind-2","preferredDefinition":"Of or relating to or practicing gynecology; pertaining to the health issues of women._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Of or relating to histology._Having determined the value, significance, or extent of._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3321258v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35D4DE2-7D83-DF95-E040-BB89AD432B3E","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3321265","version":"1","preferredName":"Person Conization Hemorrhage Risk Clinical Trial Eligibility Criteria Ind-4","preferredDefinition":"Person; a human being._Surgical removal of a cone-shaped portion of tissue from the uterine cervix._The flow of blood from a ruptured blood vessel._The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._the indicator for eligibility with values of yes, no, unknown, or not applicable.","longName":"3321263v1.0:2774784v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B35D4DE2-7DDA-DF95-E040-BB89AD432B3E","latestVersionIndicator":"Yes","beginDate":"2011-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323082","version":"1","preferredName":"Treating Radiation Oncologist Questionnaire Complete Ind-2","preferredDefinition":"Treating; providing treatment for._(ray-dee-AY-shun on-KOL-o-jist) A doctor who specializes in using radiation to treat cancer._Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3323079v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AC5B-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323135","version":"1","preferredName":"Radiation Therapy Plan Boost Administration Type","preferredDefinition":"information related to the planned administration of radiation therapy boost, an supplement or increase in treatment of a disease by means of exposure of the target or the whole body to radiation._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Boost; increase or raise._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Type; a subdivision of a particular kind of thing.","longName":"2679886v1.0:3323134v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B372D0BB-DDC9-DB78-E040-BB89AD43725B","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323152","version":"1","preferredName":"Uterine Corpus Cancer Distal Vaginal Involvement Ind-2","preferredDefinition":"A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma._Distal; situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline or mesial plane of the body._Relating to the vagina or to any sheath._To have a connection by participation or association or use; sharing in an activity or process._the yes/no indicator related to a current bone assessment.","longName":"3323151v1.0:2236220v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B372D0BB-DE2E-DB78-E040-BB89AD43725B","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"SARAHB","dateModified":"2017-07-21","changeNote":"Replaced VD Diagnosis Current Ind-2 2236222v1 with VD ID#3506068 - Yes No Indicator   - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323169","version":"1","preferredName":"Residual Disease Physical Examination Diagnostic Imaging Detected Ind-3b","preferredDefinition":"Cancer cells that remain after attempts to remove the cancer have been made._A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual's health assessment._Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.._Detected; perceived or discerned._an assessment response or indicator that can have a value of yes, no, or not applicable.","longName":"3323168v1.0:2958018v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AD69-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"SPRINGERL","dateModified":"2018-08-14","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323194","version":"1","preferredName":"Surgical Procedure Exenteration Performed Ind-3b","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._Removal of internal organs and tissues, usually radical removal of the contents of a body cavity._Performed; carried out._an assessment response or indicator that can have a value of yes, no, or not applicable.","longName":"3323193v1.0:2958018v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-ADAD-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"BONANNIR","dateModified":"2017-03-20","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323216","version":"1","preferredName":"Recurrent Disease Chemotherapy Neoadjuvant Therapy Administered Ind-3b","preferredDefinition":"the return of a sign, symptom, or disease after a remission._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._The act of having given something (e.g., a medication or test)._an assessment response or indicator that can have a value of yes, no, or not applicable.","longName":"3323213v1.0:2958018v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B17D-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"SARAHB","dateModified":"2019-05-03","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323244","version":"1","preferredName":"Disease or Disorder Urethra Obstruction Ind-2","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Blockage of the normal flow of urine in the urethra occurring following a procedure or pharmaceutical intervention._the yes/no indicator related to a patient's diagnosis.","longName":"3323243v1.0:2404918v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B1C0-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2023.7.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323250","version":"1","preferredName":"Surgical Procedure Kidney Stent Performed Ind-3b","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat._A device designed to support a tubular structure, especially the small stainless steel expandable mesh tube inserted within an artery._Performed; carried out._an assessment response or indicator that can have a value of yes, no, or not applicable.","longName":"3323249v1.0:2958018v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B208-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-06","modifiedBy":"SARAHB","dateModified":"2019-09-20","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3324323","version":"1","preferredName":"Institution IMRT Preclinical Testing Complete Ind-3b","preferredDefinition":"An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research; also used to refer to a building or buildings occupied or used by such organization._An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.:A study performed on animal subjects to determine the toxicity of a new drug or invasive device prior to a clinical trial._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"3324322v1.0:2958018v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B383183A-C443-A419-E040-BB89AD435A2C","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2023.7.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3333743","version":"1","preferredName":"Specimen Processing Occurrence Collection Time","preferredDefinition":"information related to the occurrence or time for specimen processing._the time of the collection of specimen.","longName":"2190841v1.0:2413115v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B412D276-C276-DB73-E040-BB89AD433B53","latestVersionIndicator":"Yes","beginDate":"2011-12-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334442","version":"1","preferredName":"Gynecologic Neoplasm Specimen Anatomic Site","preferredDefinition":"amed locations of, or within, the body in proximity to the female reproductive organs from which a sample of atypical neoplastic tissue or tumor is collected.","longName":"2010616v3.0:3334440v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4137FA7-86DE-DAB1-E040-BB89AD433775","latestVersionIndicator":"Yes","beginDate":"2011-12-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"updated for ISO compliance Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334647","version":"1","preferredName":"Shipping Company Identifier Specify","preferredDefinition":"a means to uniquely identify the organization used for shipping._the free text field to related to protocol administration.","longName":"2014630v1.0:2183516v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B414FD07-79E0-5BAA-E040-BB89AD435998","latestVersionIndicator":"Yes","beginDate":"2011-12-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-14","modifiedBy":"CHANGP","dateModified":"2016-06-24","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334700","version":"1","preferredName":"Specimen Shipping Receive Number","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The act or business of transporting goods._To take, accept, or got something offered._Number","longName":"3334699v1.0:2182118v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B42393B2-749B-61E3-E040-BB89AD4363FB","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-15","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334719","version":"2","preferredName":"Specimen Processing Occurrence Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding information related to the occurrence or time for specimen processing.","longName":"SPECPROC_OCUR_YES_NO_UNKNOWN_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E024A4E7-F34C-0F27-E040-BB89AD430756","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334801","version":"1","preferredName":"Specimen Charge Slide Submission Count","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The quantity of unbalanced electricity in a body (either positive or negative) and construed as an excess or deficiency of electrons._A flat rectangular piece of glass on which specimens can be mounted for microscopic study._Submitted; referred for judgment or consideration._the quantity of the specified item.","longName":"3334799v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B42727B5-B9ED-CFAC-E040-BB89AD4356AF","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-15","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334804","version":"1","preferredName":"Specimen Charge Slide Submission Thickness Measurement","preferredDefinition":"Numerical value of the charged slide thickness measurement.","longName":"3334799v1.0:3334803v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4278BF8-5DBC-A861-E040-BB89AD435A26","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-15","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt_Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334808","version":"1","preferredName":"Specimen Negation Charge Slide Submission Count","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._An operation in which a term denies or inverts the meaning of another term or construction._The quantity of unbalanced electricity in a body (either positive or negative) and construed as an excess or deficiency of electrons._A flat rectangular piece of glass on which specimens can be mounted for microscopic study._Submitted; referred for judgment or consideration._the quantity of the specified item.","longName":"3334807v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B427CB9D-CD9C-BCD8-E040-BB89AD434695","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-15","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3334809","version":"1","preferredName":"Specimen Negation Charge Slide Submission Thickness Measurement","preferredDefinition":"Numerical value of the uncharged slide thickness measurement.","longName":"3334807v1.0:3334803v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B427CB9D-CDBB-BCD8-E040-BB89AD434695","latestVersionIndicator":"Yes","beginDate":"2011-12-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-15","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt_ Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3335200","version":"1","preferredName":"Scroll Specimen Submission Count","preferredDefinition":"A piece of tissue cut on a microtome so that it rolls up on itself giving it an appearance similar to a paper scroll._Submitted; referred for judgment or consideration._the quantity of the specified item.","longName":"3335199v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B474218C-CC3E-99D7-E040-BB89AD430815","latestVersionIndicator":"Yes","beginDate":"2011-12-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3335201","version":"1","preferredName":"Scroll Specimen Submission Thickness Measurement","preferredDefinition":"Numerical value of the tissue scroll thickness measurement.","longName":"3335199v1.0:3334803v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B474218C-CC5D-99D7-E040-BB89AD430815","latestVersionIndicator":"Yes","beginDate":"2011-12-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-19","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3335205","version":"1","preferredName":"Core Specimen Submission Count","preferredDefinition":"A cylindrical piece of tissue, such as that resulting from a core biopsy._Submitted; referred for judgment or consideration._the quantity of the specified item.","longName":"3335204v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B474218C-CC9D-99D7-E040-BB89AD430815","latestVersionIndicator":"Yes","beginDate":"2011-12-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-19","modifiedBy":"TITARENKOI","dateModified":"2020-04-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3335208","version":"1","preferredName":"Core Specimen Submission Diameter Measurement","preferredDefinition":"A cylindrical piece of tissue, such as that resulting from a core biopsy._Submitted; referred for judgment or consideration._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Submitted; referred for judgment or consideration._Diameter; the length of a straight line passing through the center of a circle and connecting two points on the circumference._Measurement; the size or magnitude of something.","longName":"3335204v1.0:3335207v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B474218C-CCE9-99D7-E040-BB89AD430815","latestVersionIndicator":"Yes","beginDate":"2011-12-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342755","version":"1","preferredName":"Quality of Life Low Blood Cell Count Sickness Evaluation Response Type","preferredDefinition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.:A minimum level or position or degree; less than normal in degree, intensity or amount._The determination of the number of red blood cells, white blood cells, and platelets in a biospecimen._A state of ill health, bodily malfunction, or discomfort._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._the response type or report regarding an assessment.","longName":"3342754v1.0:2503812v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5A6AB37-8498-1336-E040-BB89AD434A4A","latestVersionIndicator":"Yes","beginDate":"2012-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-03","modifiedBy":"KUMMEROA","dateModified":"2023-07-24","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2023.7.24 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342940","version":"1","preferredName":"Chemotherapy Quality of Life Time Disruption Assessment Type","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._the continuum of experience in which events pass from the future through the present to the past._Disruption; an event that results in a displacement or discontinuity._The final result of a determination of the value, significance, or extent of._the response type or report regarding an assessment.","longName":"3342939v1.0:2178127v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B51348-4FDE-49DA-E040-BB89AD43153C","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342955","version":"1","preferredName":"Chemotherapy Quality of Life Method Disruption Assessment Type","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Disruption; an event that results in a displacement or discontinuity._The final result of a determination of the value, significance, or extent of._the response type or report regarding an assessment.","longName":"3342943v1.0:2178127v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B51348-5007-49DA-E040-BB89AD43153C","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342960","version":"1","preferredName":"Quality of Life Number Chemotherapy Cycle Assessment Type","preferredDefinition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence._The final result of a determination of the value, significance, or extent of._the response type or report regarding an assessment.","longName":"3342959v1.0:2178127v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B51348-502F-49DA-E040-BB89AD43153C","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342965","version":"1","preferredName":"Quality of Life Number Therapeutic Procedure Weekly Assessment Type","preferredDefinition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._A numeral or string of numerals expressing value, quantity, or identification. (NCI)_An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Every week._The final result of a determination of the value, significance, or extent of._the response type or report regarding an assessment.","longName":"3342964v1.0:2178127v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B51348-5085-49DA-E040-BB89AD43153C","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3342970","version":"1","preferredName":"Quality of Life Chemotherapy Life Disruption Assessment Scale","preferredDefinition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_Life; the organic phenomenon that distinguishes living organisms from nonliving ones._Disruption; an event that results in a displacement or discontinuity._The final result of a determination of the value, significance, or extent of._the scale to determine the patient's assessment for quality of life.","longName":"3342969v1.0:2503812v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B51348-50DB-49DA-E040-BB89AD43153C","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3345072","version":"1","preferredName":"Quality of Life Stomach pain Interference Evaluation Scale","preferredDefinition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._A disorder characterized by a sensation of marked discomfort in the stomach._The act of hindering or obstructing or impeding._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._the scale used on FACT Quality of Life questionnaires to assess patient.","longName":"3345071v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5E2C84B-6E76-CE4C-E040-BB89AD435B04","latestVersionIndicator":"Yes","beginDate":"2012-01-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-06","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3346101","version":"1","preferredName":"Surgical Procedure Full Lymphadenectomy Performed Indicator","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)_Performed; carried out._The yes/no/unknown/not applicable indicator whether an event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3346100v1.0:2753450v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61B639D-45D3-E16B-E040-BB89AD43295D","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3349972","version":"1","preferredName":"Gynecologic Therapeutic Procedure Grouping Type","preferredDefinition":"Gynecologic therapeutic procedure grouping type.","longName":"3349794v1.0:3349968v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6447DEA-3222-9C9D-E040-BB89AD434EC1","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3350420","version":"1","preferredName":"Patient Lower Extremity Lymphedema Personal Medical History Ind-2","preferredDefinition":"the yes/no indicator related to an account of all medical events and problems a person has experienced regarding excess fluid collection in tissues, causing swelling in the lower extremity.","longName":"3350419v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6463E4B-BA26-EAA2-E040-BB89AD434EEA","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3350428","version":"1","preferredName":"Patient Lower Extremity Swelling Personal Medical History Ind-2","preferredDefinition":"the yes/no indicator related to a record of a patient's background regarding health and the occurrence of disease events of the individual regarding enlargement in the lower extremity area.","longName":"3350425v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B645D146-0E06-1E1F-E040-BB89AD435ACD","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3350436","version":"1","preferredName":"Participant Personal Medical History Lower Extremity Surgical Procedure Exclusion Criteria Eligibility Ind-2","preferredDefinition":"Someone who takes part in an activity._an account of all medical events and problems a person has experienced._Definition not available._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._Exclusion; the act of restricting entrance or barring from participation._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3350432v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B645D146-0E5A-1E1F-E040-BB89AD435ACD","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3350451","version":"1","preferredName":"Elective Surgical Procedure During Operative Event Exclusion Criteria Ind-2","preferredDefinition":"Surgery that is undertaken by the recipient's choice rather than for medical necessity._At some point in a given period of time._Occurring during or associated with a surgical procedure._Event; something that happens at a given place and time._Exclusion; the act of restricting entrance or barring from participation._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3350450v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B645D146-0EC2-1E1F-E040-BB89AD435ACD","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"NAIRA","dateModified":"2022-01-11","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3350619","version":"1","preferredName":"Limb Measurement Study Site Personnel Training Ind-2","preferredDefinition":"A body region referring to an upper or lower extremity._Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard._A person who performs a particular role within the context of a specific study site._To teach with hands-on experience_the yes/no indicator related to protocol administration.","longName":"3350618v1.0:2018304v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6469DED-568E-8A1B-E040-BB89AD4353D3","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3351896","version":"1","preferredName":"Laboratory Procedure HER2/neu in situ Hybridization Outcome Value","preferredDefinition":"information relating to the result (outcome) of a laboratory test (a medical procedure that involves testing a sample of blood, urine, or other substance from the body) using in situ hybridization (ISH; use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues) to determine the level of HER2/neu (the ERBB2 gene at 17q21.1 which encodes ERRB2 receptor protein tyrosine kinase)._A numerical quantity measured or assigned or computed for HER2/neu Copy Number Polymorphisms.","longName":"2854069v1.0:3155942v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B66F0E4C-AD9E-F4B2-E040-BB89AD431135","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"THOMASJ","dateCreated":"2012-01-13","modifiedBy":"SARAHB","dateModified":"2019-01-07","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3355102","version":"1","preferredName":"Breast Feeding Stop Agreement Ind-4","preferredDefinition":"the indicator for eligibility with values of yes, no, unknown, or not applicable related to agreement to putting an end to the nursing of an infant at the mother's breast.","longName":"Brea_Stop_Agre_ELIGIB_IND4","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D26246-2A5C-757F-E040-BB89AD434978","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"SPRINGERL","dateModified":"2021-02-03","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357326","version":"1","preferredName":"Low Cancer Risk Trophoblastic Tumor Diagnosis Type","preferredDefinition":"Indicator of whether diagnosis type is low cancer risk trophoblastic tumor.","longName":"Low_Canc_Trop_Diag_3357321v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D2999F-E911-5972-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_sm; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357333","version":"1","preferredName":"Complete Partial Hydatidiform Mole Excision","preferredDefinition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion._Partial; being or affecting only a part; not total_A gestational disorder characterized by an abnormal placenta with marked enlargement of the chorionic villi and hyperplasia of the villous trophoblastic cells.  According to the amount of villous involvement, a hydatidiform mole is defined as complete or partial.  Most molar pregnancies are complete and are characterized by generalized hydropic villous changes.  Partial moles are characterized by a mixture of large hydropic villi and normal placenta tissue.  Complete moles are usually diploid and typically present between the eleventh and twenty-fifth week of pregnancy, whereas partial moles are usually triploid and usually present around the nineteenth week of pregnancy.  The incidence of choriocarcinoma is higher in patients with complete hydatidiform mole.  When a hydatidiform mole invades the myometrium and broad ligament, or it is found in distant sites as vagina, vulva, and lung, it is referred as invasive mole._The act of cutting out; the surgical removal of part or all of a structure or organ.","longName":"Hyda_Exci","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D2999F-E962-5972-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357352","version":"1","preferredName":"Gestational Trophoblastic Tumor Definition Reduced Type","preferredDefinition":"Type of Gestational Trophoblastic Tumor.","longName":"Gest_Defi_Redu_Huma_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D2999F-EA50-5972-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357361","version":"1","preferredName":"Gestational Trophoblastic Tumor Definition Increase Type","preferredDefinition":"Type of Gestational Trophoblastic Tumor defined as increase in hCG.","longName":"Gest_Defi_Incr_Huma_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D2999F-EB9C-5972-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Revised definition to human readable_smt_Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_Revised definition to human readable_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357364","version":"1","preferredName":"Gestational Trophoblastic Tumor Definition Type","preferredDefinition":"A group of interrelated trophoblastic diseases arising from pregnancy. They are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread._A concise explanation of the meaning of a word or phrase or symbol._Retained; never-ceasing._Elevated; raised or increased._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_Type; a subdivision of a particular kind of thing.","longName":"Gest_Defi_Pers_Elev_Huma_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D3AE7F-B0EA-F576-E040-BB89AD43343A","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357392","version":"1","preferredName":"Histologic Metastatic Nonmetastatic Choriocarcinoma Diagnosis Type","preferredDefinition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._Cancer that has not spread from the primary site (place where it started) to other places in the body._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","longName":"Hist_Meta_Nonm_Chor_Diag_Nonm_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D3AE7F-B1DC-F576-E040-BB89AD43343A","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357403","version":"1","preferredName":"Histologic Metastatic Choriocarcinoma Diagnosis Ind-4","preferredDefinition":"Of or relating to histology._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._the indicator for eligibility with values of yes, no, unknown, or not applicable.","longName":"Hist_Meta_Chor_Diag_ELIGIB_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D4B2E6-1803-5F56-E040-BB89AD434EB4","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357416","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Diagnosis Value","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._Value; a numerical quantity measured or assigned or computed.","longName":"3357406v1.0:3357408v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D4B2E6-185E-5F56-E040-BB89AD434EB4","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357420","version":"1","preferredName":"Negation Gestational Choriocarcinoma Diagnosis Ind-2","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._The period of fetal development in the uterus from the start of conception until its birth._An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3357419v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D4B2E6-189F-5F56-E040-BB89AD434EB4","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357427","version":"1","preferredName":"Placental-Site Gestational Trophoblastic Tumor Diagnosis Eligibility Ind-2","preferredDefinition":"A rare gestational trophoblastic tumor characterized by the presence of a diffuse cellular infiltrate composed of intermediate trophoblasts and cytotrophoblasts and by the absense of a significant population of syncytiotrophoblasts._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._the yes/no indicator related to the patient's eligibility to participate in the clinical trial.","longName":"3357426v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D4B2E6-1959-5F56-E040-BB89AD434EB4","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3357800","version":"1","preferredName":"Gynecologic Malignant Neoplasm Overall Negation Confirmed Response Status","preferredDefinition":"Of or relating to or practicing gynecology; pertaining to the health issues of women._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004_Including everything._An operation in which a term denies or inverts the meaning of another term or construction._Confirmed; having been established or verified._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._The condition or state of a gynecologic tumor following treatment at a particular time.","longName":"3357799v1.0:2771434v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6E49C51-B255-51A6-E040-BB89AD4318A6","latestVersionIndicator":"Yes","beginDate":"2012-01-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359465","version":"1","preferredName":"Computed Tomography Magnetic Resonance Imaging Brain Medical Imaging Outcome Result Type","preferredDefinition":"A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium._In medicine, any technology which helps in visualization of any biological process, cell, tissue or organ for the screening, diagnosis, surgical procedure or therapy._The result of an action._the outcome of a computed tomography diagnostic procedure.","longName":"3359464v1.0:2190474v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6E84E15-D3E7-64D1-E040-BB89AD435F5E","latestVersionIndicator":"Yes","beginDate":"2012-01-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-19","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359470","version":"1","preferredName":"Computed Tomography Ultrasound Imaging Magnetic Resonance Imaging Diagnostic Imaging Liver Outcome Type","preferredDefinition":"the type related to result of the diagnostic imaging of either a method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis or a technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer or imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues for the large organ located in the upper abdomen.","longName":"3359469v1.0:2190474v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6E84E15-D47A-64D1-E040-BB89AD435F5E","latestVersionIndicator":"Yes","beginDate":"2012-01-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-19","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359766","version":"1","preferredName":"Creatinine Isotope Dilute Mass Spectrometry Method Type","preferredDefinition":"The breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.(NCI)_Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Substances having the same number of protons in their nuclei and hence having the same atomic number, but differing in the number of neutrons and therefore, in the mass number._To reduce in strength or concentration, especially by the addition of water._An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced._Type; a subdivision of a particular kind of thing.","longName":"Isot_Dilu_Mass_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F6A9C0-EA11-225A-E040-BB89AD43381E","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359817","version":"1","preferredName":"Computed Tomography Ultrasound Imaging Magnetic Resonance Imaging Liver Medical Imaging Outcome Date","preferredDefinition":"A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile._In medicine, any technology which helps in visualization of any biological process, cell, tissue or organ for the screening, diagnosis, surgical procedure or therapy._The result of an action._the date on which an observation was made or an event occurred.","longName":"3359469v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F85CAC-58C8-BA4F-E040-BB89AD4315D1","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359821","version":"1","preferredName":"Ultrasonogram Pelvis Assessment Outcome","preferredDefinition":"the result of the a computer picture of areas inside the structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates.","longName":"3359820v1.0:2181266v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F85CAC-590A-BA4F-E040-BB89AD4315D1","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359822","version":"1","preferredName":"Ultrasonogram Pelvis Assessment Date","preferredDefinition":"(SON-o-gram) A computer picture of areas inside the body created when sound waves bounce off organs and other tissues._The structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs or corresponding parts in other vertebrates._Having determined the value, significance, or extent of._the date on which an observation was made or an event occurred.","longName":"3359820v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F87464-1AB9-96A6-E040-BB89AD430416","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359839","version":"1","preferredName":"Assessment Abnormal Outcome Text","preferredDefinition":"Having determined the value, significance, or extent of._Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm._The result of an action._the text field related to an unspecified assessment.","longName":"Asse_Abno_Outc_ASSESSM_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F87464-1AE9-96A6-E040-BB89AD430416","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359852","version":"1","preferredName":"Person Contraception Method Type","preferredDefinition":"Person; a human being._The prevention of conception or impregnation by the use of devices or drugs or surgery._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._The prevention of conception or impregnation by the use of devices or drugs or surgery._Type; a subdivision of a particular kind of thing.","longName":"2730353v1.0:3359847v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F87464-1BDC-96A6-E040-BB89AD430416","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359857","version":"1","preferredName":"Week Pregnancy Uterus Size Excision Number","preferredDefinition":"Any period of seven consecutive days._A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_The act of cutting out; the surgical removal of part or all of a structure or organ._Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._the quantity of the specified item.","longName":"3359856v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F87464-1C32-96A6-E040-BB89AD430416","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359877","version":"1","preferredName":"Previous Gynecologic History Text","preferredDefinition":"Occurring prior to something else._Of or relating to or practicing gynecology; pertaining to the health issues of women._The aggregate of past events; the continuum of events occurring in succession leading from the past to the present; a record or narrative description of past events._the free-text field related to protocol administration.","longName":"3359864v1.0:2411350v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6F9980E-8ECC-E602-E040-BB89AD431341","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359904","version":"1","preferredName":"Previous Report Trophoblastic Tumor Present Assessments Ind-2","preferredDefinition":"Occurring prior to something else._A short textual account; having provided a short account._A gestational or non-gestational neoplasm composed of neoplastic trophoblastic cells. Representative examples include hydatidiform mole and choriocarcinoma._Being or existing in a specified place or at the specified time._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3359903v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0ACE-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359908","version":"1","preferredName":"First Curettage Procedure Administered Date","preferredDefinition":"Preceding all others in time or space or degree._(kyoo-reh-TAHZH) Removal of tissue with a curette, a spoon-shaped instrument with a sharp edge._The act of having given something (e.g., a medication or test)._The final result of a determination of the value, significance, or extent of._The particular day, month and year an event has happened or will happen.","longName":"3359907v1.0:2555208v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0B29-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359911","version":"1","preferredName":"First Curettage Procedure Complication Text","preferredDefinition":"Preceding all others in time or space or degree._(kyoo-reh-TAHZH) Removal of tissue with a curette, a spoon-shaped instrument with a sharp edge._Complication; any disease or disorder that occurs during the course of (or because of) another disease._a free text field to specify information on the evaluations of the patient and the patient's disease","longName":"3359910v1.0:2018321v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0B59-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359915","version":"1","preferredName":"Second Curettage Procedure Performed Ind-2","preferredDefinition":"Coming next after the first in position in space or time or degree or magnitude._(kyoo-reh-TAHZH) Removal of tissue with a curette, a spoon-shaped instrument with a sharp edge._Performed; carried out._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3359914v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0B9A-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359919","version":"1","preferredName":"Second Curettage Procedure Performed Reason Text","preferredDefinition":"Coming next after the first in position in space or time or degree or magnitude._(kyoo-reh-TAHZH) Removal of tissue with a curette, a spoon-shaped instrument with a sharp edge._Performed; carried out._An explanation of the cause of some phenomenon or action._a free text field to specify information on the evaluations of the patient and the patient's disease","longName":"3359918v1.0:2018321v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0BDE-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3359920","version":"1","preferredName":"Second Curettage Procedure Performed Date","preferredDefinition":"Coming next after the first in position in space or time or degree or magnitude._(kyoo-reh-TAHZH) Removal of tissue with a curette, a spoon-shaped instrument with a sharp edge._Performed; carried out._the date on which an observation was made or an event occurred.","longName":"3359914v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6FB28DE-0BFD-147F-E040-BB89AD436E8A","latestVersionIndicator":"Yes","beginDate":"2012-01-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361323","version":"1","preferredName":"Previous Report Chemotherapy Therapeutic Procedure Ind-2","preferredDefinition":"Occurring prior to something else._A short textual account; having provided a short account._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"3361322v1.0:2018320v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7344AE8-2836-FBB6-E040-BB89AD432B57","latestVersionIndicator":"Yes","beginDate":"2012-01-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-23","modifiedBy":"CARPSE","dateModified":"2017-03-16","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361878","version":"1","preferredName":"Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Upper Limit of Normal Outcome Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"Value of upper limit of normal of beta-hCG.","longName":"LP_BHCG_ULN_VALU","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B747ABC0-F368-8BB8-E040-BB89AD436EB9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361888","version":"1","preferredName":"Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Labo_Huma_Valu_Huma_Valu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B747ABC0-F3D6-8BB8-E040-BB89AD436EB9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361894","version":"1","preferredName":"Initial Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Outcome Value","preferredDefinition":"occurring at the beginning._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_The result of an action._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Init_Labo_Huma_Valu_Huma_Valu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6A69-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361898","version":"1","preferredName":"Initial Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Value Outcome Date","preferredDefinition":"the date related to initial laboratory procedure from the beta subunit of human chorionic gonadotropin.","longName":"Init_Labo_Huma_Valu_Date_ASSES","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6AB9-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361902","version":"1","preferredName":"Laboratory Procedure Human Chorionic Gonadotropin Beta Subunit Bioassay Assessment Text","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. (from MSH98)_a free text field to specify information on the evaluations of the patient and the patient's disease","longName":"Labo_Huma_Bioa_ASSESS_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7482C68-6B0E-05FF-E040-BB89AD4359C9","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361932","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Required Report Type","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._Required; necessary, not optional._A short textual account; having provided a short account._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A short textual account; having provided a short account._Something distinguishable as an identifiable class based on common qualities.","longName":"Dise_FIGO_Requ_Repo_FIGO_Repo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B748E3B7-EEFB-76C3-E040-BB89AD4364F0","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361937","version":"1","preferredName":"FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Report Ind-2","preferredDefinition":"A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A short textual account; having provided a short account._the yes/no indicator related to protocol administration.","longName":"FIGO_Repo_PROT_ADM_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-0D39-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361941","version":"1","preferredName":"FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Specify","preferredDefinition":"A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._Be specific about something; define clearly._the free text field to related to protocol administration.","longName":"FIGO_Spec_PROT_ADM_SPEC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-0D69-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361947","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Age Diagnosis","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._How long something has existed; elapsed time since birth._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._How long something has existed; elapsed time since birth.","longName":"Dise_FIGO_Age_Diag_FIGO_Diag_A","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-0DD6-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361952","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Age Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._How long something has existed; elapsed time since birth._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._How long something has existed; elapsed time since birth._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Age_Diag_Score","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-0E64-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361961","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Pregnancy Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The condition of having a developing embryo or fetus in the body, after union of an ovum and spermatozoon. (Dorland, 27th ed)_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Preg_Diag_FIGO_Preg_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-0F3A-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361984","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Interval Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The period of time or the distance separating two instances, events, or occurrences._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The period of time or the distance separating two instances, events, or occurrences._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Inte_Diag_FIGO_Inte_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-108B-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3361995","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Serum HCG Measurement Diagnosis Value","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Dise_FIGO_Seru_Diag_Seru_Huma_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3E0-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362002","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Serum HCG Measurement Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Seru_Diag_FIGO_Seru_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3FF-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362006","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Tumor size Diagnosis Value","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The size of a tumor in its greatest dimension._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body. Also called tumor load._A numerical quantity measured or assigned or computed.","longName":"Dise_FIGO_Tumo_Diag_Value","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D444-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2023.7.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362012","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Tumor size Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The size of a tumor in its greatest dimension._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The size of a tumor in its greatest dimension._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Tumo_Diag_FIGO_Tumo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D4F3-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2023.7.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362022","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms CancerSite Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._class to hold instances used as the filler for the property has_cancer_site_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._class to hold instances used as the filler for the property has_cancer_site_A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Canc_Diag_FIGO_Canc_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D5EB-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362032","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Metastatic Lesion Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A tumor arising at a location distant to the primary lesion._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A tumor arising at a location distant to the primary lesion._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Meta_Diag_FIGO_Meta_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-1236-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362041","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Prior Chemotherapy Diagnosis Score","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._Earlier in time or order._The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._ (NCI04)_A number or range of numeric values measuring performance, function, quality, or ability.","longName":"Dise_FIGO_Prio_Chem_Diag_FIGO_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749402C-130D-FCFF-E040-BB89AD433131","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3362044","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Diagnosis Value","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A numerical quantity measured or assigned or computed.","longName":"Dise_FIGO_Diag_Value","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D60A-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3371625","version":"1","preferredName":"Prior Vaginal Brachytherapy Administered Ind-2","preferredDefinition":"Earlier in time or order._Relating to the vagina or to any sheath._(ray-dee-AY-shun) A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor. Also called brachytherapy, internal radiation, or interstitial radiation._The act of having given something (e.g., a medication or test)._the yes/no indicator related to a patient's/participant's therapy.","longName":"Prio_Vagi_Brac_Admi_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B861EE80-0F53-FCEF-E040-BB89AD4377D6","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-07","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3371718","version":"1","preferredName":"Head and Neck Neoplasm Clinical T4 Stage Finding Stage","preferredDefinition":"the extent of a primary head and neck tumor T4 Stage determined based on evidence from clinical assessment parameters (e.g., physical exam, imaging, biopsy) following AJCC staging criteria.","longName":"3371633v1.0:2179724v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8636E64-A859-EB62-E040-BB89AD43442B","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3376310","version":"1","preferredName":"Head and Neck Neoplasm  Pathologic T4 Stage Finding Stage","preferredDefinition":"the extent of a primary head and neck tumor T4 Stage determined based on evidence from pathological assessment parameters (e.g., biopsy) following AJCC staging criteria.","longName":"3376307v1.0:2854426v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B88A827D-5941-6DAE-E040-BB89AD433D1D","latestVersionIndicator":"Yes","beginDate":"2012-02-09","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-09","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3376368","version":"1","preferredName":"Specimen Laboratory Received Location Text","preferredDefinition":"information related to the lab that received the bit of tissue or blood or urine._The textual identifier of an organization that is conducting a trial, a central laboratory delivering the data or a laboratory performing a lab test.","longName":"SPEC_LAB_RCVD_LCTN_LAB_NM_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B88DC9B9-4F8F-68C6-E040-BB89AD4309F3","latestVersionIndicator":"Yes","beginDate":"2012-02-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-09","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379153","version":"1","preferredName":"Beta Human Chorionic Gonadotropin Histologically Metastatic Confirmed Ind-4","preferredDefinition":"Vo value exists._A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.(NCI)_Involving the use of histology or histological techniques._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._Confirmed; having been established or verified._the indicator for eligibility with values of yes, no, unknown, or not applicable.","longName":"Beta_Huma_Hist_Meta_Conf_ELIGI","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-AF41-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-16","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380302","version":"1","preferredName":"Person Prior Stereotactic Radiosurgery Excision Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to a person have prior radiation therapy technique involving a rigid head frame that is attached to the skull or the surgical removal of part or all of a structure or organ as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"3380301v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5FC-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-21","modifiedBy":"SARAHB","dateModified":"2017-01-12","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3382689","version":"1","preferredName":"Person Negation Central Nervous System Penetration ERBB2 Receptor Protein-Tyrosine Kinase Block Clinical Trial Eligibility Criteria  Indicator","preferredDefinition":"the indicator related to a person using non-CNS penetrating HER2 blockade which is necessary to allow an individual to participate in a specific clinical trial.","longName":"NONCNS_PNETRT_ELIG_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B99068EB-6B3F-AE1D-E040-BB89AD4362C9","latestVersionIndicator":"Yes","beginDate":"2012-02-22","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-22","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_Added Short Name_smt_Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":"12/18/23_Added Short Name_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387801","version":"1","preferredName":"Maintenance Therapy Complete Clinical Pathologic Response Ind-2","preferredDefinition":"Treatment that is given to help a primary (original) treatment keep working. Maintenance therapy is often given to help keep cancer in remission._To possess every necessary or normal part or component or step; having come or been brought to a conclusion._Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity._Caused by or altered by or manifesting disease or pathology._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._the yes/no indicator related to a patient's/participant's therapy.","longName":"Main_Comp_Clin_Path_Resp_TX_IN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F44EF5-B623-5A94-E040-BB89AD4302E2","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387806","version":"1","preferredName":"Patient No Progressive Disease Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to the disease process that is not increasing in scope or severity as an element of the personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_No_PD_Clin_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F44EF5-B679-5A94-E040-BB89AD4302E2","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"VUJANOVA","dateModified":"2019-08-01","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387810","version":"1","preferredName":"Maintenance Therapy Prior Recurrent Disease Discontinue Indicator","preferredDefinition":"the yes/no indicator related to having had stopping permanently or temporarily the treatment that is given to help a primary (original) treatment keep working prior to disease that shows a return of a sign, symptom, or disease after a remission.","longName":"Main_Prio_Recu_Disc_TX_INDIC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F44EF5-B6C0-5A94-E040-BB89AD4302E2","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387815","version":"1","preferredName":"Complete Remission Post First-Line Therapy Confirmation Ind-4","preferredDefinition":"The indicator for eligibility with values of yes, no, unknown, or not applicable for the disappearance of all signs of cancer in response to treatment.","longName":"Comp_Post_Firs_Conf_ELIGIB_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F57D82-7CD1-4B58-E040-BB89AD437DD8","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"SARAHB","dateModified":"2021-09-23","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387816","version":"1","preferredName":"Hormone Therapy Discontinued Indicator","preferredDefinition":"information related to the stopping of the administered hormone therapy to an individual._The yes/no/unknown/not applicable indicator whether an event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"HORMONALTX_DISCONT_TX_INDIC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F57D82-7CF0-4B58-E040-BB89AD437DD8","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387817","version":"1","preferredName":"Primary Neoplasm Pathology Complete Remission Ind-4","preferredDefinition":"information related to the disappearance of all signs of a tumor at the original site of origin based on microscopic structural and functional changes in the tumor cells as a result from treatment._a response or indicator that can have a value of yes, no, unknown, or not applicable for an assessment.","longName":"PRIMNEO_PATH_CR_3107580v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F57D82-7D0F-4B58-E040-BB89AD437DD8","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-4 3107580v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387872","version":"1","preferredName":"Head and Neck Tumor Histologic Classification Clinical Trial Eligibility Criteria Category","preferredDefinition":"information related to the histologic classification or category of a head and neck tumor which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2195124v1.0:3387843v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F7013B-6238-E4F5-E040-BB89AD4340FD","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-27","modifiedBy":"RODGERSC","dateModified":"2019-11-13","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387873","version":"1","preferredName":"Paclitaxel Agent Recurrent Disease Administered Therapy Indicator","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)_An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)._the return of a sign, symptom, or disease after a remission._The act of having given something (e.g., a medication or test)._The yes/no/unknown/not applicable indicator whether an event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"Pacl_Agen_Recu_Admi_TX_INDIC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F7013B-6259-E4F5-E040-BB89AD4340FD","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3387878","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Low Neuropathy Ind-4","preferredDefinition":"information related to the CTC adverse event of neuropathy (a condition of the nervous system that causes numbness, tingling, burning or weakness) that is at a minimum level or degree._the indicator for eligibility with values of yes, no, unknown, or not applicable.","longName":"CTC_AE_LO_NEUROP_ELIGIB_IND4","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9F7013B-6286-E4F5-E040-BB89AD4340FD","latestVersionIndicator":"Yes","beginDate":"2012-02-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3389749","version":"1","preferredName":"Neuropathy Medication Therapeutic Procedure Preventive Intervention Receive Therapy Ind-2","preferredDefinition":"A disorder affecting the cranial nerves or the peripheral nervous system.  It is manifested with pain, tingling, numbness, and muscle weakness.  It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs. -- 2004_A drug or medicine that treats or prevents or alleviates the symptoms of disease._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.__An attempt to prevent disease._To take, accept, or got something offered._the yes/no indicator related to a patient's/participant's therapy.","longName":"Neur_Medi_Ther_Prev_Rece_TX_IN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA084EA7-EF31-DB83-E040-BB89AD434AFD","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-28","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3389757","version":"1","preferredName":"Supplements Vitamin E Compound Daily Intake Use Ind-2","preferredDefinition":"Products in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. Nutritional supplements do not require FDA approval to be marketed. (NCI)_A fat-soluble vitamin which is primarily a chain-breaking antioxidant that prevents the propagation of lipid peroxidation._Occurring or done each day._The process of taking in a substance, especially by eating or drinking, or the quantities thereof; admittance of people to a place or organization at a particular time._A manner, or usual, or accepted practice of using something._the yes/no indicator related to a patient's/participant's therapy.","longName":"Supp_Vita_Dail_Inta_Use_TX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA08CD62-A19A-5045-E040-BB89AD435C6A","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-28","modifiedBy":"KUMMEROA","dateModified":"2022-12-20","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2022.12.20 AQT added for ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3389766","version":"1","preferredName":"Agent Paclitaxel Administered","preferredDefinition":"information related to compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity being administered._The amount of the compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity given at a specific time.","longName":"Agen_Pacl_Dose_Admi_Pacl_Agen_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA08F23E-A697-0664-E040-BB89AD4316A0","latestVersionIndicator":"Yes","beginDate":"2012-02-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-28","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3392416","version":"1","preferredName":"Patient Neurocognitive Function Quality of Life Consent Ind-2","preferredDefinition":"the yes/no indicator that asks whether the patient has consented to take part in the neurocognitive function and quality of life component of the study.","longName":"3392415v1.0:2018303v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA1BFE49-E77A-21F3-E040-BB89AD437106","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-02-29","modifiedBy":"WISEM","dateModified":"2016-09-20","changeNote":"Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3392430","version":"1","preferredName":"Germline Mutation BRCA1 Gene Or BRCA2 Gene Present Yes No Unknown Indicator","preferredDefinition":"Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., \"generative\" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not._Tumor suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._BRCA2 putatively functions as a tumor suppressor gene, however, its exact function has not been well characterized. The similarity of, and functional analysis of, BRCA2 and BRCA1 proteins, suggests that these proteins function in the same genetic pathway. BRCA1 and BRCA2 have transcriptional activation potential and the two proteins are associated with the activation of double-strand break repair and/or homologous recombination. The two proteins have been shown to coexist and colocalize in a biochemical complex. (from LocusLink)_Being or existing in a specified place or at the specified time._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"Germ_BRCA_Or_BRCA_Pres_ASSESS_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA1D3885-35CE-1541-E040-BB89AD437FB0","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-29","modifiedBy":"TIFFANIS","dateModified":"2019-10-14","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3392434","version":"1","preferredName":"First-Line Therapy Biological Therapy Receive Ind-2","preferredDefinition":"the yes/no indicator related to receiving the preferred standard treatment for a particular condition as the therapeutic action to produce an effect that is intended to alter the course of a pathologic process for a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.","longName":"Firs_Biol_Rece_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA1D202C-74F7-2FBF-E040-BB89AD4379D1","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-29","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3392439","version":"1","preferredName":"Disease or Disorder Platinum Refractory Present Ind-2","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A metal that is an important component of some anticancer drugs, such as cisplatin and carboplatin._In medicine, describes a disease or condition that does not respond to treatment._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Being or existing in a specified place or at the specified time._the yes/no indicator related to the evaluation of the patient and patient's disease.","longName":"Dise_Plat_Refr_Pres_ASSESS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA1D3885-36C3-1541-E040-BB89AD437FB0","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-29","modifiedBy":"SARAHB","dateModified":"2022-04-21","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3392443","version":"1","preferredName":"Therapeutic Procedure Veliparib Receive Ind-2","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation_To take, accept, or got something offered._the yes/no indicator related to a patient's/participant's therapy.","longName":"Ther_Veli_Rece_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA1D202C-755B-2FBF-E040-BB89AD4379D1","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-02-29","modifiedBy":"KUMMEROA","dateModified":"2022-12-20","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"2022.12.20 AQT added for ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3396968","version":"1","preferredName":"Patient Contact Information Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to information regarding the means of contacting a person receiving medical attention, care, or treatment which is necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_Cont_Clin_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34696C-2358-6EF8-E040-BB89AD4348D6","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-01","modifiedBy":"TSESU","dateModified":"2023-06-23","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397315","version":"1","preferredName":"Patient Enrollment Medical Dietary Intervention Clinical Trials Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related information regarding enrollment in a medical dietary intervention of a person who receiving medical attention, care, or treatment which is necessary in regards to participation in a specific clinical trial.","longName":"Pati_Enro_Medi_Diet_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA3532EB-4DFF-1C5F-E040-BB89AD4378F6","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-01","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397326","version":"1","preferredName":"Chronic Disease or Disorder Walking Restriction Assessment Ind-2","preferredDefinition":"the yes/no indicator related to information regarding a disease or condition that persists or progresses over a long period of time that limits the ability of traveling by foot.","longName":"Chro_Dise_Walk_Rest_Asse_ASSES","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA3595C1-3209-02B4-E040-BB89AD4303E8","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-01","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397334","version":"1","preferredName":"Patient Communication Medical Record Review Consent Ind-3","preferredDefinition":"The yes/no/unknown indicator related to permission by person who receives medical attention, care, or treatment for the exchange of information and review of their medical records.","longName":"3397329v1.0:2189909v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA34F3E4-930F-41C1-E040-BB89AD433B93","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"THOMASJ","dateCreated":"2012-03-01","modifiedBy":"TITARENKOI","dateModified":"2020-04-20","changeNote":"Replaced VD Patient Consent Ind-3 2189909v1 with VD ID#3506034 - Yes No Unknown Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397629","version":"1","preferredName":"Patient Vegan Diet Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"yes/no indicator related to the patient's eligibility to participate in the clinical trial based on a type of vegetarian diet that excludes all animal products, including dairy, eggs, meat, poultry, fish, and animal fats.","longName":"Pati_Vega_Clin_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA44FFB7-B93C-0033-E040-BB89AD435E08","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397637","version":"1","preferredName":"Report Weight Loss Program Enrollment Ind-2","preferredDefinition":"the yes/no indicator related to the patient's eligibility to participate in the clinical trial based on a short textual account in registration in a program to receive a reduction in overall body mass.","longName":"Repo_Weig_Prog_Enro_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA4551E4-1ED3-965A-E040-BB89AD434B6A","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397646","version":"1","preferredName":"Patient Endurance Physical Activity Participation Ind-2","preferredDefinition":"yes/no indicator related to the patient's eligibility to participate in the clinical trial in regards to taking part and having the ability to sustain an activity over a period of time.","longName":"Pati_Endu_Phys_Part_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA45A3EA-F301-B3A5-E040-BB89AD432C7E","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3399853","version":"1","preferredName":"Vulvar Carcinoma Malignant Neoplasm Diagnosis Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence of  a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues arising from the vulva.","longName":"Vulv_Mali_Diag_DX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA49A0AF-7A40-B8F3-E040-BB89AD4378E9","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3399860","version":"1","preferredName":"Patient Cardiac Medical Device Implantation Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related regards to elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial. regarding a person who has any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions in the heart.","longName":"Pati_Card_Medi_Impl_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA49A0AF-7AAD-B8F3-E040-BB89AD4378E9","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"HARTLEYG","dateModified":"2020-05-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3399877","version":"1","preferredName":"Patient Upper Extremity Lymphedema Personal Medical History Ind-2","preferredDefinition":"the yes/no indicator related to the patient's eligibility to participate in the clinical trial based on receiving medical attention account of all medical events and problems regarding Excess fluid collection in tissues, causing swelling in the region of the body that includes the arm, the forearm, and hand.","longName":"Pati_Uppe_Lymp_Pers_ELIG_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA4A5DD5-2BA2-64D7-E040-BB89AD433773","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"MORENOC","dateModified":"2019-04-29","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3399889","version":"1","preferredName":"Patient Electrocardiography Electrode Hypersensitivity Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to A local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized to A conductor used to make electrical contact with some part of a circuit for A procedure which records the electrical current in the heart in the form of a continuous strip graph by person who receives medical attention which is necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_Elec_Elec_Hype_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA4AA756-A94A-F10D-E040-BB89AD4375F1","latestVersionIndicator":"Yes","beginDate":"2012-03-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-02","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3400032","version":"2","preferredName":"Prior Malignant Neoplasm Location ICD-O-3 Code","preferredDefinition":"information related to the location of a prior malignant neoplasm._The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"PRIOR_MALIGNANCY_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D79ECEB-21F7-533C-E053-F662850A95A8","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-08","modifiedBy":"PATELV","dateModified":"2017-11-08","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014 Retired VD replaced with new version of the VD- 2018548, VP 11/8/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3400033","version":"2","preferredName":"Second Tumor Location ICD-O-3 Code","preferredDefinition":"information related to the location of a second tumor._The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"SECOND_PRIMARY_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D79F801-F5C1-089C-E053-F662850AEED5","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-08","modifiedBy":"PATELV","dateModified":"2017-11-08","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014 Retired VD updated with the new version 2018548, VP 11/8/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3402663","version":"1","preferredName":"Diagnostic Imaging Post Primary Surgical Procedure Performed Indicator","preferredDefinition":"The yes/no/unknown/not applicable indicator whether earlier diagnostic or treatment procedure performed by manual and/or instrumental means before the act of giving a special type of magnetic resonance imaging happening after a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Diag_Post_Prim_Surg_Perf_TX_IN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA85A70C-EB39-7C6C-E040-BB89AD430169","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-05","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3408544","version":"1","preferredName":"Chemotherapy Quality of Life Clinical Study Treatment Regimen Ind-2","preferredDefinition":"the yes/no indicator related to the subjective measurement of an individual's sense of well-being and ability to enjoy life based upon the use of synthetic or naturally-occurring chemicals for the treatment of diseases for research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects.","longName":"Chem_Qual_Clin_Trea_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAAA3DC4-5FF4-572D-E040-BB89AD430E2A","latestVersionIndicator":"Yes","beginDate":"2012-03-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-07","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412249","version":"1","preferredName":"Uterus Leiomyosarcoma Malignant Neoplasm High Grade Diagnosis Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease of an uncommon, aggressive malignant smooth muscle neoplasm that contain tumor samples that exhibit poorly differentiated or undifferentiated cells, usually occurring in post-menopausal women.","longName":"Uter_Leio_Mali_High_Diag_DX_IN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD26E7E-33D2-052C-E040-BB89AD4343C1","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412257","version":"1","preferredName":"Pathology Mitotic Count Rate Diagnosis Ind-2","preferredDefinition":"Tthe yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease by the medical science, and specialty practice, concerned with all aspects of disease, determining the number of mitoses identified under the microscope in tumors.","longName":"Path_Mito_Rate_Diag_DX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD2A0B4-A15A-878D-E040-BB89AD434BFA","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412258","version":"1","preferredName":"Pathology Report Mitotic Count Rate Malignant Neoplasm Diagnosis Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to the investigation, analysis and recognition of the presence and nature of malignant disease by a report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment by determining the number of mitoses identified under the microscope in tumors.","longName":"Path_Mito_Rate_Mali_Diag_29686","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD2A0B4-A179-878D-E040-BB89AD434BFA","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412270","version":"1","preferredName":"Uterine Corpus Leiomyosarcoma Malignant Neoplasm FIGO Stage I Diagnosis Ind-2","preferredDefinition":"The yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease of a FIGO stage defining an aggressive malignant smooth muscle neoplasm, arising from the uterine corpus.","longName":"Uter_Mali_FIGO_Diag_DX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD2A0B4-A20D-878D-E040-BB89AD434BFA","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"BOWSERC","dateModified":"2021-11-22","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412280","version":"1","preferredName":"Persistent Disease or Disorder Metastasis Imaging Technique Documented Ind-2","preferredDefinition":"the yes/no indicator related to any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person documented by tests that produce pictures of areas inside the body of retained cancer that has spread from the organ in which it first appeared to another organ.","longName":"Pers_Dise_Meta_Imag_Docu_ASSES","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD3322E-8FCA-EF6C-E040-BB89AD437A2D","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"SBR","dateModified":"2016-10-13","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412285","version":"1","preferredName":"Patient Excision Imaging Technique Performed Clinical Trials Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial regarding A person who receives surgical removal of part or all of a structure or organ. and tests that produce pictures of areas inside the body.","longName":"Pati_Exci_Imag_Perf_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD4597C-964F-8E3D-E040-BB89AD432DBB","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412300","version":"1","preferredName":"Hormone Replacement Therapeutic Procedure Concurrent Medication Documented Indicator","preferredDefinition":"The yes/no/unknown/not applicable indicator of a documented use of treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production at the same time as other therapy.","longName":"Horm_Repl_Ther_Conc_Medi_Docu_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD48B15-3667-4589-E040-BB89AD435660","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412347","version":"1","preferredName":"Patient Uterus Serosa Involvement Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial regarding an association of a membrane lining the external walls of the body cavities within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Pati_Uter_Sero_Invo_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD57EE8-7343-D4B0-E040-BB89AD431A12","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-09","modifiedBy":"HARTLEYG","dateModified":"2019-10-24","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412597","version":"1","preferredName":"Reduced Lipid Agent Administered Therapy Ind-3","preferredDefinition":"the yes/no/unknown indicator related to the lipid-reducing agent being administered to a patient on cancer therapy.","longName":"2199743v1.0:2018278v2.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB0C7E76-6799-3943-E040-BB89AD43359B","latestVersionIndicator":"Yes","beginDate":"2012-03-12","endDate":null,"createdBy":"PATELV","dateCreated":"2012-03-12","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420425","version":"1","preferredName":"Surgical Procedure Consent Form Signed Ind-2","preferredDefinition":"the yes/no indicator related to information related to a signed consent form for a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Surg_Cons_Sign_ASSESS_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-3B47-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420431","version":"1","preferredName":"Conization Or Loop Electrosurgical Excision Surgical Margin High Grade Dysplasia Diagnosis Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease of poorly differentiated or undifferentiated cells associated with altered architectural tissue patterns that may lead to cancer based on the edge or border of the tissue removed by a cone-shaped portion of tissue from the uterine cervix or using a thin, low-voltage electrified wire loop to cut out a thin layer of abnormal tissue; generally used to remove abnormal cells on the surface of the cervix.","longName":"Coni_Or_Loop_Surg_High_Dysp_Di","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-3CA4-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420435","version":"1","preferredName":"Abdominal Cavity Computed Tomography Magnetic Resonance Imaging Diagnostic Imaging No Metastasis Observed Ind-2","preferredDefinition":"the yes/no indicator related to the observation of non-affirmative spreading of cancer from the organ in which it first appeared to another organ based on a method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis in the portion of the body that lies between the thorax and the pelvis.","longName":"Abdo_Comp_Magn_Diag_No_Meta_Ob","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-3CE9-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"DASCOMBS","dateModified":"2015-09-01","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420439","version":"1","preferredName":"Pelvis Lymph Node Pathology Diagnosis Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease in an organ composed predominantly of lymphocytes and its main function is immune protection in the structure of the vertebrate skeleton supporting the lower limbs in humans and the hind limbs.","longName":"Pelv_Lymp_Path_Diag_DX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-4058-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420444","version":"1","preferredName":"Clear Cell Or Neuroendocrine Cell Disease or Disorder Diagnosis Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease of a cell with empty-appearing cytoplasm when viewed with a light microscope or an endocrine cell that produces and releases hormones and regulatory proteins such as neurotransmitters and neuropeptide hormones.","longName":"Clea_Or_Neur_Dise_Diag_DX_IND-","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-4077-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420448","version":"1","preferredName":"Depth Tumor Cell Invasion Disease or Disorder Observed Ind-2","preferredDefinition":"the yes/no indicator related to the observed depth of the local spread of a malignant neoplasm by infiltration or destruction of adjacent tissue of any abnormal condition of the body.","longName":"Dept_Tumo_Dise_Obse_ASSESS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBD6F1B4-40DD-B65B-E040-BB89AD432DD1","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-03-22","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3422100","version":"1","preferredName":"Protocol Administration Digital Report Submission Ind-2","preferredDefinition":"The Yes/No indicator related to submission of digital data.","longName":"PROT_DIGIT_SUBM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC39AC36-BB55-6A39-E040-BB89AD431833","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-03-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3432455","version":"1","preferredName":"Patient Vulva Malignant Neoplasm Diagnosis Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to the investigation, analysis and recognition of the presence and nature of disease of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues located in the external, visible part of the female genitalia surrounding the urethral and vaginal opening of a person who receives medical attention, care, or treatment which are necessary to allow for participation in a specific clinical trial.","longName":"Pati_Vulv_Mali_Diag_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCF1A9A7-3548-6D08-E040-BB89AD431867","latestVersionIndicator":"Yes","beginDate":"2012-04-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-05","modifiedBy":"MORENOC","dateModified":"2017-09-21","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3432719","version":"1","preferredName":"Disease Assessment TNM Classification Stage","preferredDefinition":"examination of a malignant condition of the body with the intention to categorize extent of cancer using a system describing the size of the tumor, any lymph nodes that are involved, and presence of metastasis.","longName":"DZ_ASSESS_TNM_CLASS_TNM_Stag","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCF27E5F-2513-C93C-E040-BB89AD436034","latestVersionIndicator":"Yes","beginDate":"2012-04-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-05","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3432770","version":"1","preferredName":"Patient Radical Chemoradiotherapy Tolerance Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related to being able to participate in a specific cliical trial based on having the ability to have an increased resistance to the usual effects of an administration of chemoradiotherapy agents directed to the root or source of a morbid process.","longName":"Pati_Radi_Chem_Tole_Clin_ELIG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCF2EA3F-C125-DC6E-E040-BB89AD4321F4","latestVersionIndicator":"Yes","beginDate":"2012-04-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-05","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3435159","version":"1","preferredName":"Biopsy Post Chemoradiotherapy Performed Ind-2","preferredDefinition":"the yes/no indicator related to information related to the removal and pathologic examination of specimens in the form of small pieces of tissue from the living body occuring after treatment that combines chemotherapy with radiation therapy.","longName":"Biop_Post_Chem_Perf_DX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C2A5-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3435977","version":"1","preferredName":"Biopsy Right Inguinal Region Result Type","preferredDefinition":"the result of a biopsy which indicates if cancer is present in a biopsy specimen collected from the right side of the groin from a patient.","longName":"Biop_Righ_Ingu_Outc_BX_RES_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C2EA-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3435981","version":"1","preferredName":"Biopsy Left Inguinal Region Result Type","preferredDefinition":"the result of a biopsy which indicates if cancer is present in a biopsy specimen collected from the left side of the groin from a patient.","longName":"Biop_Left_Ingu_Outc_BX_RES_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C32F-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3435985","version":"1","preferredName":"Biopsy Midline Inguinal Region Result Type","preferredDefinition":"the result of a biopsy which indicates if cancer is present in a biopsy specimen collected from the mid-line of the groin from a patient.","longName":"Biop_Midl_Ingu_Outc_BX_RES_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C374-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3435987","version":"1","preferredName":"Surgical Procedure Lymphadenectomy Performed Date","preferredDefinition":"the date on which an observation was made or an event occurred related to a surgical procedure in which the lymph nodes are removed and examined to see whether they contain cancer.","longName":"2430054v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C393-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436023","version":"2","preferredName":"Pathology Left Femoral Inguinal Lymph Node Outcome Type","preferredDefinition":"Left femoral inguinal lymph node pathology outcome type.","longName":"LFT_INGFEM_LYMPH_PATH_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CD0FEC6-B548-70B6-E063-731AD00A6042","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-12-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_New version due to revised Short Name and definition_smt; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_New version due to revised Short Name and definition_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436027","version":"2","preferredName":"Pathology Right Femoral Inguinal Lymph Node Result Type","preferredDefinition":"Right femoral inguinal lymph node pathology outcome type.","longName":"RGHT_INGFEM_LYMPH_PATH_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CD11616-D46A-7517-E063-731AD00A74D2","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-12-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_New version due to new short name and defintion_smt; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_New version due to new short name and defintion_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436032","version":"1","preferredName":"Pathologic Left Inguinal Lymph Node N Stage","preferredDefinition":"information regarding one criteria of the TNM staging system. N refers to the extent of lymph node involvement determined bypathology located in a superficial or deep lymph node located on the left side of the inguinal area.","longName":"Path_Left_Ingu_N St_GYN_TUMOR_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C474-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436036","version":"1","preferredName":"Pathologic Right Inguinal Lymph Node N Stage","preferredDefinition":"information regarding one criteria of the TNM staging system. N refers to the extent of lymph node involvement determined bypathology located in a superficial or deep lymph node located on the right side of the inguinal area.","longName":"Path_Righ_Ingu_N St_GYN_TUMOR_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD41945E-C4B9-072C-E040-BB89AD431AF6","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436058","version":"2","preferredName":"Surgical Procedure Gynecologic Excision Performed Anatomic Site","preferredDefinition":"Anatomical site of gynecologic excision performed.","longName":"GYN_EXC_PERF_ANAT_STE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CD139DB-3695-7D8D-E063-731AD00A623B","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-12-18","modifiedBy":"TSESU","dateModified":"2023-12-18","changeNote":"12/18/23_New version due to new short name and defintion_smt; Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"12/18/23_New version due to new short name and defintion_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436261","version":"1","preferredName":"Surgical Procedure Ligation Performed Type","preferredDefinition":"information regarding the technique used to close a cut made in the body to perform surgery.","longName":"Surg_Tech_Liga_Perf_LIG_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5569E4-4A3F-F494-E040-BB89AD432C65","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-10","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436381","version":"1","preferredName":"Surgical Procedure Subcutaneous Drainage Use Ind-2","preferredDefinition":"information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin during a diagnostic or treatment procedure performed by manual and/or instrumental means","longName":"Surg_Subc_Drai_Use_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD59339B-0EE4-905F-E040-BB89AD4313C1","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-10","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436499","version":"1","preferredName":"Surgical Procedure Subcutaneous Drainage Location","preferredDefinition":"Information regarding the position, site, or point where a systematic withdrawal of fluids and discharges from a wound, sore or cavity was placed beneath the skin during a diagnostic or treatment procedure performed by manual and/or instrumental means._Named location within the body where the device used for the withdrawal of fluids and discharges from a wound, sore or cavity was placed.","longName":"Surg_Subc_Drai_Loca_Drai_Anat","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD6BC20F-0719-A7DC-E040-BB89AD4332E1","latestVersionIndicator":"Yes","beginDate":"2012-04-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-11","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436606","version":"1","preferredName":"Surgical Procedure Subcutaneous Drainage Use Type","preferredDefinition":"Information regarding the identifiable class based on common qualities of a device used for withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin.","longName":"Surg_Subc_Drai_Use_Subc_Drai_T","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7CCCBB-FE08-E446-E040-BB89AD436ABE","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436609","version":"1","preferredName":"Surgical Procedure Subcutaneous Drainage Use Specify","preferredDefinition":"information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin during a diagnostic or treatment procedure performed by manual and/or instrumental means","longName":"Surg_Subc_Drai_Use_TX_SPEC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7CCCBB-FE50-E446-E040-BB89AD436ABE","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436615","version":"1","preferredName":"Surgical Procedure Subcutaneous Drainage Removed Date","preferredDefinition":"the date on which information regarding a device used for the withdrawal of fluids and discharges from a wound, sore or cavity placed beneath the skin being removed after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Surg_Subc_Drai_Remo_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7CCCBB-FEC1-E446-E040-BB89AD436ABE","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436629","version":"1","preferredName":"Surgical Procedure Pelvis Drainage Use Ind-2","preferredDefinition":"information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed in the pelvis during a diagnostic or treatment procedure performed by manual and/or instrumental means_the yes/no indicator related to a patient's/participant's therapy.","longName":"Surg_Pelv_Drai_Use_TX_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7D949D-CD05-E87E-E040-BB89AD431343","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436631","version":"1","preferredName":"Surgical Procedure Pelvis Drainage Use Type","preferredDefinition":"information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed in the pelvis during a diagnostic or treatment procedure performed by manual and/or instrumental means","longName":"Surg_Pelv_Drai_Use_Drai_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7DCA2E-D3FA-55F2-E040-BB89AD43532B","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436645","version":"1","preferredName":"Surgical Procedure Pelvis Drainage Use Specify","preferredDefinition":"information regarding the systematic withdrawal of fluids and discharges from a wound, sore or cavity placed in the pelvis during a diagnostic or treatment procedure performed by manual and/or instrumental means_the free text field related to therapy.","longName":"Surg_Pelv_Drai_Use_TX_SPEC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7DCA2E-D419-55F2-E040-BB89AD43532B","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436650","version":"1","preferredName":"Surgical Procedure Pelvis Drainage Removed Date","preferredDefinition":"the date on which information regarding a device used for the withdrawal of fluids and discharges from a wound, sore or cavity placed within the pelvis being removed after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Surg_Pelv_Drai_Remo_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7DCA2E-D45E-55F2-E040-BB89AD43532B","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436707","version":"1","preferredName":"Surgical Procedure Adhesion Preventive Intervention Technique Type","preferredDefinition":"Information regarding a practiced skill used in a diagnostic or treatment procedure performed by manual and/or instrumental means used to prevent adhesiions.","longName":"Surg_Adhe_Prev_Tech_Adhe_Prev_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7E44DA-E6B2-B381-E040-BB89AD433BC5","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436708","version":"1","preferredName":"Lymphedema Disease or Disorder Infection Infection Grade","preferredDefinition":"A position on a scale of intensity or amount or quality used to determine infection as the result of obstruction of lymphatic vessels or lymph nodes.","longName":"Lymp_Dise_Infe_Infe_Grad","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7E44DA-E6D1-B381-E040-BB89AD433BC5","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436715","version":"1","preferredName":"Lymphocele Disease or Disorder Occurrence Ind-2","preferredDefinition":"a yes/no indicator of an occurrence of a formation of a cystic lesion containing lymph which usually results from injury, gynecologic surgery, or urologic surgery.","longName":"Lymp_Dise_Occu_DZ_DESC_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7ED3F7-8819-7305-E040-BB89AD435A75","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Disease Description Ind-2 2181448v1 with VD ID#3506068 - Yes No Indicator   - dbw Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436718","version":"1","preferredName":"Surgical Procedure Adhesion Preventive Intervention Technique Specify","preferredDefinition":"Information regarding a practiced skill used in a diagnostic or treatment procedure performed by manual and/or instrumental means used to prevent adhesiions.","longName":"Surg_Adhe_Prev_Tech_TX_SPEC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F2D06-1085-56C1-E040-BB89AD435E76","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436726","version":"1","preferredName":"Lymphocele Disease or Disorder Formation Occurrence Grade","preferredDefinition":"Occurrence of a formation of a cystic lesion containing lymph. It usually results from injury, gynecologic surgery, or urologic surgery._A cystic lesion containing lymph. It usually results from injury, gynecologic surgery, or urologic surgery._A position on a scale of intensity or amount or quality of a cystic lesion containing lymph. It usually results from injury, gynecologic surgery, or urologic surgery.","longName":"Lymp_Dise_Occu_Lymp_Grad","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F2D06-1173-56C1-E040-BB89AD435E76","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436730","version":"1","preferredName":"Lymphedema Disease or Disorder Assessment Ind-3","preferredDefinition":"The yes/no/unknown indicator related to the assessment of the abnormal condition of the body or mind that causes discomfort, dysfunction, or distress in the form of excess fluid collection in tissues, causing swelling. It is the result of obstruction of lymphatic vessels or lymph","longName":"Lymp_Dise_Asse_ASSESS_IND-3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-4641-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"MORENOC","dateModified":"2019-02-26","changeNote":"Replaced VD Assessment Ind-3 (2018441v1) with VD Yes No Unknown Indicator (3506034v1) - dbw Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436735","version":"1","preferredName":"Lymphedema Disease or Disorder Assessment Status","preferredDefinition":"Having determined the value of the result of an assessment of the abnormal condition of the body or mind that causes discomfort, dysfunction, or distress in the form of excess fluid collection in tissues, causing swelling. It is the result of obstruction of lymphatic vessels or lymph nodes.","longName":"Lymp_Dise_Asse_PRES_STAT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F2D06-11A2-56C1-E040-BB89AD435E76","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436743","version":"1","preferredName":"Lymph Node Excision Lymph Node Removed Anatomic Site","preferredDefinition":"Named locations within the body where lymph node was removed.","longName":"LN_RES_Lymp_Remo_Anat","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F2D06-1305-56C1-E040-BB89AD435E76","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436748","version":"1","preferredName":"Lymph Node Left Pelvis Involvement Count","preferredDefinition":"Information regarding the numeric count of the surgical removal of lymph nodes from the left pelvis.","longName":"Lymp_Left_Pelv_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-46E8-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436752","version":"1","preferredName":"Lymph Node Left Pelvis Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the left pelvis.","longName":"Lymp_Left_Pelv_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7FF1C7-A38F-AD73-E040-BB89AD43480C","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436788","version":"1","preferredName":"Lymph Node Left Pelvis Involvement Status","preferredDefinition":"Information regarding the surgical removal of lymph nodes from the left pelvis.","longName":"Lymp_Left_Pelv_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD8069DE-15B7-A4E5-E040-BB89AD4344D6","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436794","version":"1","preferredName":"Lymph Node Right Pelvis Involvement Count","preferredDefinition":"Information regarding the numeric count of surgically removed of lymph nodes from the right pelvis.","longName":"Lymp_Righ_Pelv_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-49F7-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436795","version":"1","preferredName":"Lymph Node Right Pelvis Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the right pelvis.","longName":"Lymp_Righ_Pelv_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-4A1A-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436796","version":"1","preferredName":"Lymph Node Right Pelvis Involvement Status","preferredDefinition":"Information regarding the surgical removal of lymph nodes from the right pelvis.","longName":"Lymp_Righ_Pelv_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-4A3D-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436808","version":"1","preferredName":"Lymph Node Left Common Iliac Involvment Count","preferredDefinition":"Information related to the numeric count regarding the surgical removal of lymph nodes from the left common iliac.","longName":"Lymp_Left_Comm_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD7F8235-4B31-F2A1-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"SOKKERL","dateModified":"2020-06-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436812","version":"1","preferredName":"Lymph Node Left Common Iliac Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the left common iliac.","longName":"Lymp_Left_Comm_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80B6A8-045E-2E31-E040-BB89AD43170C","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436813","version":"1","preferredName":"Lymph Node Left Common Iliac Involvement Status","preferredDefinition":"Information regarding the surgical removal of lymph nodes from the left common iliac.","longName":"Lymp_Left_Comm_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80B6A8-047D-2E31-E040-BB89AD43170C","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436817","version":"1","preferredName":"Lymph Node Right Common Iliac Involvement Count","preferredDefinition":"Information related to the numeric count of the surgical removal of lymph nodes from the right common iliac.","longName":"Lymp_Righ_Comm_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E102-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"SOKKERL","dateModified":"2020-06-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436819","version":"1","preferredName":"Lymph Node Right Common Iliac Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the right common iliac.","longName":"Lymp_Righ_Comm_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E132-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436820","version":"1","preferredName":"Lymph Node Right Common Iliac Involvement Status","preferredDefinition":"Identifiable qualities based on observation regarding the surgical removal of lymph nodes from the right common iliac.","longName":"Lymp_Righ_Comm_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E151-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436825","version":"1","preferredName":"Laboratory Procedure Albumin Result Ind-3","preferredDefinition":"the yes/no/unknown indicator related to assessment of the information related to the medical procedure that involves testing a sample of blood for albumin, the main protein in blood plasma.","longName":"LAB_ALB_RSLT_ASSESS_IND-3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80B6A8-049C-2E31-E040-BB89AD43170C","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessment Ind-3 (2018441v1) with VD Yes No Unknown Indicator (3506034v1) - dbw Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436832","version":"1","preferredName":"Lymph Node Left Paraaortic Involvement Count","preferredDefinition":"Information regarding the numeric count of the surgical removal of lymph nodes from the left periaortic.","longName":"Lymp_Left_Para_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E21F-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436833","version":"1","preferredName":"Lymph Node Left Paraaortic Region Involvement Ind-4","preferredDefinition":"response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the left periaortic.","longName":"Lymp_Left_Para_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E23E-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436838","version":"1","preferredName":"Lymph Node Left Peraaortic Involvement Status","preferredDefinition":"Identifiable qualities based on observation regarding the surgical removal of lymph nodes from the left periaortic.","longName":"Lymp_Left_Para_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E294-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436849","version":"1","preferredName":"Patient Dominant Foot Assessment Anatomic Site","preferredDefinition":"the side of a foot that exercises greater control in a person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"Pati_Domi_Foot_Asse_SIDE_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E37A-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436853","version":"1","preferredName":"Lymph Node Right Paraaortic Involvement Count","preferredDefinition":"Information related to the numeric count regarding the surgical removal of lymph nodes from the right periaortic.","longName":"Lymp_Righ_Para_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E3B1-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436854","version":"1","preferredName":"Patient Dominant Arm Assessment Anatomic Site","preferredDefinition":"information related to arm or hand that exercises greater control in a person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"Pati_Domi_Arm_Asse_SIDE_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD81746C-63AD-F4DE-E040-BB89AD432609","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-12","modifiedBy":"LISU","dateModified":"2023-08-17","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436855","version":"1","preferredName":"Lymph Node Right Paraaortic Region Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the right periaortic.","longName":"Lymp_Righ_Para_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD81746C-63BD-F4DE-E040-BB89AD432609","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436856","version":"1","preferredName":"Lymph Node Right Paraaortic Involvement","preferredDefinition":"Identifiable qualities based on observation regarding the surgical removal of lymph nodes from the right periaortic.","longName":"Lymp_Righ_Para_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E3D0-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436860","version":"1","preferredName":"Lymph Node Left Groin Involvement Count","preferredDefinition":"Information related to the numeric count of the surgical removal of lymph nodes from the left groin.","longName":"Lymp_Left_Ingu_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E412-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436861","version":"1","preferredName":"Lymph Node Left Groin Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the left groin.","longName":"Lymp_Left_Ingu_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E431-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436862","version":"1","preferredName":"Lymph Node Left Groin Involvement Status","preferredDefinition":"Identifiable qualities based on observation regarding the surgical removal of lymph nodes from the left groin.","longName":"Lymp_Left_Ingu_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E450-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436866","version":"1","preferredName":"Lymph Node Right Groin Involvement Count","preferredDefinition":"Information related to the numeric count of the surgical removal of lymph nodes from the right groin.","longName":"Lymp_Righ_Ingu_Invo_LN_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E492-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436867","version":"1","preferredName":"Lymph Node Right Groin Involvement Ind-4","preferredDefinition":"a response or indicator that can have a value of yes, no, unknown, or not applicable related to information regarding the surgical removal of lymph nodes from the right groin.","longName":"Lymp_Righ_Ingu_Invo_2968655v1.","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E4A2-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-4 2968655v1 VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436868","version":"1","preferredName":"Lymph Node Right Groin Involvement Status","preferredDefinition":"Information regarding the surgical removal of lymph nodes from the right groin.","longName":"Lymp_Righ_Ingu_Invo_Lymp_Invo_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E4C1-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436886","version":"1","preferredName":"Surgical Procedure Nodal Dissection Technique Type","preferredDefinition":"Information regarding a skill or technique used to dissect a node removed during surgery.","longName":"Surg_Noda_Diss_Tech_Noda_Diss_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E5D2-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436894","version":"1","preferredName":"Surgical Procedure Paraaortic Lymph Node Dissection Extent Type","preferredDefinition":"Information regarding the evaluation of the extent of the periaortic dissection.","longName":"Surg_Para_Diss_Exte_Para_Diss_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD80E821-E675-6C9F-E040-BB89AD434369","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436905","version":"1","preferredName":"Surgical Procedure Left Saphenous Vein Assessment Ind-2","preferredDefinition":"the yes/no indicator related information regarding the assessment of the left superficial veins of the leg and thigh after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Surg_Left_Saph_Asse_ASSESS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-824D-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436912","version":"1","preferredName":"Surgical Procedure Right Saphenous Vein Assessment Ind-2","preferredDefinition":"the yes/no indicator related information regarding the assessment of the right superficial veins of the leg and thigh after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Surg_Righ_Saph_Asse_ASSESS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD822090-82DC-307C-E040-BB89AD433070","latestVersionIndicator":"Yes","beginDate":"2012-04-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-12","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436941","version":"1","preferredName":"Post Surgical Procedure Vascular Insufficient Assessment Ind-2","preferredDefinition":"the yes/no indicator related to information regarding determining if there was vascular insufficiency occuring after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Post_Surg_Vasc_Insu_Asse_ASSES","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD906A9F-6855-FC06-E040-BB89AD436CEB","latestVersionIndicator":"Yes","beginDate":"2012-04-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-13","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436951","version":"1","preferredName":"Post Surgical Procedure Venous Thromboembolism Preventive Intervention Technique Type","preferredDefinition":"Information regarding the technique used to prevent occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream in the veins after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Post_Surg_Veno_Thro_Prev_Tech_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD91533C-32CA-C34D-E040-BB89AD433FC8","latestVersionIndicator":"Yes","beginDate":"2012-04-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-13","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3436954","version":"1","preferredName":"Post Surgical Procedure Venous Thromboembolism Preventive Intervention Technique Therapies Specify","preferredDefinition":"Information regarding the technique used to prevent occlusion of the lumen of a vessel by a thrombus that has migrated from a distal site via the blood stream in the veins after a diagnostic or treatment procedure performed by manual and/or instrumental means.","longName":"Post_Surg_Veno_Thro_Text_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD91533C-3313-C34D-E040-BB89AD433FC8","latestVersionIndicator":"Yes","beginDate":"2012-04-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-13","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3437736","version":"1","preferredName":"Patient Extremity Assessment Ind-2","preferredDefinition":"The yes/no indicator related to having determined the value, significance, or extent of an annotation used to indicate the size or magnitude of something that was determined by comparison to a standard of a body region referring to an upper or lower extremity.","longName":"Pati_Limb_Asse_ASSESS_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF5D6BF-FB02-E29D-E040-BB89AD431679","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438572","version":"1","preferredName":"Patient Negation Extremity Measurement Assessment Reason","preferredDefinition":"The reason a patient assessment was not performed to indicate the size or magnitude of something that was determined by comparison to a standard of a body region referring to an upper or lower extremity.","longName":"Pati_Nega_Limb_Meas_Asse_Asse_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3C93-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438582","version":"1","preferredName":"Patient Measurement Perform Name","preferredDefinition":"The name a person is known by who performed a measurement.","longName":"Pati_Meas_Perf_Iden_INDS_NAME","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3CCE-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438588","version":"1","preferredName":"Patient Extremity Measurement Occurrence Begin Time","preferredDefinition":"The time an annotation used to indicate the size or magnitude of a patient's upper or lower extremity that was determined by comparison to a standard began.","longName":"Pati_Limb_Meas_Occu_BEG_TM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3D61-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438589","version":"1","preferredName":"Patient Extremity Measurement Occurrence End Time","preferredDefinition":"The time an annotation used to indicate the size or magnitude of a patient's upper or lower extremity that was determined by comparison to a standard ended.","longName":"Pati_Limb_Meas_Occu_END_TM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3D71-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438664","version":"1","preferredName":"Patient Stay Out of Bed Assessment Hour Duration","preferredDefinition":"Having determined the period of time, in hours, of a patient's ability to maintain the energy required to be out of bed.","longName":"Pati_Stay_Asse_Hour_Dura","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFB7D0D-DDC2-DB14-E040-BB89AD436EB0","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438680","version":"1","preferredName":"Medical Device Measurement Use Ind-3","preferredDefinition":"The yes/no indicator related to any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions put into action or service to determine by measurement.","longName":"Medi_Meas_Use_ASSESS_IND-3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFB09E5-9F23-66B5-E040-BB89AD4365C0","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Assessment Ind-3 (2018441v1) with VD Yes No Unknown Indicator (3506034v1) - dbw Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438690","version":"1","preferredName":"Patient Leg Length Measurement","preferredDefinition":"Measurement of the length, the linear extent in space from one end to the other, of one of the two lower extremities in humans used for locomotion and support.","longName":"Pati_Leg_Leng_C25337:3116463v1","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFB7D0D-DE74-DB14-E040-BB89AD436EB0","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438723","version":"1","preferredName":"Left Lower Extremity Metatarsophalangeal Joint Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of a left spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe.","longName":"Left_Lowe_Meta_Circ_Quan_Firs_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFC1AC0-692F-AE3E-E040-BB89AD43445B","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438724","version":"1","preferredName":"Left Lower Extremity Metatarsophalangeal Joint Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of a left spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe.","longName":"Left_Lowe_Meta_Circ_Quan_Seco_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFC1AC0-693F-AE3E-E040-BB89AD43445B","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3438729","version":"1","preferredName":"Left Lower Extremity Integer Ten Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of a person who receives medical attention, care, or treatment's left leg 10 centimeters from heel.","longName":"Left_Lowe_Inte_Ten_Cent_Circ_Q","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDFC1AC0-697D-AE3E-E040-BB89AD43445B","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440152","version":"1","preferredName":"Left Lower Extremity Integer Ten Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 10 centimeters from the heel.","longName":"Lt_Low_Int_10_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0FB753-E2B3-337F-E040-BB89AD4319B9","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440153","version":"1","preferredName":"Left Lower Extremity Integer::20 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 20 centimeters from the heel.","longName":"Lt_Low_Int_20_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-4733-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440155","version":"1","preferredName":"Left Lower Extremity Integer::20 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 20 centimeters from the heel.","longName":"Left_Lowe_Inte_20_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-475E-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440156","version":"1","preferredName":"Left Lower Extremity Integer::30 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 30 centimeters from the heel.","longName":"Left_Lowe_Inte_30_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-476E-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440157","version":"1","preferredName":"Left Lower Extremity Integer::30 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 30 centimeters from the heel.","longName":"Lt_Low_Int_30_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-477E-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440158","version":"1","preferredName":"Left Lower Extremity Integer::40 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 40 centimeters from the heel.","longName":"Left_Lowe_Inte_40_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-478E-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440159","version":"1","preferredName":"Left Lower Extremity Integer::40 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 40 centimeters from the heel.","longName":"Lt_Low_Int_40_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-479E-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440160","version":"1","preferredName":"Left Lower Extremity Integer::50 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 50 centimeters from the heel.","longName":"Left_Lowe_Inte_50_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-47AE-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440161","version":"1","preferredName":"Left Lower Extremity Integer::50 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the left limb that is composed of the hip, thigh, leg and foot 50 centimeters from the heel.","longName":"Lt_Low_Int_50_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE104663-47BE-FAF9-E040-BB89AD43685E","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-19","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440230","version":"1","preferredName":"Lower Extremity Distance Value","preferredDefinition":"A numerical quantity measured or assigned or computed of the length of the space between two objects or points on the limb that is composed of the hip, thigh, leg and foot.","longName":"Lowe_Dist_Pati_Leg_Leng_Valu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9C05-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440233","version":"1","preferredName":"Left Lower Extremity Specified Centimeter Distance First Measurement","preferredDefinition":"First measurement of a clearly and explicitly stated space measured in centimeters between two objects or points on the left limb that is composed of the hip, thigh, leg and foot.","longName":"Left_Lowe_Spec_Cent_Dist_Firs_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D46EA-0314-40E5-E040-BB89AD431652","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440234","version":"1","preferredName":"Left Lower Extremity Specified Centimeter Distance Second Measurement","preferredDefinition":"Second measurement of a clearly and explicitly stated space measured in centimeters between two objects or points on the left limb that is composed of the hip, thigh, leg and foot.","longName":"Left_Lowe_Spec_Cent_Dist_Seco_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D46EA-0383-40E5-E040-BB89AD431652","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440237","version":"1","preferredName":"Left Lower Extremity Total Volume First Volume Value","preferredDefinition":"First measurement of the complete amount of three dimensional space occupied by the left limb that is composed of the hip, thigh, leg and foot.","longName":"Left_Lowe_Tota_Volu_Firs_Volu_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9C45-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440239","version":"1","preferredName":"Left Lower Extremity Total Volume Second Volume Value","preferredDefinition":"Second measurement of the complete amount of three dimensional space occupied by the left limb that is composed of the hip, thigh, leg and foot.","longName":"Left_Lowe_Tota_Volu_Seco_Volu_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9C55-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440245","version":"1","preferredName":"Right Lower Extremity Metatarsophalangeal Joint Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of a right spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe.","longName":"Righ_Lowe_Meta_Circ_Quan_Firs_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9C94-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440246","version":"1","preferredName":"Right Lower Extremity Metatarsophalangeal Joint Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of a right spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe.","longName":"Righ_Lowe_Meta_Circ_Quan_Seco_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9CA4-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440292","version":"1","preferredName":"Right Lower Extremity Integer Ten Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 10 centimeters from the heel.","longName":"Righ_Lowe_Inte_10_Cent_Circ_Q_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9D5A-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440298","version":"1","preferredName":"Right Lower Extremity Integer Ten Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 10 centimeters from the heel.","longName":"Rt_Low_Int_10_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-6808-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440300","version":"1","preferredName":"Right Lower Extremity Integer::20 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 20 centimeters from the heel.","longName":"Righ_Lowe_Inte_20_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9EAB-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440302","version":"1","preferredName":"Right Lower Extremity Integer::20 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 20 centimeters from the heel.","longName":"Rt_Low_Int_20_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9ED7-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440303","version":"1","preferredName":"Right Lower Extremity Integer::30 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 30 centimeters from the heel.","longName":"Righ_Lowe_Inte_30_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-6833-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440304","version":"1","preferredName":"Right Lower Extremity Integer::30 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 30 centimeters from the heel.","longName":"Rt_Low_Int_30_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9EE8-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440307","version":"1","preferredName":"Right Lower Extremity Integer::40 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 40 centimeters from the heel.","longName":"Righ_Lowe_Inte_40_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9F79-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440316","version":"1","preferredName":"Right Lower Extremity Integer::40 Centimeter Circumference Quantity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 40 centimeters from the heel.","longName":"Rt_Low_Int_40_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-698C-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440317","version":"1","preferredName":"Right Lower Extremity Integer::50 Centimeter Circumference Quantity First Measurement","preferredDefinition":"First measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 50 centimeters from the heel.","longName":"Righ_Lowe_Inte_50_Cent_Circ_Qu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-699D-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440318","version":"1","preferredName":"Right Lower Extremity Integer::50 Centimeter Circumference Quantity Lower Extremity Second Measurement","preferredDefinition":"Second measurement of the total circumference of  the right limb that is composed of the hip, thigh, leg and foot 50 centimeters from the heel.","longName":"Rt_Low_Int_50_Cent_Circ_2nd_Me","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-69BA-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440325","version":"1","preferredName":"Right Lower Extremity Specified Centimeter Distance First Measurement","preferredDefinition":"First measurement of a clearly and explicitly stated space measured in centimeters between two objects or points on the right limb that is composed of the hip, thigh, leg and foot.","longName":"Righ_Lowe_Spec_Cent_Dist_Firs_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-69CB-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440326","version":"1","preferredName":"Right Lower Extremity Specified Centimeter Distance Second Measurement","preferredDefinition":"Second measurement of a clearly and explicitly stated space measured in centimeters between two objects or points on the right limb that is composed of the hip, thigh, leg and foot.","longName":"Righ_Lowe_Spec_Cent_Dist_Seco_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-69DC-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440327","version":"1","preferredName":"Right Lower Extremity Total Volume First Volume Value","preferredDefinition":"First measurement of the complete amount of three dimensional space occupied by the right limb that is composed of the hip, thigh, leg and foot.","longName":"Righ_Lowe_Tota_Volu_Firs_Volu_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-9F9A-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440329","version":"1","preferredName":"Right Lower Extremity Total Volume Second Volume Value","preferredDefinition":"Second measurement of the complete amount of three dimensional space occupied by the right limb that is composed of the hip, thigh, leg and foot.","longName":"Righ_Lowe_Tota_Volu_Seco_Volu_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1E2E88-69ED-177F-E040-BB89AD431745","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440363","version":"1","preferredName":"Diagnostic Imaging Abdominal Pelvic Ultrasound Imaging Performed Outcome","preferredDefinition":"The result of and ultrasound performed on the structure of the vertebrate skeleton supporting the lower limbs in humans.","longName":"2321520v1.0:2842597v1.0_Pelv_U","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1F71DD-4C8C-D710-E040-BB89AD4326BB","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440409","version":"1","preferredName":"Diagnostic Imaging Abdominal Pelvic Ultrasound Imaging Performed Specify","preferredDefinition":"information related to a diagnostic evaluation that uses sound waves (called ultrasound) to produce a visual images of organs or tissues of the abdomen, the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs, or the pelvis, the lower part of the abdomen located between the hip bones.","longName":"2321520v1.0:2842597v1.0_DX_SPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE1D8FA6-A15F-642A-E040-BB89AD435F64","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440638","version":"1","preferredName":"Patient Negation Extremity Measurement Assessment Other Specify","preferredDefinition":"The free text field related to the other specify non-affirmative response to having determined the value, significance, or extent of an annotation used to indicate the size or magnitude of something that was determined by comparison to a standard of a body region on a patient referring to an upper or lower extremity.","longName":"Pati_Nega_Limb_Meas_Asse_Othe_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE22C5E7-BB03-F3AA-E040-BB89AD434684","latestVersionIndicator":"Yes","beginDate":"2012-04-20","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-04-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440922","version":"1","preferredName":"Gynecologic Malignant Neoplasm Myometrial Invasion Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues within the invasion within the myometrium.","longName":"GYN_MALNEO_MYMTR_INV_Gyne_Mali","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE59AD03-5CE2-3F1A-E040-BB89AD43309B","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-10-24","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3440923","version":"1","preferredName":"Gynecologic Malignant Neoplasm Myometrial Invasion Percentage Value","preferredDefinition":"the numerical quantity measured or assigned or computed as a fraction or ratio with 100 understood as the denominator related to the spread of atypical neoplastic cells (or tumor) into the muscular tissue of the uterus or other female reproductive organ","longName":"GYN_MALNEO_MYMTR_INV_PCT_VAL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5A8104-6812-F04E-E040-BB89AD435B43","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-10-24","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3441685","version":"1","preferredName":"Uterus Malignant Neoplasm Length Measurement","preferredDefinition":"Measurement of the length of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Mali_Leng_Quan_TUMOR_DIM_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5B2C68-3939-1CA9-E040-BB89AD432940","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-23","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3441689","version":"1","preferredName":"Uterus Malignant Neoplasm Width Measurement","preferredDefinition":"Measurement of the width of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Mali_Widt_Quan_TUMOR_DIM_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5B478A-043A-099F-E040-BB89AD430EC5","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-23","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3441693","version":"1","preferredName":"Uterus Malignant Neoplasm Height Measurement","preferredDefinition":"Measurement of the height of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Mali_Heig_Quan_TUMOR_DIM_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5B478A-047E-099F-E040-BB89AD430EC5","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-23","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3443145","version":"1","preferredName":"Hepatocellular Carcinoma Liver Volume  Percentage Value","preferredDefinition":"the numerical quantity measured of volume of malignant tumor that arises from hepatocytes represented as a ratio with 100 understood as the denominator and representing the total liver volume.","longName":"3443075v1.0:3443141v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE97079E-D1A2-DF2F-E040-BB89AD432FD4","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-04-26","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3443294","version":"1","preferredName":"Hepatocellular Carcinoma Vascular Involvement Anatomic Site","preferredDefinition":"The association of large vessels in the hepatic vasculature  with presence of a tumor or malignant cell growth.","longName":"3443227v1.0:3443291v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE97BA11-830C-0B53-E040-BB89AD432198","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-04-26","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3443472","version":"1","preferredName":"Radiation Therapy Modality Administered Type","preferredDefinition":"the type related to the specific manner, characteristic, pattern of application or the employment of, radiation therapy (treatment of a disease by means of exposure of the target or the whole body to radiation) being given.","longName":"3443467v1.0:3443468v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE996456-9B61-833F-E040-BB89AD430A65","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-04-26","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3443571","version":"1","preferredName":"Address Region Type","preferredDefinition":"The  land surface of part of the world  designed according to some biological,administrative, economic demographic,etc. criteria as they relate to address and /or geographic location/region.","longName":"2405240v1.0:3443488v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE99A381-00ED-95F3-E040-BB89AD432C7B","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-04-26","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447785","version":"1","preferredName":"Hepatocellular Carcinoma Barcelona Criteria Description Category","preferredDefinition":"barcelona criteria staging of hepatocellular carcinoma","longName":"3447766v1.0:3447784v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF11D9C2-0E31-4F2F-E040-BB89AD436229","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"COOPERM","dateModified":"2017-12-13","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447844","version":"1","preferredName":"Sorafenib Agent Prior Use Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there was proir use of sorafenib","longName":"3447804v1.0:2018279v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C1C9-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"BERGANTW","dateModified":"2017-09-20","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447855","version":"1","preferredName":"Hepatocellular Carcinoma Large Size Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there is hepatocellular carcinoma is greater than 15cm.","longName":"3447851v1.0:2404918v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF13063E-DD31-363D-E040-BB89AD43716E","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447860","version":"1","preferredName":"Hepatocellular Carcinoma Stomach Lower Gastrointestinal Tract Bile Duct Involvement Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there is direct tumor extension into the stomach duodenum small bowel or large bowel","longName":"3447858v1.0:2180012v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C2E6-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Involvement Extent Disease Ind-2 - 2180012v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447865","version":"1","preferredName":"Hepatocellular Carcinoma Measurable Bile Duct Involvement Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there is measurable common or main branch biliary duct involvement with HCC","longName":"3447863v1.0:2180012v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C357-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Involvement Extent Disease Ind-2 - 2180012v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447869","version":"1","preferredName":"Hepatocellular Carcinoma Pathologic  Diagnosis Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there is pathologic diagnosis of hepatocellular carcinoma","longName":"3447867v1.0:2404918v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C3B4-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"BERGANTW","dateModified":"2017-02-01","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447875","version":"1","preferredName":"Patient Hepatocellular Carcinoma Vascular Thrombosis Clinical Trial Eligibility Criteria  Ind-2","preferredDefinition":"The Yes/No indicator that asks whether there is vascular thrombosis on imaging for eligibility purposes","longName":"3447872v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C427-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"BERGANTW","dateModified":"2017-02-01","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3447881","version":"1","preferredName":"Histamine-2 Receptor Antagonist Administered Ind-2","preferredDefinition":"The Yes/No indicator that asks whether the patient received histamine-2 receptor antagonist therapy","longName":"3447879v1.0:2018279v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF12D653-C491-0043-E040-BB89AD43315C","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-02","modifiedBy":"SARMIENTOL","dateModified":"2016-02-24","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448101","version":"1","preferredName":"Neoplasm Thrombosis Present Status","preferredDefinition":"the current asssessment of disease status information relating to current examination of the body by auscultation, palpation, percussion, inspection, and olfaction to assess for  thrombosis of the  primary tumor.","longName":"3447885v1.0:2226944v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF228FC9-2A56-E31F-E040-BB89AD4319C7","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448111","version":"1","preferredName":"Patient Hepatocellular Carcinoma Diagnostic Imaging Technique Vascular Thrombosis Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator that asks whether the patient has at least 1 solid liver lesion >1cm on CT or MRI in the setting of cirrhosis or chronic hepatitis B or C  without cirrhosis for eligibility purposes.","longName":"3448107v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF228FC9-2AC8-E31F-E040-BB89AD4319C7","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448116","version":"1","preferredName":"Patient Refractory Inappropriate Transarterial Chemoembolization Drug-eluting Embolic Bead Clinical Trial Eligibility Criteria  Ind-2","preferredDefinition":"The Yes/No indicator that asks whetherthe patient is unsuitable ;for refractory chemoembolization or  drug eluding beads","longName":"3448114v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF228FC9-2B3C-E31F-E040-BB89AD4319C7","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-03","modifiedBy":"BERGANTW","dateModified":"2014-09-08","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448125","version":"1","preferredName":"Uterus Artery Pulsatility Index Assessment Type","preferredDefinition":"Information regarding a diagnostic indicator of vascular resistance that is calculated by dividing the difference between the peak systolic and minimum diastolic blood velocities by the mean velocity in the vessels carrying blood away from the heart within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Arte_Puls_Asse_Uter_Puls_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF228FC9-2C18-E31F-E040-BB89AD4319C7","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448130","version":"1","preferredName":"Uterus Artery Pulsatility Index Assessment Left Measurement","preferredDefinition":"Annotation used to indicate the size or magnitude of a diagnostic indicator of vascular resistance that is calculated by dividing the difference between the peak systolic and minimum diastolic blood velocities by the mean velocity within the left side of a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Arte_Puls_Asse_Left_Meas_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF244C7A-7BE6-3456-E040-BB89AD4365A2","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3448142","version":"1","preferredName":"Uterus Artery Pulsatility Index Assessment Right Measurement","preferredDefinition":"Annotation used to indicate the size or magnitude  of a diagnostic indicator of vascular resistance that is calculated by dividing the difference between the peak systolic and minimum diastolic blood velocities by the mean velocity on the right side within a hollow, thick-walled, muscular organ located within the pelvic cavity of a woman.","longName":"Uter_Arte_Puls_Asse_Righ_Meas","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF228FC9-2E94-E31F-E040-BB89AD4319C7","latestVersionIndicator":"Yes","beginDate":"2012-05-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3449383","version":"1","preferredName":"Patient Inappropriate Excision Transplant Radiofrequency Ablation Clinical Trial Eligibility Criteria  Ind-2","preferredDefinition":"The Yes/No indicator that asks whetherthe patient is unsuitable for excision or transplant or RFA for eligibility purposes","longName":"3449362v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF363F47-FB60-6CE3-E040-BB89AD435BFF","latestVersionIndicator":"Yes","beginDate":"2012-05-04","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3451587","version":"1","preferredName":"Protocol Agent Dose Modification Scale","preferredDefinition":"the scale related to the dose modification of a protocol agent.","longName":"2192837v1.0:3451583v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF3BDBD6-87E7-C447-E040-BB89AD436994","latestVersionIndicator":"Yes","beginDate":"2012-05-04","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460765","version":"1","preferredName":"Laboratory Procedure Magnesium Result Date","preferredDefinition":"information related to the date on which the result of the medical procedure that involves testing a sample of blood for magnesium occurred.","longName":"LAB_MAGNESIUM_RSLT_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-9497-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460766","version":"1","preferredName":"Laboratory Procedure Phosphate Measurement Result Date","preferredDefinition":"information related to the date on which the result of a medical procedure that involves testing a sample of blood for a quantitative measurement of the amount of phosphate present in a sample occurred.","longName":"LAB_PHOSPH_RSLT_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-94B6-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460767","version":"1","preferredName":"Laboratory Procedure Sodium Electrolytes Outcome Date","preferredDefinition":"information related to the date on which the medical procedure that involves testing a sample of blood for sodium electrolytes, a mineral needed by the body to keep body fluids in balance occurred.","longName":"LAB_NA_ELEC_OC_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-94D5-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460768","version":"1","preferredName":"Laboratory Procedure Potassium Electrolytes Outcome Date","preferredDefinition":"information related to the date on which the medical procedure that involves testing a sample of blood for potassium electrolytes, substances that break up into ions (electrically charged particles) when they are dissolved in body fluids and are primarily responsible for the movement of nutrients into cells and the movement of wastes out of cells occurred.","longName":"LAB_K_ELE_OC_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-94F4-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460769","version":"1","preferredName":"Laboratory Procedure Chloride Ion Electrolytes Outcome Date","preferredDefinition":"information related to the date on which the medical procedure that involves testing a sample of blood for chloride electrolytes, an anion that forms the negatively charged part of certain salts, including sodium and hydrogen chloride salts, and is an essential electrolyte located in all body fluids responsible for maintaining acid/base balance occurred.","longName":"LAB_CL_ELEC_OC_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-9513-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2013-08-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3460772","version":"1","preferredName":"Laboratory Procedure Carbon Dioxide Measurement Outcome Value","preferredDefinition":"information related to measurement of the medical procedure that involves a measurement of the carbon dioxide gas in a biological specimen.","longName":"LAB_CO2_OC_Carb_Valu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC97399-9559-8CB9-E040-BB89AD4352B8","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-11","modifiedBy":"HARTLEYG","dateModified":"2016-04-06","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461705","version":"1","preferredName":"Sentinel Lymph Node Post Neoadjuvant Therapy Involved Ind-2","preferredDefinition":"the yes/no indicator whether there was evaluation or systematic appraisal of the first lymph node(s) that the cancer may spread, located in the armpit that drains the lymphatic vessels that originate from the breast tissue following neoadjuvant chemotherapy treatment.","longName":"3461700v1.0:2180012v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03C496A-BD11-0EBD-E040-BB89AD431ABD","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-05-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Replaced VD Involvement Extent Disease Ind-2 - 2180012v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3462186","version":"1","preferredName":"Patient Diagnostic Imaging Confirmed Measurable Hepatic Disease or Disorder Neoplasm Vascular Thrombosis Present Clinical Trial Criteria Eligibility Ind-2","preferredDefinition":"the yes/no indicator related to the patient's eligibility to participate in the clinical trial related to the presence of measurable hepatic disease and or presence of tumor vascular thrombosis on diagnostic imaging for eligiblity purposes.","longName":"3462179v1.0:2018257v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A39B6B-2FD7-019D-E040-BB89AD432D3D","latestVersionIndicator":"Yes","beginDate":"2012-05-22","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-05-22","modifiedBy":"BERGANTW","dateModified":"2017-07-03","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3462280","version":"1","preferredName":"Pathology Deidentified Report Receive Ind-3","preferredDefinition":"the yes/no/unknown indicator related to information regarding receiving of a short textual account regarding all aspects of a disease, with special reference to the essential nature, causes, and development of abnormal conditions which has had identification removed.","longName":"Path_Not _Repo_Rece_ASSESS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0B56B41-D9A4-0B7D-E040-BB89AD4306C9","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-05-23","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Replaced VD Assessment Ind-3 (2018441v1) with VD Yes No Unknown Indicator (3506034v1) - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3474361","version":"1","preferredName":"Neoplasm Thrombosis Event Status","preferredDefinition":"A condition or state at a particular time for the event in the tumor for the formation of a blood clot in the lumen of a vessel.","longName":"3474321v1.0:3474347v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1AA0200-9CF9-95F4-E040-BB89AD432C3D","latestVersionIndicator":"Yes","beginDate":"2012-06-04","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-06-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475231","version":"1","preferredName":"Clinical Study Chemotherapy Stratification Type","preferredDefinition":"something distinguishable as an identifiable class based on chemotherapy as part of the randomization process or for purposes of data analysis in a clinical trial.","longName":"3475228v1.0:3475229v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D21108-1FEC-7C6A-E040-BB89AD43585A","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"BONANNIR","dateCreated":"2012-06-06","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475235","version":"1","preferredName":"External Beam Radiation Therapy Administered Total Dose","preferredDefinition":"The total radiation therapy dose the patient is anticipated to receive","longName":"2199642v1.0:3475232v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D21108-2067-7C6A-E040-BB89AD43585A","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"BONANNIR","dateCreated":"2012-06-06","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3506582","version":"1","preferredName":"Agent Cytokine Other Administered Yes No Indicator","preferredDefinition":"indicator of yes/no to the administration of a cytokine, a unique family of growth factors secreted primarily from leukocytes stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells different than the one(s) previously specified or mentioned.","longName":"Agen_Cyto_Othe_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C38D9A75-CBF7-E89D-E040-BB89AD43703F","latestVersionIndicator":"Yes","beginDate":"2012-06-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-06-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3506620","version":"1","preferredName":"Agent Cytokine Colony Stimulating Factor 3 Administered Yes No Indicator","preferredDefinition":"indicator of yes/no to the administration of a cytokine, a unique family of growth factors secreted primarily from leukocytes stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells that controls the production, differentiation, and function of granulocytes.","longName":"Agen_Cyto_Colo_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C38ECB13-FAF3-B0EE-E040-BB89AD437A46","latestVersionIndicator":"Yes","beginDate":"2012-06-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-06-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3506624","version":"1","preferredName":"Agent Cytokine Thrombopoietin Administered Yes No Indicator","preferredDefinition":"indicator of yes/no to the administration of a cytokine, a unique family of growth factors secreted primarily from leukocytes stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells that stimulates the production of blood cells, especially platelets, during chemotherapy.","longName":"Agen_Cyto_Thro_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C38EE073-E643-F74D-E040-BB89AD433844","latestVersionIndicator":"Yes","beginDate":"2012-06-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-06-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3506677","version":"1","preferredName":"Agent Cytokine Erythropoietin Administered Yes No Indicator","preferredDefinition":"indicator of yes/no to the administration of a cytokine, a unique family of growth factors secreted primarily from leukocytes stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells. the humoral and cellular immune responses, as well as the activation of phagocytic cells secreted chiefly by the kidney in the adult and the liver in the fetus, that acts on erythroid stem cells of the bone marrow to stimulate proliferation and differentiation.","longName":"Agen_Cyto_Eryt_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C38ECB13-FB5E-B0EE-E040-BB89AD437A46","latestVersionIndicator":"Yes","beginDate":"2012-06-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-06-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3526801","version":"1","preferredName":"Immunotherapy Medication Administration Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator related to the administration of immunotherapy or immunosuppressants.","longName":"3526800v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4BAA2E3-6BB1-A55D-E040-BB89AD435740","latestVersionIndicator":"Yes","beginDate":"2012-07-13","endDate":null,"createdBy":"PATELV","dateCreated":"2012-07-13","modifiedBy":"TYRRELLM","dateModified":"2024-01-04","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":"01.04.2024 Added AQT and Alt Short Name per request ticket CADSR0003248_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3526805","version":"1","preferredName":"Adverse Event Ipilimumab Immune System Attribution Yes No Unknown Indicator","preferredDefinition":"Yes/no/unknown indicator of an adverse event triggered by the study drug Ipilimumab resulting in an  immune-mediated response.","longName":"3526804v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4BAA2E3-6C5B-A55D-E040-BB89AD435740","latestVersionIndicator":"Yes","beginDate":"2012-07-13","endDate":null,"createdBy":"PATELV","dateCreated":"2012-07-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3526808","version":"1","preferredName":"Personal Medical History Physical Examination Performed Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator whether a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual's health assessment and a record of a patient's background regarding health and the occurrence of disease events of the individual, was performed.","longName":"2013854v3.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4BAECDB-D4A4-0048-E040-BB89AD430EC3","latestVersionIndicator":"Yes","beginDate":"2012-07-13","endDate":null,"createdBy":"PATELV","dateCreated":"2012-07-13","modifiedBy":"BOWSERC","dateModified":"2021-11-18","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3533965","version":"1","preferredName":"Disease or Disorder Motor Neuropathy Personal Medical History Yes No Unknown Indicator","preferredDefinition":"Yes/no/unknown indicator of a history of a disorder characterized by inflammation or degeneration of the peripheral motor nerves.","longName":"MOTOR_NEURO_DZ_IND3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5331E71-AD44-9751-E040-BB89AD4348C2","latestVersionIndicator":"Yes","beginDate":"2012-07-19","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-07-19","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534024","version":"1","preferredName":"Disease or Disorder Toxic Epidermal Necrolysis Personal Medical History Yes No Unknown Indicator","preferredDefinition":"Yes/no/unknown indicator of a history of a systemic, serious, life-threatening disorder characterized by erythemous and necrotic lesions in the skin and mucous membranes.","longName":"TOX_EPID_NECR_DZ_IND3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C535AF2F-7C24-1195-E040-BB89AD436A83","latestVersionIndicator":"Yes","beginDate":"2012-07-19","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-07-19","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534066","version":"1","preferredName":"Relevant Laboratory Test Yes No Unknown Indicator","preferredDefinition":"Yes/no/unknown indicator of the relevant laboratory test","longName":"REL_LAB_TEST_IND3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5448560-1699-37FF-E040-BB89AD430A03","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-07-20","modifiedBy":"MORENOC","dateModified":"2017-02-14","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534146","version":"1","preferredName":"Received Therapy Protocol Contraindicated Yes No Unknown Not Applicable Indicator","preferredDefinition":"information related to treatment contraindicated by the protocol received.","longName":"REC_TX_PROT_CON_YES_NO_UNKNOWN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C547805B-3E98-397F-E040-BB89AD436473","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-07-20","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534201","version":"1","preferredName":"Metastasis Below Tentorium Cerebelli Present Yes No Unknown Indicator","preferredDefinition":"Yes/no/unknown indicator of presence of cancer that has spread from the organ in which it first appeared to below the tentorium or beyond the cranial vault.","longName":"METS_BLW_TENT_CEREB_PRES_IND3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C54946D1-6AD7-EA30-E040-BB89AD4371C5","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-07-20","modifiedBy":"RODGERSC","dateModified":"2018-09-21","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534520","version":"1","preferredName":"Woman Pre Term Pregnancy Occurrence Count","preferredDefinition":"the number of times for which a female participant conceived and became pregnant, but did not carry fetus to full term due to natural occurrences or problems during the pregnancy.","longName":"Woma_Prio_Term_Preg_Occu_PREG_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C594BB71-23CC-9E1A-E040-BB89AD4378CB","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534524","version":"1","preferredName":"Person Infertility Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator of the history of a woman's inability to produce children.","longName":"Pers_Infe_Pers_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C594FB61-FE0B-8A0E-E040-BB89AD4354A5","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534525","version":"1","preferredName":"Person Infertility Personal Medical History Individuals Text","preferredDefinition":"Text to describe the diagnosis woman's inability to produce children.","longName":"Pers_Infe_Pers_INDS_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C594FB61-FE2B-8A0E-E040-BB89AD4354A5","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534719","version":"1","preferredName":"Patient Current Duration Pregnancy Week Count","preferredDefinition":"Time in weeks with regard to a patient's current or previous pregnancy.","longName":"Pati_Curr_Dura_Preg_Week_Coun","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2DE3-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534720","version":"1","preferredName":"Patient Planned Attempt Pregnancy Yes No Indicator","preferredDefinition":"The yes/no indicator relating to a patient's planned attempt to become pregnant.","longName":"Pati_Plan_Atte_Preg_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C59818CB-2E03-BB74-E040-BB89AD435111","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"TIFFANIS","dateModified":"2019-10-14","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534721","version":"1","preferredName":"Patient Active Attempt Pregnancy Yes No Indicator","preferredDefinition":"The yes/no indicator relating to the patient actively attempting to become pregnant.","longName":"Pati_Acti_Atte_Preg_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-8923-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534722","version":"1","preferredName":"Patient Active Attempt Pregnancy Begin Date","preferredDefinition":"Date the patient began actively attempting to become pregnant.","longName":"Pati_Acti_Atte_Preg_BEG_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-8943-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534723","version":"1","preferredName":"Patient Stop Attempt Pregnancy Yes No Indicator","preferredDefinition":"The yes/no indicator relating to the patient's stopped attempt at becoming pregnant.","longName":"Pati_Stop_Atte_Preg_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-8963-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534728","version":"1","preferredName":"Patient Stop Attempt Pregnancy End Date","preferredDefinition":"Date of the patient's stopped attempt at becoming pregnant.","longName":"Pati_Stop_Atte_Preg_END_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-89B0-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534729","version":"1","preferredName":"Patient Successful Pregnancy Yes No Indicator","preferredDefinition":"The yes/no indicator relating to the patient's successful pregnancy.","longName":"Pati_Succ_Preg_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-89D3-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534735","version":"1","preferredName":"Person Spontaneous Abortion Pregnancy Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator related to the spontaneous expulsion of the products of conception before the completion of gestation without deliberate interference as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"Pers_Spon_Preg_Outc_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-8A35-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"ZHANGWE","dateModified":"2014-10-16","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534736","version":"1","preferredName":"Person Spontaneous Abortion Pregnancy Outcome Week Count","preferredDefinition":"Time in weeks with regard to the spontaneous expulsion of the products of conception before the completion of gestation without deliberate interference as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"Pers_Spon_Preg_Outc_Week_Coun","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C598C4FE-8A5A-9E89-E040-BB89AD433D30","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534738","version":"1","preferredName":"Person Preterm Birth Pregnancy Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator related to the pre-term birth, delivery prior to 37 weeks of gestation, as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"Pers_Pret_Preg_Outc_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E0F4-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534740","version":"1","preferredName":"Person Preterm Birth Pregnancy Outcome Week Count","preferredDefinition":"Time in weeks with regard to the pre-term birth, delivery prior to 37 weeks of gestation, as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"3534682v1.0:3534601v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E13A-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"ZHANGWE","dateModified":"2021-02-09","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534741","version":"1","preferredName":"Patient Birth Method of Delivery Pregnancy Type","preferredDefinition":"Type of the method by which a fetus is delivered","longName":"2233604v1.0:3534689v1.0_Birt_M","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E15A-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534742","version":"1","preferredName":"Patient Pregnancy Complication Yes No Indicator","preferredDefinition":"The yes/no indicator relating to a pregnancy complication (the co-occurrence of pregnancy and a medical problem that occurs during a disease or disorder).","longName":"Pati_Preg_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E17A-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534743","version":"1","preferredName":"Patient Pregnancy Complication Specify","preferredDefinition":"Description of a pregnancy complication (the co-occurrence of pregnancy and a medical problem that occurs during a disease or disorder).","longName":"Pati_Preg_ASSESS_SPEC","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E19A-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534752","version":"1","preferredName":"Person Full Term Birth Pregnancy Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator related to the full-term birth, gestation greater than 37 weeks, as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"Pers_Full_Preg_Outc_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E23D-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534753","version":"1","preferredName":"Person Full Term Birth Pregnancy Outcome Week Count","preferredDefinition":"Time in weeks with regard to the full-term birth, gestation greater than 37 weeks, as an outcome of pregnancy, a condition of having a developing embryo or fetus in human female.","longName":"Pers_Full_Preg_Outc_Week_Coun","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E25D-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534754","version":"1","preferredName":"Pregnancy Surgical Procedure Performed Yes No Indicator","preferredDefinition":"The yes/no indicator regarding a surgical procedure that involves stitching shut the cervix, done preventively at 12 to 14 weeks of pregnancy before the cervix thins out, or as an emergency measure after the cervix has thinned, used to prevent miscarriage.","longName":"Preg_Surg_Cerv_Perf_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5991AF8-E27D-33A0-E040-BB89AD4376A8","latestVersionIndicator":"Yes","beginDate":"2012-07-24","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-07-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3536720","version":"1","preferredName":"Inappropriate Antidiuretic Hormone Secretion Syndrome Personal Medical History Yes No Indicator","preferredDefinition":"indication of yes/no regarding an account of the medical events and problems related to a syndrome characterized by abnormal secretion of antidiuretic hormone in conjunction with neoplastic growth occurring anywhere in the body._The preferred Value Domain to","longName":"Inap_Dise_Pers_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C621C38D-947F-A527-E040-BB89AD43329A","latestVersionIndicator":"Yes","beginDate":"2012-07-31","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-07-31","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564190","version":"2","preferredName":"Trail Making Test Assessment First Part Last Number Complete Value","preferredDefinition":"The last number completed by the patient on the neurocognitive evaluation Trail Making Test.","longName":"TMT_ASMT_LAST_NUMBER","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"429B9B5A-8A90-2509-E053-F662850A2C24","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"PATELV","dateCreated":"2016-12-01","modifiedBy":"PATELV","dateModified":"2016-12-01","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014 Data Element Concept updated for harmonization Dec 1 2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564210","version":"2","preferredName":"Trail Making Test Assessment Second Part Last Character Complete Value","preferredDefinition":"The last number or letter completed by the patient on the neurocognitive evaluation Trail Making Test.","longName":"TMT_ASMT_LAST_CHARACTER","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"429B9B5A-8B0A-2509-E053-F662850A2C24","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"PATELV","dateCreated":"2016-12-01","modifiedBy":"PATELV","dateModified":"2016-12-01","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014 Data Element Concept updated for harmonization Dec 1 2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3565320","version":"1","preferredName":"Treatment Delayed Cycle Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to a delayed cycle of treatment.","longName":"TX_DELAYED_CYCLE_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C806CADA-17E5-4914-E040-BB89AD4341A4","latestVersionIndicator":"Yes","beginDate":"2012-08-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-08-24","modifiedBy":"STARGELM","dateModified":"2020-09-11","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3566839","version":"1","preferredName":"Hopkins Verbal Learning Test-Revised Delay Recognition Test Upper Case Letter Total Score","preferredDefinition":"The sum of all responses to the upper case letter delayed recognition test of the Hopkins Verbal Learning Test-Revised.","longName":"HVLT-R_DLY_RECOG_UPPR_CS_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C843E8D0-D98C-1179-E040-BB89AD434C40","latestVersionIndicator":"Yes","beginDate":"2012-08-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-08-27","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3566853","version":"1","preferredName":"Hopkins Verbal Learning Test-Revised Delay Recognition Test Lower Case Letter Total Score","preferredDefinition":"The sum of all responses to the lower case letter delayed recognition test of the Hopkins Verbal Learning Test-Revised.","longName":"HVLT-R_DLY_RECOG_LWR_CS_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C84543EE-6605-D4B0-E040-BB89AD4312F5","latestVersionIndicator":"Yes","beginDate":"2012-08-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-08-27","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3566891","version":"1","preferredName":"Woman Full Term Pregnancy Occurrence Count","preferredDefinition":"User entered numerical value to describe the number of full-term pregnancies that a woman has experienced","longName":"WOMA_FULL_TERM_PREG_OCCU_COUNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C84543EE-6625-D4B0-E040-BB89AD4312F5","latestVersionIndicator":"Yes","beginDate":"2012-08-27","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-08-27","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":"Curated to support GOG-0278 PREG_HIST Form Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3567405","version":"1","preferredName":"Diagnostic Imaging Organ Motion Assessment Method Type","preferredDefinition":"the diagnostic imaging procedure used to assess the internal organ motion.","longName":"IMG_MOT_ASSMT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8535046-8FD3-08F4-E040-BB89AD431CE9","latestVersionIndicator":"Yes","beginDate":"2012-08-28","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-08-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3567446","version":"1","preferredName":"Radiation Therapy Motion Control Technique Type","preferredDefinition":"The type of procedure performed to assess or management of the movement (motion) of organs and the surrounding tissue in radiation therapy.","longName":"Radi_Moti_Cont_Tech_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8535046-9259-08F4-E040-BB89AD431CE9","latestVersionIndicator":"Yes","beginDate":"2012-08-28","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-08-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577249","version":"1","preferredName":"Patient Left Leg Length Distance Measurement","preferredDefinition":"Length, the linear extent in space from one end to the other, of the left leg.","longName":"Pati_Left_Leg_Leng_3434105v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8903376-143B-9EE2-E040-BB89AD43172A","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-08-31","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577250","version":"1","preferredName":"Patient Right Leg Length Distance Measurement","preferredDefinition":"Length, the linear extent in space from one end to the other, of the right leg.","longName":"Pati_Righ_Leg_Leng_Dist_Meas","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8903376-145E-9EE2-E040-BB89AD43172A","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-08-31","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577251","version":"1","preferredName":"Person Left Mid-Upper Arm Circumference Distance Measurement","preferredDefinition":"Measurement of the mid-upper left arm circumference at the mid-point between the tip of the shoulder and the tip of the elbow, aged 2 months and older.","longName":"Pers_Left_Midd_Uppe_Arm_Circ_3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8903376-147E-9EE2-E040-BB89AD43172A","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-08-31","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577252","version":"1","preferredName":"Person Right Mid-Upper Arm Circumference Distance Measurement","preferredDefinition":"Measurement of the mid-upper right arm circumference at the mid-point between the tip of the shoulder and the tip of the elbow, aged 2 months and older.","longName":"Pers_Righ_Midd_Uppe_Arm_Circ_3","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8903376-149E-9EE2-E040-BB89AD43172A","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-08-31","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577270","version":"2","preferredName":"Adverse Event Absent Adverse Event Grade Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator regarding information related to the absence of Adverse Events or within normal limits or values (Grade 0 CTCAEv4.0).","longName":"Adve_Abse_Grad_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E7B34C-6911-9467-E040-BB89AD434F88","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0 Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577271","version":"2","preferredName":"Adverse Event Mild Adverse Event Grade Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator regarding information related to an experience that is usually transient, and requires no special treatment or intervention. The event does not generally interfere with usual daily activities. Includes transient laboratory test alterations(Grade 1 CTCAEv4.0). See NCI Common Terminology Criteria for Adverse Events.","longName":"Adve_Mild_Grad_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E7B34C-6939-9467-E040-BB89AD434F88","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0 Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577272","version":"2","preferredName":"Adverse Event Moderate Adverse Event Grade Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator regarding information related to an experience that is alleviated with simple therapeutic treatments. The event impacts usual daily activities. Includes laboratory test alterations indicating injury, but without long-term risk(Grade 2 CTCAEv4.0).  See NCI Common Terminology Criteria for Adverse Events.","longName":"Adve_Mode_Grad_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E7B34C-6961-9467-E040-BB89AD434F88","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0 Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577273","version":"2","preferredName":"Adverse Event Severe Adverse Event Grade Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator regarding information related to an adverse event experience that requires intensive therapeutic intervention and interrupts usual daily activities(Grade 3 CTCAEv4.0).","longName":"Adve_Seve_Grad_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E7B34C-6989-9467-E040-BB89AD434F88","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0 Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577274","version":"2","preferredName":"Adverse Event Life Threatening or Disabling Adverse Event Grade Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator regarding information related to any adverse event that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death. (Grade 4 CTCAEv4.0).","longName":"Adve_Life_Grad_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E80ACB-C505-6AC3-E040-BB89AD430A8A","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0 Changed from CTEP to GOG for LEVENTHM by script Thu Aug 1 14:43:02 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577321","version":"1","preferredName":"Non-Protocol Diagnostic Procedure Performed Yes No Indicator","preferredDefinition":"The yes/no indicator whether a procedure used to diagnose or evaluate a medical condition that was not specified in a protocol was performed.","longName":"NON_PROT_DIAG_PROC_PERF_IND2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C891B1FA-20D8-1A7D-E040-BB89AD43735A","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-08-31","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577447","version":"1","preferredName":"Case Report Form Absent  Name","preferredDefinition":"The name of the case report form, a printed, optical, or electronic document designed to record all of the clinical study-required information stipulated in the protocol to be reported to the sponsor on each clinical trial subject, missing or absent","longName":"2178067v1.0:3577444v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C894BC03-3C63-E65E-E040-BB89AD435BA0","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-31","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3578157","version":"1","preferredName":"Non-Protocol Therapeutic Procedure Performed Yes No Indicator","preferredDefinition":"The yes/no indicator whether an action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process that was not specified in a protocol was performed.","longName":"NON_PROT_THER_PROC_PERF_IND2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8E1DC58-E0F4-448C-E040-BB89AD437190","latestVersionIndicator":"Yes","beginDate":"2012-09-04","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3579657","version":"2","preferredName":"Non-Protocol Specified Intervention or Procedure Performed  Reason","preferredDefinition":"The reason an action, intervention, or procedure was used to diagnose or treat the course of a pathologic process that was not specified in a protocol.","longName":"NON_PROT_SPEC_PROC_PERF_RSN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9AB5C45-BDBA-0149-E040-BB89AD433808","latestVersionIndicator":"Yes","beginDate":"2012-09-05","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3585923","version":"2","preferredName":"Non-Protocol Diagnostic Procedure Performed Anatomic Site","preferredDefinition":"The anatomic site of the procedure used to diagnose or evaluate a medical condition that was not specified in a protocol.","longName":"NON_PROT_DIAG_PROC_PERF_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9AA4643-0350-D6BC-E040-BB89AD433F85","latestVersionIndicator":"Yes","beginDate":"2012-09-06","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"9/14/12-updated value domain max length Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3587301","version":"1","preferredName":"Disease or Disorder Severe Autoimmune Or Immune Symptomatic Personal Medical History Yes No Indicator","preferredDefinition":"Yes/no indicator for the history of severe autoimmune disease, a condition in which the body recognizes its own tissues as foreign and directs an immune response against them, as an abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.","longName":"DIS_SEV_AUTO_IMM_MEDHX_IND2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C91E06B1-912B-0262-E040-BB89AD437B09","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-07","modifiedBy":"BOWSERC","dateModified":"2021-06-22","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3587392","version":"1","preferredName":"Docetaxel Agent First Day Administered Dose","preferredDefinition":"the dose related to the first day of Docetaxel agent.","longName":"2200474v1.0:3587391v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C921E286-4A7D-F316-E040-BB89AD4319AD","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3587394","version":"1","preferredName":"Doxorubicin Agent Course Dose","preferredDefinition":"the dose of the course or cycle of doxorubicin that produces a specific effect.","longName":"2946945v1.0:3587393v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C921E286-4AE8-F316-E040-BB89AD4319AD","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3587398","version":"1","preferredName":"Preparative Regimen Cyclophosphamide Planned Administered Dose","preferredDefinition":"the dose related to the planned administration of a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"2671487v1.0:3587393v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9221AD0-EA13-B081-E040-BB89AD435267","latestVersionIndicator":"Yes","beginDate":"2012-09-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-07","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"6/23/08mn-chgd 'cyclophophamide' in qstn txt.\\\\\\Changed names and defs due to changes in DEC. SW 01/21/2010 Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3588297","version":"1","preferredName":"Patient Physical Examination Pregnancy Breast Feeding Contraindicated Yes No Not Applicable Indicator","preferredDefinition":"Yes/No/NA indicator related to the contraindicated assessment regarding pregnancy, nursing, etc.","longName":"PT_PREG_BF_CON_IND3B","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C95CCD60-668D-F24C-E040-BB89AD430E95","latestVersionIndicator":"Yes","beginDate":"2012-09-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-10","modifiedBy":"BOWSERC","dateModified":"2021-05-12","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3588325","version":"2","preferredName":"Non-Protocol Therapeutic Procedure Performed Type","preferredDefinition":"Information related to the type of action or administration of therapeutic agents used to produce an effect that is intended to alter the course of a pathologic process that was not specified in a protocol.","longName":"NON_PROT_THER_PROC_PERF_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9ABC5D4-838D-9A1F-E040-BB89AD4320CD","latestVersionIndicator":"Yes","beginDate":"2012-09-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3588547","version":"1","preferredName":"Radiation Therapy Target Volume Administered Count","preferredDefinition":"The number of planning target volume planned for a patient receiving radiation therapy on a clinical trial.","longName":"Radi_Targ_Volu_Admi_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C96DEF2F-88D0-FD0A-E040-BB89AD4308D6","latestVersionIndicator":"Yes","beginDate":"2012-09-11","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-09-11","modifiedBy":"REEVESD","dateModified":"2015-02-04","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3588939","version":"1","preferredName":"Surgical Procedure Adverse Event Occurrence Yes No Indicator","preferredDefinition":"the yes/no indicator related to an occurrence of any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Surg_Adve_Occu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99634FD-9F02-37C4-E040-BB89AD434CBA","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-09-13","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589095","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Satisfaction Assessment Scale","preferredDefinition":"the scale used on FACT Quality of Life questionnaires related to evaluation of satisfaction as it related to a question designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589094v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A40E4-0775-8F5F-E040-BB89AD432692","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589099","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Relaxation Assessment Scale","preferredDefinition":"the scale related to relaxation assessment as part of a set of questions designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589098v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A4FDF-0B44-FB6D-E040-BB89AD4304C9","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589103","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Sleep Difficulty Assessment Scale","preferredDefinition":"the scale used for to evaluation of sleep difficulty as it related to a question designed to evaluate patient-reported perceptions of difficulty sleeping, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589102v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A40E4-07B5-8F5F-E040-BB89AD432692","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589110","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Problem Assessment Scale","preferredDefinition":"the scale related to evaluation of trouble sleeping as it related to a question designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589763v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"PCM:Patient Care Monitor","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A40E4-07F3-8F5F-E040-BB89AD432692","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589116","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Quality Assessment Scale","preferredDefinition":"the scale used to evaluation of sleep quality as it related to a question designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589115v1.0:2527725v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A7BF3-EFF7-6E5F-E040-BB89AD434D2E","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589117","version":"1","preferredName":"Patient Dyspnea Assessment Status","preferredDefinition":"information related to the assessment of a patient's dyspnea._the condition of the severity of QOL question.","longName":"2194230v1.0:2018076v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99A40E4-0823-8F5F-E040-BB89AD432692","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589175","version":"1","preferredName":"Non-Protocol Corticosteroid Systemic Therapy Administered Stratification Dose","preferredDefinition":"information related to the administration of non-protocol corticosteroid used as a low or high dose stratification variable.","longName":"CORTICOSTER_STRATIF_DOSE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99ABEF9-6B92-9587-E040-BB89AD43613A","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589176","version":"1","preferredName":"PROMIS Adult Sleep-Related Impairment Item Bank Sufficient Assessment Scale","preferredDefinition":"the scale used for evaluation of sufficiency of sleep as it related to a question designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.","longName":"3589112v1.0:2016847v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99ABEF9-6BB2-9587-E040-BB89AD43613A","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589177","version":"1","preferredName":"Quality of Life Dyspnea Interference Assessment Status","preferredDefinition":"the condition as related to the result of the act of hindering from difficult, painful breathing or shortness of breath as the subjective measurement of an individual's sense of well-being and ability to enjoy life.","longName":"3589120v1.0:2018076v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C99AF703-75B5-0FEC-E040-BB89AD4338DB","latestVersionIndicator":"Yes","beginDate":"2012-09-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589281","version":"1","preferredName":"Agent First Quantity Dose","preferredDefinition":"the dose related to the amount of the first dose of an agent or drug administered to the patient.","longName":"2188675v1.0:3587393v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9ABECBA-E87E-1FE1-E040-BB89AD430804","latestVersionIndicator":"Yes","beginDate":"2012-09-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"updated for ISO compliance; merged into 1 element common across diseases Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589421","version":"1","preferredName":"Paclitaxel Agent Third Quantity Dose","preferredDefinition":"the dose of the third measure of the drug paclitaxel administered.","longName":"3589413v1.0:3587393v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9ADE3B6-FE5B-E51F-E040-BB89AD434F5E","latestVersionIndicator":"Yes","beginDate":"2012-09-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589428","version":"1","preferredName":"Paclitaxel Agent Second Quantity Dose","preferredDefinition":"th dose related to the second amount of the drug paclitaxel administered.","longName":"3589424v1.0:3587393v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9ADE3B6-FE93-E51F-E040-BB89AD434F5E","latestVersionIndicator":"Yes","beginDate":"2012-09-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"Curated to support MGH adoption of C3D Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589463","version":"1","preferredName":"Agent Dose Administered Count","preferredDefinition":"the name or list as related to the administration of the amount of an active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"2222491v1.0:3589459v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9ADE3B6-FFBB-E51F-E040-BB89AD434F5E","latestVersionIndicator":"Yes","beginDate":"2012-09-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589742","version":"1","preferredName":"Document Diagnostic Procedure Upload Type","preferredDefinition":"the type of file that is transferred which contains information about methods, procedures, and tests performed to diagnose disease, disordered function, or disability.","longName":"Docu_Diag_Uplo_Desc_Docu_Diag_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-28A1-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-09-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589776","version":"1","preferredName":"List of Threatening Experiences Questionnaire Injury Self Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events regarding damage inflicted on oneself.","longName":"3589775v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2AB0-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589780","version":"1","preferredName":"List of Threatening Experiences Questionnaire Injury Self Assessment Yes No Indicator","preferredDefinition":"the yes/no indicator related to a 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following damage inflicted on oneself.","longName":"3589779v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2AED-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589784","version":"1","preferredName":"List of Threatening Experiences Questionnaire Injury Relative Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following injury of relative.","longName":"3589783v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2B23-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589785","version":"1","preferredName":"List of Threatening Experiences Questionnaire Injury Relative Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess the quality of life of a patient before, during and following the stressful life events of injury of a relative.","longName":"3589783v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2B33-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589789","version":"1","preferredName":"List of Threatening Experiences Questionnaire Death Parent Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following death of a parent.","longName":"3589788v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2B69-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589790","version":"1","preferredName":"List of Threatening Experiences Questionnaire Death Parent Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the stressful life event of the death of a parent occurred.","longName":"3589788v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2B79-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589794","version":"1","preferredName":"List of Threatening Experiences Questionnaire Death Friend Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events regarding an absence of life or state of being dead of a friend or relative.","longName":"3589793v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2BAF-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589795","version":"1","preferredName":"List of Threatening Experiences Questionnaire Death Friend Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather stressful life eventsof a friend dying occurred.","longName":"3589793v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2BBF-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589799","version":"1","preferredName":"List of Threatening Experiences Questionnaire Marriage Relationship Assessment  Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events: separation due to marital/relationship difficulties","longName":"3589798v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2BF5-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589800","version":"1","preferredName":"List of Threatening Experiences Questionnaire Marriage Relationship Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life events occurred: separation due to marital/relationship difficulties","longName":"3589798v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2C05-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589804","version":"1","preferredName":"List of Threatening Experiences Questionnaire End Relationship Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following the end of relationship.","longName":"3589803v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2C3B-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589805","version":"1","preferredName":"List of Threatening Experiences Questionnaire End Relationship Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life events occurred: The termination of a relationship","longName":"3589803v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2C4B-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589809","version":"1","preferredName":"List of Threatening Experiences Questionnaire Problem Friend Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events of problems of a friend.","longName":"3589808v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2C81-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589810","version":"1","preferredName":"List of Threatening Experiences Questionnaire Problem Friend Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life event occurred: A difficulty, with a close friend, neighbor, relative","longName":"3589808v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2C91-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589814","version":"1","preferredName":"List of Threatening Experiences Questionnaire Unemployment Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following lossing a job.","longName":"3589813v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2CC6-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589815","version":"1","preferredName":"List of Threatening Experiences Questionnaire Unemployment Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life event occurred: The state of not having a job for more than one month","longName":"3589813v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2CD6-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589819","version":"1","preferredName":"List of Threatening Experiences Questionnaire Removed Occupation Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life event of losing a job or occupation.","longName":"3589818v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D0C-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589820","version":"1","preferredName":"List of Threatening Experiences Questionnaire Removed Occupation Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life event occurred: Removed or fired from job or occupation","longName":"3589818v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D1C-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589824","version":"1","preferredName":"List of Threatening Experiences Questionnaire Financial Difficulty Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following a major financial crisis.","longName":"3589823v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D52-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589825","version":"1","preferredName":"List of Threatening Experiences Questionnaire Financial Difficulty Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life event occurred: Major financial crisis (significant debt or unable to pay epenses)","longName":"3589823v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D62-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589828","version":"1","preferredName":"List of Threatening Experiences Questionnaire Problem Assessment  Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following problems.","longName":"3589827v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D83-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589829","version":"1","preferredName":"List of Threatening Experiences Questionnaire Problem Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess weather the following stressful life event of a problem occurred.","longName":"3589827v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2D93-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589833","version":"1","preferredName":"List of Threatening Experiences Questionnaire Lost Assessment Scale","preferredDefinition":"A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events of loss.","longName":"3589832v1.0:3589766v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2DC8-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3589834","version":"1","preferredName":"List of Threatening Experiences Questionnaire Lost Assessment Yes No Indicator","preferredDefinition":"A yes/no indicator designed to assess the quality of life of a patient before, during and following loss.","longName":"3589832v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EB783F-2DD8-D829-E040-BB89AD433575","latestVersionIndicator":"Yes","beginDate":"2012-09-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-09-17","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3595838","version":"1","preferredName":"Patient Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Diagnosis Date","preferredDefinition":"the date of the diagnosis of disease recurrence and/or progression following a platinum-based chemotherapy regimen.","longName":"Pati_Plat_Chem_Recu_Dise_Diag_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA7887F9-EF79-8326-E040-BB89AD4376CE","latestVersionIndicator":"Yes","beginDate":"2012-09-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-09-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3595867","version":"1","preferredName":"Neoplasm Bowel Involvement Yes No Indicator","preferredDefinition":"the yes/no indicator relating to the association of the bowel with presence of a tumor or malignant cell growth.","longName":"Neop_Bowe_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA7887F9-EFBD-8326-E040-BB89AD4376CE","latestVersionIndicator":"Yes","beginDate":"2012-09-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-09-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3600793","version":"1","preferredName":"Laboratory Procedure Prior Participation Glioblastoma Clinical Trial MGMT Methylation Assay Performed Yes No Indicator","preferredDefinition":"the yes/no indicator related to participation in a previous glioblastoma multiforme clinical trial and determination of MGMT methylation status.","longName":"PREV_MGMT_PART_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAC5E27F-0E2E-E1AF-E040-BB89AD433D7D","latestVersionIndicator":"Yes","beginDate":"2012-09-28","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3601078","version":"1","preferredName":"Laboratory Procedure  MGMT Methylation Assay Non-Protocol  Performed Yes No Indicator","preferredDefinition":"The yes/no indicator related to a non-protocol determination of MGMT methylation status.","longName":"MGMT_NONPROT_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB01723C-7B45-3B14-E040-BB89AD433F3A","latestVersionIndicator":"Yes","beginDate":"2012-10-01","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-10-01","modifiedBy":"FINCHAMB","dateModified":"2023-10-20","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3603689","version":"1","preferredName":"Questionnaire Assessment Negation Participant Language Availability Performed Text","preferredDefinition":"the text field to capture whether the questionnaire assessments were not available in a participant's language.","longName":"ASMT_NOT_AVAIL_PART_LANG","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB3D7C18-4A60-A022-E040-BB89AD4326FA","latestVersionIndicator":"Yes","beginDate":"2012-10-04","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3607893","version":"1","preferredName":"Clinical Study Protocol Blinded Agent Administered Course Type","preferredDefinition":"the type of protocol-defined administration of a blinded agent.","longName":"PROT_BLIND_AGT_ADM_CRSE_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA311A1-E3B5-6FAA-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3608182","version":"1","preferredName":"Radiology Disease Physician Decision Response Yes No Indicator","preferredDefinition":"the yes/no indicator related to the confirmation of a disease response by a physician.","longName":"RAD_DZ_RESP_PHYSICIAN_DEC_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA60FC6-B7A5-CF70-E040-BB89AD4377C1","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3610085","version":"1","preferredName":"Image Guided Radiation Therapy  Precision Margin Reduced Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of a procedure that uses a computer to create a picture of a tumor to help guide the radiation beam during radiation therapy, providing greater accuracy and causing less damage to healthy tissue during patient positioning and margin reduction.","longName":"IGRT_MARG_RED_ADM_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBB515F0-3AE1-28B7-E040-BB89AD431F75","latestVersionIndicator":"Yes","beginDate":"2012-10-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-10","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3610123","version":"1","preferredName":"Clinical Report Submission Type","preferredDefinition":"the method used in the submission of a report relating to the examination and treatment of patients dependent on direct observation.","longName":"Clin_Repo_Subm_Clin_Subm_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBB5D260-922D-32F2-E040-BB89AD43585F","latestVersionIndicator":"Yes","beginDate":"2012-10-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-10-10","modifiedBy":"CHANGP","dateModified":"2016-06-24","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3613617","version":"1","preferredName":"Prior Surgery Performed Type","preferredDefinition":"information related to a type of prior surgical procedure performed.","longName":"PRIOR_SRG_PERF_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC19E8B5-AE4A-6BD0-E040-BB89AD436383","latestVersionIndicator":"Yes","beginDate":"2012-10-15","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-15","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3621648","version":"1","preferredName":"Patient Age Stratification Range","preferredDefinition":"the range related to the process of classifying patients into strata as part of the randomization process or for purposes of data analysis based on age.","longName":"PT_AGE_STRAT_RANGE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC423984-E8C9-AF27-E040-BB89AD437ABC","latestVersionIndicator":"Yes","beginDate":"2012-10-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3622221","version":"1","preferredName":"Oropharynx Primary Malignant Neoplasm Diagnosis Yes No Indicator","preferredDefinition":"the yes/no indicator related to the presence of the original site of a tumor composed of atypical neoplastic being in the part of the pharynx between the soft palate and the upper portion of the epiglottis.","longName":"Orop_Prim_Mali_Diag_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC5785B6-E45A-F941-E040-BB89AD434E07","latestVersionIndicator":"Yes","beginDate":"2012-10-18","endDate":null,"createdBy":"PATELV","dateCreated":"2012-10-18","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3622688","version":"1","preferredName":"Laboratory Procedure Lipase Outcome Yes No Indicator","preferredDefinition":"the yes/no indicator related to the result of the medical procedure that involves testing a sample of blood for lipase, an enzyme secreted in the digestive tract that catalyzes the breakdown of fats into individual fatty acids that can be absorbed into the bloodstream.","longName":"LAB_LIPASE_OC_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC6EAE24-70C3-17DB-E040-BB89AD430FED","latestVersionIndicator":"Yes","beginDate":"2012-10-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-10-19","modifiedBy":"SARAHB","dateModified":"2022-03-28","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3622692","version":"1","preferredName":"Laboratory Procedure Phosphorus Calcium Magnesium Potassium Assessment Yes No Indicator","preferredDefinition":"the yes/no indicator related to any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting to obtain the value of phosphorus, calcium, magnesium, and potassium within the sample.","longName":"Labo_Phos_Calc_Magn_Pota_Asse_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC6EBCA2-BFBE-7ED8-E040-BB89AD434B3C","latestVersionIndicator":"Yes","beginDate":"2012-10-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-10-19","modifiedBy":"REBOYJ","dateModified":"2014-10-06","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3622693","version":"1","preferredName":"Pancreatitis Disease Present Yes No Indicator","preferredDefinition":"the yes/no indicator related to the presence of pancreatitis, an inflammation of the pancreas, that causes discomfort, dysfunction, or distress to the person affected.","longName":"PANCR_DZ_PRES_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC6EBCA2-BFE3-7ED8-E040-BB89AD434B3C","latestVersionIndicator":"Yes","beginDate":"2012-10-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-10-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3626696","version":"1","preferredName":"Case Report Form Study Questionnaire Absent Yes No Indicator","preferredDefinition":"the yes/no indicator related to a case report form with information regarding a study questionnaire being missing or absent.","longName":"3626692v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE9F14F5-44E2-4B69-E040-BB89AD433C60","latestVersionIndicator":"Yes","beginDate":"2012-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-11-16","modifiedBy":"SARAHB","dateModified":"2016-09-13","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3626697","version":"1","preferredName":"Case Report Form Medical Condition Questionnaire Absent Yes No Indicator","preferredDefinition":"the yes/no indicator related to a case report form with information regarding a medical condition being missing or absent.","longName":"3626695v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE9F3931-ADAA-3785-E040-BB89AD435CFC","latestVersionIndicator":"Yes","beginDate":"2012-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-11-16","modifiedBy":"SARAHB","dateModified":"2016-09-13","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3645952","version":"1","preferredName":"Disease or Disorder Atypical Glandular Cell Diagnosis Type","preferredDefinition":"the type of an identifiable class of abnormal cells that come from inside the cervix or from the lining of the uterus. These abnormal cells are found in a small number of Pap smears (a procedure used to detect cervical cancer) and may be a sign of more serious lesions or cancer.","longName":"Dise_Atyp_Glnd_Cel_Diag_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1232FFE-0574-7F6E-E040-BB89AD4302C0","latestVersionIndicator":"Yes","beginDate":"2012-12-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646288","version":"1","preferredName":"Laboratory Procedure SMAD4 Gene Cytology Assessment Outcome","preferredDefinition":"the result or outcome of an SMAD4 gene cytology analysis.","longName":"Labo_SMAD_Cyto_Asse_SMAD_Cyto_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1399942-0900-FF58-E040-BB89AD4341E1","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646291","version":"1","preferredName":"Bile Duct Obstruction Finding Yes No Indicator","preferredDefinition":"the yes/no indicator related to finding a blockage in the tubes that carry bile from the liver to the gallbladder and small intestine.","longName":"Bile_Obst_Find_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13A8E89-E5A4-A1E0-E040-BB89AD431C4C","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646320","version":"1","preferredName":"Surgical Procedure Biliary Stenting Performed Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a surgical procedure involving biliary stenting was performed.","longName":"Bili_Sten_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13A8E89-E6D1-A1E0-E040-BB89AD431C4C","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646354","version":"1","preferredName":"Tumor Marker CA-19-9 Test Outcome","preferredDefinition":"the result or outcome of a laboratory procedure for tumor marker CA19-9 as an indicator of the presence or status of a tumor or cancer.","longName":"TMMKR_CA-19-9_TST_Outc","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13A8E89-E93B-A1E0-E040-BB89AD431C4C","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2012-12-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646486","version":"1","preferredName":"Person Bone Marrow Eye Biopsy Specimen Related Cancer Research Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to the consent and collection of bone marrow or eye biopsy specimens used in cancer research.","longName":"Pers_Bone_Eye_Biop_Spec_Rela_C","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14ACCAF-D0E3-6699-E040-BB89AD433202","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646487","version":"1","preferredName":"Bariatric Surgical Procedure Performed Yes No Indicator","preferredDefinition":"the yes/no indicator for related to a surgical procedure executed in morbidly obese patients to help promote weight loss.","longName":"Bari_Surg_Perf_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14ACCAF-D103-6699-E040-BB89AD433202","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646547","version":"1","preferredName":"Buccal Mucosa Cell Specimen Malignant Neoplasm Related Cancer Research Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to the consent and collection of buccal mucosa cell specimens used in cancer research.","longName":"Bucc_Cell_Spec_Mali_Rela_Canc_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14B9D0B-1FE1-E95A-E040-BB89AD435780","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646690","version":"1","preferredName":"Bone Marrow Eye Biopsy Specimen Other Diseases and Disorders Future Research Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to the consent and collection of bone marrow or eye biopsy specimens used in research.","longName":"Bone_Eye_Biop_Spec_Othe_Dise_F","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14DFDD1-5546-EDDE-E040-BB89AD430C11","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3646901","version":"1","preferredName":"Buccal Mucosa Cell Specimen Malignant Neoplasm Cancer Research Other Disease or Disorder Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to the consent and collection of a buccal mucosa cell specimen used in research.","longName":"Bucc_Cell_Spec_Mali_Canc_Othe_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14DFDD1-561D-EDDE-E040-BB89AD430C11","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647034","version":"1","preferredName":"Person Person Cerebrospinal Fluid Collection Other Disease or Disorder Research Activity Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to the consent and collection of a cerebrospinal fluid specimen used in research.","longName":"Pers_Cere_Coll_Othe_Dise_Rese_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D14DFDD1-574C-EDDE-E040-BB89AD430C11","latestVersionIndicator":"Yes","beginDate":"2012-12-20","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2012-12-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647523","version":"1","preferredName":"Prior Cytotoxic Chemotherapy Sex Cord-Stromal Tumor Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to anticancer drugs administered earlier in time for a neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations.","longName":"Prio_Cyto_Sex _Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1D95F17-CC0D-D9DA-E040-BB89AD432B18","latestVersionIndicator":"Yes","beginDate":"2012-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647532","version":"1","preferredName":"Surgical Procedure New Diagnosis Stage at Diagnosis Performed Indicator","preferredDefinition":"the indicator related to a diagnostic or treatment procedure performed by manual and/or instrumental means executed to recognize the presence of a disease or the extent of cancer spread at the time of the original diagnosis or the reemergence of a malignant neoplasm after a period of remission.","longName":"Surg_New_Stag_Perf_Indi","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1D95F17-CCDD-D9DA-E040-BB89AD432B18","latestVersionIndicator":"Yes","beginDate":"2012-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647657","version":"1","preferredName":"Physical Examination Clinically Significant Hearing Loss Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator related to a physical examination of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine whether a finding or condition is clinically significant based on judgment that there is a partial or complete loss of hearing in one or both ears which are necessary to allow an individual to participate in a specific clinical trial.","longName":"Phys_Clin_Hear_Clin_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1DCA45F-29EA-6CED-E040-BB89AD43692A","latestVersionIndicator":"Yes","beginDate":"2012-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647703","version":"1","preferredName":"Patient Prior Chemotherapy Hypersensitivity Personal Medical History Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to information related to an account of all medical events and problems a person has experienced regarding a local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized to an earlier use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"Pati_Prio_Chem_Hype_Pers_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1ED5B3E-6633-871C-E040-BB89AD43349E","latestVersionIndicator":"Yes","beginDate":"2012-12-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-28","modifiedBy":"SARAHB","dateModified":"2019-05-03","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647707","version":"1","preferredName":"Patient Cervical Carcinoma Diagnosis Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator related to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial regarding if a person receiving medical care, or treatment has the investigation, analysis and recognition of the presence of cervical carcinoma.","longName":"Pati_Cerv_Diag_Clin_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1EDA6B0-D75B-9889-E040-BB89AD4343F5","latestVersionIndicator":"Yes","beginDate":"2012-12-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-28","modifiedBy":"VUJANOVA","dateModified":"2018-09-17","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647977","version":"1","preferredName":"Neoadjuvant Chemotherapy Doxorubicin Hydrochloride Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of AC (or CA): adriamycin (doxorubicin) and cyclophosphamide was administered.","longName":"3647261v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2503645-006A-F096-E040-BB89AD43188C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647978","version":"1","preferredName":"Neoadjuvant Chemotherapy Cyclophosphamide Methotrexate Fluorouracil Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of CMF: cyclophosphamide, methotrexate, and 5-fluorouracil was administered.","longName":"3647265v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B2EA-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647979","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of FAC: 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide was administered.","longName":"3647270v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B2FA-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647980","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Epirubicin Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of FEC: 5-fluorouracil, epirubicin, and cyclophosphamide was administered.","longName":"3647274v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B30A-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647981","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Doxorubicin Hydrochloride Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of TAC: taxotere (docetaxel), adriamycin (doxorubicin), and cyclophosphamide was administered.","longName":"3647277v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2503645-007F-F096-E040-BB89AD43188C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647982","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel) and cyclophosphamide was administered.","longName":"3647280v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B31A-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647983","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Carboplatin Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel), carboplatin, and cyclophosphamide was administered.","longName":"3647283v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2503645-008F-F096-E040-BB89AD43188C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647984","version":"1","preferredName":"Neoadjuvant Chemotherapy Paclitaxel Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of taxol (paclitaxel) was administered.","longName":"3647286v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B32A-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647985","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel) was administered.","longName":"3647289v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B33A-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647986","version":"1","preferredName":"Neoadjuvant Chemotherapy Capecitabine Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a neoadjuvant chemotherapy regimen consisting of xeloda (capecitabine) was administered.","longName":"3647292v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B34A-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647993","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a dose-dense neoadjuvant chemotherapy regimen consisting of AC (or CA): adriamycin (doxorubicin) and cyclophosphamide was administered.","longName":"3647989v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B3A9-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3647994","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Paclitaxel Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether a dose-dense neoadjuvant chemotherapy regimen consisting of paclitaxel was administered.","longName":"3647992v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D24FFBD0-B3B9-38BA-E040-BB89AD43458C","latestVersionIndicator":"Yes","beginDate":"2013-01-02","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-02","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649077","version":"1","preferredName":"Invasive Breast Carcinoma Present Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether residual invasive carcinoma was present in the breast specimen.","longName":"2009018v2.31:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D27DFAA2-0654-0A28-E040-BB89AD43425B","latestVersionIndicator":"Yes","beginDate":"2013-01-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-01-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-14","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649588","version":"1","preferredName":"Patient Non-cytotoxic Agent Combined With Cytotoxic Chemotherapy Administered Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to the act of having given a pharmacologic substance that does not directly kill cells, but instead affects cellular transport and metabolic functions to ultimately produce cell death in combination with a anticancer drugs that kill cells, especially cancer cells.","longName":"Pati_Non-_Comb_With_Cyto_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B96676-A802-D1C0-E040-BB89AD436BAC","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649591","version":"1","preferredName":"Patient Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Diagnosis Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to the diagnosis of disease recurrence and/or progression following a platinum-based chemotherapy regimen.","longName":"Plat_Chem_Recu_Dise_Diag_Indic","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B96676-A821-D1C0-E040-BB89AD436BAC","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649598","version":"1","preferredName":"Patient Agreement Immunocompromised Person Avoidance Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator regarding the information regarding a person who receives medical treatment agreement to avoid a person whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.","longName":"Pati_Agre_Immu_Pers_Avoi_Clin_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B96676-A868-D1C0-E040-BB89AD436BAC","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649603","version":"1","preferredName":"Patient Agreement Pregnant Lactating Person Avoidance Clinical Trials Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator regarding the information regarding a person who receives medical treatment agreeing to avoid pregnant or lactating people to participate in a specific clinical trial.","longName":"Pati_Agre_Grav_Lact_Pers_Avoi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B96676-A8B1-D1C0-E040-BB89AD436BAC","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649607","version":"1","preferredName":"Prior Therapy Reolysin Paclitaxel Treatment Regimen Yes No Indicator","preferredDefinition":"the yes/no indicator relating to a previous treatment plan that specifies the dosage, the schedule, and the duration of treatment of a serotype 3 Dearing strain (T3D) of reovirus (Respiratory Enteric Orphan VIRUS) that is able to replicate specifically in cancer cells bearing an activated Ras pathway or Paclitaxel which binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.","longName":"Prio_Ther_Reol_Pacl_Trea_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2BA5DC4-4D3B-CE60-E040-BB89AD437723","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649608","version":"1","preferredName":"Laboratory Procedure Troponin I Outcome Yes No Indicator","preferredDefinition":"the yes/no indicator related to the result from a laboratory procedure for troponin I, one of the three polypeptide chains that make up the TROPONIN complex.","longName":"2543047v1.0:2978393v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2BA5DC4-4D5A-CE60-E040-BB89AD437723","latestVersionIndicator":"Yes","beginDate":"2013-01-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3649921","version":"1","preferredName":"Disease or Disorder Whole Lung Atelectasis Present Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether atelectasis is present in the entire lung.","longName":"ATELECTASIS_PRES_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2CD1BEC-3884-6683-E040-BB89AD437DE6","latestVersionIndicator":"Yes","beginDate":"2013-01-08","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-01-08","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3652581","version":"1","preferredName":"Person Priority Gynecologic Oncology Group Clinical Trial Eligibility Criteria Text","preferredDefinition":"the free text field to describe the reason a higher priority protocol was not used for a person's eligibility for a high-priority clinical trial sponsored by the Gynecologic Oncology Group as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3178329v1.0_Reas_P","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D35B23EE-DA84-DEC7-E040-BB89AD431051","latestVersionIndicator":"Yes","beginDate":"2013-01-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-15","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3652732","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinue Clinical Trial Eligibility Criteria Type","preferredDefinition":"information related to the status of the disease as it relates to prior platinum compound chemotherapy for a primary neoplasm.","longName":"2236731v1.0:3192313v1.0_Prio_P","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36A1FED-D7E0-F005-E040-BB89AD43139E","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-16","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3652741","version":"1","preferredName":"Diagnostic Electrocardiogram Performed Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator regarding information related to a diagnostic electrocardiogram performed.","longName":"DIAGNS_EKG_PERFORMED_YES_NO_NA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36A1FED-D996-F005-E040-BB89AD43139E","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-16","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3652808","version":"1","preferredName":"Intestinal Disease or Disorder Block Portacath Placement Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator regarding information regarding any abnormal condition within the intestines as part of a personal medical history which will prevent the placement of a catheter to allow an individual to participate in a specific clinical trial.","longName":"Inte_Dise_Bloc_Port_Clin_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36B1B10-B109-45C4-E040-BB89AD4326AB","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-16","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3652983","version":"1","preferredName":"Laboratory Procedure Disease Screening Biomarker Absent Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether a specific biomarker is absent at screening.","longName":"LAB_SCRN_BIOMARKER_ABSENT_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36F0F5A-AF56-EAB7-E040-BB89AD430FD5","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-01-16","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653462","version":"1","preferredName":"Patient Clear Cell Ovarian Malignant Neoplasm Clinical Trials Eligibility Criteria Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator related to a person who receives medical treatment with a malignant neoplasm with the characteristics of a cell with empty-appearing cytoplasm when viewed with a light microscope within the ovaries which is necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_Clea_Ovar_Mali_Clin_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-8483-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653466","version":"1","preferredName":"Patient Biopsy Confirmed Clear Cell Ovary Malignant Neoplasm Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to a person who receives medical treatment that had removal and pathologic examination of specimens in the form of small pieces of tissue from the living body to confirm that a malignant neoplasm within the ovary is of the morphology of a cell with empty-appearing cytoplasm when viewed with a light microscope which is necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_Biop_Conf_Clea_Ovar_Mali_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-84CB-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"SARAHB","dateModified":"2018-06-06","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653475","version":"1","preferredName":"Patient Primary Neoplasm Recurrent Neoplasm Negative Finding WT1 Protein ER Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"the indicator related to criteria to determine eligibility of patients for medical care programs and services based on primary tumor or recurrent tumor showing a lack of immunoreactivity or negative for expression of WT-1 antigen and Estrogen Receptor antigen.","longName":"Pati_Prim_Recu_Nega_WT1 _ER_Cl","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D393E2D1-8594-C573-E040-BB89AD431BF0","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653644","version":"1","preferredName":"Person Prior Antiangiogenesis Therapy Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to information related to a person having had a prior therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels, platelets, and or fibroblasts, as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3182762v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D39611D4-F36C-F992-E040-BB89AD433AA2","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"DASCOMBS","dateModified":"2015-11-19","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653776","version":"1","preferredName":"Laboratory Procedure Serum Glutamic Pyruvic Transaminase Serum Glutamic Oxaloacetic Transferase Eligibility Determination Indicator","preferredDefinition":"the indicator related to the medical procedure that involves testing a sample of blood, urine, or other substance for SGOT or SGPT for normal limits based on liver function for determination if a subject is suitable for enrollment in a study according to specific protocol criteria.","longName":"LAB_SGPT_SGOT_ELIG_Liv_SGPT_SG","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3972A39-126C-6A3B-E040-BB89AD4374EB","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-18","modifiedBy":"MORENOC","dateModified":"2018-02-01","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653969","version":"1","preferredName":"Bile Duct Obstruction Not Recovered or Not Resolved Finding Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator related to finding a blockage in the tubes that carry bile from the liver to the gallbladder and small intestine that has not resolved or improved.","longName":"Bile_Obst_Not _Find_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E3F58B-EE73-161C-E040-BB89AD434F3B","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-01-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653988","version":"1","preferredName":"Mesenteric Venous Occlusion Disease or Disorder Finding Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator related to the obstruction or closure of the mesenteric vein.","longName":"Mese_Veno_Occl_Dise_Find_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E5E1D1-CF81-EE50-E040-BB89AD435A42","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-01-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3654133","version":"1","preferredName":"Diagnostic Imaging Metastatic Lesion Finding Count","preferredDefinition":"the number or amount of metastatic lesions related to radiographic confirmation of tumor(s) arising at a location distant to or evolving from the primary lesion.","longName":"Imag_Meta_Find_3462577v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E5E1D1-D119-EE50-E040-BB89AD435A42","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-01-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3654554","version":"1","preferredName":"Laboratory Procedure Partial Thromboplastin Time Performed Yes No Indicator","preferredDefinition":"the yes/no indicator related to partial thromboplastin time performed.","longName":"2543047v1.0:3310500v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3FA6A93-9AB4-64AF-E040-BB89AD4342AF","latestVersionIndicator":"Yes","beginDate":"2013-01-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-23","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3654718","version":"1","preferredName":"Person Malignant Neoplasm Endocrine Therapy Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to a person having a malignant neoplastic tumor treated with any treatment modality that produces the desired therapeutic effect by means of change of hormone/hormone levels as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3178383v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D40B8596-3277-5022-E040-BB89AD433654","latestVersionIndicator":"Yes","beginDate":"2013-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3666533","version":"1","preferredName":"Prior Biological Therapy Administered Begin Date","preferredDefinition":"the start date that biological therapy administration previously began.","longName":"PRIOR_BIOTX_ADM_BEG_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4602909-843C-5385-E040-BB89AD433DAD","latestVersionIndicator":"Yes","beginDate":"2013-01-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-01-28","modifiedBy":"MORENOC","dateModified":"2017-10-09","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3680305","version":"1","preferredName":"Multiple Primary Lesion Present Yes No Indicator","preferredDefinition":"The Yes/No indicator related to whether there are multiple primary lesions present.","longName":"Mult_Prim_Lesi_Pres_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D500B486-D6CD-BE18-E040-BB89AD43635D","latestVersionIndicator":"Yes","beginDate":"2013-02-05","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-02-05","modifiedBy":"GRANTD","dateModified":"2014-04-03","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3684797","version":"1","preferredName":"Pelvis Lymph Node Pathology Diagnosis Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding the investigation, analysis and recognition of the presence and nature of disease in an organ composed predominantly of lymphocytes, located in the structure of the vertebrate skeleton supporting the lower limbs and hind limbs in humans.","longName":"Pelv_Lymp_Path_Diag_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D58A765B-4533-B324-E040-BB89AD435DC7","latestVersionIndicator":"Yes","beginDate":"2013-02-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-02-12","modifiedBy":"VUJANOVA","dateModified":"2018-09-18","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3685656","version":"1","preferredName":"Medical Device Description Type","preferredDefinition":"the type of medical device used.","longName":"MEDDEV_DESC_MEDDEV_DESC_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5A78283-8CD0-7F99-E040-BB89AD4367B5","latestVersionIndicator":"Yes","beginDate":"2013-02-13","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-02-13","modifiedBy":"MORENOC","dateModified":"2016-08-22","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3689260","version":"1","preferredName":"Patient Breast Reconstruction Consent Indicator","preferredDefinition":"the yes/no/unknown/NA indicator related to consent from a person to participate in a clinical trial involving surgery to rebuild a breast's shape after breast conserving surgery or a mastectomy.","longName":"Pati_Brea_Reco_Cons_RES_CONS_I","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D62B8718-8E3F-F9C9-E040-BB89AD430D9F","latestVersionIndicator":"Yes","beginDate":"2013-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-02-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3689491","version":"1","preferredName":"Inoperable Malignant Neoplasm Present Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator related to a malignant neoplasm that is not suitable for surgery.","longName":"INOP_MALIGNEO_PRES_YES_NO_NA_I","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D63C9D42-058E-41E7-E040-BB89AD435CA7","latestVersionIndicator":"Yes","beginDate":"2013-02-21","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-02-21","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3690513","version":"1","preferredName":"Diabetes Mellitus Current Therapeutic Procedure Indicator","preferredDefinition":"the indicator related to whether and when a person has received therapeutic agents to produce an effect that is intended to alter the course of diabetes.","longName":"DIABETES_CUR_TX_PERMEDHIST_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6A36BC2-D114-C337-E040-BB89AD432E29","latestVersionIndicator":"Yes","beginDate":"2013-02-26","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-02-26","modifiedBy":"FORMBUILDER","dateModified":"2014-09-03","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3690514","version":"1","preferredName":"Person High Cholesterol Indicator","preferredDefinition":"the indicator related to whether and when a person has an elevated level of cholesterol.","longName":"PERS_HI_CHOLEST_PERMEDHIST_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6A3D493-0E01-2AED-E040-BB89AD43345F","latestVersionIndicator":"Yes","beginDate":"2013-02-26","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-02-26","modifiedBy":"FORMBUILDER","dateModified":"2014-09-03","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3694775","version":"1","preferredName":"Diagnostic Imaging Retropharyngeal Lymph Node Metastasis Present Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator relating to whether the patient has evidence of retropharyngeal lymph node metastasis.","longName":"Diag_Retr_Meta_Pres_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7A94E8D-17E5-C298-E040-BB89AD4360FC","latestVersionIndicator":"Yes","beginDate":"2013-03-11","endDate":null,"createdBy":"PATELV","dateCreated":"2013-03-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3694791","version":"1","preferredName":"Patient American Society of Anesthesiologists Physical Examination Status Clinical Trial Eligibility Criteria Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator relating to the American Society of Anesthesiologists physical status classification category prior to enrolling on the study.","longName":"Pati_Amer_Phys_Stat_Clin_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7A94E8D-182D-C298-E040-BB89AD4360FC","latestVersionIndicator":"Yes","beginDate":"2013-03-11","endDate":null,"createdBy":"PATELV","dateCreated":"2013-03-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3694795","version":"1","preferredName":"Patient Endotracheal Intubation Procedure Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator relating to whether an endotracheal intubation procedure was done prior to enrolling on the study.","longName":"Pati_Endo_Intu_Proc_Clin_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7A9B39A-B775-81AD-E040-BB89AD431FE0","latestVersionIndicator":"Yes","beginDate":"2013-03-11","endDate":null,"createdBy":"PATELV","dateCreated":"2013-03-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3694801","version":"1","preferredName":"Patient Barium Swallow Evaluation Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator that asks whether a modified barium swallow to assess swallowing function was done prior to enrolling a patient on the study.","longName":"Pati_Bari_Swal_Eval_Clin_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7A9B39A-B7CF-81AD-E040-BB89AD431FE0","latestVersionIndicator":"Yes","beginDate":"2013-03-11","endDate":null,"createdBy":"PATELV","dateCreated":"2013-03-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3702735","version":"1","preferredName":"Radiation Therapy Internal Mammary Lymph Node Whole Breast Chest Wall Administered Yes No Indicator","preferredDefinition":"the yes/no indicator asking if any lymph nodes of the breast have been treated with radiation, including whole breast and/or breast chest wall.","longName":"3702734v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D861D6BA-5F64-CD04-E040-BB89AD4347E7","latestVersionIndicator":"Yes","beginDate":"2013-03-20","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-03-20","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3714555","version":"1","preferredName":"Pain Medication Neural Block Administered Yes No Indicator","preferredDefinition":"the yes/no indicator that asks if a neural block (a procedure in which medicine is injected directly into or around a nerve or into the spine to block pain) to control pain was administered.","longName":"Pain_Medi_Neur_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D964CF21-1767-9385-E040-BB89AD4344C1","latestVersionIndicator":"Yes","beginDate":"2013-04-02","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-04-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3715844","version":"1","preferredName":"Lung Neoplasm Pathologic N Stage Procedure Type","preferredDefinition":"the method or type of procedure that was used for determining the pathologic N stage for a lung tumor.","longName":"LUNG_NPLSM_PATH_NST_PROC_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9762895-30B9-EC62-E040-BB89AD433406","latestVersionIndicator":"Yes","beginDate":"2013-04-03","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-04-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3718876","version":"1","preferredName":"Patient Endotracheal Intubation Procedure Clinical Trial Eligibility Criteria Category","preferredDefinition":"the Mallampatti category based on the visualization of four anatomical structures found in the oropharynx.","longName":"PT_ENDO_INT_PR_CL_TR_EC_CATE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9F056C1-434D-DFFD-E040-BB89AD433524","latestVersionIndicator":"Yes","beginDate":"2013-04-09","endDate":null,"createdBy":"PATELV","dateCreated":"2013-04-09","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3738691","version":"1","preferredName":"Nutritional Support  Feeding Tube Administered  Type","preferredDefinition":"the type of feeding tube inserted in a patient for administration of nutritional support.","longName":"Nutr_Feed_Admi_NUT_SUP_FEED_TU","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBAC5EC2-1B53-B08C-E040-BB89AD43695E","latestVersionIndicator":"Yes","beginDate":"2013-05-01","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-01","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3741975","version":"1","preferredName":"Patient Barium Swallow Evaluation Study Site Credential Checklist Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether the credentialing checklist for a modified barium swallow  was completed by the study site prior to enrolling a patient.","longName":"Pati_Bari_Swal_Eval_Stud_Cred_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBBF225F-C132-D3E4-E040-BB89AD4378F6","latestVersionIndicator":"Yes","beginDate":"2013-05-02","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3741980","version":"1","preferredName":"Surgical Procedure Tumor Mass Focal Approach Midline Neck Present Yes No Indicator","preferredDefinition":"the yes/no indicator related to a tumor epicenter that approaches the middle of the neck.","longName":"Surg_Tumo_Foca_Appr_Midl_Neck_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBBF9EB5-09FB-2FC0-E040-BB89AD432366","latestVersionIndicator":"Yes","beginDate":"2013-05-02","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743289","version":"1","preferredName":"Adverse Event Postoperative Dental Lip Injury Present Yes No Indicator","preferredDefinition":"the yes/no indicator related to the postoperative injury experienced to the mouth, including the teeth and/or lips.","longName":"Adve_Post_Dent_Lip_Inju_Pres_Y","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD20992-15F8-49BC-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743346","version":"1","preferredName":"Adverse Event Oral Postoperative Bleeding Present Yes No Indicator","preferredDefinition":"The yes/no indicator related to the bleeding in the mouth as a result of surgery","longName":"Adve_Oral_Post_Pres_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD20992-163F-49BC-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743347","version":"1","preferredName":"Margin Result Involvement Extent Disease Ind","preferredDefinition":"the indicator related to the whether the final surgical margins are clear.","longName":"MARG_RESULT_INV_EXT_DZ_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD287C2-1B82-9040-E040-BB89AD430A99","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743388","version":"1","preferredName":"Neck Margin Closest Distance   Measurement","preferredDefinition":"the measurement in millimeters of the distance from the closest point of the lesion to the closest point of the surgical margin.","longName":"NECK_MARG_CLO_DIST_SURG_MARG_D","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD31395-53C7-F8BF-E040-BB89AD434B2B","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743390","version":"2","preferredName":"Neck Margin Closest Distance Source","preferredDefinition":"the source of the closest surgical margins that were taken.","longName":"NECK_MARG_CLO_DIST_NK_MAR_CLST","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBC1D1B4-442F-1AC2-E053-731AD00AD294","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-15","modifiedBy":"TSESU","dateModified":"2023-05-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743391","version":"1","preferredName":"Surgical Margin Frozen Section Diagnosis  Status","preferredDefinition":"the status related to the pathological assessment of frozen section margins.","longName":"SUR_MAR_FR_SEC_DIA_STS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD31395-5446-F8BF-E040-BB89AD434B2B","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743413","version":"1","preferredName":"Surgical Margin Status Assessment Type","preferredDefinition":"the type of surgical margin assessment.","longName":"SUR_MARG_ST_ASSESS_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD4B1B6-976A-7B0B-E040-BB89AD436F3F","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743511","version":"1","preferredName":"Surgical Margin Frozen Section Diagnosis Type","preferredDefinition":"the type of frozen section margins, related to location and distance.","longName":"SUR_MAR_FR_SEC_DIA_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD62673-2CD6-C572-E040-BB89AD433094","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743531","version":"1","preferredName":"Head and Neck Pharynx Superior Constrictor Muscle Involvement Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator related to the involvement of the superior constrictor muscle.","longName":"Head_Phar_Supe_Invo_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD62673-2E6B-C572-E040-BB89AD433094","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743535","version":"1","preferredName":"Head and Neck Pharynx Superior Constrictor Muscle Extend Present Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator related to the extension of the tumor into the superior pharyngeal constrictor muscle.","longName":"Head_Phar_Supe_Exte_Pres_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD688BD-6704-6623-E040-BB89AD430978","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743540","version":"1","preferredName":"Head and Neck Pharynx Superior Constrictor Muscle Thickness Present Measurement","preferredDefinition":"the measurement of the thickness of the superior pharyngeal constrictor muscle.","longName":"Head_Phar_Supe_Thic_Pres_TUMOR","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD688BD-677B-6623-E040-BB89AD430978","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743655","version":"1","preferredName":"Extracapsular Disease Present  Type","preferredDefinition":"the type or extent of extracapsular disease present.","longName":"EXTCP_DZ_PRES_EX_DIS_PRE_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC0E22F1-3682-479F-E040-BB89AD432996","latestVersionIndicator":"Yes","beginDate":"2013-05-06","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3744360","version":"1","preferredName":"Head and Neck Larynx Penetration Present  Type","preferredDefinition":"the type of laryngeal penetration based on the modified barium swallow assessment.","longName":"Head_Lary_Pene_Pres_LARX_PEN_T","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC11EB71-60AD-5249-E040-BB89AD435B61","latestVersionIndicator":"Yes","beginDate":"2013-05-06","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3744940","version":"1","preferredName":"Head and Neck Pharynx Residue Present Type","preferredDefinition":"the type of pharyngeal residue based on the modified barium swallow assessment.","longName":"Head_Phar_Resi_Pres_Pha_Res_Tp","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC229CEB-DADE-AB2A-E040-BB89AD432F0C","latestVersionIndicator":"Yes","beginDate":"2013-05-07","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3745032","version":"1","preferredName":"Head and Neck Larynx Unintentional Material Aspiration Present Indicator","preferredDefinition":"the indicator related to laryngeal aspiration based on the modified barium swallow assessment.","longName":"Head_Lary_Unin_Pres_Larx_Asp_I","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC25B461-AA44-1B7A-E040-BB89AD433990","latestVersionIndicator":"Yes","beginDate":"2013-05-07","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3754438","version":"1","preferredName":"Credential Person Certificate License Present Type","preferredDefinition":"the type of license or certificate held by an individual.","longName":"Cred_Pers_Cert_Lice_Pres_Cr_Pr","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC366737-5C5E-BFDF-E040-BB89AD4362F5","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-08","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3755219","version":"1","preferredName":"Lesion Code","preferredDefinition":"the coded value used to classify patients based on the number of lesions.","longName":"LES_QTY_LES_CDE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC38EECE-7C24-E7DD-E040-BB89AD4307AF","latestVersionIndicator":"Yes","beginDate":"2013-05-08","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-05-08","modifiedBy":"CARTERS","dateModified":"2022-04-14","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3771154","version":"1","preferredName":"Tracheostomy Current Use Yes No Unknown Indicator","preferredDefinition":"the yes/no/unknown indicator related to whether a tracheostomy is currently being used on a patient.","longName":"Trac_Curr_Use_YNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD6328A5-D0F8-5592-E040-BB89AD4313EA","latestVersionIndicator":"Yes","beginDate":"2013-05-23","endDate":null,"createdBy":"PATELV","dateCreated":"2013-05-23","modifiedBy":"ROUILLAS","dateModified":"2015-02-26","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3771980","version":"1","preferredName":"Study Site Agent Transfer Required Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether the study site requires expedited drug service.","longName":"St_Ste_Agt_Tr_Req_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDDBF743-AA33-E208-E040-BB89AD434765","latestVersionIndicator":"Yes","beginDate":"2013-05-29","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-05-29","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3772622","version":"1","preferredName":"Tumor Marker CA-19-9 Test  Range","preferredDefinition":"information related to a test for tumor marker CA-19-9._The reported range in the value of a test for tumor marker CA19-9 used for  protocol stratification.","longName":"TMMKR_CA-19-9_TST_Rang","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDE00C8E-F3B2-5C6C-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2013-05-29","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-05-29","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3773742","version":"1","preferredName":"Person European Organization for Research and Treatment of Cancer Enrollment Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether a person is being enrolled onto a protocol coordinated by another group via the European Organization for Research and Treatment of Cancer (EORTC).","longName":"Pers_Euro_Enro_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDF517D1-2A26-218A-E040-BB89AD4315E4","latestVersionIndicator":"Yes","beginDate":"2013-05-30","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-05-30","modifiedBy":"GRANTD","dateModified":"2014-04-02","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3774693","version":"1","preferredName":"Patient N Stage Stratification Factors Code","preferredDefinition":"information relating to N stage (N refers to the extent of lymph node involvement) for stratification purposes indicating the selected pre-treatment factor by which patients are randomly assigned to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol._The term representing the nodal status used for stratifiation purposes._A system of numbered categories for representation of data.","longName":"Pati_N St_Stra_Code","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE559E3B-DEDD-6EBF-E040-BB89AD430947","latestVersionIndicator":"Yes","beginDate":"2013-06-04","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-06-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3774864","version":"1","preferredName":"Lymph Node Greater Than Three Centimeter Maximum Diameter Yes No Indicator","preferredDefinition":"the yes/no indicator related to the maximum diameter of N2 lymph nodes.","longName":"Lymph_N_max_diameter_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE58AB71-DA5C-00D4-E040-BB89AD434F97","latestVersionIndicator":"Yes","beginDate":"2013-06-04","endDate":null,"createdBy":"GEINOZS","dateCreated":"2013-06-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3774911","version":"1","preferredName":"Surgeon Thoracic Name","preferredDefinition":"the name related to identifying a specific thoracic surgeon.","longName":"Surg_Thor_Iden_INDS_NAME","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE5A72DE-EBAB-911B-E040-BB89AD435AE7","latestVersionIndicator":"Yes","beginDate":"2013-06-04","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2013-06-04","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3775355","version":"1","preferredName":"Patient Type 2 Diabetes Mellitus Diagnosis Clinical Trial Eligibility Criteria Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator related to the presence of diabetes, characterized by the ability to survive without ketoacidosis in the absence of insulin therapy, for a person who receives medical attention, care, or treatment as an element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"Pati_Type_Diag_Clin_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6B07AC-84D8-3499-E040-BB89AD4359E0","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-05","modifiedBy":"SARAHB","dateModified":"2017-03-16","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3775394","version":"1","preferredName":"Agent Herbal Supplement Administration Yes No Indicator","preferredDefinition":"the yes/no indicator related to the use of a product taken by mouth, made from a plant that is thought to be useful in treating disease or staying healthy.","longName":"Agen_Herb_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6E750B-2407-5F6A-E040-BB89AD43383E","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-05","modifiedBy":"MORENOC","dateModified":"2018-04-03","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3775534","version":"1","preferredName":"Disease or Disorder Visible Retinal Pathology Assessment Yes No Indicator","preferredDefinition":"the yes/no indicator related to determining an abnormal visual condition relating to or involving the retina.","longName":"Dise_Visi_Reti_Path_Asse_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE7D9D3A-E4AD-08AD-E040-BB89AD4351AE","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3775554","version":"1","preferredName":"Cardiac Metastasis Diagnosis Yes No Indicator","preferredDefinition":"the yes/no indicator related to the identification or diagnosis of cancer that has spread to locations outside the heart.","longName":"Card_Meta_Diag_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE7DE01D-2344-E657-E040-BB89AD4356E9","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3783583","version":"1","preferredName":"Patient Antiandrogen Therapy Stratification Factors Duration","preferredDefinition":"the duration or length of time androgen deprivation therapy was administered to a patient as a stratification factor for participation on a clinical trial.","longName":"Pati_Anti_Stra_AntAnd_Th_St_Ft","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DEF95B41-B764-E633-E040-BB89AD430D85","latestVersionIndicator":"Yes","beginDate":"2013-06-12","endDate":null,"createdBy":"PATELV","dateCreated":"2013-06-12","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3783740","version":"1","preferredName":"Vital Signs Report Timepoint Assessment Text","preferredDefinition":"the free text field to specify information related to a specific point in time where an account of a person's pulse, temperature, respiratory rate, and blood pressure measurements have been determined.","longName":"Vita_Repo_Time_Asse_ASSESS_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DEFB8A5C-FA8D-7342-E040-BB89AD4335AC","latestVersionIndicator":"Yes","beginDate":"2013-06-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-12","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787052","version":"1","preferredName":"Hospital Visit Count","preferredDefinition":"the count or number related to a hospital visit.","longName":"2233245v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-6087-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"MORENOC","dateModified":"2017-11-01","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787080","version":"1","preferredName":"Healthcare Facility Clinical Oncology Visit Count","preferredDefinition":"the count or number related to a person's visit to a clinical oncology facility.","longName":"3787073v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-60F9-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"MORENOC","dateModified":"2017-10-31","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787104","version":"1","preferredName":"Healthcare Facility Clinical Endocrinology Visit Count","preferredDefinition":"the count or number related to a person's visit to a clinical endocrinology facility.","longName":"3787090v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-613B-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787108","version":"1","preferredName":"Healthcare Facility Pulmonary Medicine Visit Count","preferredDefinition":"the count or number related to a person's visit to a pulmonary medicine facility.","longName":"3787107v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-616C-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787171","version":"1","preferredName":"Person Medical Examination Visit Count","preferredDefinition":"the count or number related to a routine medical examination visit.","longName":"3787170v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-619C-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787192","version":"1","preferredName":"Hospital Visit Specify","preferredDefinition":"the free text field to specify information relating to a hospital visit.","longName":"2233245v1.0:2018806v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0FC24C-61DE-7048-E040-BB89AD4353C8","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787215","version":"1","preferredName":"Packed Red Blood Cell Transfusion Received","preferredDefinition":"Information related to the red blood cell transfusion administered.","longName":"2013983v1.0:2181553v1.1","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF1E3894-5559-7B8B-E040-BB89AD432F30","latestVersionIndicator":"Yes","beginDate":"2013-06-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"  Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787219","version":"1","preferredName":"Bronchoscopy Performed Count","preferredDefinition":"the count or number related to bronchoscopies performed.","longName":"2188753v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF1E3894-559D-7B8B-E040-BB89AD432F30","latestVersionIndicator":"Yes","beginDate":"2013-06-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"ISO 11179 Compliance Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787225","version":"1","preferredName":"Health Insurance Identifier Number","preferredDefinition":"the unique identifier related to a health insurance plan.","longName":"3787223v1.0:3190378v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF1E3894-5603-7B8B-E040-BB89AD432F30","latestVersionIndicator":"Yes","beginDate":"2013-06-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787230","version":"1","preferredName":"Person Healthcare Payer Name","preferredDefinition":"the name of the individual or group who is responsible for healthcare payments for an individual.","longName":"2012406v4.0:3787229v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF1E3894-5645-7B8B-E040-BB89AD432F30","latestVersionIndicator":"Yes","beginDate":"2013-06-14","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-06-14","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787493","version":"1","preferredName":"Patient Histologic Borderline Ovarian Neoplasm Diagnosis Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding a histologic diagnosis of a borderline benign or malignant, primary or metastatic neoplasm involving the ovary in a person who receives medical attention, care, or treatment.","longName":"Pati_Hist_Bord_Ovar_Diag_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF5CEE6D-F9AB-D556-E040-BB89AD43151A","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"SARAHB","dateModified":"2020-01-17","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787574","version":"1","preferredName":"Patient Luteinizing Hormone Follicle Stimulating Hormone Measurement Postmenopausal Evaluation Yes No Unknown Not Applicable Indicator","preferredDefinition":"The yes/no/unknown/not applicable indicator related to the amount of luteinizing hormone present and the amount of follicle stimulating hormone present at the time after menopause for a person who receives medical attention, care, or treatment.","longName":"Pati_Lute_Foll_Post_Eval_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF5DC853-D379-A44A-E040-BB89AD430D10","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3787617","version":"1","preferredName":"Patient Plan Control Group Treatment Regimen Type","preferredDefinition":"the type of treatment plan that specifies the dosage, the schedule, and the duration of treatment planned for the control group and used as a standard for a person who receives medical attention, care, or treatment.","longName":"Pati_Plan_Cont_Trea_Cont_Prot_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6019E4-1159-F5E8-E040-BB89AD437848","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"GEDEONL","dateModified":"2016-01-19","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3788637","version":"1","preferredName":"Patient Postmenopausal Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator related to the time after menopause, the time in a woman's life when menstrual periods stop permanently.","longName":"PT_PMENP_YES_NO_UNKNOWN_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF84EB68-06BE-BAFF-E040-BB89AD43155C","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-19","modifiedBy":"TAYLORT","dateModified":"2022-02-08","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3793462","version":"1","preferredName":"Person Body Mass Index Type","preferredDefinition":"An individual's weight to height ratio according to a study protocol.","longName":"PRSN_BMI_Stud_Pati_Body_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFFCE1D9-29FD-A1E8-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2013-06-25","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-25","modifiedBy":"RAGUNATU","dateModified":"2022-04-23","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3793483","version":"1","preferredName":"Measurement Vital Signs Test Occurrence Yes No Indicator","preferredDefinition":"the yes/no indicator relating to the state of an evaluation of vital signs.","longName":"MEAS_VS_OCC_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFFCE1D9-2AEF-A1E8-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2013-06-25","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-25","modifiedBy":"MAESKEB","dateModified":"2016-03-21","changeNote":"Curated to support Duke University adoption of C3D. Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3794815","version":"1","preferredName":"Patient Risk Eligibility Determination Type","preferredDefinition":"the type or number of risk factors as described in the eligibility criteria that will determine how a patient will be stratified on a clinical trial.","longName":"PT_RSK_ELIG_DTMN_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0138B69-11B9-3D7E-E040-BB89AD434BD2","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"PATELV","dateCreated":"2013-06-26","modifiedBy":"VUJANOVA","dateModified":"2019-11-04","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3794844","version":"1","preferredName":"Diagnostic Procedure Adult Comorbidity Evaluation Performed  Status","preferredDefinition":"the status of the numeric score of the Adult Comorbidity Evaluation-27(ACE-27), a 27-item comorbidity index for patients with cancer, as a test performed to diagnose disease, disordered function, or disability used for stratification purposes.","longName":"DGNTC_PRO_ADULT_COMO_EVAL_STUS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E013F024-0F6E-A60F-E040-BB89AD431682","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"PATELV","dateCreated":"2013-06-26","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3796387","version":"1","preferredName":"Biospecimen Collection Date/Time","preferredDefinition":"a specified date and time related to a collection of any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions.","longName":"BSPC_CLLCT_DT-TM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E024A4E7-F267-0F27-E040-BB89AD430756","latestVersionIndicator":"Yes","beginDate":"2013-06-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-27","modifiedBy":"HARTLEYG","dateModified":"2019-05-01","changeNote":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812160","version":"1","preferredName":"Patient Specimen Consent Indicator","preferredDefinition":"the yes/no indicator related to information for a person who receives medical attention, care, or treatment giving permission to obtain a substance, or portion of material for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","longName":"Pati_Spec_Cons_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E18FB79F-ED75-0287-E040-BB89AD432DA6","latestVersionIndicator":"Yes","beginDate":"2013-07-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-07-15","modifiedBy":"ZHWENDY","dateModified":"2023-02-20","changeNote":"Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":"9/13/22 added AQT and OID, CCTG for CCTG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812859","version":"1","preferredName":"Hospital Admission Since Evaluation Occurrence Count","preferredDefinition":"Information related to the number of occurrences of hospital admissions since last evaluation","longName":"HOSP_ADM_EVAL_OCCUR_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1B7C5D2-34B6-90A1-E040-BB89AD430331","latestVersionIndicator":"Yes","beginDate":"2013-07-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812905","version":"1","preferredName":"Person Home Health Assistance Weekly Occurrence Average Number Day Count","preferredDefinition":"Information related to the average number of days per week a home health assistant or paid individual was used.","longName":"PRSN_HHA_WKLY_AVE_DAY_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1BA78D6-9D41-4498-E040-BB89AD435681","latestVersionIndicator":"Yes","beginDate":"2013-07-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812920","version":"1","preferredName":"Person Home Health Assistance Family Member Friend Weekly Occurrence Average Number Day Count","preferredDefinition":"Information related to the occurrence of the number of days per week an individual is assisted by family member, friend, or other unpaid individual.","longName":"FAM_FRND_HHA_WKLY_DAT_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1BA78D6-9E45-4498-E040-BB89AD435681","latestVersionIndicator":"Yes","beginDate":"2013-07-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812936","version":"1","preferredName":"Person Home Health Assistance Occurrence Average Hour Day Count","preferredDefinition":"Information related to the occurrence of the number of hours per day a home health assistant or paid individual is used to assist an individual.","longName":"PRSN_HHA_HR_DAY_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1BBFC07-EBE0-7101-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2013-07-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812977","version":"1","preferredName":"Person Home Health Assistance Family Member Friend Occurrence Average Hour Day Count","preferredDefinition":"Information related to the occurrence of the average number of hours per day an individual is assisted by a family member, friend, or other unpaid individual.","longName":"FAM_FRD_HHA_AVG_HR_DAY_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CAEFC2-C6BD-47F9-E040-BB89AD436FDA","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-18","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3812999","version":"1","preferredName":"Person Nursing Home Long-Term Care Facility Length Day Count","preferredDefinition":"Information related to the number of days an individual spent in a nursing home or long-term care facility.","longName":"PRSN_NH_LTCF_LNGTH","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CDDAD0-CBF8-520B-E040-BB89AD430DEA","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-18","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3813008","version":"1","preferredName":"Person Rehabilitation Facility Length Day Count","preferredDefinition":"Information related to the number of days an individual spent in a rehabilitation facility.","longName":"PRSN_REHAB_FAC_DAY_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CC4283-D233-A91B-E040-BB89AD43126C","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-18","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3813066","version":"1","preferredName":"Diagnostic Method Test Type","preferredDefinition":"Information related to the method or test type used to diagnose a condition.","longName":"DX_METH_TEST_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1CE73D0-A49F-B30B-E040-BB89AD437A80","latestVersionIndicator":"Yes","beginDate":"2013-07-18","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-18","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3813187","version":"1","preferredName":"Health Care Provider Patient Visit Type","preferredDefinition":"Information related to the provider type of a patient's health care visit.","longName":"HCP_PT_VIS_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DF02FA-0666-BFDD-E040-BB89AD437A06","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-07-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3849491","version":"1","preferredName":"Proton beam Radiation Therapy Institution Availability Yes No Indicator","preferredDefinition":"Yes/No indicator of the availability of proton beam radiation therapy at an enrolling institution.","longName":"PROT_BEAM_RAD_THR_AVAL_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E371916D-47D9-819A-E040-BB89AD432027","latestVersionIndicator":"Yes","beginDate":"2013-08-08","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-08","modifiedBy":"MORENOC","dateModified":"2018-04-10","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3851298","version":"1","preferredName":"Photon Beam Radiation Therapy Institution Availability Yes No Indicator","preferredDefinition":"Yes/No indicator for the availability of photon beam radiation therapy at an enrolling institution.","longName":"PHOT_BEAM_RAD_THR_AVAL_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E37344FF-FBC3-289E-E040-BB89AD4367AA","latestVersionIndicator":"Yes","beginDate":"2013-08-08","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-08","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3854331","version":"1","preferredName":"Person Supplement Oxygen Use Quantity Stable Yes No Indicator","preferredDefinition":"The Yes/No indicator for the stability of the amount of supplemental oxygen a person uses.","longName":"PRSN_SUP_OX_STABLE_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3D8C082-9A5C-A916-E040-BB89AD430904","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-13","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3854577","version":"1","preferredName":"Pulmonologist Consultation Date","preferredDefinition":"The date a pulmonologist consultation visit was performed.","longName":"PULM_CONSLT_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3D96EAF-C1DC-C439-E040-BB89AD437994","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-13","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3854623","version":"1","preferredName":"Breast Tumor Clinical Nodal Stage","preferredDefinition":"information related to the clinical N stage for a breast tumor.","longName":"2188688v1.0:3854625v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"BOLD:Breast Oncology Local Disease Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DAEAF9-425F-758D-E040-BB89AD4354D8","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"Curated to support Breast Oncology Local Disease (BOLD) Initiative Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3855381","version":"1","preferredName":"Quantitative Lung Ventilation Perfusion Scan Date","preferredDefinition":"Information related to the date a V/Q scan which is a test measuring air (ventilation) and blood flow (perfusion) in the lungs was performed.","longName":"VQ_SCAN_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3EE0720-5FE2-F3CA-E040-BB89AD430DDB","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3856066","version":"1","preferredName":"Single Photon Emission Computed Tomography Performed Date","preferredDefinition":"The date when a special type of computed tomography (CT) scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells was performed.","longName":"SPECT_PERF_DT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E40221B2-27A8-3D1E-E040-BB89AD43505F","latestVersionIndicator":"Yes","beginDate":"2013-08-15","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-15","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861373","version":"1","preferredName":"KRAS Gene Mutation Testing Outcome","preferredDefinition":"The result of testing the gene involved in signal transduction and apoptosis.","longName":"KRAS_GENE_MUT_DET_KRAS_Test_Ou","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48A4D41-D3D5-DC47-E040-BB89AD437408","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-08-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":"Curated for the Center for Cancer Research","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861416","version":"1","preferredName":"Patient Prior mTOR Inhibitor Combined With Cytotoxic Chemotherapy Administered Indicator","preferredDefinition":"the yes/no/not applicable indicator related to a person who receives medical attention is given medications taken previously with the joint of  any agents that inhibit mTOR (FK506 binding protein 12-rapamycin associated protein 1), one of the protein kinases mediate cellular responses to stresses and an anticancer drugs that kill cancer cells.","longName":"PT_PRI_MTOR_CYTO_TX_ADM_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48B2588-E567-D3FA-E040-BB89AD435DA5","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-08-22","modifiedBy":"SARAHB","dateModified":"2022-03-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861471","version":"1","preferredName":"Laboratory Procedure Fasting Glucose Measurement Assessment","preferredDefinition":"the yes/no indicator regarding information related to the value of the amount of glucose present in a sample of blood while abstaining from food.","longName":"Labo_Fast_Gluc_Asse_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48B2588-E651-D3FA-E040-BB89AD435DA5","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-08-22","modifiedBy":"BRETTS","dateModified":"2016-05-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3862596","version":"1","preferredName":"Study Site FMISO PET CT Participation Yes No Indicator","preferredDefinition":"The Yes/No indicator to a study site's participation in the FMISO-PET/CT component.","longName":"SITE_FMISO_PT_CT_PART_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48DCEA6-30D4-3BB5-E040-BB89AD433544","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-22","modifiedBy":"CLOHNES","dateModified":"2022-09-26","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":"9/26/22 added alt OID for CCTG for Chad Winch cjl; 9/23/22 added AQT for CCTG for Chad Winch cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3862601","version":"1","preferredName":"Patient Consent FMISO PET CT Participation Yes No Indicator","preferredDefinition":"The Yes/No indicator of a patient's consent to participate in the FMISO-PET/CT component.","longName":"CONST_FMISO_PT_CT_PART_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48DCEA6-3138-3BB5-E040-BB89AD433544","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3862602","version":"1","preferredName":"Patient Ability FMISO PET CT Participation Yes No Indicator","preferredDefinition":"The Yes/No indicator of a patient's ability to participate in the FMISO-PET/CT component.","longName":"PT_ABLE_FMISO_PT_CT_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48DCEA6-3158-3BB5-E040-BB89AD433544","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3865422","version":"1","preferredName":"Photon Beam Radiation Therapy  Administration Count","preferredDefinition":"Information related to the number of times photon beam radiation therapy was administered.","longName":"PHOT_RT_ADM_CNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4EF44DE-DB98-4C6C-E040-BB89AD435952","latestVersionIndicator":"Yes","beginDate":"2013-08-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3865423","version":"1","preferredName":"Photon Beam Radiation Therapy  Administration Date","preferredDefinition":"Information related to the date photon beam radiation therapy was administered.","longName":"PHOT_RT_ADM_DATE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4EF44DE-DC1C-4C6C-E040-BB89AD435952","latestVersionIndicator":"Yes","beginDate":"2013-08-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-27","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3865426","version":"1","preferredName":"Radiation Therapy Plan Yes No Indicator","preferredDefinition":"The Yes/No indicator related to the planning of Radiation Therapy.","longName":"RT_PLAN_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4EF44DE-DCAD-4C6C-E040-BB89AD435952","latestVersionIndicator":"Yes","beginDate":"2013-08-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-08-27","modifiedBy":"TSESU","dateModified":"2023-06-20","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3867181","version":"1","preferredName":"Laboratory Procedure Glycosylated Hemoglobin Measurement Outcome Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding information related to the result from a quantitative measurement of the amount of glycosylated hemoglobin (A1C) present in a sample of blood.","longName":"2543047v1.0:3294667v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4F3A6CB-C85F-0A8C-E040-BB89AD43143E","latestVersionIndicator":"Yes","beginDate":"2013-08-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-08-27","modifiedBy":"DWARZEL","dateModified":"2016-06-08","changeNote":"Replaced VD Assessment Ind-3 (2018441v1) with VD Yes No Unknown Indicator (3506034v1) - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3867394","version":"1","preferredName":"Participant Surgery Refusal Yes No Indicator","preferredDefinition":"The yes/no indicator pertaining to the participants decision to receive surgery","longName":"PT_SURGERY_REFUSAL_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5031E0E-47AD-EEA2-E040-BB89AD4358CC","latestVersionIndicator":"Yes","beginDate":"2013-08-28","endDate":null,"createdBy":"SERIANNJ","dateCreated":"2013-08-28","modifiedBy":"KENNISHM","dateModified":"2021-12-29","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3867592","version":"1","preferredName":"Carboplatin Agent Administered Carboplatin Agent Administered Dose","preferredDefinition":"The information related to administration of carboplatin.","longName":"3287793v1.0:3867591v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E507A5A3-BCF8-B525-E040-BB89AD437EB6","latestVersionIndicator":"Yes","beginDate":"2013-08-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-28","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3867639","version":"1","preferredName":"Goserelin Acetate Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of goserelin","longName":"2864830v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E507B0FA-1FB1-C36C-E040-BB89AD433087","latestVersionIndicator":"Yes","beginDate":"2013-08-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-28","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":". Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3867671","version":"1","preferredName":"Goserelin Agent Administered Day Count","preferredDefinition":"The information related to the number of days the the agent goserelin was administered.","longName":"3867653v1.0:2018594v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E507B0FA-2006-C36C-E040-BB89AD433087","latestVersionIndicator":"Yes","beginDate":"2013-08-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-28","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3870398","version":"1","preferredName":"Neoplasm Physical Examination Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to tumor assessment by physical exam.","longName":"3870397v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5184AC1-C150-9921-E040-BB89AD434BAC","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"Replace VD Specimen Characteristics Ind-2 2018362v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3870402","version":"1","preferredName":"Neoplasm Imaging Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to the assessment of a tumor by clinical imaging.","longName":"3870401v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5184AC1-C229-9921-E040-BB89AD434BAC","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":"Replace VD Specimen Characteristics Ind-2 2018362v1 with VD ID#3506068 - Yes No Indicator - dbw Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3870414","version":"1","preferredName":"Neoplasm Palpable Yes No Indicator","preferredDefinition":"The yes/no indicator for weather a tumor is palpable.","longName":"3870412v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5183B45-4BB1-EAF5-E040-BB89AD433910","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3870421","version":"1","preferredName":"Neoplasm Baseline Present Yes No Indicator","preferredDefinition":"The yes/no indicator for whether a baseline tumor is still present or not.","longName":"3870420v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5183B45-4C40-EAF5-E040-BB89AD433910","latestVersionIndicator":"Yes","beginDate":"2013-08-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-08-29","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3874235","version":"1","preferredName":"Angiotensin-Converting Enzyme 2 Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of an ACE inhibitor","longName":"3872857v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E58F441B-2029-BF1D-E040-BB89AD4320AD","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-09-04","modifiedBy":"SARAHB","dateModified":"2019-09-30","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3874236","version":"1","preferredName":"Beta-2-Adrenergic Receptor Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of a beta blocker.","longName":"3872890v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E58F441B-2039-BF1D-E040-BB89AD4320AD","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3874237","version":"1","preferredName":"Adrenergic Receptor Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of an ARB.","longName":"3872875v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E58F441B-2067-BF1D-E040-BB89AD4320AD","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3874238","version":"1","preferredName":"Cardiac Glycoside Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of cardiac glycoside.","longName":"3872879v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E58F441B-2086-BF1D-E040-BB89AD4320AD","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2014-01-24","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3874239","version":"1","preferredName":"Diuretic Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of a diuretic agent.","longName":"3872883v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E58F441B-20A5-BF1D-E040-BB89AD4320AD","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-09-04","modifiedBy":"NYCHM","dateModified":"2016-07-22","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3876094","version":"1","preferredName":"Patient Plasma Epstein-Barr Virus DNA Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The Yes/No indicator  related to the eligibility requirement of detectable EBV DNA prior to randomization.","longName":"Pt_Pl_EBV_DNA_YN_Ind","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5A78CC5-B228-8C80-E040-BB89AD435722","latestVersionIndicator":"Yes","beginDate":"2013-09-05","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-09-05","modifiedBy":"WONGW","dateModified":"2015-08-18","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3896586","version":"1","preferredName":"Radiation Therapy Gross Tumor Volume No Ability Yes No Indicator","preferredDefinition":"The  yes/no  indicator related to the inability of the gross tumor volume to be defined for radiation therapy treatment","longName":"Radi_Gros_Tumo_No_Abil_YES_NO_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6486365-B677-A7BC-E040-BB89AD4341CB","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"BERGANTW","dateCreated":"2013-09-13","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3907041","version":"1","preferredName":"Patient Plasma Epstein-Barr Virus DNA Clinical Trial Eligibility Criteria Status","preferredDefinition":"Presence or Absence of EBV DNA in plasma collected from a patient participating in a clinical trial","longName":"Pt_Plas_EBV_DNA_St","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E736772F-6ABE-C2BA-E040-BB89AD436D13","latestVersionIndicator":"Yes","beginDate":"2013-09-25","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-09-25","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3908724","version":"1","preferredName":"Overlap Distance Assessment Yes No Indicator","preferredDefinition":"The Yes/No indicator related to the assessment of overlapping distant metastatic sites.","longName":"3227691v1.0:2177731v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E74E3681-D0AF-452D-E040-BB89AD430DD5","latestVersionIndicator":"Yes","beginDate":"2013-09-26","endDate":null,"createdBy":"BERGANTW","dateCreated":"2013-09-26","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3909504","version":"1","preferredName":"Proton beam Radiation Therapy Availability Institution Identifier Code","preferredDefinition":"The institution code related to the availability of proton beam radiation therapy at a site involved in a clinical trial.","longName":"PROTON_RT_INST_CD","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E761A29C-6CDD-B22D-E040-BB89AD432686","latestVersionIndicator":"Yes","beginDate":"2013-09-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-09-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3909655","version":"1","preferredName":"Photon Beam Radiation Therapy Availability Institution Identifier Code","preferredDefinition":"The institution code related to the availability of photon beam radiation therapy at a site involved in a clinical trial.","longName":"PHOTON_RT_INST_CD","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E762050B-855A-ACC5-E040-BB89AD432B78","latestVersionIndicator":"Yes","beginDate":"2013-09-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-09-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3912796","version":"1","preferredName":"Patient Prostate Gland Malignant Neoplasm Pathology T Stage Clinical Trial Eligibility Criteria Stage","preferredDefinition":"A pathologic finding about one or more characteristics of prostate cancer for eligibility and stratification","longName":"Pt_Pros_MN_CTEC_St","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B3346A-AF27-CF7F-E040-BB89AD435648","latestVersionIndicator":"Yes","beginDate":"2013-10-01","endDate":null,"createdBy":"PATELV","dateCreated":"2013-10-01","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3914495","version":"1","preferredName":"Neoplasm Thrombosis Present Yes No Not Applicable Indicator","preferredDefinition":"The Yes/No/Not applicable indicator as to whether a thrombosis of the primary tumor is present.","longName":"2176931v1.0:3447883v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7DB49BC-C95F-2CDD-E040-BB89AD4315BB","latestVersionIndicator":"Yes","beginDate":"2013-10-03","endDate":null,"createdBy":"BERGANTW","dateCreated":"2013-10-03","modifiedBy":"BERGANTW","dateModified":"2018-06-07","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3918185","version":"1","preferredName":"Patient Demographics Work Questionnaire Complete Yes No Indicator","preferredDefinition":"The yes/no indicator that asks whether the patient has completed the demographic work status questionnaire.","longName":"Pt_Demo_Work_Ques_Comp_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8640125-7592-B3AE-E040-BB89AD43091B","latestVersionIndicator":"Yes","beginDate":"2013-10-10","endDate":null,"createdBy":"PATELV","dateCreated":"2013-10-10","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3918189","version":"1","preferredName":"Patient Computer Base Self Interview Survey Complete Yes No Indicator","preferredDefinition":"The yes/no indicator that asks whether the patient has completed the computer assisted self interview survey.","longName":"Pt_Com_Self_Int_Sur_Com_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E864C661-D0DA-DC21-E040-BB89AD437DFF","latestVersionIndicator":"Yes","beginDate":"2013-10-10","endDate":null,"createdBy":"PATELV","dateCreated":"2013-10-10","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3918201","version":"1","preferredName":"Patient Human Papillomavirus-16 Positive Finding Yes No Indicator","preferredDefinition":"The yes/no indicator of the p16 result finding based on central testing.","longName":"Pt_HPV_16_Pos_Find_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E864C661-D212-DC21-E040-BB89AD437DFF","latestVersionIndicator":"Yes","beginDate":"2013-10-10","endDate":null,"createdBy":"PATELV","dateCreated":"2013-10-10","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3919816","version":"1","preferredName":"Primary Anatomic Site Malignant Neoplasm Disease Progression Absent Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether there is absence of disease progression at the primary tumor site","longName":"Prim_Anat_Mali_Dise_Abse_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C80-0066-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"BERGANTW","dateCreated":"2013-10-15","modifiedBy":"GRANTD","dateModified":"2014-03-31","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3921531","version":"1","preferredName":"Radiation Therapy Metastatic Neoplasm Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to treatment of therapeutic radiation given to an individual for disease that has spread from its original site of growth to another site.","longName":"RT_MET_NEO_ADM_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8DF14C6-F6FC-FCFD-E040-BB89AD435F6E","latestVersionIndicator":"Yes","beginDate":"2013-10-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-10-16","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3923117","version":"1","preferredName":"Hepatic Lesion Screening Assessment Type","preferredDefinition":"The findings/results related to hepatic lesion screening assessment.","longName":"HEP_LES_SCR_ASSES_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8F50327-8482-DC4A-E040-BB89AD433C87","latestVersionIndicator":"Yes","beginDate":"2013-10-17","endDate":null,"createdBy":"BERGANTW","dateCreated":"2013-10-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3923171","version":"1","preferredName":"Prophylactic Cranial Irradiation Approach RT Administered Type","preferredDefinition":"Information related to the type of radiation therapy that will be used on a patient's head to reduce the risk that cancer will spread to the brain.","longName":"PCI_RT_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8F5F736-7544-C072-E040-BB89AD430465","latestVersionIndicator":"Yes","beginDate":"2013-10-17","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2013-10-17","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3928464","version":"1","preferredName":"Hysterectomy Surgical Procedure No Evidence Leiomyosarcoma Observed Indicator","preferredDefinition":"the yes/no/unknown/not applicable regarding information related to an operation in which the uterus is removed for diagnostic or treatment reasons that shows no knowledge on which to base belief of an uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women being observed.","longName":"Hyst_Surg_No_Evid_Leio_Obse_YE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96D6B66-9715-6954-E040-BB89AD431C71","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-10-23","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3928558","version":"1","preferredName":"Non-Malignant Liver Disease or Disorder  Diagnosis Type","preferredDefinition":"Any non -neoplastic disease or dysfunction of the liver as a result of the investigation, analysis,and recognition of the presence and nature of such diseases as expressed as signs and symptoms or via  the concise results of such an investigation.","longName":"Non-_Live_Dise_Diag_Non-_Live_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"REAL Classification","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96E7DE5-B832-BB83-E040-BB89AD435461","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"GRANTD","dateCreated":"2013-10-23","modifiedBy":"TITARENKOI","dateModified":"2020-04-28","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3935771","version":"1","preferredName":"Hormone Therapy Luteinizing Hormone-releasing Hormone Agonist Administration Month Duration","preferredDefinition":"The planned duration of the administration of the LHRH agonist therapy.","longName":"HTX_LHRHA_ADM_DURTN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D10813-1FD4-045B-E040-BB89AD432BC1","latestVersionIndicator":"Yes","beginDate":"2013-10-28","endDate":null,"createdBy":"PATELV","dateCreated":"2013-10-28","modifiedBy":"TSESU","dateModified":"2023-03-22","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943730","version":"1","preferredName":"Baseline Surgical Procedure Orthopedics Lower Extremity Performed Indicator","preferredDefinition":"the yes/no indicator regarding information related to the baseline surgical procedure performed on the skeletal system (bones and joints) of the limb that is composed of the hip, thigh, leg and foot.","longName":"Base_Surg_Orth_Lowe_Perf_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA21CA5D-45BC-D87B-E040-BB89AD43325D","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943796","version":"1","preferredName":"Baseline Surgical Procedure Orthopedics Lower Extremity Performed Lower Extremity Orthopedics Anatomic Site","preferredDefinition":"The names and location of the limb that is composed of the hip, thigh, leg and foot where surgery broadly concerned with the skeletal system (bones and joints) performed.","longName":"Base_Surg_Orth_Lowe_Perf_Lowe_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA21FA3C-C595-678D-E040-BB89AD43397A","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943900","version":"1","preferredName":"Baseline Surgical Procedure Orthopedics Lower Extremity Performed Other Specify Text","preferredDefinition":"The free text field when other is chosen from a list of values regarding information related to the baseline surgical procedure performed on the skeletal system (bones and joints) of the limb that is composed of the hip, thigh, leg and foot.","longName":"Base_Surg_Orth_Lowe_Perf_OTHR_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA226B4D-4ED6-6C0E-E040-BB89AD435E26","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943905","version":"1","preferredName":"Patient Visit Surgical Procedure Orthopedics Lower Extremity Performed Indicator","preferredDefinition":"the yes/no indicator regarding information related to the clinical encounter that encompasses planned and unplanned trial intervention surgical procedure performed on the skeletal system (bones and joints) of the limb that is composed of the hip, thigh, leg and foot.","longName":"Pati_Surg_Orth_Lowe_Perf_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA226B4D-4F1A-6C0E-E040-BB89AD435E26","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943911","version":"1","preferredName":"Patient Visit Surgical Procedure Orthopedics Lower Extremity Performed Lower Extremity Orthopedics Anatomic Site","preferredDefinition":"The names and location of the limb that is composed of the hip, thigh, leg and foot where surgery broadly concerned with the skeletal system (bones and joints) performed in a clinical encounter that encompasses planned and unplanned trial intervention.","longName":"Pati_Surg_Orth_Lowe_Perf_Lowe_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA226B4D-4F3C-6C0E-E040-BB89AD435E26","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3943913","version":"1","preferredName":"Patient Visit Surgical Procedure Orthopedics Lower Extremity Performed Other Specify Text","preferredDefinition":"The free text field when other is chosen from a list of values for information related to the clinical encounter that encompasses planned and unplanned trial intervention surgical procedure performed on the skeletal system (bones and joints) of the limb that is composed of the hip, thigh, leg and foot.","longName":"Pati_Surg_Orth_Lowe_Perf_OTHR_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA226B4D-4F5B-6C0E-E040-BB89AD435E26","latestVersionIndicator":"Yes","beginDate":"2013-11-01","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-11-01","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3952314","version":"1","preferredName":"Person Neurocognitive Test Certification Name","preferredDefinition":"Information related to the name of the person certified at the site for Neurocognitive Testing.","longName":"NEURO_CERTIF_PERS_NAME","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB29EA4B-47BA-67E2-E040-BB89AD433E86","latestVersionIndicator":"Yes","beginDate":"2013-11-14","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2013-11-14","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3978219","version":"1","preferredName":"Diagnostic Imaging Response Evaluation Criteria in Solid Tumors Assessment Count","preferredDefinition":"Numeric value of information related to the  final result of a determination of the value, significance, or extent of documenting response of solid tumors to treatment using a method of visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","longName":"Diag_Resp_Asse_Resp_Asse_Coun","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECCEE026-5A41-5FFE-E040-BB89AD431B34","latestVersionIndicator":"Yes","beginDate":"2013-12-05","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-12-05","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4012134","version":"1","preferredName":"BRCA1 Mutation Consent Form Signed Date","preferredDefinition":"The date on which the consent form allowing BRCA mutation testing to occur was signed.","longName":"4012133v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBE9895-72A8-B0DF-E040-BB89AD43311A","latestVersionIndicator":"Yes","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4012138","version":"1","preferredName":"Tumor Tissue Consent Form Signed Date","preferredDefinition":"The date which the consent form was signed that allows tumor tissue to be collected.","longName":"4012137v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBE9895-72D2-B0DF-E040-BB89AD43311A","latestVersionIndicator":"Yes","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4012194","version":"1","preferredName":"BRCA1 Mutation Testing Consent Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient consenting to BRCA mutation testing.","longName":"4012193v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC0DC3B-EB25-B76C-E040-BB89AD432D3E","latestVersionIndicator":"Yes","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"JOOSTENT","dateModified":"2016-09-26","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4012210","version":"1","preferredName":"Tumor Tissue Consent Yes No Indicator","preferredDefinition":"The yes/no indicator related to the collection of consent for tumor tissue collection.","longName":"4012209v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC0DC3B-EB55-B76C-E040-BB89AD432D3E","latestVersionIndicator":"Yes","beginDate":"2013-12-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2013-12-17","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4030358","version":"1","preferredName":"Maintenance Therapy Post Platinum-Based Chemotherapy Administered Indicator","preferredDefinition":"information related to the administration of medication for the continuation of treatment for an extended period of time to prevent relapse happening at a time subsequent to the use of synthetic or naturally-occurring chemicals for the treatment of diseases derived from or containing platinum.","longName":"Main_Post_Plat_Chem_Admi_Main_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE8A701B-79C3-DF68-E040-BB89AD433D67","latestVersionIndicator":"Yes","beginDate":"2013-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4030378","version":"1","preferredName":"Cytotoxic Chemotherapy Maintenance Therapy Discontinued Prior Recurrent Disease Diagnosis Indicator","preferredDefinition":"information related to the discontinuation of the anticancer drugs that kill cells used as a continuation of treatment for an extended period of time to prevent relapse prior to the  recognition of the presence of the return of a disease after a period of remission.","longName":"Cyto_Main_Disc_Prio_Recu_Diag_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE8AA58B-55F2-C96C-E040-BB89AD436566","latestVersionIndicator":"Yes","beginDate":"2013-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4030385","version":"1","preferredName":"Biological Maintenance Therapy Discontinued Prior Recurrent Disease Diagnosis Biological Maintenance Therapy Discontinued Indicator","preferredDefinition":"information related to the discontinuation of the biologic therapy used as a continuation of treatment for an extended period of time to prevent relapse prior to the recognition of the presence of the return of a disease after a period of remission.","longName":"4030379v1.0:4030372v1.0_Biol_M","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE8AA58B-5699-C96C-E040-BB89AD436566","latestVersionIndicator":"Yes","beginDate":"2013-12-27","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-12-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4035154","version":"1","preferredName":"Agent Unknown Dose Indicator","preferredDefinition":"the yes/no indicator related to information regarding the not known, not observed, not recorded, or refused quantity of an agent (such as substance or energy) administered or taken of a substance.","longName":"Agen_Unkn_Dose_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEC68C4D-B0D8-0641-E040-BB89AD435667","latestVersionIndicator":"Yes","beginDate":"2013-12-30","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-12-30","modifiedBy":"FORMBUILDER","dateModified":"2018-05-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4040191","version":"1","preferredName":"Cardiovascular Disease Present Indicator","preferredDefinition":"the yes/no/not applicable indicator regarding information related to the any abnormal condition of the heart or blood vessels that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person being found.","longName":"CV_DZ_PRES_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF143141-FB15-8665-E040-BB89AD430DAB","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"BERGANTW","dateModified":"2020-09-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4040211","version":"1","preferredName":"Gynecologic Oncology Group Major Surgery Indicator","preferredDefinition":"the yes/no/not applicable indicator regarding information related to GOG major surgery.","longName":"GOG_MAJORSURGERY_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF143141-FB96-8665-E040-BB89AD430DAB","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"SARAHB","dateModified":"2017-09-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4040234","version":"1","preferredName":"Person Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Clinical Trial Eligibility Criteria Platinum-Based Chemotherapy Discontinue Recurrent Disease Duration","preferredDefinition":"information related the period of time during which return of a disease occured following the stop or end of platinum-based synthetic or naturally-occurring chemical-based agents to treat cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192319v1.0_Plat_C","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF14F6BF-295A-4FD6-E040-BB89AD431B8B","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4050992","version":"1","preferredName":"Laboratory Procedure HER2/neu in situ Hybridization Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator relating to the result (outcome) of a laboratory test (a medical procedure that involves testing a sample of blood, urine, or other substance from the body) using in situ hybridization (ISH; use of a DNA or RNA probe to detect the presence of complementary sequences in chromosomes, cells, or tissues) to determine the level of HER2/neu (the ERBB2 gene at 17q21.1 which encodes ERRB2 receptor protein tyrosine kinase).","longName":"2854069v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF676F9A-8915-01EE-E040-BB89AD4375E2","latestVersionIndicator":"Yes","beginDate":"2014-01-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-07","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4060153","version":"1","preferredName":"Person Clinical Trial BRCA1 Mutation BRCA2  Mutation Status","preferredDefinition":"Information related to the category of mutation that is typically a heritable, permanent change in the nucleotide sequence of the either BRCA1 or BRCA2 genes, who are participating in the type of research study that tests how well new medical treatments or other interventions work.","longName":"3289550v1.0:2876255v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF8CF480-D765-8D88-E040-BB89AD4365D8","latestVersionIndicator":"Yes","beginDate":"2014-01-09","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-09","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4061433","version":"1","preferredName":"BRCA1 Mutation Status Performed Yes No Indicator","preferredDefinition":"The yes or no indicator related to the status of the BRCA1 gene.","longName":"4061432v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF8F16E6-CEFB-CD4A-E040-BB89AD436A9C","latestVersionIndicator":"Yes","beginDate":"2014-01-09","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-09","modifiedBy":"VUJANOVA","dateModified":"2019-09-07","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4061754","version":"1","preferredName":"BRCA1 Gene Mutation Type","preferredDefinition":"The information related to the type of BRCA gene mutation.","longName":"2437514v1.0:4061755v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF8F44E4-DCAF-D5B9-E040-BB89AD4333DE","latestVersionIndicator":"Yes","beginDate":"2014-01-09","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-09","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4061827","version":"1","preferredName":"BRCA1 Gene Mutation Laboratory Identifier","preferredDefinition":"The information related to the laboratory used to assess the BRCA1 gene mutation","longName":"2437514v1.0:4061825v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF8F44E4-DD36-D5B9-E040-BB89AD4333DE","latestVersionIndicator":"Yes","beginDate":"2014-01-09","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-09","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4062355","version":"1","preferredName":"Patient Metformin Associated Lactic Acidosis Condition Present Indicator","preferredDefinition":"the yes/no indicator referring to information regarding an exisiting condition of aetabolic acidosis characterized by the accumulation of lactate in the body linked to the use of Metformin which exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores on a person who receives medical attention, care, or treatment.","longName":"Pati_Metf_Asso_Lact_Cond_Pres_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF917A11-A7C0-6743-E040-BB89AD437239","latestVersionIndicator":"Yes","beginDate":"2014-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-09","modifiedBy":"FORMBUILDER","dateModified":"2014-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4094795","version":"1","preferredName":"Translational Research Specimen Fine-Needle Aspiration Biopsy Submission Indicator","preferredDefinition":"the yes/no indicator relating to information regarding the sumission of a portion of obtained materials removed from tissue or fluid with a thin needle for examination under a microscope used for studies designed to translate basic science findings into clinically useful tools and applications.","longName":"Tran_Spec_Fine_Biop_Subm_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EFF4DC77-BAFB-0FB1-E040-BB89AD4369A7","latestVersionIndicator":"Yes","beginDate":"2014-01-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-14","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4118034","version":"1","preferredName":"Estrogen Receptor Family Difference Yes No Indicator","preferredDefinition":"The yes/no indicator related to the estrogen receptor status","longName":"4118033v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10A457A-C856-4C7F-E040-BB89AD43235D","latestVersionIndicator":"Yes","beginDate":"2014-01-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4118037","version":"1","preferredName":"Lesion Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to the outcome of a disease assessment","longName":"4118036v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10A457A-C886-4C7F-E040-BB89AD43235D","latestVersionIndicator":"Yes","beginDate":"2014-01-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4118271","version":"1","preferredName":"Breast Carcinoma Surgical Involvement Type","preferredDefinition":"The information related to the type of breast carcinoma margin involvement","longName":"3290705v1.0:4118196v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10BEF55-0E91-99E0-E040-BB89AD432543","latestVersionIndicator":"Yes","beginDate":"2014-01-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4118743","version":"1","preferredName":"Malignant Neoplasm Invasive Surgical Margin Specify","preferredDefinition":"The information related to the type of invasive tumor margins.","longName":"4118742v1.0:4118736v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10E9208-123A-9F8A-E040-BB89AD432F89","latestVersionIndicator":"Yes","beginDate":"2014-01-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4119301","version":"1","preferredName":"Electrocardiography Diagnostic Procedure Corrected QT Interval Calculation Documented","preferredDefinition":"the documented source of calculating the interval between the start of the Q wave and the end of the T wave in the cardiac cycle from electrocardiography (a procedure which records the electrical current in the heart in the form of a continuous strip graph).","longName":"Elec_Diag_Corr_Calc_Docu_Corr_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10F4762-3E12-9CFC-E040-BB89AD43544B","latestVersionIndicator":"Yes","beginDate":"2014-01-28","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4122137","version":"1","preferredName":"Simple Mastectomy Performed Yes No Indicator","preferredDefinition":"Easy, not involved or complicated, not elaborate, having few parts._Surgical removal of the breast._Easy, not involved or complicated, not elaborate, having few parts._Surgical removal of the breast._Executed and carried through to completion._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4122136v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F136F23E-D305-FEAD-E040-BB89AD434EFF","latestVersionIndicator":"Yes","beginDate":"2014-01-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-30","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4122141","version":"1","preferredName":"Radical Mastectomy Performed Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not a radical mastectomy was performed.","longName":"4122140v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F136F23E-D342-FEAD-E040-BB89AD434EFF","latestVersionIndicator":"Yes","beginDate":"2014-01-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-30","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4122145","version":"1","preferredName":"Breast Re-excision Surgical Margin Yes No Indicator","preferredDefinition":"The yes/no indicator related to the re-excision of surgical margins.","longName":"4122144v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F136F23E-D374-FEAD-E040-BB89AD434EFF","latestVersionIndicator":"Yes","beginDate":"2014-01-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-30","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4122149","version":"1","preferredName":"Partial Breast Mastectomy Performed Yes No Indicator","preferredDefinition":"The yes/no indicator related to a partial mastectomy.","longName":"4122147v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F136F23E-D3EE-FEAD-E040-BB89AD434EFF","latestVersionIndicator":"Yes","beginDate":"2014-01-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-30","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4122251","version":"1","preferredName":"Definitive Breast Cancer Surgery Yes No Indicator","preferredDefinition":"The yes/ no indicator related to having other breast cancer surgery.","longName":"2185577v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F136E662-A221-376F-E040-BB89AD4357E9","latestVersionIndicator":"Yes","beginDate":"2014-01-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-30","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126011","version":"1","preferredName":"Adjuvant Therapy Paclitaxel Albumin-Stabilized Nanoparticle Formulation Administered Yes No Indicator","preferredDefinition":"The yes/ no indicator related to the administration of Abraxane","longName":"3812534v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FE30-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126012","version":"1","preferredName":"Adjuvant Therapy Alendronic Acid Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of Alendronate.","longName":"4125833v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FE4F-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126013","version":"1","preferredName":"Adjuvant Therapy Clodronate Disodium Administered Yes No Indicator","preferredDefinition":"The yes/ no indicator related to the administration of Clondronate","longName":"4125836v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FE6E-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126014","version":"1","preferredName":"Adjuvant Therapy Ibandronate Sodium Administered Yes No Indicator","preferredDefinition":"The yes/ no indicator related to the administration of Ibandronate","longName":"4125839v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FEE4-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126015","version":"1","preferredName":"Adjuvant Therapy Ixabepilone Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of Ixabepilone","longName":"4125842v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FF03-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126016","version":"1","preferredName":"Adjuvant Therapy Vindesine Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of Vindesine","longName":"4125845v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FF22-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4126017","version":"1","preferredName":"Adjuvant Therapy Zoledronate Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of Zoledronic Acid","longName":"4125851v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F14B4E06-FF41-2118-E040-BB89AD43452F","latestVersionIndicator":"Yes","beginDate":"2014-01-31","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-01-31","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4132742","version":"1","preferredName":"RT Planned Administered Dose","preferredDefinition":"The planned/prescribed Radiation Therapy dose.","longName":"RT_P_ADM_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F19A12C5-EBC4-015A-E040-BB89AD431E94","latestVersionIndicator":"Yes","beginDate":"2014-02-04","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-04","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4143613","version":"1","preferredName":"Radiation Therapy Other Site Specify","preferredDefinition":"The specific location of radiotherapy administered.","longName":"4143612v1.0:2666713v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1C31118-E9DB-1BD3-E040-BB89AD430228","latestVersionIndicator":"Yes","beginDate":"2014-02-06","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-06","modifiedBy":"MORENOC","dateModified":"2017-10-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4143638","version":"1","preferredName":"Laboratory Procedure Erythrocyte Outcome","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm and little else; biconcave, anucleate discs, 7nm diameter in mammals._The result of an action._The value (units unspecified) for a red blood cell lab test","longName":"4143634v1.0:4143631v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1C3E2F2-2AD1-114E-E040-BB89AD436ED7","latestVersionIndicator":"Yes","beginDate":"2014-02-06","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-06","modifiedBy":"REEVESD","dateModified":"2015-11-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4143639","version":"1","preferredName":"Laboratory Procedure Neutrophil Result Neutrophils Unspecified Lab Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes._The result of an action._The value (units unspecified) for a lab test for neutrophils","longName":"4143637v1.0:4143632v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1C3E2F2-2AF0-114E-E040-BB89AD436ED7","latestVersionIndicator":"Yes","beginDate":"2014-02-06","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeNote":null,"administrativeNotes":"2023.7.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4143989","version":"1","preferredName":"Laboratory Procedure Creatinine Upper Limit of Normal Outcome Indicator","preferredDefinition":"they yes/no/not applicable indicator regarding information related to the medical procedure that involves testing a sample of blood for creatinine, the breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function for which the result is related by the top value of the range of statistical characteristics.","longName":"LAB_CREATIN_ULN_RSLT_YES_NO_NA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D589C5-1934-400E-E040-BB89AD433B2C","latestVersionIndicator":"Yes","beginDate":"2014-02-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-07","modifiedBy":"ZHWENDY","dateModified":"2023-10-12","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"9/1/2023: added AQT per cadsr0002804.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4143997","version":"1","preferredName":"Laboratory Procedure Creatinine Result Indicator","preferredDefinition":"the yes/no/not applicable indicator regarding information related to the medical procedure that involves testing a sample of blood for creatinine, the breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.","longName":"LAB_CREATIN_RSLT_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D589C5-195F-400E-E040-BB89AD433B2C","latestVersionIndicator":"Yes","beginDate":"2014-02-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-07","modifiedBy":"ZHWENDY","dateModified":"2022-08-15","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"8/15/2022: removed the apstorphe from AQT for Alliance.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4148140","version":"1","preferredName":"Radiation Therapy Anatomic Site","preferredDefinition":"The anatomical site where radiotherapy has occurred.","longName":"4148139v1.0:2017313v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F228216E-A2D0-0AAD-E040-BB89AD43216B","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-11","modifiedBy":"REEVESD","dateModified":"2016-05-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4148392","version":"1","preferredName":"Clinical Study Involvement Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's involvement with a clinical study.","longName":"4148391v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F228B298-F587-9115-E040-BB89AD434D73","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-11","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4151645","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Disease Disease Progression Diagnosis Malignant Neoplasm Recurrent Disease Documented Type","preferredDefinition":"information related to the diagnosis of the return of signs and symptoms of cancer after a period of improvement based on the doumented return of a tumor.","longName":"2236731v1.0:3178332v1.0_Mali_R","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2381D0F-C750-F453-E040-BB89AD4318DE","latestVersionIndicator":"Yes","beginDate":"2014-02-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-12","modifiedBy":"FORMBUILDER","dateModified":"2014-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4152006","version":"1","preferredName":"First Disease Recurrence CA-125 Antigen Result Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator relating to information regarding an antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum) useful for monitoring clinical responses to the treatment and recurrence of disease.","longName":"FIR_REC_CA125_RSL_YES_NO_UNKNO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2386DE7-FB41-695B-E040-BB89AD4338E8","latestVersionIndicator":"Yes","beginDate":"2014-02-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-12","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":"Curated to support TCGA projects","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4152066","version":"1","preferredName":"Person Malignant Neoplasm Detection Evaluation Method Clinical Trial Eligibility Criteria Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding information related to the method or test used to determine the presence of a malignant neoplastic tumor as information that can be used to judge response to treatment as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192271v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2386DE7-FB61-695B-E040-BB89AD4338E8","latestVersionIndicator":"Yes","beginDate":"2014-02-12","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-12","modifiedBy":"KENNISHM","dateModified":"2021-06-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4155294","version":"1","preferredName":"Tissue Whole Blood Specimen Yes No Indicator","preferredDefinition":"The yes/no indicator related to the collection of a whole blood tissue specimen.","longName":"4155293v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F24C373B-65B4-4EAF-E040-BB89AD436BF2","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-13","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4155831","version":"1","preferredName":"Lymph Node Confirmed Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator whether a lymph node confirmed by pathologic means.","longName":"LN_CONF_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F24E843E-556B-5FFD-E040-BB89AD430BF9","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2014-02-13","modifiedBy":"KENNISHM","dateModified":"2021-08-11","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4155931","version":"1","preferredName":"Protocol Agent Prior Hypersensitivity Yes No Indicator","preferredDefinition":"The yes/no indicator relating to an existing hypersensitivity, a local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized, to a therapeutic agent (drug, intervention therapy) used in a clinical trial protocol.","longName":"2854924v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F24F7D6C-3607-C4D8-E040-BB89AD43606A","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2014-02-13","modifiedBy":"ARAGONP","dateModified":"2018-09-07","changeNote":"03-09-2018 Removed space at end of Question Text. DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4155954","version":"1","preferredName":"Patient Prior Therapeutic Procedure Confirmation Indicator","preferredDefinition":"The yes/no indicator regarding the administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process for a person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"Pati_Prio_Ther_Conf_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F24F7D6C-3680-C4D8-E040-BB89AD43606A","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2014-02-13","modifiedBy":"SOKKERL","dateModified":"2023-02-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4156018","version":"1","preferredName":"Autoimmune Disease or Disorder Diagnosis Indicator","preferredDefinition":"The yes/no indicator relating to the investigation, analysis and recognition of the presence and nature of any abnormal condition of the body's autoimmunity that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person.","longName":"Auto_Dise_Diag_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F250136F-E909-44FD-E040-BB89AD436D96","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"LEVENTHM","dateCreated":"2014-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeNote":"6/2/16 jk added alt question text for UWI2014-03-01.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4158335","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Disease Disease Progression Diagnosis Malignant Neoplasm Measurable Disease Evaluation Method Type","preferredDefinition":"the type or method of evaluation used to determine information related to the diagnosis of the return of signs and symptoms of cancer after a period of improvement.","longName":"2236731v1.0:3178332v1.0_317902","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F260FE8E-C349-B418-E040-BB89AD434FD7","latestVersionIndicator":"Yes","beginDate":"2014-02-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4158339","version":"1","preferredName":"Person Malignant Neoplasm Recurrent Disease Disease Progression Therapeutic Procedure Receive Chemotherapy Regimen Receive Type","preferredDefinition":"information related to a person having received non-cytoxic therapeutic agents to produce an effect that is intended to alter the course of a pathologic process following the return of signs and symptoms of cancer after a period of improvement.","longName":"2236731v1.0:3178964v1.0_317903","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F260FE8E-C3E4-B418-E040-BB89AD434FD7","latestVersionIndicator":"Yes","beginDate":"2014-02-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"FORMBUILDER","dateModified":"2014-08-29","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4158483","version":"1","preferredName":"Patient Serious Concomitant Disease or Disorder Eligibility Determination Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding information related to criteria to determine eligibility of patients for medical care programs and services based on serious concomitant illness.","longName":"2177068v1.0:3153660v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F26328D4-E180-7A9B-E040-BB89AD437946","latestVersionIndicator":"Yes","beginDate":"2014-02-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"REBOYJ","dateModified":"2014-03-25","changeNote":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4158484","version":"1","preferredName":"Heart Valve Leaflet Device Component Use Yes/No/Unknown/NA Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator regarding information related to heart pace-maker being used.","longName":"HVLDC_USE_YES_NO_UNKNOWN_NA_IN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F26328D4-E1B2-7A9B-E040-BB89AD437946","latestVersionIndicator":"Yes","beginDate":"2014-02-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"SARAHB","dateModified":"2016-07-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4158519","version":"1","preferredName":"Patient Eligibility Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable regarding information that identifies whether eligibility criteria have been met for the patient to participate in the clinical study.","longName":"PT_ELIG_YES_NO_UNKNOWN_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F26328D4-E1FB-7A9B-E040-BB89AD437946","latestVersionIndicator":"Yes","beginDate":"2014-02-14","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-02-14","modifiedBy":"REBOYJ","dateModified":"2014-03-25","changeNote":"Replaced VD Eligibility Ind-3 (2018259v1) with VD Yes No Unknown Indicator (3506034v1) - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4163175","version":"1","preferredName":"Lung Stereotactic Body Radiation Therapy Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intention to treat the lung with SBRT","longName":"Lung_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2C6177F-49CB-AAA0-E040-BB89AD430C65","latestVersionIndicator":"Yes","beginDate":"2014-02-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-19","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4163263","version":"1","preferredName":"Peripheral Lung Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intention to treat the peripheral lung with SBRT","longName":"Peri_Lung_Ster_Body_Radi_Inte_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2C86C6A-DB46-4A86-E040-BB89AD430E63","latestVersionIndicator":"Yes","beginDate":"2014-02-19","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-19","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4165856","version":"1","preferredName":"Liver Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intent to treat a liver neoplasm with SBRT(Stereotactic Body Radiotherapy).","longName":"Live_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2D91770-8734-D7EA-E040-BB89AD430E7E","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-20","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4166049","version":"1","preferredName":"Nodal Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is intention to treat a nodal area of neoplastic disease with SBRT(Stereotactic Body Radiotherapy)","longName":"Noda_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2D9951B-6B81-A00F-E040-BB89AD435E50","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-20","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4166331","version":"1","preferredName":"Central Nervous System Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intention to treat the CNS structures with SBRT(Stereotactic Body Radiotherapy).","longName":"Cent_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DB4E57-E857-23D8-E040-BB89AD436F54","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-20","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4167467","version":"1","preferredName":"Bone Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intention to treat as osseous/skeletal structure with SBRT(Stereotactic Body Radiotherapy).","longName":"Bone_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DBBD18-D5B9-027C-E040-BB89AD436EE1","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-20","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4167818","version":"1","preferredName":"Abdominal Stereotactic Body Radiation Intent Administration Yes No Indicator","preferredDefinition":"The yes/no indicator whether there is the intention to treat neoplastic disease of the Abdominal-Pelvic region with SBRT(Stereotactic Body Radiotherapy) .","longName":"Abdo_Ster_Body_Radi_Inte_Admi_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DC16D2-36F4-5893-E040-BB89AD430749","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-02-20","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4171112","version":"1","preferredName":"Patient Right Cochlea Radiation Therapy Administered Mean Dose","preferredDefinition":"The mean dose in Grays received to the right cochlea of a patient undergoing radiation therapy for head and neck cancer.","longName":"PT_RT_COC_RT_ADM_MEAN_DOSE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F32AFFDD-3B8F-6C7D-E040-BB89AD431DC1","latestVersionIndicator":"Yes","beginDate":"2014-02-24","endDate":null,"createdBy":"RUETERJ","dateCreated":"2014-02-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4171113","version":"1","preferredName":"Patient Right Cochlea Radiation Therapy Administered Maximum Dose","preferredDefinition":"The maximum dose in Grays received to the right cochlea of a patient undergoing radiation therapy for head and neck cancer.","longName":"PT_RT_COC_RT_ADM_MAX_DOSE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F32AFFDD-3BAF-6C7D-E040-BB89AD431DC1","latestVersionIndicator":"Yes","beginDate":"2014-02-24","endDate":null,"createdBy":"RUETERJ","dateCreated":"2014-02-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4171130","version":"1","preferredName":"Patient Left Cochlea Radiation Therapy Administered Mean Dose","preferredDefinition":"The mean dose in Grays received to the left cochlea of a patient undergoing radiation therapy for head and neck cancer.","longName":"PT_LT_COC_RT_ADM_MEAN_DOSE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F32AFFDD-3BCF-6C7D-E040-BB89AD431DC1","latestVersionIndicator":"Yes","beginDate":"2014-02-24","endDate":null,"createdBy":"RUETERJ","dateCreated":"2014-02-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4171131","version":"1","preferredName":"Patient Left Cochlea Radiation Therapy Administered Maximum Dose","preferredDefinition":"The maximum dose in Grays received to the left cochlea of a patient undergoing radiation therapy for head and neck cancer.","longName":"PT_LT_COC_RT_ADM_MAX_DOSE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F32AFFDD-3BEF-6C7D-E040-BB89AD431DC1","latestVersionIndicator":"Yes","beginDate":"2014-02-24","endDate":null,"createdBy":"RUETERJ","dateCreated":"2014-02-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4179096","version":"1","preferredName":"Eastern Cooperative Oncology Group Performance Status Questionnaire Performed Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not an ECOG performance status was obtained.","longName":"4179095v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3562286-8729-5905-E040-BB89AD435B14","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-26","modifiedBy":"BRETTS","dateModified":"2014-10-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4180989","version":"1","preferredName":"Other Pregnancy Specify","preferredDefinition":"Information related to other pregnancies.","longName":"4180843v1.0:2556910v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3698997-023A-76CC-E040-BB89AD43338F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-27","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4181797","version":"1","preferredName":"Pregnancy Risk Factor Specify","preferredDefinition":"Information related to pregnancy risk factors that may be present.","longName":"4181018v1.0:2556910v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3698997-026A-76CC-E040-BB89AD43338F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-27","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182265","version":"1","preferredName":"Pregnancy Medication Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to the administration of medications during pregnancy","longName":"4182263v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36AA2C8-1C51-0A9E-E040-BB89AD431253","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-27","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4183763","version":"1","preferredName":"Pregnancy Outcome Number","preferredDefinition":"Information related to the number of babies born as the result of a pregnancy.","longName":"4183756v1.0:2182118v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37C951B-D16F-91F6-E040-BB89AD433AC7","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4183821","version":"1","preferredName":"Spontaneous Birth Medical Reason Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not the medical condition in question was the cause of a spontaneous birth.","longName":"4183773v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37C951B-D1C1-91F6-E040-BB89AD433AC7","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184686","version":"1","preferredName":"Elective Surgical Procedure Medical Reason Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the medical condition in question was the cause for an elective birth.","longName":"4183820v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37C951B-D1E0-91F6-E040-BB89AD433AC7","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184696","version":"1","preferredName":"Pregnancy Birth Outcome","preferredDefinition":"Information related to the outcome of a pregnancy","longName":"3007099v1.0:4184695v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37C951B-D2AD-91F6-E040-BB89AD433AC7","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184713","version":"1","preferredName":"Pregnancy Offspring Sex Type","preferredDefinition":"The information related to the sex of the offspring born as the result of a pregnancy.","longName":"4184712v1.0:4184700v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37C951B-D32A-91F6-E040-BB89AD433AC7","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184972","version":"1","preferredName":"Adverse Event Nausea Begin Date","preferredDefinition":"The date on which nausea began.","longName":"4184967v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C779-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184976","version":"1","preferredName":"Adverse Event Nausea Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator related to the occurrence of nausea.","longName":"4184975v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C7BA-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"MORENOC","dateModified":"2018-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184980","version":"1","preferredName":"Adverse Event Vomiting Occurrence Yes No Indicator","preferredDefinition":"The yes/no indicator related to the occurrence of vomiting","longName":"4184979v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C809-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184984","version":"1","preferredName":"Adverse Event Nausea Adverse Event Outcome Type","preferredDefinition":"Information related to the outcome of nausea","longName":"4184967v1.0:2015367v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D697D-98BD-39CD-E040-BB89AD43304C","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4184985","version":"1","preferredName":"Adverse Event Nausea End Date","preferredDefinition":"The date on which the adverse event nausea ended","longName":"4184967v1.0:2188674v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C8A2-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185011","version":"1","preferredName":"Adverse Event Nausea Occurrence Time","preferredDefinition":"The time in which the occurrence of nausea happens","longName":"4184967v1.0:4185006v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C975-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185061","version":"1","preferredName":"Adverse Event Nausea Overall Time","preferredDefinition":"The information related to the overall time nausea is occurring.","longName":"4184967v1.0:4185060v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-C9F7-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185078","version":"1","preferredName":"Adverse Event Nausea Day Time","preferredDefinition":"The amount of time during the day the adverse event nausea is present.","longName":"4184967v1.0:4185070v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D89BB-CABD-4FA0-E040-BB89AD433578","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185086","version":"1","preferredName":"Adverse Event Nausea Weekly Time","preferredDefinition":"The amount of time per week the adverse event nausea is occurring","longName":"4184967v1.0:4185083v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-D9C7-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185090","version":"1","preferredName":"Adverse Event Nausea Treatment Yes No Indicator","preferredDefinition":"The yes/no indicator related to treatment received for nausea","longName":"4185089v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-D9F7-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4185129","version":"1","preferredName":"Adverse Event Nausea Current Outcome","preferredDefinition":"The current outcome of the adverse event nausea.","longName":"4184967v1.0:4185128v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DA16-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187422","version":"1","preferredName":"Adverse Event Nausea Medication Dose","preferredDefinition":"Information related to the dose of medication received for nausea.","longName":"4184967v1.0:4187418v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DB42-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187433","version":"1","preferredName":"Laboratory Procedure CD4 Expressing Cell Count Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator determining if the laboratory procedure CD4 lympocyte count was completed","longName":"LAB_PROC_CD4_CNT_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DB61-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2014-02-28","modifiedBy":"CARTERS","dateModified":"2021-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187452","version":"1","preferredName":"Adverse Event Vomiting Begin Date","preferredDefinition":"The date on which the adverse event vomiting began","longName":"4187450v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DBF2-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187454","version":"1","preferredName":"Adverse Event Vomiting Occurrence Time","preferredDefinition":"The time in which the adverse event vomiting occurrs.","longName":"4187450v1.0:4185006v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37E8166-1BD0-7A2C-E040-BB89AD43217C","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187455","version":"1","preferredName":"Adverse Event Vomiting Overall Time","preferredDefinition":"The overall time in which the vomiting is occurring","longName":"4187450v1.0:4185060v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37E8166-1BEF-7A2C-E040-BB89AD43217C","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187456","version":"1","preferredName":"Adverse Event Vomiting Outcome Type","preferredDefinition":"The information related to the outcome of the adverse event vomiting.","longName":"4187450v1.0:2015367v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37E8166-1C14-7A2C-E040-BB89AD43217C","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187459","version":"1","preferredName":"Adverse Event Vomiting Treatment Yes No Indicator","preferredDefinition":"The yes/no indicator related to any treatment received for vomiting.","longName":"4187458v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DC11-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187460","version":"1","preferredName":"Adverse Event Vomiting Current Outcome","preferredDefinition":"The current outcome of the adverse event vomiting.","longName":"4187450v1.0:4185128v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DC30-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187461","version":"1","preferredName":"Adverse Event Vomiting Medication Dose","preferredDefinition":"Information related to the dose of medication taken for the adverse event vomiting","longName":"4187450v1.0:4187418v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37DF567-DC4F-5FD2-E040-BB89AD4378FE","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187537","version":"1","preferredName":"Special Interest Adverse Event Occurrence Adverse Event Yes or No Response","preferredDefinition":"The yes/no indicator related to the occurrence of an adverse event of special interest.","longName":"3729294v1.0:4187534v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37F0C83-D4D1-7BCF-E040-BB89AD436070","latestVersionIndicator":"Yes","beginDate":"2014-02-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-02-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187639","version":"1","preferredName":"Olaparib Dose Modification Dose Modification Status","preferredDefinition":"Information related to the dosing modification of the agent Olaparib_the dose modification status.","longName":"4187638v1.0:2188246v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3B5BB57-C9C0-C38E-E040-BB89AD430A94","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"SARAHB","dateModified":"2021-09-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187712","version":"1","preferredName":"Adverse Event Result Olaparib Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not Olaparib had a result on the adverse event.","longName":"4187706v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3B6CF14-6169-47A0-E040-BB89AD432823","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4187723","version":"1","preferredName":"Adverse Event Therapeutic Procedure Yes or No Response","preferredDefinition":"A yes/no indicator to select if treatment was given and/or procedures were performed for the adverse event.","longName":"3735415v1.0:4187713v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3B6CF14-622D-47A0-E040-BB89AD432823","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188080","version":"1","preferredName":"Audiogram Testing  Result in Decibels Score","preferredDefinition":"The decibel threshold level of each ear in response to measured frequency levels of sound during an audiogram test.","longName":"AUD_TST_RSLT_dB_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3B9AC54-DF63-F632-E040-BB89AD430CC0","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"PATELV","dateCreated":"2014-03-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188234","version":"1","preferredName":"Adverse Event Study Procedure Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the adverse event was caused by a study procedure.","longName":"4188233v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-146A-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188238","version":"1","preferredName":"Serious Adverse Event Other Criterion Yes No Indicator","preferredDefinition":"The yes/no indicator for when a serious adverse event is not covered by any other criteria that would describe it as \"serious\"","longName":"4188237v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-14AE-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188243","version":"1","preferredName":"Investigational Product Overdose Start Date","preferredDefinition":"The start date for the overdose of the investigational product","longName":"4188242v1.0:2179512v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-151B-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188244","version":"1","preferredName":"Investigational Product Overdose Agent End Date","preferredDefinition":"The end date of the overdose of the investigational product.","longName":"4188242v1.0:2179511v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-153A-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188248","version":"1","preferredName":"Investigational Product Intent Overdose Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not the investigational product overdose was intentional.","longName":"4188247v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-157E-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188252","version":"1","preferredName":"Adverse Event Associated Overdose Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not the investigational product overdose was associated with an adverse event.","longName":"4188251v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BB0253-15C2-257F-E040-BB89AD433F06","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188601","version":"1","preferredName":"Liver Symptom Intermittent Yes No Indicator","preferredDefinition":"The yes/no indicator related to the occurrence of liver symptoms","longName":"4188600v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3C9FA68-9C7B-DB1C-E040-BB89AD43523F","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-04","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188604","version":"1","preferredName":"Liver Symptom Specify","preferredDefinition":"Information relating to the specification of liver symptoms.","longName":"4188603v1.0:2556910v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CAFF32-EC63-8ECF-E040-BB89AD437BDA","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-04","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188633","version":"1","preferredName":"Liver Risk Factor Yes No Indicator","preferredDefinition":"The yes/no indicator related to the presence of a liver risk factor.","longName":"4188632v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CB7F0D-5DF6-A7F8-E040-BB89AD437D8B","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-04","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190080","version":"1","preferredName":"Prior Therapy Administered Chemotherapy Agent Name","preferredDefinition":"The name of the chemotherapy agent administered.","longName":"2197794v1.0:3145827v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DED8F3-9900-4891-E040-BB89AD4356BF","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190240","version":"1","preferredName":"Liver Symptom Name","preferredDefinition":"The name of the liver symptom experienced.","longName":"4188603v1.0:4190231v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DE6F34-4D02-704A-E040-BB89AD432216","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190698","version":"1","preferredName":"Liver Risk Factor Name","preferredDefinition":"The name of the risk factor associated with liver disease.","longName":"4188632v1.0:4190642v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DE6F34-4F8E-704A-E040-BB89AD432216","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190703","version":"1","preferredName":"Liver Risk Factor Start Date","preferredDefinition":"The start date of the liver risk factor.","longName":"4188632v1.0:2016970v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DF724F-FF0A-DE0C-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190704","version":"1","preferredName":"Liver Risk Factor End Date","preferredDefinition":"The end date of the liver risk factor.","longName":"4188632v1.0:2188674v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DF724F-FF29-DE0C-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190705","version":"1","preferredName":"Liver Risk Factor Details Text","preferredDefinition":"Free text field to describe the liver risk factor.","longName":"4188632v1.0:2815290v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DF724F-FF48-DE0C-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4190707","version":"1","preferredName":"Liver Risk Factor Reference Time","preferredDefinition":"Information about the time frame of the liver risk factor.","longName":"4188632v1.0:4190706v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3DF724F-FF67-DE0C-E040-BB89AD433D39","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192277","version":"1","preferredName":"Liver Diagnostic Investigation Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not a liver diagnostic investigation was performed.","longName":"4192273v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E22050-5F6E-FEF1-E040-BB89AD4367D7","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192292","version":"1","preferredName":"Liver Diagnostic Investigation Specify","preferredDefinition":"Specify details of the liver diagnostic investigation","longName":"4192273v1.0:2556910v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E20D12-E17F-C0BA-E040-BB89AD434702","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192296","version":"1","preferredName":"Liver Diagnostic Investigation Date","preferredDefinition":"The date of the liver diagnostic investigation.","longName":"4192273v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E22050-5FB7-FEF1-E040-BB89AD4367D7","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"ZHANGWE","dateModified":"2017-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192303","version":"1","preferredName":"Liver Diagnostic Investigation Result","preferredDefinition":"The result of the liver diagnostic investigation","longName":"4192273v1.0:2017166v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E22050-5FD6-FEF1-E040-BB89AD4367D7","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192358","version":"1","preferredName":"Liver Diagnostic Investigation Type","preferredDefinition":"The type of liver diagnostic investigation that was performed.","longName":"4192273v1.0:4192338v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E20D12-E20B-C0BA-E040-BB89AD434702","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-05","modifiedBy":"ZHANGWE","dateModified":"2017-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4192359","version":"1","preferredName":"Patient Quality of Life Clinical Study Vendor Refuse Consent Reason","preferredDefinition":"Information related to the reasons why a person is refusing to agree to participate in a Quality of Life electronic data capture system._The reasons why a patient is refusing to participate in quality of life electronic data capture system.","longName":"PT_QOLCS_VEN_REF_CNST_REA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E22050-6257-FEF1-E040-BB89AD4367D7","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"PATELV","dateCreated":"2014-03-05","modifiedBy":"AUGERG","dateModified":"2020-09-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4193694","version":"1","preferredName":"Proton RT Modality Type","preferredDefinition":"Information related to the type of proton radiation treatment modality being delivered.","longName":"PROT_RT_MOD_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E2CB8D-7CF3-DA4B-E040-BB89AD432541","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2014-03-05","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4203701","version":"1","preferredName":"Prior Steroid Therapy Administered Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator determining if the prior steroid therapy was administered","longName":"PR_STER_ADMIN_YNNA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F407690A-9F95-7A2E-E040-BB89AD4322CA","latestVersionIndicator":"Yes","beginDate":"2014-03-07","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2014-03-07","modifiedBy":"OBROPTAJ","dateModified":"2015-05-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4203825","version":"1","preferredName":"Audiogram Test Transmission Sound Assessment  Type","preferredDefinition":"The transmission of sound to the inner ear through the vibration of air down the ear canal, through the middle ear and to the very delicate cochlea or transmission of sound to the inner ear through the bone of the skull to the cochlea and hearing nerves.","longName":"AUD_TST_TRAN_SND_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4095F3A-F451-B2CB-E040-BB89AD430317","latestVersionIndicator":"Yes","beginDate":"2014-03-07","endDate":null,"createdBy":"PATELV","dateCreated":"2014-03-07","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4217871","version":"1","preferredName":"Estrogen Receptor Progesterone Receptor Analysis Performed Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not HER2 and ER/PgR was assessed","longName":"2774748v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F46FC946-1D86-4CE3-E040-BB89AD436E7A","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-12","modifiedBy":"TSESU","dateModified":"2022-11-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4233103","version":"1","preferredName":"Post Obstruction Pneumonia Disease or Disorder Present Yes No Not Applicable Indicator","preferredDefinition":"The Yes/No/NA indicator of information related to the presence of post-obstructive pneumonia, an inflammation focally or diffusely affecting the lung parenchyma, caused by a blockage or obstruction of the airway.","longName":"POST_OBST_PNEUM_YNNA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4F57F18-97A2-8C11-E040-BB89AD433512","latestVersionIndicator":"Yes","beginDate":"2014-03-19","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2014-03-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4233310","version":"1","preferredName":"Lung Pleural Effusion Yes No Not Applicable Indicator","preferredDefinition":"The Yes/No/NA Indicator for information related to pleural effusion pertaining to the lung.","longName":"LNG_PLR_EFF_YNNA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4FACC1C-F4A2-327A-E040-BB89AD436C0C","latestVersionIndicator":"Yes","beginDate":"2014-03-19","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2014-03-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4242466","version":"1","preferredName":"Radiation Therapy Image Guided Radiation Therapy Institution Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator whether an institution administering Image Guided Radiation Therapy is credentialed.","longName":"RT_IGRT_INST_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F51E84A4-EA68-C03D-E040-BB89AD433B6B","latestVersionIndicator":"Yes","beginDate":"2014-03-21","endDate":null,"createdBy":"PATELV","dateCreated":"2014-03-21","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4250608","version":"1","preferredName":"Patient Bilateral Breast Carcinoma Hormone Level Inclusion Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the hormonal status reported applies to bilateral breast cancer","longName":"4250607v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F574F17B-2F01-8C0B-E040-BB89AD4333A1","latestVersionIndicator":"Yes","beginDate":"2014-03-25","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-03-25","modifiedBy":"FINCHAMB","dateModified":"2023-04-03","changeNote":null,"administrativeNotes":"2/9/23 AQT added per EA request. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4255353","version":"1","preferredName":"Radiation Therapy Boost Administered Sequence Type","preferredDefinition":"Information related to the sequence the radiation therapy boost is administered.","longName":"RT_BOOST_ADM_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AC8904-5B79-FD1C-E040-BB89AD4340BB","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"GEINOZS","dateCreated":"2014-03-28","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261287","version":"1","preferredName":"Person Neurocognitive Hopkins Verbal Learning Test Revised Assessment Administered Indicator","preferredDefinition":"The reasons why the neurocognitive assessment HVLT-R test  was not completed or partially completed or completed.","longName":"PR_NEU_HVLTR_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F611F113-0307-9F08-E040-BB89AD4346E9","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"PATELV","dateCreated":"2014-04-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261296","version":"2","preferredName":"Trail Making Test Assessment Administered Indicator","preferredDefinition":"The reasons why the neurocognitive assessment Trail Making Test was not completed or partially completed or completed.","longName":"TMT_ASSESSMENT_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"429CA601-4FC5-4CF5-E053-F662850A6632","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"PATELV","dateCreated":"2016-12-01","modifiedBy":"PATELV","dateModified":"2016-12-01","changeNote":"Data Element Concept updated in effort to harmonize CDEs Dec 1 2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261318","version":"1","preferredName":"Person Neurocognitive Controlled Oral Word Association Test Assessment Administered Indicator","preferredDefinition":"The reasons why the neurocognitive assessment Controlled Oral Word Association test  was not completed or partially completed or completed.","longName":"PR_NEU_COWA_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F611F113-0501-9F08-E040-BB89AD4346E9","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"PATELV","dateCreated":"2014-04-02","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4264696","version":"1","preferredName":"Evaluation Performed Yes, No, or Unknown Response","preferredDefinition":"A  yes/no/survival status only response","longName":"2014519v1.0:4264695v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F679D28C-1636-F10E-E040-BB89AD432CC2","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-04-07","modifiedBy":"SARAHB","dateModified":"2021-02-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265211","version":"1","preferredName":"Peripheral Lung Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the Peripheral Lung as per assignment at study entry.","longName":"Peri_Lung_Radi_Admi_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68BF921-5D19-4035-E040-BB89AD43688A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-08","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265456","version":"1","preferredName":"Liver Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the liver as per assignment at study entry.","longName":"Live_Radi_Admi_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F69F3639-89A3-C3F1-E040-BB89AD431B31","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-09","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4273456","version":"1","preferredName":"Intensity-Modulated Spot-Scanning Proton Radiation Therapy Modality Type","preferredDefinition":"Information related to the specific manner radiation therapy is delivered as a form of intensity-modulated radiation therapy that uses narrow pencil beams of protons to deliver radiation to a precise target while sparing surrounding tissues.","longName":"Spot_Scan_IMPT_type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F72F1E39-BECB-0BB2-E040-BB89AD4333F4","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"GEINOZS","dateCreated":"2014-04-16","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4276331","version":"1","preferredName":"Karnofsky Performance Status Unknown Response Evaluation Yes No Indicator","preferredDefinition":"Information related to the unknown response of the score from the Karnofsky Performance status scale, representing the functional capabilities of a person.","longName":"KPS_UNKNOWN_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7912C8F-3E49-8E6B-E040-BB89AD436231","latestVersionIndicator":"Yes","beginDate":"2014-04-21","endDate":null,"createdBy":"GEINOZS","dateCreated":"2014-04-21","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4280769","version":"1","preferredName":"Mediastinal Cervical Node Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the mediasinal/cervical lymph node as per assignment at study entry.","longName":"Medi_Cerv_Node_Radi_Admi_Tota_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7BB5DE0-3570-0309-E040-BB89AD436A02","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-23","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4280818","version":"1","preferredName":"Bone Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the bone(osseous) as per assignment at study entry.","longName":"Bone_Radi_Admi_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7BB5973-9ED7-ADAC-E040-BB89AD4354C6","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-23","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4281894","version":"1","preferredName":"Nonmetastatic Primary Breast Neoplasm Neoadjuvant Therapy Negation Pathologic Complete Response Evidence Yes No Indicator","preferredDefinition":"The yes or no indicator related to the evidence of non-metastatic primary breast cancer showing evidence of non pathological complete response.","longName":"4281849v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F81B5639-F133-8BD1-E040-BB89AD434AF0","latestVersionIndicator":"Yes","beginDate":"2014-04-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-04-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4281895","version":"1","preferredName":"Nonmetastatic Primary Breast Neoplasm Negation Pathologic Complete Response Surgery Evidence Yes No Indicator","preferredDefinition":"The yes/no indicator related to the evidence of non-metastatic primary breast cancer showing evidence of non pathological complete response at surgery.","longName":"4281868v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F81B5639-F152-8BD1-E040-BB89AD434AF0","latestVersionIndicator":"Yes","beginDate":"2014-04-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-04-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4281896","version":"1","preferredName":"Nonmetastatic Primary Breast Neoplasm Positive Lymph Node Surgery Evidence Yes No Indicator","preferredDefinition":"The yes/no indicator related to non-metastatic primary breast cancer showing axillary node-positive or axillary node-negative.","longName":"4281893v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F81A8B67-FB45-EA20-E040-BB89AD4368F3","latestVersionIndicator":"Yes","beginDate":"2014-04-28","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-04-28","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4281954","version":"1","preferredName":"Abdominal Pelvis Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the abdominal-pelvic area of the body as per assignment at study entry.","longName":"Abdo_Pelv_Radi_Admi_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F81BB550-A0D1-9192-E040-BB89AD434CB6","latestVersionIndicator":"Yes","beginDate":"2014-04-28","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-28","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4282058","version":"1","preferredName":"Satellite Lesion Present Number","preferredDefinition":"The number of satellite lesions present.","longName":"SATELLITE_LES_NUM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F81D1D5D-7AA5-5FB6-E040-BB89AD43249A","latestVersionIndicator":"Yes","beginDate":"2014-04-28","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-28","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4282730","version":"1","preferredName":"Lesion Maximum Diameter Assessment Measurement","preferredDefinition":"The maximum measurement of a lesion.","longName":"Les_Max_Diam_Asmt_Meas","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F82EEDF0-F9DF-538D-E040-BB89AD437A83","latestVersionIndicator":"Yes","beginDate":"2014-04-29","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-29","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4283552","version":"1","preferredName":"Prior Therapy Administered Name","preferredDefinition":"The name of the prior neoadjuvant therapy agent administered.","longName":"2197794v1.0:4283550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F834A2E0-E6DF-938A-E040-BB89AD431A2F","latestVersionIndicator":"Yes","beginDate":"2014-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-04-29","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4285050","version":"1","preferredName":"Central Nervous System Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to structures of the central nervous system as per assignment at study entry.","longName":"CNS_Rad_Ther_Admin_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F84480CD-6728-7BD7-E040-BB89AD436CEA","latestVersionIndicator":"Yes","beginDate":"2014-04-30","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-30","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4285141","version":"1","preferredName":"Lung Radiation Therapy Administered Total Dose","preferredDefinition":"The total dose of Radiation to be administered to the lung as per assignment at study entry.","longName":"Lung_Radi_Admi_Tota_Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F844E8EC-BDC1-BE05-E040-BB89AD437ED6","latestVersionIndicator":"Yes","beginDate":"2014-04-30","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-04-30","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4287023","version":"1","preferredName":"Metastatic Neoplasm Documented Location Yes No Indicator","preferredDefinition":"The yes/no indicator to ask whether there is documentation of the location of distinct metastases","longName":"TUMOR_DOC_LCTN_IND-2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8576036-F325-1E7E-E040-BB89AD4326D6","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-01","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4287047","version":"1","preferredName":"Metastatic Neoplasm Treatment Plan Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator that asks whether there is a treatment plan for the treatment of distinct metastases.","longName":"MET_NEO_Tx_ASSMT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F858137E-4C76-27CA-E040-BB89AD431246","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-01","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4287189","version":"1","preferredName":"Dose Level Closure Alert Text","preferredDefinition":"Text to indicate that a dose closure alert is to be generated.","longName":"DOSE_LEV_CLSR_ALRT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-DF92-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-01","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4288830","version":"1","preferredName":"Malignant Neoplasm Longest Dimension Value","preferredDefinition":"The list that represents the values of the dimensional measurement of a neoplastic lesion.","longName":"MALIG_LNG__DIM_VAL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F86DF4F8-4EDF-4A5A-E040-BB89AD432026","latestVersionIndicator":"Yes","beginDate":"2014-05-02","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-02","modifiedBy":"BERGANTW","dateModified":"2017-01-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4288942","version":"1","preferredName":"Satellite Lesion Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator to ask whether an assessment was performed to determine the presence of satellite lesions at baseline or follow up evaluation.","longName":"SAT_LES_ASSES_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F86EA052-68F8-EADF-E040-BB89AD43615A","latestVersionIndicator":"Yes","beginDate":"2014-05-02","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-02","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4289352","version":"1","preferredName":"Intrahepatic Cholangiocarcinoma Pathologic Diagnosis Yes No Indicator","preferredDefinition":"The yes/no indicator that asks whether there is pathologic diagnosis of intrahepatic cholangiocarcinoma.","longName":"INTR_HEP_CHOL_PATH_DX","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F870E751-F777-D67E-E040-BB89AD43392D","latestVersionIndicator":"Yes","beginDate":"2014-05-02","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-02","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4291584","version":"1","preferredName":"Patient Neck Radiation Therapy Plan Defined Stratification CriterionType","preferredDefinition":"Radiation therapy given to the neck depending on the extent of the disease.","longName":"PT_NK_RT_PLN_STRAT_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8ABEA26-60F6-ED7C-E040-BB89AD4312B2","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"PATELV","dateCreated":"2014-05-05","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4291603","version":"1","preferredName":"Regional Matted Lymph Nodes Present Yes No Unknown Indicator","preferredDefinition":"a yes/no indicator to ask if clustered or matted lymph nodes are present.","longName":"REG_MATT_LN_PR_YNUNK_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8ABEA26-6152-ED7C-E040-BB89AD4312B2","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"PATELV","dateCreated":"2014-05-05","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4291826","version":"1","preferredName":"Image Guided Radiation Therapy Type","preferredDefinition":"The type of IGRT.","longName":"IMG_RAD_THER_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8AD0F3F-D67F-8EB0-E040-BB89AD4346D2","latestVersionIndicator":"Yes","beginDate":"2014-05-05","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-05","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4293401","version":"1","preferredName":"Extrahepatic Metastasis Status Yes No Indicator","preferredDefinition":"The yes/no question that asks whether extrahepatic metastasis is present.","longName":"EXTRA_HEP_MET_STA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8C14988-A23C-68DA-E040-BB89AD437166","latestVersionIndicator":"Yes","beginDate":"2014-05-06","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-06","modifiedBy":"GRANTD","dateModified":"2015-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4296965","version":"1","preferredName":"Lymph Node Progression Criteria Yes No Unknown Not Applicable Indicator","preferredDefinition":"The yes/no/unknown/not applicable indicator that asks if evidence of progression was seen by assessment of the Lymph nodes","longName":"LN_PRO_CRITERI_IND-4","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9359C3F-69A9-AC18-E040-BB89AD432D0B","latestVersionIndicator":"Yes","beginDate":"2014-05-12","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-05-12","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4325602","version":"1","preferredName":"Drug Company Agent Manufacturer  Name","preferredDefinition":"The name of the maufacturer of a pharmaceutical/ biologic agent.","longName":"Drug_Agen_Manu_MAN_NAME","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9D86B18-5029-9065-E040-BB89AD432E05","latestVersionIndicator":"Yes","beginDate":"2014-05-20","endDate":null,"createdBy":"PATELV","dateCreated":"2014-05-20","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4329885","version":"1","preferredName":"Individual Income Type","preferredDefinition":"Patient's primary income type.","longName":"INVD_INC_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9ED927E-A708-DCB0-E040-BB89AD433963","latestVersionIndicator":"Yes","beginDate":"2014-05-21","endDate":null,"createdBy":"PATELV","dateCreated":"2014-05-21","modifiedBy":"ROUILLAS","dateModified":"2015-03-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4330781","version":"1","preferredName":"Patient Laryngoscopy Physical Examination Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to the fiberoptic exam with laryngopharyngoscopy done on a patient who is participating on a clinical trial.","longName":"PT_LARYN_EX_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9EE9147-8B88-AE33-E040-BB89AD430615","latestVersionIndicator":"Yes","beginDate":"2014-05-21","endDate":null,"createdBy":"PATELV","dateCreated":"2014-05-21","modifiedBy":"PATELV","dateModified":"2017-10-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4339263","version":"1","preferredName":"Malignant Neoplasm Radioresistance Histology Subtype Present Category","preferredDefinition":"Histologic subtype related to radioresistant tumors","longName":"Neop_Resi_Hist_Subt_Pres_MET_T","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA110C7-15BB-4B53-E040-BB89AD4328EE","latestVersionIndicator":"Yes","beginDate":"2014-05-30","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-05-30","modifiedBy":"FORMBUILDER","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4360181","version":"1","preferredName":"Positron Emission Tomography Computed Tomography Outcome Result Score","preferredDefinition":"A tumor response evaluation score that decribes the radiologist's impression of the PET/CT.","longName":"PET_CT_OTCM_RSLT_SCR","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC30AB4F-8646-EA1F-E040-BB89AD430C52","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"PATELV","dateCreated":"2014-06-19","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4379963","version":"1","preferredName":"Person Suspected Clinical Diagnosis Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"the yes/no indicator regarding information related to the likely diagnosis made from a study of the signs and symptoms of a disease as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:2950730v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6D95-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-07-02","modifiedBy":"DASCOMBS","dateModified":"2016-04-07","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4395735","version":"1","preferredName":"Malignant Neoplasm Plan Minimum Invasive Surgical Procedure Indicator","preferredDefinition":"they yes/no indicator regarding information related to a planned diagnostic or treatment procedure performed by manual and/or instrumental means by the least invasive way possible for a benign or malignant tissue growth resulting from uncontrolled cell proliferation.","longName":"Mali_Neop_Plan_Mini_Inva_Surg_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB8F754-D2CE-8D06-E040-BB89AD437F49","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-07-21","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4439687","version":"1","preferredName":"Antibody CDKN2A Gene Name","preferredDefinition":"The name of the  antibody clone used for p16 analysis.","longName":"ANTI_CDKN_AB_NM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FFFA3585-69BD-B4CB-E040-BB89AD436673","latestVersionIndicator":"Yes","beginDate":"2014-08-06","endDate":null,"createdBy":"PATELV","dateCreated":"2014-08-06","modifiedBy":"PATELV","dateModified":"2014-08-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4439909","version":"1","preferredName":"Drug Company Agent Manufacturer Name","preferredDefinition":"The name of the manufacturer of a pharmaceutical/ biologic agent.","longName":"DRUG_AGEN_MANU_NAME","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FFFB55A4-A8A1-65E2-E040-BB89AD4361E2","latestVersionIndicator":"Yes","beginDate":"2014-08-06","endDate":null,"createdBy":"PATELV","dateCreated":"2014-08-06","modifiedBy":"PATELV","dateModified":"2014-08-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4448974","version":"1","preferredName":"Person Rehabilitation Facility Documented Indicator","preferredDefinition":"the yes/no indicator regarding information related to the documentation of an individual spending time in a rehabilitation facility.","longName":"Pers_Reha_Faci_Docu_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00881754-1322-1B79-E050-BB89AD431109","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-13","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449876","version":"1","preferredName":"Patient Hospital Repeat Admission Indicator","preferredDefinition":"the yes/no indicator relating to information regarding a person who receives medical attention, care, or treatment being brought back and admitted to an institution that provides medical, surgical, or psychiatric care and treatment.","longName":"Pati_Hosp_Repe_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008937B3-9D6F-6170-E050-BB89AD436387","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-13","modifiedBy":"KUMMEROA","dateModified":"2022-11-16","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":"2022.11.16 AQT added for ticket request CADSR0001698. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4449877","version":"1","preferredName":"Adjuvant Chemotherapy Administered Day Duration","preferredDefinition":"information related to the number of days adjuvant chemotherapy is administered.","longName":"ADJ_CT_ADM_D_DUR","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008937B3-9DA6-6170-E050-BB89AD436387","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-13","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457105","version":"1","preferredName":"Post Surgical Procedure Cardiac Arrest Complication Indicator","preferredDefinition":"The yes/no indicator relating to information regarding the sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation that occurs after a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Post_Surg_Card_Comp_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00ADA61B-7950-23D7-E050-BB89AD4324C1","latestVersionIndicator":"Yes","beginDate":"2014-08-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-15","modifiedBy":"MORENOC","dateModified":"2016-05-09","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457115","version":"1","preferredName":"Post Surgical Procedure Return Operating Room Complication Indicator","preferredDefinition":"the yes/no indicator relating to Information regarding the return to a room in a health care facility equipped for the performance of surgical operations and procedures due to complication occurring after a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Post_Surg_Retu_Oper_Comp_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00AE14C0-7885-9B72-E050-BB89AD432219","latestVersionIndicator":"Yes","beginDate":"2014-08-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-15","modifiedBy":"MORENOC","dateModified":"2017-10-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457214","version":"1","preferredName":"Chemotherapy Prior Surgical Procedure Administered Yes No Unknown Not Applicable Indicator","preferredDefinition":"the yes/no/unknown/not applicable indicator relating to Information regarding the use of synthetic or naturally-occurring chemical-based agents for the treatment of cancer before a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Chem_Prio_Surg_Admi_YES_NO_UNK","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00B13E47-A976-7172-E050-BB89AD43326E","latestVersionIndicator":"Yes","beginDate":"2014-08-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-15","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457219","version":"1","preferredName":"No Primary Surgical Procedure Performed Reason","preferredDefinition":"Information for the reason a primary diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue would not have occurred.","longName":"PRM_SX_PROC_PERF_No_Prim_Surg_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00B13E47-AA20-7172-E050-BB89AD43326E","latestVersionIndicator":"Yes","beginDate":"2014-08-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-15","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457326","version":"1","preferredName":"Surgical Procedure Repeat Questionnaire Collected Indicator","preferredDefinition":"the yes/no indicator relating to information regarding collecting a Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument again around the time of a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Surg_Repe_Ques_Coll_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00E8F190-6032-BE94-E050-BB89AD434F80","latestVersionIndicator":"Yes","beginDate":"2014-08-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-18","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457333","version":"1","preferredName":"Surgical Procedure Weight Performance Status Collection Indicator","preferredDefinition":"The yes/no indicator relating to information regarding the act of gathering the weight and measure of how well a patient is able to perform ordinary tasks and carry out daily activities of a patient for a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Surg_Weig_Perf_Coll_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00E8F190-609E-BE94-E050-BB89AD434F80","latestVersionIndicator":"Yes","beginDate":"2014-08-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-18","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4457676","version":"1","preferredName":"Post Surgical Procedure Information Collection Indicator","preferredDefinition":"the yes/no indicator relating to information regarding the gathering of knowledge derived from study, experience, or instruction happening after a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"Post_Surg_Info_Coll_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00EA79F7-AC9A-3D16-E050-BB89AD43712F","latestVersionIndicator":"Yes","beginDate":"2014-08-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-18","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4458974","version":"1","preferredName":"Patient Reported Outcome Eye Assessment Type","preferredDefinition":"Information related to an assessment of a patient reported outcome on eyesight regarding the qualities of the perception of objects by the eye at a particular time.","longName":"PROEYE_Sigh_Stat_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113C2A7-4627-F113-E050-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15; Created new CDE to accommodate need for PV string text. JR 8/20/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4458975","version":"1","preferredName":"Patient Reported Outcome Eye Assessment Interference Quantity 3 Point Scale","preferredDefinition":"Information related to an assessment of a patient reported outcome on eyesight._The act of hindering or obstructing or impeding._How much there is of something that you can measure; the total amount or number._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._The precise location of something; a spatially limited location._an ordered reference standard.","longName":"PROEYE_QUAN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113E79D-CE0D-FB17-E050-BB89AD435567","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4458976","version":"1","preferredName":"Patient Reported Outcome Hearing Assessment Interference Quantity 3 Point Scale","preferredDefinition":"Information related to the assessment of a patient reported outcome regarding hearing._The act of hindering or obstructing or impeding._How much there is of something that you can measure; the total amount or number._A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one._The precise location of something; a spatially limited location._an ordered reference standard.","longName":"HEARSTAT_QUAN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113F447-708F-3D3D-E050-BB89AD435569","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4458980","version":"1","preferredName":"Patient Reported Outcome Hearing Assessment Type","preferredDefinition":"Information related to the assessment of a patient reported outcome regarding hearing based on common qualities of the auditory faculty, the perception of sound by the ear at a particular time.","longName":"PROHEAR_Hear_Stat_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113F447-7125-3D3D-E050-BB89AD435569","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459013","version":"1","preferredName":"Patient Weight Loss Assessment Value","preferredDefinition":"Information related to a numerical quantity measured of a finding characterized by a decrease in overall body weight.","longName":"PT_WTLOSS_ASSESS_Weig_Valu","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113F447-717A-3D3D-E050-BB89AD435569","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459019","version":"1","preferredName":"Person Past 6 Months Weight Value","preferredDefinition":"Information regarding the numerical result  of a person from a period of time consisting of the 6 months before the present.","longName":"Pers_Past_Weig_WT_VAL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CSAERS:Chemoprevention Serious Adverse Event System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0113F447-71EB-3D3D-E050-BB89AD435569","latestVersionIndicator":"Yes","beginDate":"2014-08-20","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-20","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459372","version":"1","preferredName":"Medical Outcomes Study Social Activities Past 6 Months Change in Socializing Due to Change in Physical Health or Emotional Condition Score Category","preferredDefinition":"A survey of multiple dimensions of support, representing the social activities scale._A period of time consisting of the 6 months before the present._The act of alteration or modification; changed or altered in form or character._Interactions with one or more individuals, usually with a common purpose or with regards to a common topic of interest._Caused by or resulting from._The act of alteration or modification; changed or altered in form or character._The state of a person's physical and emotional well-being._A number or range of numeric values measuring performance, function, quality, or ability._A grouping of items based on some commonality or by user defined characteristics regarding a question about an individual's level of social activity.","longName":"MOS_CHG_SOC_HLTH_CATE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"MOS:Medical Outcomes Study, Sherbourne, C. D., 1991 and Stewart, A. L. and J. E. Ware, Jr., Eds. 1992","workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F3C0-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-21","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released  as part of draft content review; SD 12/21/15. Created new CDE to accommodate the need for PVs string text. JR 8/21/14. Created for Alliance study in Rave per request by K.Allen-Ziegler. mc 9/5/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459375","version":"1","preferredName":"Medical Outcomes Study Social Activities Age Comparison Interference with Social Activities Due To Physical Health or Emotional Problems Score Category","preferredDefinition":"A survey of multiple dimensions of support, representing the social activities scale._How long something has existed; elapsed time since birth._The examination of two or more people or things in order to detect similarities and differences._The act of impeding a person from their normal social activities._Caused by or resulting from._The state of a person's physical and emotional well-being._A number or range of numeric values measuring performance, function, quality, or ability._The act of impeding a person from their normal social activities._A grouping of items based on some commonality or by user defined characteristics.","longName":"MOS_AGECMP_SOCINF_CATE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"MOS:Medical Outcomes Study, Sherbourne, C. D., 1991 and Stewart, A. L. and J. E. Ware, Jr., Eds. 1992","workflowStatus":"RELEASED","registrationStatus":"Application","id":"01266F74-F46D-83B3-E050-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-21","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15; Created for Alliance study in Rave per request by K.Allen-Ziegler. mc 9/5/13 Created new CDE to accommodate the need of PVs in text strings. JR 8/21/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4459768","version":"1","preferredName":"Quality of Life Evaluation Questionnaire Status","preferredDefinition":"information related to the systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria as a measure of well-being and ability to enjoy life._A condition or state at a particular time._The subjective measurement of an individual's sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._A predetermined set of questions.","longName":"QOL_EVA_Qual_Ques_Stat","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"012AF088-E382-462E-E050-BB89AD4362A9","latestVersionIndicator":"Yes","beginDate":"2014-08-21","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-08-21","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4462143","version":"1","preferredName":"Patient Treat Functional Bowel Obstruction Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to any treatment (medical or surgical) for bowel obstruction done to a patient either prior to bladder cancer diagnosis or after cystectomy for bladder cancer participating on a clinical trial.","longName":"PT_TX_BWL_OBST_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"018D37BD-053A-C63B-E050-BB89AD4371F3","latestVersionIndicator":"Yes","beginDate":"2014-08-26","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-08-26","modifiedBy":"WELSHE","dateModified":"2014-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4462583","version":"1","preferredName":"Chemotherapy Administration Type","preferredDefinition":"Type of chemotherapy administered.","longName":"CHEMO_ADMIN_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"018CF523-314C-866E-E050-BB89AD4371F5","latestVersionIndicator":"Yes","beginDate":"2014-08-26","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-08-26","modifiedBy":"WELSHE","dateModified":"2014-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4473963","version":"1","preferredName":"Bladder Carcinoma Muscle Tissue Invasive Urothelial Carcinoma Histology Yes No Indicator","preferredDefinition":"The yes/no indicator related to the histologic finding of urothelial carcinoma in the bladder tumor specimen.","longName":"Blad_Ca_Mus_Invs_Uro_Y/N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"022DCDC1-1A86-69B3-E050-BB89AD4310A3","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-09-03","modifiedBy":"WELSHE","dateModified":"2014-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4473967","version":"1","preferredName":"Bladder Carcinoma Final Histology Yes No Indicator","preferredDefinition":"The yes/no indicator that the final histologic report contains either pure urothelial carcinoma or dominant urothelial carcinoma with admixture of other histologies excluding small cell variants.","longName":"Blad_Final_Hist_Y/N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"022E4F41-E1FE-9C43-E050-BB89AD43546C","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-09-03","modifiedBy":"WELSHE","dateModified":"2014-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4475792","version":"2","preferredName":"Positron Emission Tomography and Computed Tomography Scan Neoplasm Finding Status","preferredDefinition":"The summary of finding from a PET/CT scan of the tumor disease","longName":"PET_CT_NEO_FIND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBC20AEA-92EF-22A6-E053-731AD00AD2A8","latestVersionIndicator":"Yes","beginDate":"2014-09-05","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-15","modifiedBy":"TSESU","dateModified":"2023-05-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4475803","version":"1","preferredName":"Positron Emission Tomography and Computed Tomography Scan Residual Neoplasm  Anatomic Site","preferredDefinition":"The site with residual disease based on PET/CT finding","longName":"PET_CT_RES_NEO_SITE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"025724E6-2B8F-E5F1-E050-BB89AD434227","latestVersionIndicator":"Yes","beginDate":"2014-09-05","endDate":null,"createdBy":"PATELV","dateCreated":"2014-09-05","modifiedBy":"PATELV","dateModified":"2014-09-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4475810","version":"2","preferredName":"Distant Metastasis Present Indicator","preferredDefinition":"Indicator to show whether distant metastasis is present based on PET/CT finding","longName":"DIS_MET_PRE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBC027C7-07A3-4D66-E053-731AD00A65DE","latestVersionIndicator":"Yes","beginDate":"2014-09-05","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-15","modifiedBy":"CLOHNES","dateModified":"2023-12-20","changeNote":"5.15.23_New version due to removal of incorrect PV/VM and add correct VM to associated VD_smt","administrativeNotes":"12/20/23 Added AQT for CCTG ticket number CADSR0003208 cjl; 5.15.23_Created new version due to removal of incorrect PV/VM and adding correct VM_smt; 6/16/22 Added alt quest text, designated CDE to CCTG, added OID, CCTG for Chad Winch CCTG cjl","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4475831","version":"1","preferredName":"Sentinel Lymph Node Removed Count","preferredDefinition":"A number indicating how many sentinel lymph nodes were removed","longName":"4475830v1.0:2018392v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"025724E6-2D29-E5F1-E050-BB89AD434227","latestVersionIndicator":"Yes","beginDate":"2014-09-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2014-09-05","modifiedBy":"SOKKERL","dateModified":"2020-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4486276","version":"1","preferredName":"Metastatic Neoplasm Maximum Diameter Assessment Yes No Indicator","preferredDefinition":"The Yes/No indicator related to the final determination of the size of an individual metastatic lesion.","longName":"Meta_Neop_Maxi_Diam_Asse_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03449E00-E6EC-3C45-E050-BB89AD437EB8","latestVersionIndicator":"Yes","beginDate":"2014-09-17","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-09-17","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4493051","version":"1","preferredName":"Concomitant Prescription Medication Use Count","preferredDefinition":"information relating to the total number of pills taken for the use of a prescription (a doctor's order for medicine or another intervention) concomitant medication.","longName":"CONCOM_PRESC_MED_USE_TTL_MEDS_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03F8402F-CD64-9C7A-E050-BB89AD430E43","latestVersionIndicator":"Yes","beginDate":"2014-09-26","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-09-26","modifiedBy":"MALUMK","dateModified":"2020-06-08","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4493251","version":"1","preferredName":"Patient Orthotopic Neobladder Surgical Procedure Yes No Indicator","preferredDefinition":"Information related to any surgical procedure for the creation of a new bladder (neobladder) for a patient after cystectomy participating in a clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"PT_ORTHO_NEOBLADDER_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03FB8027-9281-A497-E050-BB89AD43552C","latestVersionIndicator":"Yes","beginDate":"2014-09-26","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-09-26","modifiedBy":"WELSHE","dateModified":"2015-07-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4514585","version":"1","preferredName":"Person Priority Clinical Study Protocol Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"the yes/no indicator related to information regarding a human being with a status established by order of importance of a clinical study to allow a subject to participate in a clinical study, as outlined in the study protocol.","longName":"Pers_Prio_Clin_Clin_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04D892C9-21FD-17CD-E050-BB89AD43386A","latestVersionIndicator":"Yes","beginDate":"2014-10-07","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-10-07","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15. Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531734","version":"1","preferredName":"Immunotherapy Previous Antibody Administered Indicator","preferredDefinition":"The yes/no indicator related to information regarding the previous antibody use of treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases.","longName":"Immu_Prev_Anti_Admi_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05144A63-664F-5CC6-E050-BB89AD436095","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-10-10","modifiedBy":"TSESU","dateModified":"2023-06-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531779","version":"1","preferredName":"Gynecologic Malignant Neoplasm Recurrent Or Metastatic Diagnosis Indicator","preferredDefinition":"The yes/no indicator related to Information regarding the investigation, analysis and recognition of the presence and nature of disease of a gynecologic tumor composed of atypical neoplastic that is either recurrent or has spread from the primary site (place where it started) to other places in the body.","longName":"Gyne_Mali_Recu_Or_Meta_Diag_YE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05144A63-67A5-5CC6-E050-BB89AD436095","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-10-10","modifiedBy":"SARAHB","dateModified":"2018-06-25","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4537171","version":"1","preferredName":"Surgeon Identifier Type","preferredDefinition":"The type of surgeon who performed the surgical procedure","longName":"SURGEON_ID_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0579DCCC-0A60-3DC2-E050-BB89AD433414","latestVersionIndicator":"Yes","beginDate":"2014-10-15","endDate":null,"createdBy":"WELSHE","dateCreated":"2014-10-15","modifiedBy":"WELSHE","dateModified":"2014-10-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538053","version":"1","preferredName":"Therapeutic Procedure Recurrent Disease Ttreatment Yes No Indicator","preferredDefinition":"the yes/no indicator that asks whether the recurrence was treated by specific therapeutic agent(s)","longName":"Ther_Recu_Ther_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"058BDB0C-8452-DD6B-E050-BB89AD437FA9","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-10-16","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4538476","version":"1","preferredName":"Therapy Post Surgical Procedure Type","preferredDefinition":"The type of therapy delivered after surgery.","longName":"Ther_Post_Surg_Therapy type po","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"059019D5-E6AB-26D6-E050-BB89AD4369F4","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-10-16","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4539843","version":"1","preferredName":"Metastatic Lesion Therapy Modality Administered Type","preferredDefinition":"A specific action or administration of an agent or to produce an effect that is intended to alter the pathologic process of a tumor(s) arising at a location that is distant from the primary lesion.","longName":"Met_Les_Mod_type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A1992B-8298-76CD-E050-BB89AD4365DA","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"GRANTD","dateCreated":"2014-10-17","modifiedBy":"GRANTD","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550991","version":"1","preferredName":"Disease or Disorder Radiography Evidence Hydrocephalus Ventricular Distortion Present Yes No Indicator","preferredDefinition":"The yes/no indicator related to the presence of hydrocephalus and ventricular distortion.","longName":"Dis_Rad_Hydr_Vent_Dist_Pre","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-65C9-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"WISEM","dateModified":"2020-06-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550992","version":"1","preferredName":"Disease or Disorder Renal Tubular Metabolic Acidosis Present Yes No Indicator","preferredDefinition":"The yes/no indictor related to the presence of renal tubular  acidosis or metabolic acidosis","longName":"Dis_Ren_Tub_Meta_Acid_Pre","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-65E9-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"BONANNIR","dateModified":"2014-11-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4550994","version":"1","preferredName":"Disease or Disorder Radiography Evidence Brain Metastasis External Hippocampus Present Yes No Indicator","preferredDefinition":"The yes/no indicator related to the presence of brain metastases outside 5-mm margin around either hippocampus visible on a MRI","longName":"Dis_Ra_Ev_Br_Met_Ex_Hip_Pr","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-662F-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"TIFFANIS","dateModified":"2020-10-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551017","version":"1","preferredName":"Magnetic Resonance Imaging Computed Tomography Brain Medical Imaging Prior Therapy Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to pre-surgery imaging","longName":"MRI_CT_Br_Med_Im_Pr_Th_As","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-6687-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"WISEM","dateModified":"2016-09-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551031","version":"1","preferredName":"Person Histologic Diagnosis Primary Site Exclusion Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to the exclusion of histology and primary site on a clinical trial","longName":"Pr_His_Dia_PS_Ex","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0605DE18-A70F-A2F3-E050-BB89AD437B3B","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"TSESU","dateModified":"2023-05-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551034","version":"1","preferredName":"Patient Metastasis Stratification Anatomic Site","preferredDefinition":"Stratification variable for metastatic location","longName":"Pt_Met_Strat_Ana_Site","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06050086-66ED-8652-E050-BB89AD4331C5","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-22","modifiedBy":"BONANNIR","dateModified":"2014-11-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551776","version":"1","preferredName":"Metastatic Malignant Neoplasm to the Brain Radiography Evidence Brain Metastasis External Hippocampus Present Yes No Indicator","preferredDefinition":"The Yes/No indicator related to the presence of brain metastases outside 5 mm margin around either hippocampus visible on a CT or MRI prior to surgery.","longName":"Met_Neo_Br_Rad_Ev_Ex_Hi_Pr","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"062CDB3C-0920-B0E0-E050-BB89AD43492F","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-24","modifiedBy":"FORMBUILDER","dateModified":"2019-05-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551777","version":"1","preferredName":"Pharmacologic Substance N-Methyl-D-Aspartate Receptor Antagonist Use Yes No Indicator","preferredDefinition":"The Yes/No indicator related to use of NMDA receptor antagonist","longName":"Pha_Sub_NMDA_Rec_Anta_Use","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"062CDB3C-094C-B0E0-E050-BB89AD43492F","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-10-24","modifiedBy":"FORMBUILDER","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4577526","version":"1","preferredName":"Disease or Disorder Extracranial Metastasis Present Status","preferredDefinition":"The presence or absence of extracranial metastasis on a patient participating in a clinical trial.","longName":"DIS_EXTRA_METS_PRE_STATUS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0783F5F7-11A9-12E7-E050-BB89AD4327BD","latestVersionIndicator":"Yes","beginDate":"2014-11-10","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-11-10","modifiedBy":"BONANNIR","dateModified":"2014-11-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4577527","version":"1","preferredName":"Breast Malignant Neoplasm Subtype Classification Type","preferredDefinition":"The subtype for a breast malignancy","longName":"BRE_MAL_NEO_SUB_CLASS_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0783B094-77EF-BD19-E050-BB89AD4362D6","latestVersionIndicator":"Yes","beginDate":"2014-11-10","endDate":null,"createdBy":"BONANNIR","dateCreated":"2014-11-10","modifiedBy":"FORMBUILDER","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4634857","version":"1","preferredName":"Investigator Immunomodulation Therapy Training Complete Certification Person Name","preferredDefinition":"Information related to the name of the person  in  scientific research who completed the immunomodulation therapy training/certification","longName":"INV_IMMUN_TRAIN_COMP_PERS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A56D91D-122D-3892-E050-BB89AD4311F7","latestVersionIndicator":"Yes","beginDate":"2014-12-16","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2014-12-16","modifiedBy":"OBROPTAJ","dateModified":"2014-12-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4650531","version":"1","preferredName":"Metastatic Malignant Neoplasm to the Brain Integer::4 Week Negation Disease Progression Post Magnetic Resonance Imaging Cancer Therapeutic Procedure Assessment Indicator","preferredDefinition":"The indicator response regarding whether a patient diagnosed with brain metastases or leptomeningeal metastases and have been treated show any evidence of disease progression within 4 weeks after completion of treatment.","longName":"MMN_BRA_4W_NG_PD_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BFF7295-899A-04C4-E050-BB89AD433E69","latestVersionIndicator":"Yes","beginDate":"2015-01-06","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-01-06","modifiedBy":"BOWSERC","dateModified":"2021-12-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4651414","version":"1","preferredName":"Metastatic Malignant Neoplasm to the Brain Integer::2 Week Prior Protocol Agent Administration Systemic Therapeutic Corticosteroid Negation Requirement Yes No Not Applicable Indicator","preferredDefinition":"A yes, no, not applicable indicator asking whether there was a requiment for immunosuppresive doses of systemic corticosteroids (greater than 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. This question is only asked of patients who have known brain or leptomeningeal metastases prior to entering a clinicial trial.","longName":"YES_NO_immunos_drug","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C0114FB-F3C6-7C84-E050-BB89AD433B87","latestVersionIndicator":"Yes","beginDate":"2015-01-06","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-01-06","modifiedBy":"GEDEONL","dateModified":"2015-01-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4717478","version":"1","preferredName":"Laboratory Procedure Her2/Neu Status Performed Yes No Indicator","preferredDefinition":"A yes/no indicator to indicate whether HER2 gene copy number has been reported.","longName":"4717477v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EE6F2BB-D0F5-5FC2-E050-BB89AD431C14","latestVersionIndicator":"Yes","beginDate":"2015-02-12","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-02-12","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4717485","version":"1","preferredName":"Surgical Margin Mastectomy No Neoplasm Involvement Yes No Indicator","preferredDefinition":"The yes/no indicator to detetermine the presence of residual microscopic tumor from the mastectomy margins","longName":"4717481v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EE6F2BB-D1E3-5FC2-E050-BB89AD431C14","latestVersionIndicator":"Yes","beginDate":"2015-02-12","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-02-12","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4717492","version":"1","preferredName":"BRCA1 Gene BRCA2 Gene Mutation Status Mutation Status","preferredDefinition":"The status of the BRCA mutation","longName":"4717488v1.0:4717491v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EE789CA-A523-0E17-E050-BB89AD43499D","latestVersionIndicator":"Yes","beginDate":"2015-02-12","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-02-12","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4723862","version":"1","preferredName":"Was Concurrent Agent administered with Radiation Therapy  or was Agent Administered  as Adjuvant Treatment Post Radiation Therapy Yes No Unknown Not Applicable Indicator","preferredDefinition":"A question asking if an agent was given concurrently with radiation therapy or if an agent was given as an adjuvant treatment after the completion of radiation therapy._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"Conc_With_Agen_Radi_Or_Adju_Po","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDC9539-B220-CB07-E050-BB89AD436926","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-02-24","modifiedBy":"GEDEONL","dateModified":"2015-02-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4725106","version":"1","preferredName":"Eligibility Criteria Clinical Study Protocol Agent Study Treatment  Norway Administration Indicator","preferredDefinition":"An indicator of whether or not the patient will be receiving study treatment at a site in Norway.","longName":"Clin_Prot_Stud_Norw_Admi_YES_N","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1001910D-E669-555F-E050-BB89AD437953","latestVersionIndicator":"Yes","beginDate":"2015-02-26","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-02-26","modifiedBy":"GEDEONL","dateModified":"2015-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4732322","version":"1","preferredName":"Off Study Carboplatin Administered Yes No Indicator","preferredDefinition":"The yes/no indicator to tell if any Carboplatin was administered while the patient was off study","longName":"OFF_CARBO_GIVEN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10679EF7-148B-55EA-E050-BB89AD430BCE","latestVersionIndicator":"Yes","beginDate":"2015-03-03","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-03","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4735603","version":"1","preferredName":"Protocol Therapy Last Cycle Number","preferredDefinition":"The last cycle number where protocol drug was administered.","longName":"LAST_TRT_CYCLE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"108E43FA-1387-2960-E050-BB89AD433557","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4735610","version":"1","preferredName":"Off Treatment Carboplatin Administered Yes No Indicator","preferredDefinition":"The yes/no indicator to say whether off protocol carboplatin was administered or not","longName":"OFF_CARBO_ADMIN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"108CF994-78C8-9B0A-E050-BB89AD431847","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4735674","version":"1","preferredName":"BRCA1 Gene Status Post Randomization Yes No Indicator","preferredDefinition":"The yes/no indicator to tell whether the BRCA status has been determined after randomization","longName":"BRCA_POST_RAND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"108CF994-7A57-9B0A-E050-BB89AD431847","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-05","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4749314","version":"1","preferredName":"Last Carboplatin Date","preferredDefinition":"The last date the drug carboplatin was given.","longName":"LAST_CARBO_DATE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11BDC881-A9DE-4AA8-E050-BB89AD4324EC","latestVersionIndicator":"Yes","beginDate":"2015-03-20","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-20","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4749320","version":"1","preferredName":"Cumulative Carboplatin Dose","preferredDefinition":"The cumulative dose of carboplatin given in milligrams","longName":"Cumulative Carboplatin Dose","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11BDC881-A9FD-4AA8-E050-BB89AD4324EC","latestVersionIndicator":"Yes","beginDate":"2015-03-20","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-03-20","modifiedBy":"BRETTS","dateModified":"2015-07-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4769371","version":"1","preferredName":"Known Primary Uterus Malignant Neoplasm Confirmation With Endometrial Biopsy Eligibility Determination Yes No Not Applicable Indicator","preferredDefinition":"An eligibility indicator asking whether pre-operative primary uterine cancer was confirmed by an endometrial biopsy._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures with permissible values of yes/no/not applicable.","longName":"Know_Prim_Uter_Mali_Conf_With_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12AE43F1-6FFA-7314-E050-BB89AD437A0A","latestVersionIndicator":"Yes","beginDate":"2015-04-01","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-04-01","modifiedBy":"GEDEONL","dateModified":"2015-04-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4809851","version":"1","preferredName":"Patient Prior Myocardial Infarction Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator to obtain information on whether a patient has a medical history of myocardial infarction","longName":"PT_PR_MI_IND_YNNA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"15463A4C-2689-A901-E050-BB89AD433AFB","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"OBROPTAJ","dateCreated":"2015-05-04","modifiedBy":"OBROPTAJ","dateModified":"2015-05-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4822340","version":"1","preferredName":"No Platinum Recent Patient Interval Eligibility Determination Most Recent Time Interval","preferredDefinition":"A eligibility question asking how long the patients' most recent platinum-free interval has been._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures._Nearest to the present._The period of time or the distance separating two instances of months being absent of a platinum-free interval. The first interval is less than 6 month. The second one is greater than or equal to 6 months  but less than 12 months.","longName":"No_Plat_Most_Elig_Inte_Time_In","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1595F075-D523-F6FA-E050-BB89AD43127A","latestVersionIndicator":"Yes","beginDate":"2015-05-08","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-05-08","modifiedBy":"TAYLORT","dateModified":"2015-12-23","changeNote":"released as part of draft content review; SD 12/21/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4888314","version":"1","preferredName":"Disease or Disorder Eight Week Evaluation Yes No Indicator","preferredDefinition":"A question asking if a disease evaluation or assessment was done at the eight week visit._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Dise_Eigh_Week_Eval_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"196D9837-9AD9-F6C1-E050-BB89AD434304","latestVersionIndicator":"Yes","beginDate":"2015-06-26","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-06-26","modifiedBy":"GEDEONL","dateModified":"2015-06-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5012416","version":"1","preferredName":"Patient Outpatient Inpatient Visit Reason","preferredDefinition":"The reason for patient visit to a medical facility.","longName":"PT_VISIT_RSN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1FB59B3D-8528-391D-E050-BB89AD432D68","latestVersionIndicator":"Yes","beginDate":"2015-09-14","endDate":null,"createdBy":"PATELV","dateCreated":"2015-09-14","modifiedBy":"PATELV","dateModified":"2015-10-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5021086","version":"1","preferredName":"Work Productivity and Activity Impairment General Health Problems Missing Work Day Count","preferredDefinition":"Persons' stated observation of how many days they have missed from work because of health problems.","longName":"WRK_PROD_MISS_DAY_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2009FD9F-4A67-D698-E050-BB89AD432FBA","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-18","modifiedBy":"MALUMK","dateModified":"2020-08-14","changeNote":"Curated to support NCI NRG clinical trial 9.18.2015.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5021255","version":"1","preferredName":"Primary Caregiver Work Productivity and Activity Impairment General Health Problems Missing Work Day Count","preferredDefinition":"Person's stated observation of the number of days of work missed by their primary caregiver because of the patient's treatment or the effects of treatment.","longName":"PRIM_CGV_MISS_DAY_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"200AD9E0-DAAC-3799-E050-BB89AD43675D","latestVersionIndicator":"Yes","beginDate":"2015-09-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-18","modifiedBy":"REEVESD","dateModified":"2015-09-22","changeNote":"Curated to support NCI NRG clinical trial 9.18.2015.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5024051","version":"1","preferredName":"Patient Medical Care Travel Time Period Distance Mile Count","preferredDefinition":"Distance in number of miles that a patient states were traveled for medical care during a specific time period.","longName":"CARE_TRV_DIS_MILE_CT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2083CFA3-1479-B58A-E050-BB89AD431F14","latestVersionIndicator":"Yes","beginDate":"2015-09-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-24","modifiedBy":"MALUMK","dateModified":"2021-02-04","changeNote":"Curated to support NRG clinical trial.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5025811","version":"1","preferredName":"Laboratory Procedure Immunohistochemistry Staining Method Loss of BAF250a Expression Yes No Indicator","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen._Loss of protein expression of the BRG-associated factor 250a (BAF250a).  It is caused by mutation of the tumor-suppressor gene ARID1A. It is linked to tumor progression and poor prognosis in various cancers._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5024536v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20CF9444-D7DE-BA6F-E050-BB89AD430DA9","latestVersionIndicator":"Yes","beginDate":"2015-09-28","endDate":null,"createdBy":"DASCOMBS","dateCreated":"2015-09-28","modifiedBy":"DASCOMBS","dateModified":"2015-12-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045515","version":"1","preferredName":"Person Agent Hypersensitivity Triapine Eligibility Determination Yes No Indicator","preferredDefinition":"The yes/no indicator to confirm eligibility based on a person's hypersensitivity or allergy to the study agent triapine.","longName":"5045514v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AB42EB-1638-0244-E050-BB89AD433DC3","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045534","version":"1","preferredName":"Malignant Neoplasm Pathologic Eligibility Determination Yes No Indicator","preferredDefinition":"The yes/no indicator to determine eligibility based on the pathologic diagnosis of cancer upon study entry.","longName":"5045533v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AB42EB-168D-0244-E050-BB89AD433DC3","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2018-06-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045676","version":"1","preferredName":"Laboratory Procedure Neutrophil Result Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's neutrophil count","longName":"2188764v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24ADFACE-DF0A-CBE3-E050-BB89AD435CB3","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045677","version":"1","preferredName":"Laboratory Procedure Creatinine Clearance Outcome Yes No Indicator","preferredDefinition":"the yes/no indicator related to a patient's creatinine clearance value","longName":"2190034v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-06D5-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045729","version":"1","preferredName":"Laboratory Procedure Hemoglobin Result Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's hemoglobin result","longName":"2188767v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-081A-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SHEARMA","dateModified":"2019-03-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045730","version":"1","preferredName":"Laboratory Procedure Total Bilirubin Result Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's total bilirubin result","longName":"2199563v2.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-0839-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045731","version":"1","preferredName":"Laboratory Procedure Platelet Result Yes No Indicator","preferredDefinition":"the yes/no indicator related to a patient's platelet result","longName":"2188766v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-0858-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045741","version":"1","preferredName":"Laboratory Procedure Fasting Plasma Glucose Measurement Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's fasting glucose result","longName":"2778609v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-0877-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045742","version":"1","preferredName":"Patient Glucose-6-Phosphate 1-Dehydrogenase Deficiency Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator related to a person's G6PD deficiency","longName":"4648557v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEA5EE-0896-1CF9-E050-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045743","version":"1","preferredName":"Patient Concomitant Or Prior Invasive Malignant Neoplasm Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to a person's concurrent malignancies, if any","longName":"4901082v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AEFF61-3C18-D0B2-E050-BB89AD434AB4","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"TSESU","dateModified":"2022-11-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045771","version":"1","preferredName":"Person Breast Feeding Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's breastfeeding status upon study entry","longName":"4722437v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24AF7246-D9BE-B662-E050-BB89AD4319D1","latestVersionIndicator":"Yes","beginDate":"2015-11-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-16","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046096","version":"1","preferredName":"Specimen Submitted Specimen Primary Malignant Neoplasm Submission Type","preferredDefinition":"information related to the type of specimen being submitted","longName":"2014625v1.0:2842556v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24BF4A97-83B9-DD70-E050-BB89AD430C8C","latestVersionIndicator":"Yes","beginDate":"2015-11-17","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-17","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046512","version":"1","preferredName":"Axillary Node Triple-Negative Breast Cancer Finding Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have triple negative breast cancer that was axillary node positive","longName":"5046454v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6CBB-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046513","version":"1","preferredName":"Positive Axillary Lymph Node HER2/Neu Negative Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who are HER2 negative and have positive lymph nodes","longName":"5046458v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6CDA-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046514","version":"1","preferredName":"Sentinel Lymph Node Biopsy Axillary Lymph Node Dissection Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have had sentinel lymph node biopsy or axillary dissection","longName":"5046461v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6CF9-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"TSESU","dateModified":"2022-12-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046515","version":"1","preferredName":"Breast Carcinoma Residual Disease Triple-Negative Breast Cancer Finding Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have triple negative breast cancer and resected lymph nodes","longName":"5046463v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6D1B-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046516","version":"1","preferredName":"Breast Carcinoma Residual Disease HER2/Neu Negative Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have HER2 negative cancer and residual invasive breast cancer","longName":"5046465v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6D3A-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046517","version":"1","preferredName":"Series Sentinel Lymph Node Biopsy Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have a series of possible sentinel lymph node biopsy outcomes","longName":"5046468v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6D59-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046518","version":"1","preferredName":"Axillary Lymph Node Dissection Sentinel Lymph Node Biopsy Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who have sentinel lymph node biopsy followed by axillary node dissection","longName":"5046471v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6D78-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046519","version":"1","preferredName":"Clinical Study Enrollment Phase III Trial Yes No Indicator","preferredDefinition":"The yes/no indicator related to eligibility for patients who are enrolled in clinical studies","longName":"5046474v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D38C9E-BBDA-2BB7-E050-BB89AD436D1E","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046520","version":"1","preferredName":"Pathology Histologic Grade Specimen Type","preferredDefinition":"The type of sample used for histologic grade determination","longName":"5046478v1.0:5046475v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D2EEAB-6D97-C48B-E050-BB89AD4301AD","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046521","version":"1","preferredName":"Breast Neoplasm Nuclear Description Breast Tumor Histologic Grade","preferredDefinition":"Nuclear grade","longName":"5046493v1.0:2018413v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D38C9E-BBF9-2BB7-E050-BB89AD436D1E","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046522","version":"1","preferredName":"Nuclear Grade Specimen Type","preferredDefinition":"The sample type that was used to determine nuclear grade","longName":"5046480v1.0:5046475v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D38C9E-BC18-2BB7-E050-BB89AD436D1E","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046524","version":"1","preferredName":"Clinical Stage Grouping Score Count","preferredDefinition":"A group of clinical stage values that are put together to determine a score","longName":"5046497v1.0:5046495v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D38C9E-BC37-2BB7-E050-BB89AD436D1E","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046774","version":"1","preferredName":"Person Blood Specimen Future Clinical or Research Activity Consent Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's consent to collect blood samples for future research","longName":"5046773v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D69061-A9A4-7D75-E050-BB89AD434E09","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"TAYLORT","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046811","version":"1","preferredName":"Ethnicity Identifier Person Ethnic Group Judaism Identifier","preferredDefinition":"Information about the ethnicity of a Jewish person","longName":"5046810v1.0:5046803v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D72064-ACBE-2F4C-E050-BB89AD433482","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046844","version":"1","preferredName":"Family Relative Age Identifier","preferredDefinition":"The age of a family member","longName":"5046843v1.0:5046839v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24D7A015-FC4D-B616-E050-BB89AD436CEC","latestVersionIndicator":"Yes","beginDate":"2015-11-18","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-18","modifiedBy":"SOKKERL","dateModified":"2018-04-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5050571","version":"1","preferredName":"Patient Breast Prior Lumpectomy And Radiation Therapy Administered Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient had prior breast lumpectomy and radiation therapy.","longName":"PR_BR_TX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"24FFEA1C-C04A-D291-E050-BB89AD4334D1","latestVersionIndicator":"Yes","beginDate":"2015-11-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-11-20","modifiedBy":"TSESU","dateModified":"2023-06-02","changeNote":"10.16.20 TL changed WFS from RETIRED DELETED to RETIRED ARCHIVED and added an End Date in preparation of OneData.; 11/20/15 retired CDE/tt_11/20/15 training/tt.","administrativeNotes":"6/2/2023_Reactivated for NRG use_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5053228","version":"1","preferredName":"Radiation Therapy Boost Field Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether a boost field was treated by radiation therapy","longName":"5053227v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"253A6C63-0BF0-27AF-E050-BB89AD437159","latestVersionIndicator":"Yes","beginDate":"2015-11-23","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-23","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5053695","version":"1","preferredName":"Specimen Submitted Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether or not a tumor tissue was submitted","longName":"2014625v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"254D8D9A-DC83-F88C-E050-BB89AD43591E","latestVersionIndicator":"Yes","beginDate":"2015-11-24","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-11-24","modifiedBy":"SPRINGERL","dateModified":"2019-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5073411","version":"1","preferredName":"Person Breast Feeding Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"Information related to patient eligibility based on current breast feeding status","longName":"4722437v1.0:2017177v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261A216A-4935-0970-E050-BB89AD436D8A","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-12-04","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5085457","version":"1","preferredName":"Person High Risk Lesion Present Anatomic Site","preferredDefinition":"The side on which the high risk lesion exists","longName":"5085456v1.0:4999053v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27098005-222B-E32E-E050-BB89AD4303C2","latestVersionIndicator":"Yes","beginDate":"2015-12-16","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-12-16","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5092599","version":"1","preferredName":"Positron Emission Tomography Preparation Performed Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether preparation was performed before PET scan","longName":"3342757v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"276F9E22-81C6-E057-E050-BB89AD436102","latestVersionIndicator":"Yes","beginDate":"2015-12-21","endDate":null,"createdBy":"BRETTS","dateCreated":"2015-12-21","modifiedBy":"SARAHB","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5095198","version":"1","preferredName":"Vaginal Internal Radiation Therapy Intracavitary Route of Administration Top Location Total Dose Administered Brachytherapy Prescribed Dose","preferredDefinition":"A total dose of brachytherapy given to the apex of the vagine  which radioactive material is placed directly into or near a tumor._Administration of a drug within any natural, non-pathologic cavity, .","longName":"5095195v1.0:2201467v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"280BB064-47D5-78CE-E050-BB89AD433387","latestVersionIndicator":"Yes","beginDate":"2015-12-29","endDate":null,"createdBy":"GEDEONL","dateCreated":"2015-12-29","modifiedBy":"PATELV","dateModified":"2015-12-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5104251","version":"1","preferredName":"Patient Ovarian Peritoneal Fallopian Tube Malignant Neoplasm Or High Grade Serous Adenocarcinoma Or Endometrial Neoplasm Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A question asking if patient has been diagnosed as having a high grade serous or high grade endometrioid cancer of the ovary, peritoneum or fallopian tube. A value Domain to indicate a question with permissible values of yes/no.","longName":"2233604v1.0:4900697v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"29B3DC51-2B2C-F9F5-E050-BB89AD430B92","latestVersionIndicator":"Yes","beginDate":"2016-01-19","endDate":null,"createdBy":"GEDEONL","dateCreated":"2016-01-19","modifiedBy":"SARAHB","dateModified":"2022-04-21","changeNote":"9825_Theradex_07.15.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5113098","version":"1","preferredName":"Head and Neck Alimentary Bolus Present  Grade","preferredDefinition":"The swallowing toxicity grade based on the modified barium swallow assessment.","longName":"Head_Alim_Bolus_Pre_Grade","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A435462-C4F7-1C4D-E050-BB89AD437F5C","latestVersionIndicator":"Yes","beginDate":"2016-01-26","endDate":null,"createdBy":"PATELV","dateCreated":"2016-01-26","modifiedBy":"PATELV","dateModified":"2016-03-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5118235","version":"1","preferredName":"Disease or Disorder Timepoint  Assessment","preferredDefinition":"The detrmination of the value, significance, or extent of any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person occurring at a specific point in the time continuum, including those established relative to an event._Evaluation of abnormal condition of the body. The final result of a determination of the value, significance, or extent of._A specific point in the time continuum, including those established relative to an event.","longName":"Dise_Time_Asse_5118231v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AD0A21F-DBF4-05F3-E050-BB89AD436DB8","latestVersionIndicator":"Yes","beginDate":"2016-02-02","endDate":null,"createdBy":"GEDEONL","dateCreated":"2016-02-02","modifiedBy":"GEDEONL","dateModified":"2016-02-02","changeNote":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5152234","version":"1","preferredName":"Patient Modified Barium Swallow Consent Yes No Not Applicable Indicator","preferredDefinition":"The yes/no indicator that asks whether the patient has consented to take part in a Modified Barium Swallow study.","longName":"Pati_Modi_Cons_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D75A22E-6923-B174-E050-BB89AD4321E7","latestVersionIndicator":"Yes","beginDate":"2016-03-07","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-07","modifiedBy":"PATELV","dateModified":"2016-03-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5152831","version":"1","preferredName":"Patient Barium Swallow Evaluation Study Site Credential Checklist Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator related to whether the credentialing checklist for a modified barium swallow was completed by the study site prior to enrolling a patient.","longName":"PT_MBS_CREDENTIAL_CHECKLIST","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D8E2678-22A4-6089-E050-BB89AD430AE8","latestVersionIndicator":"Yes","beginDate":"2016-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-03-08","modifiedBy":"PATELV","dateModified":"2016-03-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5211171","version":"1","preferredName":"Concomitant Medication Use Yes No Not Applicable Indicator","preferredDefinition":"The indicator of whether any concomitant medication was used.","longName":"CONCOM_MEDS_USE_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD1A697-CEC2-735E-E050-BB89AD435F61","latestVersionIndicator":"Yes","beginDate":"2016-04-06","endDate":null,"createdBy":"GEDEONL","dateCreated":"2016-04-06","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeNote":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":"2022.9.30 AQT added for ticket request CADSR0001559. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5211191","version":"1","preferredName":"Relevant Laboratory Test Indicator Yes No Unknown Not Applicable Indicator","preferredDefinition":"Relevant Laboratory Test Indicator_The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"REL_LAB_TEST_IND_YES_NO_UNKNOW","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD2072D-9E39-C6AD-E050-BB89AD436DAA","latestVersionIndicator":"Yes","beginDate":"2016-04-06","endDate":null,"createdBy":"GEDEONL","dateCreated":"2016-04-06","modifiedBy":"WELSHE","dateModified":"2017-10-02","changeNote":"Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5215743","version":"1","preferredName":"Patient Refractory Blood Transfusion Eligibility Indicator","preferredDefinition":"the yes/no indicator of patient being refractory to transfusions (red blood cell, platelet, or both) to determine clinical trial eligibility for a patient.","longName":"2233604v1.0:3438700v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FFB62AC-6F2C-9707-E050-BB89AD434997","latestVersionIndicator":"Yes","beginDate":"2016-04-08","endDate":null,"createdBy":"DASCOMBS","dateCreated":"2016-04-08","modifiedBy":"PATELV","dateModified":"2018-03-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5230892","version":"1","preferredName":"Person Tuberculosis Personal Medical History Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator that asks if a patient has known active tuberculosis.","longName":"TUBERCULOSIS_ELIG_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"31186BAA-3F8E-56F3-E050-BB89AD431767","latestVersionIndicator":"Yes","beginDate":"2016-04-22","endDate":null,"createdBy":"PATELV","dateCreated":"2016-04-22","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5230911","version":"1","preferredName":"Patient Interstitial Disease Lung Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator that asks if a patient has known interstitial lung disease.","longName":"PT_INTDZ_LUNG_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"31190E85-A9B6-8532-E050-BB89AD4322FC","latestVersionIndicator":"Yes","beginDate":"2016-04-22","endDate":null,"createdBy":"PATELV","dateCreated":"2016-04-22","modifiedBy":"TSESU","dateModified":"2023-05-04","changeNote":null,"administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak 2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236950","version":"1","preferredName":"Myocardial Infarction Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator as to whether a patient has had a myocardial infarction","longName":"MI_PT_PREV_YR_PMEDHX_YES_NO_UN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A56609-B261-D260-E050-BB89AD430B37","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-29","modifiedBy":"TYRRELLM","dateModified":"2023-10-24","changeNote":null,"administrativeNotes":"10.24.2023 Added Alt Short Name per request ticket CADSR0002996_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236951","version":"1","preferredName":"Cardiovascular Disorder Acute Coronary Syndrome Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator as to whether or not a patient has acute coronary syndrome","longName":"4450053v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A56609-B280-D260-E050-BB89AD430B37","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-29","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeNote":null,"administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236953","version":"1","preferredName":"Other Specify Yes No Unknown Indicator","preferredDefinition":"A yes/no/unknown indicator for if \"other\" needs to be selected","longName":"2192296v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A56609-B29F-D260-E050-BB89AD430B37","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-29","modifiedBy":"SARAHB","dateModified":"2017-10-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236987","version":"1","preferredName":"Coronary Artery Bypass History Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator for a patient who has had coronary artery bypass","longName":"2257067v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A56609-B2BE-D260-E050-BB89AD430B37","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-29","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5236988","version":"1","preferredName":"Patient Cardiac Medical Device Implantation Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator for a patient who has a pacemaker or implantation device","longName":"3399856v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A56609-B2DD-D260-E050-BB89AD430B37","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-29","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237331","version":"1","preferredName":"Angiotensin-Converting Enzyme 2 Agent Administered Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing ACE inhibitors","longName":"3872857v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4B0F-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237332","version":"1","preferredName":"Beta-2-Adrenergic Receptor Agent Administered Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing beta blockers","longName":"3872890v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4B2E-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237333","version":"1","preferredName":"Angiotensin-Converting Enzyme 2 Agent Contraindicated Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing angiotensin blockers","longName":"4011953v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4B4D-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237334","version":"1","preferredName":"Angina Therapy Administered Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing beta blockers","longName":"3853547v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4B6C-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237335","version":"1","preferredName":"Cardiac Glycoside Agent Administered Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing cardiac glycoside","longName":"3872879v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4B8B-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237336","version":"1","preferredName":"Diuretic Agent Administered Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing diuretics","longName":"3872883v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4BAA-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2016-07-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237337","version":"1","preferredName":"Patient Strong Cytochrome P450 3A4 Induction Medication Eligibility Determination Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient needing calcium channel blockers","longName":"3153625v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4BC9-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237338","version":"1","preferredName":"Atrial Fibrillation Or Atrial Flutter Occurrence Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient has experienced atrial fibrillation","longName":"5030941v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4BE8-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"TSESU","dateModified":"2023-05-04","changeNote":null,"administrativeNotes":"2022.12.21 AQT added for ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237339","version":"1","preferredName":"Person Ventricular Arrhythmia Arrhythmia Medication Clinical Trial Eligibility Criteria Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient having ventricular fibrillation","longName":"3179291v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4C07-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237340","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Restrictive Cardiomyopathy Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to a patient having restrictive cardiomyopathy","longName":"2197860v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31B7C73C-4C26-79D3-E050-BB89AD432CE0","latestVersionIndicator":"Yes","beginDate":"2016-04-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-04-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255355","version":"1","preferredName":"Ovarian Seromucinous Carcinoma Histologic Type Yes No Indicator","preferredDefinition":"The yes/no indicator relating to if a patient has one of the listed types of carcinoma","longName":"5210644v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32832BCA-51F0-88B4-E050-BB89AD435533","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-10","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255356","version":"1","preferredName":"Mutation Abnormality Phosphatidylinositol 3 Kinase Status Yes No Indicator","preferredDefinition":"The yes/no status to indicate whether a patient has PIK3CA gene mutation","longName":"4284424v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32832BCA-520F-88B4-E050-BB89AD435533","latestVersionIndicator":"Yes","beginDate":"2016-05-10","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-10","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255752","version":"1","preferredName":"Neoplasm Mixed Histology Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's tumor containing multiple histologies","longName":"2404689v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3291D77A-6D14-30BC-E050-BB89AD4335DA","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255753","version":"1","preferredName":"Concurrent Radiation Therapy Chemotherapy Administration Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether a patient will continue concurrent radiotherapy or not","longName":"2539211v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32928D2D-6699-B9E6-E050-BB89AD436028","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255754","version":"1","preferredName":"Non-Protocol Corticosteroid Systemic Therapy Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the patient will continue systemic corticosteroid therapy","longName":"2345418v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32928D2D-66B8-B9E6-E050-BB89AD436028","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2022-03-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255767","version":"1","preferredName":"Patient Left Ventricular Ejection Fraction Outcome Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator to whether or not a patient had LVEF according to eligibility requirements","longName":"4901086v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8CE5-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"RODGERSC","dateModified":"2019-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255885","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 6 Month Yes No Indicator","preferredDefinition":"The yes/ no indicator related to a patient having coronary disease including myocardial infarction","longName":"4619893v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8D38-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255907","version":"1","preferredName":"Human Immunodeficiency Virus Diagnosis Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether a patient has HIV infection","longName":"2195690v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8D57-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255931","version":"1","preferredName":"Adverse Event Pre-Existing Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether a patient has pre-existing toxicities","longName":"2746278v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8DA9-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255932","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether a patient is using CYP3A4 inhibitors and inducers","longName":"4473475v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8DC8-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5255942","version":"1","preferredName":"Cardiac Condition Antiarrhythmic Therapy Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient using anti-arrhythmic therapy","longName":"4363904v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8DE7-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"SOKKERL","dateModified":"2019-08-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5271351","version":"1","preferredName":"Paclitaxel Dose Not Administered Yes No Indicator","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)_A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._An operation in which a term denies or inverts the meaning of another term or construction._The act of having given something (e.g., a medication or test)._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5271333v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3334E25D-D786-7AE3-E050-BB89AD435D42","latestVersionIndicator":"Yes","beginDate":"2016-05-19","endDate":null,"createdBy":"DASCOMBS","dateCreated":"2016-05-19","modifiedBy":"PATELV","dateModified":"2018-03-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5280551","version":"1","preferredName":"Adverse Event Hemorrhage Symptom Yes No Indicator","preferredDefinition":"The yes/no indicator related to bleeding as a result of an adverse event.","longName":"AE_HEMOR_SM_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33C4191C-9BA2-B2CA-E050-BB89AD4328A9","latestVersionIndicator":"Yes","beginDate":"2016-05-26","endDate":null,"createdBy":"PATELV","dateCreated":"2016-05-26","modifiedBy":"PATELV","dateModified":"2016-06-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5280576","version":"1","preferredName":"Person Corticosteroid Immunosuppressant Therapeutic Procedure Relationship Adverse Event Administered Duration","preferredDefinition":"The duration of administration of systemic corticosteroids or other immunosuppressant as a result of treatment related adverse event.","longName":"CORT_IMMUNO_ADM_DURATION","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33C51006-EDE9-B444-E050-BB89AD4366D6","latestVersionIndicator":"Yes","beginDate":"2016-05-26","endDate":null,"createdBy":"PATELV","dateCreated":"2016-05-26","modifiedBy":"PATELV","dateModified":"2016-06-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5300923","version":"1","preferredName":"Person Interval Last Surgical Procedure Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable question as to whether a person's last time of surgery is acceptable based on eligibility criteria","longName":"3178372v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35BBA8CC-D125-03EE-E050-BB89AD434079","latestVersionIndicator":"Yes","beginDate":"2016-06-20","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-06-20","modifiedBy":"SARAHB","dateModified":"2022-04-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5337211","version":"1","preferredName":"Laboratory Procedure Phosphorus Calcium Magnesium Potassium Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's potassium, magnesium, and calcium levels being within normal range prior to randomization","longName":"3622691v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36FCF3C6-A414-C23C-E050-BB89AD433906","latestVersionIndicator":"Yes","beginDate":"2016-07-06","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-06","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5337921","version":"1","preferredName":"Disease Exclusion Yes No Indicator","preferredDefinition":"The yes/no indicator related to excluding metastatic disease","longName":"2177988v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"370E3D45-9140-CC25-E050-BB89AD437485","latestVersionIndicator":"Yes","beginDate":"2016-07-07","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-07","modifiedBy":"SPRINGERL","dateModified":"2021-11-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339197","version":"1","preferredName":"Distance Measured Rectal Examination Type","preferredDefinition":"The way distance was determined","longName":"5337955v1.0:5338151v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-7788-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339198","version":"1","preferredName":"Distal Location Yes No Indicator","preferredDefinition":"The yes/no indicator to determine if a tumor meets criteria for distal location","longName":"5337958v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-77AB-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339199","version":"1","preferredName":"Type Colon Neoplasm Yes No Indicator","preferredDefinition":"The yes/no indicator to determine if a tumor meets criteria for bulky","longName":"5339179v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-77CE-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339200","version":"1","preferredName":"Metastatic Neoplasm Risk Factor Yes No Indicator","preferredDefinition":"The yes/no indicator to determine if a tumor meets criteria for high risk of metastatic disease","longName":"5339173v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-77ED-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339201","version":"1","preferredName":"Sphincter Surgery Surgery Yes No Indicator","preferredDefinition":"The yes/no indicator to determine if a tumor meets criteria for sphincter-sparing surgical resection","longName":"5339176v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-7811-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339202","version":"1","preferredName":"Clinical Stage Neoplasm Classification Imaging Type","preferredDefinition":"The imaging type used to determine the clinical stage of the primary tumor","longName":"5339182v1.0:5339192v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-7834-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339203","version":"1","preferredName":"Clinical Nodal Status Classification Imaging Type","preferredDefinition":"The way clinical nodal status was determined","longName":"5339185v1.0:5339192v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3724B525-E5E3-C3AE-E050-BB89AD43199B","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339204","version":"1","preferredName":"Metastatic Disease or Disorder Exclusion Criteria Imaging Type","preferredDefinition":"The way metastatic disease was excluded","longName":"5339187v1.0:5339192v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-7858-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339205","version":"1","preferredName":"left bundle branch block Present Yes No Indicator","preferredDefinition":"The yes/no indicator for whether or not left bundle branch block is present","longName":"5337952v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-7881-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2018-04-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339206","version":"1","preferredName":"Dihydropyrimidine Dehydrogenase Deficiency Indicator Present Yes No Indicator","preferredDefinition":"The yes/no indicator for whether or not the patient has DPD (dihydro pyrimidine dehydrogenase) deficiency","longName":"5337945v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3724B525-E607-C3AE-E050-BB89AD43199B","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"BOWSERC","dateModified":"2021-10-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339210","version":"1","preferredName":"Reproductive System Status Yes No Indicator","preferredDefinition":"The yes/no indicator to describe if a patient is of reproductive potential","longName":"5339209v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37246CE4-78A0-7497-E050-BB89AD43237D","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5339515","version":"1","preferredName":"Patient Inadequate Hepatic Function Assessment Ind-2","preferredDefinition":"Indicates yes/no as to whether a patient has inadequate hepatic or hematologic function.","longName":"3380619v1.0:2181518v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37260EF9-F815-6442-E050-BB89AD432C9A","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-08","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeNote":"Replaced VD Labs Ind-2  2181518v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5341071","version":"1","preferredName":"Patient Decipher Prostate Cancer Test Stratification Type","preferredDefinition":"A unique genomic test analyzing the expression of 22 biomarkers across the genome performed on a subject's tissue sample, tumor, from the pathology lab which classifies post-surgery intermediate and  high-risk patients into genomic risk categories for metastasis.","longName":"DECI_PROS_CAN_TEST_STRAT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37613906-ECF2-13A2-E050-BB89AD43102D","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-11","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":"Created for Vanita Patel","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5361262","version":"1","preferredName":"Sphincter Preservation Procedure Surgery Method Type","preferredDefinition":"The type of surgery that is used to preserve the sphincter","longName":"5361253v1.0:2016213v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388E5510-7F11-6413-E050-BB89AD430AC9","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-26","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5361263","version":"1","preferredName":"Sphincter Destruction Intervention or Procedure Surgery Method Type","preferredDefinition":"The type of surgery performed without the intention of preserving the sphincter","longName":"5361260v1.0:2016213v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388E4911-6C00-5394-E050-BB89AD436E6C","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-07-26","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5361320","version":"2","preferredName":"Surgical Procedure Intention Applicable Yes No Indicator","preferredDefinition":"The yes/no indicator related to a person as a candidate for surgery","longName":"SURGICAL_PRO_INTENTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B2728C4-9ABF-358D-E053-F662850A14E0","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"PATELV","dateCreated":"2019-06-12","modifiedBy":"PATELV","dateModified":"2019-06-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5397399","version":"1","preferredName":"Simpson Grading System Scale","preferredDefinition":"The grade that defines the extent of resection involved in the removal of intracranial meningiomas.","longName":"SIMPSON_SCALE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"Simpson Grading System: Donald Simpson, The Recurrence of Intracranial Meningiomas after Surgical Treatment, J. Neurol. Neurosurg. Psychiatry 1957; 20: 22-39.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39BB8F14-0483-A3BA-E050-BB89AD4374AF","latestVersionIndicator":"Yes","beginDate":"2016-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-10","modifiedBy":"COOPERM","dateModified":"2016-08-10","changeNote":"Created for NRG brain trials in Rave. mc 8/10/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5397407","version":"1","preferredName":"Patient Proton Therapy Yes No Indicator","preferredDefinition":"The yes/no indicator for selection of proton therapy.","longName":"PT_PROTON_THERAPY_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39BC2F65-759C-70D8-E050-BB89AD434E21","latestVersionIndicator":"Yes","beginDate":"2016-08-10","endDate":null,"createdBy":"PATELV","dateCreated":"2016-08-10","modifiedBy":"FORMBUILDER","dateModified":"2019-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5407451","version":"1","preferredName":"Patient Unifocal Meningioma Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator for whether or not the patient has a newly diagnosed unifocal intracranial meningioma, gross totally resected and histologically confirmed as WHO Grade 2 based on pathology finding of the enrolling institution.","longName":"PT_MENINGIOMA_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1ED7A1-A025-278D-E050-BB89AD436C7E","latestVersionIndicator":"Yes","beginDate":"2016-08-15","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-08-15","modifiedBy":"WISEM","dateModified":"2016-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5409467","version":"1","preferredName":"Complete Excision Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator for whether or not the gross total resection (GTR) interpreted as modified Simpson grade 1-3 without gross residual dural-based or extradural tumor, was confirmed both by modified Simpson grade and by post-operative MRI findings following the most recent surgery.","longName":"COMPL_EXCIS_ELIG_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A3507A9-ADC2-E2A7-E050-BB89AD4364CA","latestVersionIndicator":"Yes","beginDate":"2016-08-16","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-08-16","modifiedBy":"GEINOZS","dateModified":"2016-09-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5409914","version":"1","preferredName":"Patient Hormonal Salvage Therapy Administration Yes No Unknown Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Relating to hormones._Treatment that is given after the cancer has not responded to other treatments._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"SALV_HORM_THERAPY","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A371585-8AD8-1EC7-E050-BB89AD430F62","latestVersionIndicator":"Yes","beginDate":"2016-08-16","endDate":null,"createdBy":"WELSHE","dateCreated":"2016-08-16","modifiedBy":"WELSHE","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5409934","version":"1","preferredName":"Patient Decipher Prostate Cancer Test Performed Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis._Executed and carried through to completion._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"DECIPHER_PROS_CA_TEST","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A373BCD-44BA-B2FE-E050-BB89AD433175","latestVersionIndicator":"Yes","beginDate":"2016-08-16","endDate":null,"createdBy":"WELSHE","dateCreated":"2016-08-16","modifiedBy":"GARRIDOJ","dateModified":"2021-10-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5416555","version":"1","preferredName":"Recurrent Malignant Neoplasm Perineum Yes No Indicator","preferredDefinition":"The yes/no indicator related to the presence of recurrence in the perineum","longName":"5416554v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A46AE51-0021-FE9C-E050-BB89AD431327","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5416589","version":"1","preferredName":"Recurrent Malignant Neoplasm Lymph Node Yes No Indicator","preferredDefinition":"A yes/no indicator relating to recurrence in the lymph nodes","longName":"5416588v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A472AA7-A0BE-2333-E050-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418312","version":"1","preferredName":"Chemotherapy Leucovorin Calcium Administered Medication Dose","preferredDefinition":"Information related to the dose of leucovorin a patient received","longName":"2820887v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4A6784-28CC-D844-E050-BB89AD4352FB","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418313","version":"1","preferredName":"Fluorouracil Agent During Reporting Period Administered Medication Dose","preferredDefinition":"Information related to the dose of 5-FU received","longName":"2501701v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4A6784-28EC-D844-E050-BB89AD4352FB","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418327","version":"1","preferredName":"Fluorouracil Administered Medication Dose","preferredDefinition":"Information related to the dose of 5-FU a patient received","longName":"2867193v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4AE379-473A-356D-E050-BB89AD433EA2","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418328","version":"1","preferredName":"Neoadjuvant Chemotherapy Capecitabine Administered Medication Dose","preferredDefinition":"Information related to the dose of capecitabine a patient received","longName":"3647292v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4A6784-290B-D844-E050-BB89AD4352FB","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418329","version":"1","preferredName":"Agent Veliparib Administered Medication Dose","preferredDefinition":"Information related to the dose of veliparib a patient received","longName":"3607842v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4A6784-292F-D844-E050-BB89AD4352FB","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5418331","version":"1","preferredName":"Chemotherapy Preoperative Oxaliplatin Administered Medication Dose","preferredDefinition":"Information related to the dose of oxaliplatin a patient received","longName":"2762653v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A4AE379-4776-356D-E050-BB89AD433EA2","latestVersionIndicator":"Yes","beginDate":"2016-08-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5423065","version":"1","preferredName":"Zubrod Performance Status Unknown Response Evaluation Yes No Indicator","preferredDefinition":"Indicator for whether or not Zubrod Performance Status is unknown.","longName":"ZUBROD_PS_UNK_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A5E2626-1CF2-99C7-E050-BB89AD434F8D","latestVersionIndicator":"Yes","beginDate":"2016-08-18","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-08-18","modifiedBy":"GEINOZS","dateModified":"2016-08-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5423711","version":"1","preferredName":"Planned Fractions Radiation Therapy Count","preferredDefinition":"information related to the planned fractions of radiation therapy.","longName":"PLAN_FRAC_RT_COUNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A5E48AF-BB13-25E4-E050-BB89AD4374A8","latestVersionIndicator":"Yes","beginDate":"2016-08-18","endDate":null,"createdBy":"GRANTD","dateCreated":"2016-08-18","modifiedBy":"GRANTD","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5424915","version":"1","preferredName":"Patient Hormonal Salvage Therapy Administration Type","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Relating to hormones._Treatment that is given after the cancer has not responded to other treatments._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._a chemical name for a hormonal compound given as treatment for cancer.","longName":"SALV_HORM_THERAPY_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6DBD38-3AB4-624A-E050-BB89AD43025E","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"WELSHE","dateCreated":"2016-08-19","modifiedBy":"WELSHE","dateModified":"2016-08-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5428020","version":"1","preferredName":"Nodal Status Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator relating to whether or not nodal status was assessed","longName":"5428016v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAE6CD3-F6C7-6B98-E050-BB89AD43751D","latestVersionIndicator":"Yes","beginDate":"2016-08-22","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-22","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5428021","version":"1","preferredName":"Clinical Stage Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator for whether or not clinical stage was assessed","longName":"5428019v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAE1185-AFE7-64AA-E050-BB89AD432C26","latestVersionIndicator":"Yes","beginDate":"2016-08-22","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-22","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5428022","version":"1","preferredName":"Nodal Status Assessment Date","preferredDefinition":"The date of nodal status assessment","longName":"5428016v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAE7D52-EF63-BE3F-E050-BB89AD431416","latestVersionIndicator":"Yes","beginDate":"2016-08-22","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-22","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5428023","version":"1","preferredName":"Clinical Stage Assessment Date","preferredDefinition":"The date of clinical stage assessment","longName":"5428019v1.0:2018550v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAE7D52-EF82-BE3F-E050-BB89AD431416","latestVersionIndicator":"Yes","beginDate":"2016-08-22","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-22","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5431743","version":"1","preferredName":"Rectal Neoplasm Palpable Yes No Indicator","preferredDefinition":"The yes/no indicator relating to whether a rectal tumor is palpable or not","longName":"5431195v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AEA4648-975B-8738-E050-BB89AD434C03","latestVersionIndicator":"Yes","beginDate":"2016-08-25","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-25","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5431744","version":"1","preferredName":"Rectal Neoplasm Visible Yes No Indicator","preferredDefinition":"The yes/no indicator relating to whether a rectal tumor is visible or not","longName":"5431198v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AEA4648-9793-8738-E050-BB89AD434C03","latestVersionIndicator":"Yes","beginDate":"2016-08-25","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-25","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5431757","version":"1","preferredName":"Proctoscopy Sigmoidoscopy Performed Yes No Indicator","preferredDefinition":"The yes/no indicator relating to whether or not a proctoscopic or signoidoscopic exam was performed","longName":"5431753v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AE9C216-DA25-8102-E050-BB89AD431794","latestVersionIndicator":"Yes","beginDate":"2016-08-25","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-25","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5432855","version":"1","preferredName":"Therapeutic Procedure Continue Yes No Indicator","preferredDefinition":"The yes no indicator related to whether or not a therapeutic procedure is ongoing","longName":"5432854v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AFF8EE0-E954-584D-E050-BB89AD432093","latestVersionIndicator":"Yes","beginDate":"2016-08-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-26","modifiedBy":"CLOHNES","dateModified":"2023-12-12","changeNote":null,"administrativeNotes":"12/12/23 Added 2 alt OIDs and AQT for CCTG ticket number CADSR0003182 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5436423","version":"1","preferredName":"Cardiopulmonary Complication Yes No Indicator","preferredDefinition":"A yes/no indicator for whether a patient had a cardiopulmonary complication","longName":"5436420v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3BD16E-9C31-762A-E050-BB89AD436EDA","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-29","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5436427","version":"1","preferredName":"Gynecologic Complication Yes No Indicator","preferredDefinition":"The yes/no indicator for whether a patient had a gynecologic complication","longName":"5436416v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3BD16E-9C50-762A-E050-BB89AD436EDA","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-29","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5440513","version":"1","preferredName":"Invasive Colorectal Carcinoma Anatomic Site Tumor Colorectal Site","preferredDefinition":"The site of a colorectal tumor","longName":"2534262v1.0:2015595v3.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B5038F1-F398-32D0-E050-BB89AD4361AA","latestVersionIndicator":"Yes","beginDate":"2016-08-30","endDate":null,"createdBy":"SARAHB","dateCreated":"2016-08-30","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5456911","version":"1","preferredName":"Patient Optic Nerve Spinal Extracranial Multiple Meningioma Hemangiopericytoma Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator for whether or not the patient has optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, or hemangiopericytoma.","longName":"MENINGIOMA_ELIG_CRIT_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C186CB2-56E7-037A-E050-BB89AD4332A0","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"WISEM","dateCreated":"2016-09-09","modifiedBy":"WISEM","dateModified":"2016-09-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5457057","version":"1","preferredName":"Patient Neurosurgeon Simpson Grading System Assessment Yes No Indicator","preferredDefinition":"Indicator for whether or not the modified Simpson grade was provided by the operative neurosurgeon.","longName":"NEURO_SURG_SIMP_GRD_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C193A0D-8DF0-0F10-E050-BB89AD436168","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"WISEM","dateCreated":"2016-09-09","modifiedBy":"WISEM","dateModified":"2016-09-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5457371","version":"1","preferredName":"Patient Metastatic Meningioma Assessment Yes No Indicator","preferredDefinition":"Indicator whether or not there is definitive evidence of metastatic meningioma.","longName":"PT_MET_MENING_ASS_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C514EB8-7845-4E65-E050-BB89AD4366F7","latestVersionIndicator":"Yes","beginDate":"2016-09-12","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-09-12","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5457397","version":"1","preferredName":"Patient Neurofibromatosis Type 2 Clinical Diagnosis Yes No Indicator","preferredDefinition":"Indicator of whether or not the patient has type II neurofibromatosis.","longName":"PT_NeuFib_T2_Diag_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C50ECAC-A0D7-7084-E050-BB89AD432B94","latestVersionIndicator":"Yes","beginDate":"2016-09-12","endDate":null,"createdBy":"SOLAKOVS","dateCreated":"2016-09-12","modifiedBy":"SOLAKOVS","dateModified":"2016-09-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5459202","version":"1","preferredName":"Patient Neurologic Disease Progression Assessment Yes No Indicator","preferredDefinition":"Indicator whether or not the patient has neurologic disease progression.","longName":"PT_NEURO_DIS_PROGR_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C65E19A-274A-56CA-E050-BB89AD432324","latestVersionIndicator":"Yes","beginDate":"2016-09-13","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-09-13","modifiedBy":"GEINOZS","dateModified":"2016-09-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5459471","version":"1","preferredName":"Not Obtained Indicator Study Refuse Consent Reason","preferredDefinition":"The reason consent to participate in neurocognitive function study was refused.","longName":"PT_REFUSE_NCF_RSN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C685251-2CC0-8825-E050-BB89AD433399","latestVersionIndicator":"Yes","beginDate":"2016-09-13","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-09-13","modifiedBy":"WISEM","dateModified":"2016-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5477187","version":"1","preferredName":"Stereotactic Body Radiation Therapy Field Count","preferredDefinition":"Information related to the number of SBRT fields.","longName":"SBRT_FIELD_COUNT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D08F4E2-708C-359A-E053-F662850A53A0","latestVersionIndicator":"Yes","beginDate":"2016-09-21","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2016-09-21","modifiedBy":"SOLAKOVS","dateModified":"2020-04-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5484941","version":"1","preferredName":"Disease or Disorder Hyperostosis Present Yes No Indicator","preferredDefinition":"Indicator whether or not there is presence of hyperostosis.","longName":"DIS_HYPEROSTOSIS_IND_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D6C2937-516E-178A-E053-F662850AA745","latestVersionIndicator":"Yes","beginDate":"2016-09-26","endDate":null,"createdBy":"GEINOZS","dateCreated":"2016-09-26","modifiedBy":"GEINOZS","dateModified":"2016-09-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5509198","version":"1","preferredName":"Patient Reduced Intimacy Present Yes No Indicator","preferredDefinition":"Patients who have decreased sexual desire after the diagnosis of cancer.","longName":"PT_RED_INTIMACY_PRE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9C5534-F51A-51E1-E053-F662850A1BE4","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"BONANNIR","dateCreated":"2016-10-11","modifiedBy":"BONANNIR","dateModified":"2016-10-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5509222","version":"1","preferredName":"Antidepressant Agent Selective Serotonin Reuptake Inhibitor Use Yes No Indicator","preferredDefinition":"Current use of the antidepressant SSRI","longName":"SSRI_USE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E9C9764-CAA6-63E0-E053-F662850AD345","latestVersionIndicator":"Yes","beginDate":"2016-10-11","endDate":null,"createdBy":"BONANNIR","dateCreated":"2016-10-11","modifiedBy":"BONANNIR","dateModified":"2016-10-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5523122","version":"1","preferredName":"Patient Meningioma Extent Surgical Excision Type","preferredDefinition":"Extent of meningioma resection type","longName":"MENING_EXT_SX_EXC_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED834D3-143F-5B12-E053-F662850AC3BC","latestVersionIndicator":"Yes","beginDate":"2016-10-14","endDate":null,"createdBy":"WISEM","dateCreated":"2016-10-14","modifiedBy":"WISEM","dateModified":"2016-10-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5527642","version":"1","preferredName":"Patient Active Bipolar Disorder Present Yes No Indicator","preferredDefinition":"Patients who have active bipolar disorder","longName":"PT_ACT_BIPOLAR_DIS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F3A1BA9-8869-2313-E053-F662850A9873","latestVersionIndicator":"Yes","beginDate":"2016-10-19","endDate":null,"createdBy":"BONANNIR","dateCreated":"2016-10-19","modifiedBy":"BONANNIR","dateModified":"2016-10-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5578285","version":"1","preferredName":"Patient English Spanish French Language Comprehension Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator specifying if the person can read/speak English or Spanish or French.","longName":"PT_ENG_SPA_FRE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"418259B5-E639-1987-E053-F662850A775A","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5580936","version":"1","preferredName":"Patient English Spanish Language Comprehension Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator specifying if the person can read/speak English or Spanish.","longName":"PT_ENG_SPA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41E53916-7987-11FA-E053-F662850A2629","latestVersionIndicator":"Yes","beginDate":"2016-11-22","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-22","modifiedBy":"SOKKERL","dateModified":"2023-08-29","changeNote":null,"administrativeNotes":"4/3/2023: Added AQT per CADSR0002247.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5623263","version":"1","preferredName":"Patient Treatment Study Impact Libido Satisfaction Scale","preferredDefinition":"Patient satisfaction with sexual desire after using the study drug","longName":"PT_TX_IMP_LIB_SAT_SCALE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D71163-D665-5E38-E053-F662850A993E","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"BONANNIR","dateCreated":"2017-01-11","modifiedBy":"BONANNIR","dateModified":"2017-01-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5623299","version":"1","preferredName":"Patient Treatment Study Benefits Against Side Effect Outcome Yes No Indicator","preferredDefinition":"The benefits of treatment were greater than the side effects of treatment","longName":"TX_BEN_VS_SIDE_EFFECTS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D71960-43CC-6AD7-E053-F662850A6D14","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"BONANNIR","dateCreated":"2017-01-11","modifiedBy":"BONANNIR","dateModified":"2017-01-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5626661","version":"1","preferredName":"Imaging Technique Confirmation Type Imaging Type","preferredDefinition":"The type of imaging that was used to confirm biopsy marker placement","longName":"5626660v1.0:5339192v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EAC20B-BFA0-14EB-E053-F662850AC29B","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5626699","version":"1","preferredName":"Receive None Yes No Indicator","preferredDefinition":"The yes/no indicator to say whether a patient received imaging or not","longName":"5626698v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EB6138-B5CC-0B59-E053-F662850A02AE","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5626745","version":"1","preferredName":"Surgical Procedure Eligible Yes No Indicator","preferredDefinition":"The yes/no indicator for whether a patient is eligible to undergo surgery","longName":"5626744v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EB9F75-EDB5-2BC6-E053-F662850A2AEA","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"TIFFANIS","dateModified":"2019-10-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5627028","version":"1","preferredName":"Number Core Specimen Known Yes No Indicator","preferredDefinition":"The yes/no indicator asking if the number of cores collected is known","longName":"5627021v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EC7128-B860-38D2-E053-F662850AACA1","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5627035","version":"1","preferredName":"Core Specimen Pathology Known Yes No Indicator","preferredDefinition":"The yes/no indicator to tell whether the pathology of core specimens is known","longName":"5627031v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EC7C28-3F59-4329-E053-F662850A8F28","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5627045","version":"1","preferredName":"Invasive Lesion Core Biopsy Specimen Number","preferredDefinition":"The number of cores containing invasive tumor","longName":"5627041v1.0:2182118v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EC7128-B8B6-38D2-E053-F662850AACA1","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5627049","version":"1","preferredName":"Ductal Breast Carcinoma In Situ Core Biopsy Specimen Number","preferredDefinition":"The number of cores containing DCIS","longName":"5627048v1.0:2182118v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45EC7128-B90A-38D2-E053-F662850AACA1","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5627067","version":"1","preferredName":"Invasive Lesion Ductal Breast Carcinoma In Situ Core Biopsy Specimen Number","preferredDefinition":"The number of cores containing DCIS and invasive tumor","longName":"5627054v1.0:2182118v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45ECADE6-F31E-5F20-E053-F662850A7ECD","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-12","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628525","version":"1","preferredName":"Stereotactic Biopsy Performed Yes No Indicator","preferredDefinition":"The yes/no indicator to say whether or not a stereotactic biopsy was performed","longName":"5628524v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464CF70E-D79F-6688-E053-F662850A6948","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628536","version":"1","preferredName":"Stereotactic Biopsy Performed Occurrence Indicator Reason","preferredDefinition":"Reason why stereotactic biopsy did not happen","longName":"5628524v1.0:5628529v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D113A-3F28-7A8C-E053-F662850ACDE9","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628540","version":"1","preferredName":"Surgical Procedure Breast Reconstruction Performed Occurrence Indicator Reason","preferredDefinition":"Reason why breast surgery did not happen","longName":"2716452v1.0:5628529v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D14BE-59C7-4A63-E053-F662850A2736","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628564","version":"1","preferredName":"Biopsy Mammotome Clip Excision Performed Yes No Indicator","preferredDefinition":"The yes/no indicator for whether or not a clip excision was performed","longName":"5628563v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D3D42-E197-0562-E053-F662850A5EBD","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628937","version":"1","preferredName":"Pneumothorax Presentation Yes No Indicator","preferredDefinition":"Pneumothorax present","longName":"5515050v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464DFA45-E378-0A5D-E053-F662850AC738","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628942","version":"1","preferredName":"Serious Adverse Event Life Threatening or Disabling Result Yes No Indicator","preferredDefinition":"Yes/no indicator for a serious life threatening event","longName":"2719197v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D3D42-E27B-0562-E053-F662850A5EBD","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628943","version":"1","preferredName":"Hematoma Presentation Yes No Indicator","preferredDefinition":"Hematoma present","longName":"5514975v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D3D42-E29A-0562-E053-F662850A5EBD","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5628944","version":"1","preferredName":"Breast Implant Present Yes No Indicator","preferredDefinition":"Breast implants present","longName":"3079282v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"464D113A-3F9E-7A8C-E053-F662850ACDE9","latestVersionIndicator":"Yes","beginDate":"2017-01-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629530","version":"1","preferredName":"Imaging Technique Confirmation Type Yes No Indicator","preferredDefinition":"Yes/no indicator for the imaging technique confirmation","longName":"5626660v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46650EA5-8851-2AE6-E053-F662850A5709","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629823","version":"1","preferredName":"Adjuvant Therapy Lapatinib Administered Agent Start Date","preferredDefinition":"The date lapatinib therapy started","longName":"3812570v1.0:2179512v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46656E3B-DE38-658E-E053-F662850A4BDD","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629824","version":"1","preferredName":"Adjuvant Therapy Lapatinib Administered Agent End Date","preferredDefinition":"The date lapatinib therapy stopped","longName":"3812570v1.0:2179511v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4663CE25-39A3-3909-E053-F662850A6878","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629825","version":"1","preferredName":"Agent Pertuzumab Administered Agent Start Date","preferredDefinition":"The date pertuzumab therapy started","longName":"3645339v1.0:2179512v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46656E3B-DE57-658E-E053-F662850A4BDD","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629831","version":"1","preferredName":"Agent Pertuzumab Administered Agent End Date","preferredDefinition":"The date pertuzumab therapy ended","longName":"3645339v1.0:2179511v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466576B1-868D-647F-E053-F662850A5C00","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629832","version":"1","preferredName":"Agent T-DM1 Administered Agent Start Date","preferredDefinition":"The date T-DM1 therapy started","longName":"3645343v1.0:2179512v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46657C79-2A54-2615-E053-F662850A9762","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629833","version":"1","preferredName":"Agent T-DM1 Administered Agent End Date","preferredDefinition":"The date T-DM1 therapy ended","longName":"3645343v1.0:2179511v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46645AEA-E1B5-17CF-E053-F662850ACFA7","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629834","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Agent Start Date","preferredDefinition":"The date other therapy started","longName":"3810854v1.0:2179512v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D30C-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629835","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Agent End Date","preferredDefinition":"The date other therapy ended","longName":"3810854v1.0:2179511v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466585DC-44CE-28C1-E053-F662850A5763","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629863","version":"1","preferredName":"Neoadjuvant Chemotherapy Cyclophosphamide Methotrexate Fluorouracil Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of CMF: cyclophosphamide, methotrexate, and 5-fluorouracil._the date on which an observation or an event began.","longName":"3647265v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665B983-DD59-2C6F-E053-F662850A2C04","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629864","version":"1","preferredName":"Neoadjuvant Chemotherapy Cyclophosphamide Methotrexate Fluorouracil Administered Therapy End Date","preferredDefinition":"Day last CMF dose given","longName":"3647265v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665BC9E-A82C-6A7C-E053-F662850AC427","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629874","version":"1","preferredName":"Neoadjuvant Chemotherapy Cyclophosphamide Methotrexate Fluorouracil Administered Treatment Course Count","preferredDefinition":"Number of cycles CMF received","longName":"3647265v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665BF80-A161-2BA9-E053-F662850A4533","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629875","version":"1","preferredName":"Neoadjuvant Chemotherapy Cyclophosphamide Methotrexate Fluorouracil Administered Agent Administration Week Count","preferredDefinition":"Intended length of CMF cycles","longName":"3647265v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46645AEA-E1D4-17CF-E053-F662850ACFA7","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629884","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Begin Date","preferredDefinition":"information related to the administration of a dose-dense neoadjuvant chemotherapy regimen consisting of AC (or CA): adriamycin (doxorubicin) and cyclophosphamide._the date on which an observation or an event began.","longName":"3647989v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665E9A6-5679-662A-E053-F662850ACD24","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629885","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Therapy End Date","preferredDefinition":"The last date dose dense AC was administered","longName":"3647989v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665E9A6-5698-662A-E053-F662850ACD24","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629886","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Treatment Course Count","preferredDefinition":"Number of cycles dose dense AC received","longName":"3647989v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665E9A6-56B7-662A-E053-F662850ACD24","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629887","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Doxorubicin Hydrochloride Cyclophosphamide Administered Agent Administration Week Count","preferredDefinition":"Intended length of dose dense AC cycles","longName":"3647989v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665F3E9-7BCC-654A-E053-F662850A6B82","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629888","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Paclitaxel Administered Begin Date","preferredDefinition":"information related to a dose-dense neoadjuvant chemotherapy regimen consisting of paclitaxel administered._the date on which an observation or an event began.","longName":"3647992v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665F6F7-DDB6-6481-E053-F662850AB92B","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629889","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Paclitaxel Administered Therapy End Date","preferredDefinition":"The last date dose dense paclitaxel was received","longName":"3647992v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46647C93-A6A9-2AEF-E053-F662850A020F","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629890","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Paclitaxel Administered Treatment Course Count","preferredDefinition":"Number of doses of dose dense paclitaxel received","longName":"3647992v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4665BF80-A180-2BA9-E053-F662850A4533","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629891","version":"1","preferredName":"Neoadjuvant Chemotherapy Dose Dense Paclitaxel Administered Agent Administration Week Count","preferredDefinition":"Intended length of dose dense paclitaxel cycles","longName":"3647992v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4666004E-133D-4C7E-E053-F662850A7AEC","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629892","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of FAC: 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide._the date on which an observation or an event began.","longName":"3647270v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466598CD-54B8-646F-E053-F662850A1C88","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629893","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Therapy End Date","preferredDefinition":"Last day of FAC","longName":"3647270v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46660B1F-F00D-260F-E053-F662850A17B4","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629894","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Treatment Course Count","preferredDefinition":"Number of cycles of FAC received","longName":"3647270v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46644781-3EE9-0A98-E053-F662850A70AF","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629895","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Doxorubicin Hydrochloride Cyclophosphamide Administered Agent Administration Week Count","preferredDefinition":"Intended length of FAC","longName":"3647270v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46645AEA-E1F3-17CF-E053-F662850ACFA7","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629928","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Epirubicin Cyclophosphamide Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of FEC: 5-fluorouracil, epirubicin, and cyclophosphamide._the date on which an observation or an event began.","longName":"3647274v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-0336-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629929","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Epirubicin Cyclophosphamide Administered Therapy End Date","preferredDefinition":"The last date FEC was administered","longName":"3647274v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D3C2-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629930","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Epirubicin Cyclophosphamide Administered Treatment Course Count","preferredDefinition":"Number of cycles of FEC received","longName":"3647274v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D3E1-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629931","version":"1","preferredName":"Neoadjuvant Chemotherapy Fluorouracil Epirubicin Cyclophosphamide Administered Agent Administration Week Count","preferredDefinition":"Intended length of FEC cycles","longName":"3647274v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D400-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629933","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Doxorubicin Hydrochloride Cyclophosphamide Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of TAC: taxotere (docetaxel), adriamycin (doxorubicin), and cyclophosphamide._the date on which an observation or an event began.","longName":"3647277v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F0F0-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629934","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Doxorubicin Hydrochloride Cyclophosphamide Administered Therapy End Date","preferredDefinition":"Date last dose of TAC administered","longName":"3647277v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F10F-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629935","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Doxorubicin Hydrochloride Cyclophosphamide Administered Treatment Course Count","preferredDefinition":"Number of cycles of TAC received","longName":"3647277v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F12E-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629936","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Doxorubicin Hydrochloride Cyclophosphamide Administered Agent Administration Week Count","preferredDefinition":"Intended length of TAC cycles","longName":"3647277v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F160-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629940","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel) and cyclophosphamide._the date on which an observation or an event began.","longName":"3647280v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46677F8A-CA74-23A7-E053-F662850A451D","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629941","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Therapy End Date","preferredDefinition":"The last date taxotere and cyclophosphamide received","longName":"3647280v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"467410E8-780F-19FB-E053-F662850AC3B9","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629942","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Treatment Course Count","preferredDefinition":"Number of cycles of taxotere and cyclophosphamide received","longName":"3647280v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D41F-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629943","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Administered Agent Administration Week Count","preferredDefinition":"Intended length of taxotere and cyclophosphamide cycles","longName":"3647280v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674D62C-D18E-21C5-E053-F662850AE3F4","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629944","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Carboplatin Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel), carboplatin, and cyclophosphamide._the date on which an observation or an event began.","longName":"3647283v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"467410E8-782E-19FB-E053-F662850AC3B9","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629945","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Carboplatin Administered Therapy End Date","preferredDefinition":"Date last dose taxotere, carboplatin, and cyclophosphamide administered","longName":"3647283v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-0379-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629946","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Carboplatin Administered Treatment Course Count","preferredDefinition":"Number of cycles of taxotere, carboplatin, and cyclophosphamide received","longName":"3647283v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46677F8A-CA9B-23A7-E053-F662850A451D","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629947","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Cyclophosphamide Carboplatin Administered Agent Administration Week Count","preferredDefinition":"Intended length of taxotere, carboplatin, and cyclophosphamide cycles","longName":"3647283v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D43E-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629948","version":"1","preferredName":"Neoadjuvant Chemotherapy Paclitaxel Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxol (paclitaxel)._the date on which an observation or an event began.","longName":"3647286v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674D62C-D1AD-21C5-E053-F662850AE3F4","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629949","version":"1","preferredName":"Neoadjuvant Chemotherapy Paclitaxel Administered Therapy End Date","preferredDefinition":"Last date taxol received","longName":"3647286v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-0398-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629950","version":"1","preferredName":"Neoadjuvant Chemotherapy Paclitaxel Administered Treatment Course Count","preferredDefinition":"Number of cycles taxol received","longName":"3647286v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46677F8A-CABA-23A7-E053-F662850A451D","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629951","version":"1","preferredName":"Neoadjuvant Chemotherapy Paclitaxel Administered Agent Administration Week Count","preferredDefinition":"Intended length of taxol cycles","longName":"3647286v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F17F-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629952","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Administered Begin Date","preferredDefinition":"information related to the administration of a neoadjuvant chemotherapy regimen consisting of taxotere (docetaxel)._the date on which an observation or an event began.","longName":"3647289v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-03B7-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629953","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Administered Therapy End Date","preferredDefinition":"Date last dose of taxotere","longName":"3647289v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46677F8A-CAD9-23A7-E053-F662850A451D","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629954","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Administered Treatment Course Count","preferredDefinition":"Number of cycles of taxotere received","longName":"3647289v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-03D6-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629955","version":"1","preferredName":"Neoadjuvant Chemotherapy Docetaxel Administered Agent Administration Week Count","preferredDefinition":"Intended length of taxotere cycles","longName":"3647289v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674141C-F19E-1FCC-E053-F662850A4B51","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629956","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Begin Date","preferredDefinition":"Information related to the administration of other therapy in a neoadjuvant setting._the date on which an observation or an event began.","longName":"3810854v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"467410E8-784D-19FB-E053-F662850AC3B9","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629957","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Therapy End Date","preferredDefinition":"Date last dose of other neoadjuvant therapy administered","longName":"3810854v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4674D62C-D1CC-21C5-E053-F662850AE3F4","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629958","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Treatment Course Count","preferredDefinition":"Number of cycles of other neoadjuvant therapy recieved","longName":"3810854v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-03F5-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629959","version":"1","preferredName":"Neoadjuvant Therapy Other Administered Agent Administration Week Count","preferredDefinition":"Intended length of other neoadjuvant therapy cycles","longName":"3810854v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-0414-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629960","version":"1","preferredName":"Prior Chemotherapy Neoadjuvant Treatment Begin Date","preferredDefinition":"information related to prior neoadjuvant chemotherapy treatment._the date on which an observation or an event began.","longName":"2190118v1.0:2188673v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D45D-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629961","version":"1","preferredName":"Prior Chemotherapy Neoadjuvant Treatment Therapy End Date","preferredDefinition":"Date last dose of other neoadjuvant therapy received","longName":"2190118v1.0:2179471v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"466583E2-D47C-2762-E053-F662850A03BA","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629962","version":"1","preferredName":"Prior Chemotherapy Neoadjuvant Treatment Treatment Course Count","preferredDefinition":"Number of other neoadjuvant therapy cycles received","longName":"2190118v1.0:2180126v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46677F8A-CAF8-23A7-E053-F662850A451D","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5629963","version":"1","preferredName":"Prior Chemotherapy Neoadjuvant Treatment Agent Administration Week Count","preferredDefinition":"Intended length of other neoadjuvant therapy cycles","longName":"2190118v1.0:2538637v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46740D8A-0433-1989-E053-F662850A788B","latestVersionIndicator":"Yes","beginDate":"2017-01-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-19","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5633739","version":"1","preferredName":"Patient Neoplasm Clinical Trial Eligibility Criteria Type","preferredDefinition":"Tumor characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol.","longName":"PT_TUMOR_CRITERIA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46F224AD-772B-2C9D-E053-F662850ABBCB","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"GRANTD","dateCreated":"2017-01-25","modifiedBy":"BERGANTW","dateModified":"2017-01-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5651753","version":"1","preferredName":"Cardiology Consultation Performed Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator that asks whether a cardiology consultation was performed.","longName":"CARDIOLOGY_CONSULT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4792E5B8-5750-476C-E053-F662850A2B20","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"PATELV","dateCreated":"2017-02-02","modifiedBy":"PATELV","dateModified":"2017-02-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5653372","version":"1","preferredName":"Laboratory Procedure Tumor Marker Antigen KI-67 Performed Yes No Unknown Indicator","preferredDefinition":"Indicator for Ki-67 testing to be done","longName":"3809578v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47A75B12-3D72-718A-E053-F662850AC3B6","latestVersionIndicator":"Yes","beginDate":"2017-02-03","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-02-03","modifiedBy":"HARTLEYG","dateModified":"2019-11-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5710613","version":"1","preferredName":"Patient Partner Present Yes No Indicator","preferredDefinition":"A person that is associated with another person in some manner or action.","longName":"PATIENT_PARTNER_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AC5E2FD-7EE8-29D9-E053-F662850A6928","latestVersionIndicator":"Yes","beginDate":"2017-03-15","endDate":null,"createdBy":"BONANNIR","dateCreated":"2017-03-15","modifiedBy":"BONANNIR","dateModified":"2017-03-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716293","version":"1","preferredName":"Personal Medical History Severe Allergic Reaction Or Hypersensitivity Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient having allergic reactions to humanized antibodies or fusion proteins","longName":"5479729v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADB7A3C-FD70-68A0-E053-F662850A4B6B","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716310","version":"1","preferredName":"Patient Personal Medical History Liver Disease or Disorder Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient having clinically significant liver disease","longName":"4889714v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADB7A3C-FD8F-68A0-E053-F662850A4B6B","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"TSESU","dateModified":"2023-03-21","changeNote":null,"administrativeNotes":"2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716615","version":"1","preferredName":"Autoimmune Or Immunodeficiency Disease or Disorder Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient having a history of autoimmune disease","longName":"4668094v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADBA890-DFAA-5926-E053-F662850AAC44","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"TSESU","dateModified":"2023-03-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716657","version":"1","preferredName":"Person Dermatologic Disease or Disorder Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to a dermatologic disease requiring low potency topical steroids","longName":"5479364v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADBA18D-D253-3A95-E053-F662850A162B","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716658","version":"1","preferredName":"Eye Examination Under Anesthesia Performed Yes No Indicator","preferredDefinition":"The/yes no indicator for an eye exam performed ruling out ocular manifestations","longName":"3021064v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADBF160-25B7-689E-E053-F662850A8827","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716674","version":"1","preferredName":"Patient Other Medical Contraindicated Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient being free from acute exacerbations of other medical contraindications","longName":"3534116v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADC09B5-00BF-69A9-E053-F662850A4842","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716889","version":"1","preferredName":"Antibiotic Administration Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to the patient requiring antibiotics prior to study entry","longName":"5577856v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADF4AC0-E6C1-7FF7-E053-F662850A71AB","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"VUJANOVA","dateModified":"2018-09-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716920","version":"1","preferredName":"Other Systemic Antifungal Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient requiring antifungal agents","longName":"4722985v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADFCF8F-D93D-6F61-E053-F662850A5D50","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5716922","version":"1","preferredName":"Human Immunodeficiency Virus Viral Load Assay Performed Yes No Not Applicable Indicator","preferredDefinition":"information relating to a human immunodeficiency virus viral load (the number of HIV viral particles in a sample of blood plasma) assay performed._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2541079v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADFD3DD-DE3B-764E-E053-F662850AE4EC","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-16","modifiedBy":"VUJANOVA","dateModified":"2020-01-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5717700","version":"1","preferredName":"Patient Have Disease or Disorder Type","preferredDefinition":"A question relating to if a patient has certain types of disease","longName":"5717699v1.0:5717695v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEE778E-4C05-300A-E053-F662850AE9F9","latestVersionIndicator":"Yes","beginDate":"2017-03-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-17","modifiedBy":"TYRRELLM","dateModified":"2023-12-19","changeNote":null,"administrativeNotes":"12.19.2023 Added AQT per request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5717704","version":"1","preferredName":"Patient Hypersensitivity Status Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient's hypersensitivity status","longName":"5717703v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEEBD6E-FAEF-7864-E053-F662850AC070","latestVersionIndicator":"Yes","beginDate":"2017-03-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-17","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeNote":null,"administrativeNotes":"2023.8.2 AQT added per ticket request CADSR0002685. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5717708","version":"1","preferredName":"Patient Central Nervous System Study Eligibility Determination Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient having a CNS study performed at baseline to determine eligibility","longName":"5717707v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEE498C-2979-59D2-E053-F662850A56E3","latestVersionIndicator":"Yes","beginDate":"2017-03-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-17","modifiedBy":"SARAHB","dateModified":"2019-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5717709","version":"1","preferredName":"PgR Result Assessment Date","preferredDefinition":"The date of PgR assessment","longName":"2185603v1.0:2555208v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEEBD6E-FB36-7864-E053-F662850AC070","latestVersionIndicator":"Yes","beginDate":"2017-03-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5719361","version":"1","preferredName":"Chemotherapy Biphosphonate Administered Yes No Indicator","preferredDefinition":"The yes/ no indicator related to bisphosphonate therapy being administered","longName":"2748313v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B2F0F67-4F62-78A3-E053-F662850AE76A","latestVersionIndicator":"Yes","beginDate":"2017-03-20","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-20","modifiedBy":"PATELV","dateModified":"2019-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722257","version":"1","preferredName":"Other Therapy Administered Yes No Indicator","preferredDefinition":"information related to other therapy administered._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2190109v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B430D66-CFA9-062E-E053-F662850ABB90","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-21","modifiedBy":"TSESU","dateModified":"2022-12-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5722258","version":"1","preferredName":"Other Systemic Therapy Administered Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._The act of having given something (e.g., a medication or test)._Be specific about something; define clearly.","longName":"2864188v1.0:5566342v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B42F6AD-150C-5A0E-E053-F662850AC3EB","latestVersionIndicator":"Yes","beginDate":"2017-03-21","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-21","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5724331","version":"1","preferredName":"Eye Examination Under Anesthesia Performed Yes No Unknown Not Applicable Indicator","preferredDefinition":"A test performed by an ophthalmologist or optometrist assessing vision and ability to focus on and discern objects, as well as other tests and examinations pertaining to the eyes._A medical inspection, qualified according to the methods employed, as physical examination, radiologic examination, diagnostic imaging examination, etc., performed under conditions of patient's complete or partial local or general insensibility to pain with or without the loss of consciousness, induced by an anesthetic agent or by non-pharmacological anesthesia technique._Executed and carried through to completion._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"3021064v1.0:3506035v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B68B01A-40EC-67B5-E053-F662850A42EB","latestVersionIndicator":"Yes","beginDate":"2017-03-23","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-23","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5724332","version":"1","preferredName":"Skin Rash Present Yes No Unknown Not Applicable Indicator","preferredDefinition":"The yes/no indicator related to skin rash being present","longName":"3188488v1.0:3506035v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B68B01A-410B-67B5-E053-F662850A42EB","latestVersionIndicator":"Yes","beginDate":"2017-03-23","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-03-23","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5759470","version":"1","preferredName":"Expanded Prostate Cancer Index Composite Urinary Domain Assessment Score","preferredDefinition":"EPIC urinary domain score evaluates the patients urinary function and bother.","longName":"EPIC_URINARY_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD38E6-9854-7D08-E053-F662850A29E2","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"PATELV","dateCreated":"2017-04-12","modifiedBy":"PATELV","dateModified":"2017-04-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5761990","version":"1","preferredName":"Expanded Prostate Cancer Index Composite Hormonal Domain Assessment","preferredDefinition":"EPIC hormonal domain score evaluates the patients hormonal symptoms and bother","longName":"EPIC_HORMONAL_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFDEF17-31E1-0541-E053-F662850AD973","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"WISEM","dateCreated":"2017-04-12","modifiedBy":"WISEM","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5763126","version":"1","preferredName":"Expanded Prostate Cancer Index Composite Intestine Domain Assessment","preferredDefinition":"EPIC bowel domain score evaluates the patients bowel function and bother","longName":"EPIC_BOWEL_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFE0A84-D5CA-1F6E-E053-F662850A6D3B","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"WISEM","dateCreated":"2017-04-12","modifiedBy":"WISEM","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5763258","version":"1","preferredName":"Expanded Prostate Cancer Index Composite Sex Behavior Domain Assessment","preferredDefinition":"EPIC sexual domain score evaluates the patients sexual symptoms and bother","longName":"EPIC_SEXUAL_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFE85F3-0971-026B-E053-F662850AC97E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"WISEM","dateCreated":"2017-04-12","modifiedBy":"ZHANGWE","dateModified":"2020-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5776972","version":"1","preferredName":"Respiratory Disease or Disorder Yes No Indicator","preferredDefinition":"The yes/no question indicating whether a patient participating on a clinical trial has any respiratory disease.","longName":"RESPIRATORY_DIS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D6244D4-6C9B-66DC-E053-F662850AC0F3","latestVersionIndicator":"Yes","beginDate":"2017-04-17","endDate":null,"createdBy":"PATELV","dateCreated":"2017-04-17","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5777157","version":"1","preferredName":"Patient Known Hypersensitivity Dacarbazine Present Yes No Indicator","preferredDefinition":"The patient has hypersensitivity to Dacarbazine.","longName":"PT_KNOWN_HY_DTIC_PRESENT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D744475-EBAD-13EF-E053-F662850AD2AE","latestVersionIndicator":"Yes","beginDate":"2017-04-18","endDate":null,"createdBy":"SOLAKOVS","dateCreated":"2017-04-18","modifiedBy":"SOLAKOVS","dateModified":"2017-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5801672","version":"1","preferredName":"Hepatic Infection Personal Medical History Yes No Indicator","preferredDefinition":"information related to the personal medical history of hepatic infection._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2195676v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E8C5C53-3678-7191-E053-F662850AFAA4","latestVersionIndicator":"Yes","beginDate":"2017-05-02","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-05-02","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5805904","version":"1","preferredName":"Patient Work Status Change Indicator","preferredDefinition":"Patient's change in work status due to diagnosis of cancer.","longName":"PT_WORK_ST_CHANGE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA07977-E981-11DE-E053-F662850AB118","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2017-05-03","modifiedBy":"TIFFANIS","dateModified":"2017-05-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5806928","version":"1","preferredName":"Radiology Proton Laboratory Identifier Number","preferredDefinition":"A unique identifier of a Proton center.","longName":"RAD_PROT_LAB_ID_NUM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CTEP:Cancer Therapy Evaluation Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EB57AD5-066F-3071-E053-F662850A00A9","latestVersionIndicator":"Yes","beginDate":"2017-05-04","endDate":null,"createdBy":"MCGLADET","dateCreated":"2017-05-04","modifiedBy":"PATELV","dateModified":"2017-05-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5810787","version":"1","preferredName":"1p/19q Codeletion Chromosome Status Yes No Indicator","preferredDefinition":"The Yes/No indicator that indicates whether the patient has combined loss of one copy of chromosome arms  1p and 19q.","longName":"1P_19Q_CODEL_STATUS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F1B3841-6F7A-2F1C-E053-F662850A5E32","latestVersionIndicator":"Yes","beginDate":"2017-05-09","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2017-05-09","modifiedBy":"JKNABLE","dateModified":"2023-10-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5831298","version":"1","preferredName":"Estrogen Receptor Family Difference Yes No Unknown Indicator","preferredDefinition":"A yes no indicator for a patient having a difference in ER status","longName":"4118033v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBD6F0A-B340-0B88-E053-F662850A6103","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-05-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5831342","version":"1","preferredName":"Progesterone Receptor Analysis Performed Yes No Unknown Indicator","preferredDefinition":"A yes no indicator related to a patient having a difference in PgR","longName":"2652005v1.0:3506034v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBCE454-230D-3FDA-E053-F662850AEED0","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-05-17","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5831386","version":"1","preferredName":"Lesion Present Yes No Indicator","preferredDefinition":"The yes/no indicator for the presence and characterization of lesions","longName":"2013935v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBD6F0A-B365-0B88-E053-F662850A6103","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-05-17","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5832559","version":"1","preferredName":"Patient Limb Amputation Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the patient underwent amputation of a limb.","longName":"PT_LIMB_AMPUTATION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FCEA159-8FF0-6ED3-E053-F662850A3837","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-18","modifiedBy":"SARAHB","dateModified":"2019-09-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5832562","version":"1","preferredName":"Lymph Node Excision Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the lymph nodes were resected.","longName":"LN_RESECTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FCF2C4B-0D84-6DED-E053-F662850AF38F","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-18","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5834770","version":"1","preferredName":"Surgical Procedure Previous Transurethral Resection Prostate Gland Performed Yes No Indicator","preferredDefinition":"The Yes/No indicator of whether or not a previous TURP was performed on a patient.","longName":"PREV_TURP_PERF_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE3FB0E-E364-3AF1-E053-F662850A671B","latestVersionIndicator":"Yes","beginDate":"2017-05-19","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2017-05-19","modifiedBy":"KRYSTKIA","dateModified":"2017-05-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836939","version":"1","preferredName":"Periosteum Excision Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the periosteum was resected.","longName":"PERIOSTEUM_RESECTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50218114-C340-6114-E053-F662850A352B","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836942","version":"1","preferredName":"Bone Excision Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether bone resection was done.","longName":"BONE_RESECTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5021957C-8548-4C15-E053-F662850ADB54","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836945","version":"1","preferredName":"Blood Vessel Excision Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the blood vessels were resected.","longName":"BLD_VESSEL_RESECTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5021957C-8567-4C15-E053-F662850ADB54","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836955","version":"1","preferredName":"Nerve Excision Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the nerves were resected.","longName":"NERVE_RESECTION_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5021957C-859D-4C15-E053-F662850ADB54","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836962","version":"1","preferredName":"Nerve Graft Performed Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether the nerves were grafted.","longName":"NERVE_GRAFT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"502296AF-616D-76FC-E053-F662850AA135","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5836973","version":"1","preferredName":"Postoperative Drainage Device Placement Yes No Unknown Indicator","preferredDefinition":"The Yes/No/Unknown indicator that indicates whether surgical drains were used to drain postoperative dead spaces.","longName":"POST_OP_DRAIN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50229FF8-5F23-5D20-E053-F662850A29EA","latestVersionIndicator":"Yes","beginDate":"2017-05-22","endDate":null,"createdBy":"KENNISHM","dateCreated":"2017-05-22","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5837148","version":"1","preferredName":"Patient Limb Amputation Other Reason Specify","preferredDefinition":"The other reason amputation was done.","longName":"PT_LIMB_AMPUTATION_SP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"503477A8-1447-63AE-E053-F662850A7CE7","latestVersionIndicator":"Yes","beginDate":"2017-05-23","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-23","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5837464","version":"1","preferredName":"Charlson Comorbidity Index Chart Review Version Score","preferredDefinition":"The numeric score of the Charlson Comorbidity Index (CCI).","longName":"CCI_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5049F9E6-B6B2-7013-E053-F662850A98E4","latestVersionIndicator":"Yes","beginDate":"2017-05-24","endDate":null,"createdBy":"PATELV","dateCreated":"2017-05-24","modifiedBy":"KRYSTKIA","dateModified":"2017-05-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5837846","version":"1","preferredName":"Patient Limb Amputation Reason","preferredDefinition":"Reason why amputation was done.","longName":"PT_LIMB_AMPUTATION_RSN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505EF37C-E6D4-6F36-E053-F662850A9A3F","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"WISEM","dateCreated":"2017-05-25","modifiedBy":"WISEM","dateModified":"2017-06-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5837850","version":"1","preferredName":"Intervention or Procedure Space Organ At Risk Performed Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether SpaceOAR procedure was performed.","longName":"SPACEOAR_PERF_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"505EAF91-5F37-630A-E053-F662850A414C","latestVersionIndicator":"Yes","beginDate":"2017-05-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2017-05-25","modifiedBy":"SERIANNJ","dateModified":"2017-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5842420","version":"1","preferredName":"I-PSS Total Score","preferredDefinition":"The total score for the International Prostate Symptom Score (I-PSS).","longName":"5842419v1.0:2861136v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5137B9A0-E67E-2864-E053-F662850AA1B8","latestVersionIndicator":"Yes","beginDate":"2017-06-05","endDate":null,"createdBy":"TSESU","dateCreated":"2017-06-05","modifiedBy":"KRYSTKIA","dateModified":"2017-06-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5844935","version":"1","preferredName":"Patient Antibody Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Information related to patient receiving treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells, as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3534679v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"513C7495-50D4-554F-E053-F662850A8B39","latestVersionIndicator":"Yes","beginDate":"2017-06-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-06-05","modifiedBy":"PATELV","dateModified":"2019-08-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5844946","version":"1","preferredName":"Patient Contraception Eligibility Determination Yes No Indicator","preferredDefinition":"information related to patient's criteria to determine eligibility based on the use of prevention of conception or impregnation by the use of devices or drugs or surgery._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3151263v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"513C8BA6-E3E1-6220-E053-F662850A3189","latestVersionIndicator":"Yes","beginDate":"2017-06-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-06-05","modifiedBy":"VUJANOVA","dateModified":"2019-07-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5859187","version":"1","preferredName":"Patient Eligibility Determination Toxicity Recovery Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Criteria to determine eligibility of patients for medical care programs and services._The finding of bodily harm due to the poisonous effects of something._A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4722618v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"51650F0D-11D7-6A0C-E053-F662850AFA14","latestVersionIndicator":"Yes","beginDate":"2017-06-07","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-06-07","modifiedBy":"SARAHB","dateModified":"2017-10-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5889877","version":"1","preferredName":"Target Lesion Identification Follow-up Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator related to target lesion having been evaluated during follow up.","longName":"TARGET_LESION_ASMT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52F68C8E-6AC7-6689-E053-F662850A9E98","latestVersionIndicator":"Yes","beginDate":"2017-06-27","endDate":null,"createdBy":"PATELV","dateCreated":"2017-06-27","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914780","version":"1","preferredName":"Patient Uterus Excision Surgery Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient having excision of the uterus by any surgical modality","longName":"5914779v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D5DCBA-D984-5F7E-E053-F662850A952D","latestVersionIndicator":"Yes","beginDate":"2017-07-21","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-07-21","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914849","version":"1","preferredName":"Performance Status Assessment Yes No Indicator","preferredDefinition":"The yes/no indicator that tells if a person has completed an ECOG performance status assessment","longName":"2012412v3.1:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D4BF31-79DB-5607-E053-F662850AA8B4","latestVersionIndicator":"Yes","beginDate":"2017-07-21","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-07-21","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5914867","version":"1","preferredName":"Therapeutic Procedure Last Dose Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator to state whether a patient has ever taken vorinostat, panobinostat, or romidespin","longName":"5865113v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D6B277-698F-37B8-E053-F662850A43F9","latestVersionIndicator":"Yes","beginDate":"2017-07-21","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-07-21","modifiedBy":"SARAHB","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5915966","version":"1","preferredName":"Rectal Balloon Dilation Current Therapy Yes or No Response","preferredDefinition":"Of or pertaining to the rectum._An endoscopic therapeutic procedure in which a balloon device is used to dilate a narrowed lumen._The name of the therapy that is currently being administered._A response or indicator that can have a value of either yes or no.","longName":"5915964v1.0:5915965v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"553D6BFB-C6C6-6BE2-E053-F662850AFFCD","latestVersionIndicator":"Yes","beginDate":"2017-07-26","endDate":null,"createdBy":"MCGLADET","dateCreated":"2017-07-26","modifiedBy":"MCGLADET","dateModified":"2017-10-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916261","version":"1","preferredName":"Geriatric Screening Tool Assessment Score","preferredDefinition":"The numeric score calculated using the Geriatric Screening tool (G-8).","longName":"G-8_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5550E1DF-743D-0D7A-E053-F662850AF1BC","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"PATELV","dateCreated":"2017-07-27","modifiedBy":"TYRRELLM","dateModified":"2023-10-24","changeNote":null,"administrativeNotes":"10.24.2023 Added alt short name per request ticket CADSR0002996_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916266","version":"1","preferredName":"Cumulative Illness Rating Scale for Geriatrics Assessment Score","preferredDefinition":"The numeric score calculated using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G).","longName":"CIRS-G_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5551255C-D045-59C0-E053-F662850A4F6B","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"PATELV","dateCreated":"2017-07-27","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916273","version":"1","preferredName":"Cancer and Aging Research Group Chemo Toxicity Calculator Assessment Score","preferredDefinition":"The percentage score calculated from a clinical assessment tool designed to evaluate the risk for chemotherapy toxicity in geriatric cancer patients.","longName":"CARG_TOXICITY_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55516D9F-792F-3595-E053-F662850A2909","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"PATELV","dateCreated":"2017-07-27","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5916280","version":"1","preferredName":"Patient Questionnaire Complete Indicator","preferredDefinition":"The indicator question that asks whether the patient completed the questionnaire on paper or ePRO","longName":"PT_QUESTIONNAIRE_COMP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5551AABB-2EFC-0F13-E053-F662850A9A20","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"PATELV","dateCreated":"2017-07-27","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5917263","version":"1","preferredName":"Generalized Competing Event Model for Cancer Risk Assessment Score","preferredDefinition":"The numeric score calculated using the generalized competing event (GCE) model for cancer risk assessment.","longName":"GCE_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55DAD6FC-7D84-06DF-E053-F662850A854E","latestVersionIndicator":"Yes","beginDate":"2017-08-03","endDate":null,"createdBy":"PATELV","dateCreated":"2017-08-03","modifiedBy":"PATELV","dateModified":"2020-04-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5917271","version":"1","preferredName":"Patient De-Identified Medical Report Yes No Unknown Indicator","preferredDefinition":"The yes/no/unknown indicator related to information regarding the availability of de-identified medical reports of a patient.","longName":"DE_IDENTIFIED_MED_REPORT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55DAD6FC-7DD9-06DF-E053-F662850A854E","latestVersionIndicator":"Yes","beginDate":"2017-08-03","endDate":null,"createdBy":"PATELV","dateCreated":"2017-08-03","modifiedBy":"PATELV","dateModified":"2017-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975540","version":"1","preferredName":"Patient Status BRAF Gene Mutation Status","preferredDefinition":"The status of a patient's BRAF gene mutation","longName":"2013085v3.0:5975534v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58AFC4FC-B813-3303-E053-F662850AB92D","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-08","modifiedBy":"COBARRUBIAK","dateModified":"2019-07-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975561","version":"1","preferredName":"Patient Specimen Availability Or Biopsy Consent Yes No Indicator","preferredDefinition":"The yes no indicator to whether a person has adequate availability of archived tumor tissue","longName":"5026393v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58AFC4FC-B832-3303-E053-F662850AB92D","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-08","modifiedBy":"BOWSERC","dateModified":"2021-11-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975647","version":"1","preferredName":"Surgical Procedure Intervention or Procedure Clinical Study Protocol Administration Yes No Indicator","preferredDefinition":"The yes no indicator related to whether a patient needs surgical intervention for primary tumor","longName":"4360033v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B01A10-4859-2932-E053-F662850AE287","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-08","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975687","version":"1","preferredName":"Microsatellite Instability Identifier Yes No Indicator","preferredDefinition":"The yes no indicator related to a patient's tumor having mismatch repair deficiency","longName":"2678231v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-CF7C-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-08","modifiedBy":"BOWSERC","dateModified":"2021-10-19","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5975732","version":"1","preferredName":"Prostate Gland Malignant Neoplasm Classification Type","preferredDefinition":"The subtype of prostate malignancy which can  be obtained by the PAM50 gene expression.","longName":"PROSTATE_CANCER_SUBTYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58B03C6C-D08A-5B3B-E053-F662850A0A30","latestVersionIndicator":"Yes","beginDate":"2017-09-08","endDate":null,"createdBy":"WELSHE","dateCreated":"2017-09-08","modifiedBy":"WELSHE","dateModified":"2017-10-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5977167","version":"1","preferredName":"Patient Monoclonal Antibody Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator related to a patient experiencing past effects of an antibody","longName":"4461733v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58EEC4C0-6839-4B61-E053-F662850AAEE9","latestVersionIndicator":"Yes","beginDate":"2017-09-11","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-11","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5978329","version":"1","preferredName":"Agent Dose Level Interrupted Or Not Completed Reason","preferredDefinition":"The reason why the agent was interrupted or not completed","longName":"2200383v1.0:3028818v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59180AB2-7784-3474-E053-F662850AB07C","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5978332","version":"1","preferredName":"Agent Dose Level Interrupted Reason","preferredDefinition":"The reason that an agent was interrupted","longName":"2200383v1.0:5978331v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59181BBF-BE51-27D9-E053-F662850AE546","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5978818","version":"1","preferredName":"Questionnaire Confirmation Yes No Indicator","preferredDefinition":"A confirmation about the questionnaire","longName":"5978817v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5918E4BF-966E-20AC-E053-F662850A5DC9","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989648","version":"1","preferredName":"Appendix Involvement Yes No Indicator","preferredDefinition":"Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Appe_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD22A81-42D8-1655-E053-F662850A516F","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989652","version":"1","preferredName":"Ascending Colon Involvement Yes No Indicator","preferredDefinition":"The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Asce_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD18F85-4B79-7E05-E053-F662850AD68B","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989653","version":"1","preferredName":"Hepatic Flexure Involvement Yes No Indicator","preferredDefinition":"The bend of the colon at the juncture of its ascending and transverse portions._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Hepa_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD21093-0DDD-1138-E053-F662850A3619","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989654","version":"1","preferredName":"Transverse Colon Involvement Yes No Indicator","preferredDefinition":"The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Tran_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD349DA-F670-0AF9-E053-F662850A998E","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989655","version":"1","preferredName":"Splenic Flexure Involvement Yes No Indicator","preferredDefinition":"The bend at the junction of the transverse and descending colon._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Sple_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD34B8F-B89B-139B-E053-F662850A02AD","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989656","version":"1","preferredName":"Descending Colon Involvement Yes No Indicator","preferredDefinition":"The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Desc_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD31791-EB7B-5A7E-E053-F662850A7A8E","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989665","version":"1","preferredName":"Cecum Colonoscopy Involvement Yes No Indicator","preferredDefinition":"A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine._Endoscopic examination of the luminal surface of the colon._To have a connection by participation or association or use; sharing in an activity or process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Cecu_Colo_Invo_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD35B51-71CF-6043-E053-F662850A0839","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"RAGUNATHANU","dateModified":"2022-09-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989682","version":"1","preferredName":"Training Complete Yes No Indicator","preferredDefinition":"To teach with hands-on experience_To possess every necessary or normal part or component or step; having come or been brought to a conclusion._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"Trai_Comp_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD33CC0-CF60-4339-E053-F662850A09D1","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-05","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6004929","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"information related to a person's recovery from prior therapy as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3244787v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BBF5BB3-E4FF-0A70-E053-F662850A2BA9","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-10-17","modifiedBy":"SARAHB","dateModified":"2018-03-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6021677","version":"1","preferredName":"Patient Androgen Suppression Personal Medical History Yes No Not Applicable Indicator","preferredDefinition":"The Yes/No/Not applicable related to a patient's personal medical history, an account of all medical events and problems a person has experienced, including androgen suppression, treatment to suppress or block the production of male hormones.","longName":"PT_ANDSUP_PMH_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D17FAEB-5BF6-38B2-E053-F662850AE21A","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"KENNISHM","dateCreated":"2017-11-03","modifiedBy":"CLOHNES","dateModified":"2023-11-17","changeNote":"Replaced VD Therapy Ind-2 VD ID#3506068 - Yes No Indicator - to VD #3506036 Yes No NA indicator mk","administrativeNotes":"11/17/23 Added AQT and alt OID for CCTG ticket number CADSR0003085 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6021678","version":"1","preferredName":"Patient No Concurrent Medication Treatment Eligibility Determination Yes No Unknown Not Applicable Indicator","preferredDefinition":"The Yes/No/Not applicable indicator related to eligibility of patient based on not having any concurrent drug therapy.","longName":"PT_CONCURRENT_MEDS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D1895EE-CE62-16BD-E053-F662850A508E","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"KENNISHM","dateCreated":"2017-11-03","modifiedBy":"KENNISHM","dateModified":"2020-03-25","changeNote":"Replaced VD Eligibility Ind-2 VD ID#3506068 - Yes No Indicator - with VD Ind 4 3506035 Yes No Unk NA Indicator mk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6024490","version":"1","preferredName":"Adverse Event Hemorrhage Symptom Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator related to bleeding as a result of an adverse event.","longName":"AE_HEMOR_SYMPTOM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D54FB97-5514-405A-E053-F662850A970C","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-06","modifiedBy":"PATELV","dateModified":"2018-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6024683","version":"1","preferredName":"Adverse Event Medical Intervention or Procedure Requirement Yes No Not Applicable Indicator","preferredDefinition":"Patient medical intervention required as a result of an adverse event.","longName":"AE_MEDICAL_INTERVEN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D538EF3-3C08-7A19-E053-F662850A591F","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-06","modifiedBy":"LEEW","dateModified":"2020-01-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6024722","version":"1","preferredName":"Laboratory Procedure Alanine Aminotransferase Measurement Aspartate Aminotransferase Measurement Outcome Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator related to an elevated test result and the medical procedure that involves testing a sample of blood, urine, or other substance for serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transferase.","longName":"ALT_AST_ULN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D5753C7-B2D6-0973-E053-F662850A19FB","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-06","modifiedBy":"PATELV","dateModified":"2018-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6024873","version":"1","preferredName":"Adverse Event Associated Clinical Sign or Symptom Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator that indicates whether an adverse event is associated with clinical signs or symptoms.","longName":"AE_ASSOC_CLN_SIGN_SYMP_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D56D010-6A8E-223E-E053-F662850A15BB","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-06","modifiedBy":"PATELV","dateModified":"2018-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6024905","version":"1","preferredName":"Adverse Event Attribution Local Antitumor Response Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator related to whether an adverse event is attributed to local antitumor response.","longName":"AE_ATTRI_LOCAL_ANTITUM_RES","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D57AE2B-BC67-3715-E053-F662850AA1EB","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"PATELV","dateCreated":"2017-11-06","modifiedBy":"PATELV","dateModified":"2018-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6183689","version":"1","preferredName":"Ceritinib Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the agent ceritinib was administered.","longName":"CERITINIB_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6994F44B-E043-4121-E053-F662850A7EAB","latestVersionIndicator":"Yes","beginDate":"2018-04-11","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-11","modifiedBy":"KRYSTKIA","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199557","version":"1","preferredName":"Alectinib Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the agent alectinib was administered.","longName":"ALECTINIB_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F8FED9-8EEF-70B9-E053-F662850A1EA5","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"KRYSTKIA","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199562","version":"1","preferredName":"Ensartinib Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the agent ensartinib was administered.","longName":"ENSARTINIB_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F8FED9-8F37-70B9-E053-F662850A1EA5","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"KRYSTKIA","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199756","version":"1","preferredName":"Brigatinib Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the agent brigatinib was administered.","longName":"BRIGATINIB_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CA92-0D98-7845-E053-F662850AC5DF","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"KRYSTKIA","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199783","version":"1","preferredName":"Lorlatinib Agent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the agent lorlatinib was administered.","longName":"LORLATINIB_ADM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F92944-F634-70B5-E053-F662850AB221","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"KRYSTKIA","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6230805","version":"1","preferredName":"Survivorship Concern Type","preferredDefinition":"Text term that represents a concern of a cancer survivor.","longName":"SURVR_CNCRN_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6AC4D3CA-09FA-5B48-E053-F662850AF3EE","latestVersionIndicator":"Yes","beginDate":"2018-04-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-26","modifiedBy":"TIFFANIS","dateModified":"2018-09-17","changeNote":"Created for NRG-CC007CD 4.24.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6230813","version":"1","preferredName":"Lifestyle or Behavior Change Type","preferredDefinition":"Text term that represents a kind of lifestyle or behavior change.","longName":"LFSYL_BEHVR_CHNG_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6AC4E2B2-0A30-6FCF-E053-F662850A809F","latestVersionIndicator":"Yes","beginDate":"2018-04-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-26","modifiedBy":"TIFFANIS","dateModified":"2018-09-17","changeNote":"Created for NRG-CC007CD 4.24.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6272291","version":"1","preferredName":"Flibanserin Medication Use Yes No Indicator","preferredDefinition":"The yes/no response to a question that asks about previous or concurrent use of Flibanserin.","longName":"FLIBANSERIN_USE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BCC420B-BD37-29E8-E053-F662850A05C6","latestVersionIndicator":"Yes","beginDate":"2018-05-09","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2018-05-09","modifiedBy":"TIFFANIS","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6289224","version":"1","preferredName":"Patient Inherited Mutation Result Consent Yes No Indicator","preferredDefinition":"The Yes No indicator that indicates whether the patient chooses to be told about inherited mutations that are uncovered in their DNA during this study.","longName":"PT_INHERIT_MUT_RESULT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C446C94-8844-7750-E053-F662850A8F70","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"WISEM","dateCreated":"2018-05-15","modifiedBy":"WISEM","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6289478","version":"1","preferredName":"Patient Authorization Inherited Mutation Result Consent Yes No Indicator","preferredDefinition":"The Yes No inidcator that indicates whether the patient chooses to have their study doctor to receive information about inherited mutations uncovered in this study.","longName":"PT_AUTH_INHER_MUT_RES_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C44C486-80A2-4673-E053-F662850A98A9","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"ROBINSONJ","dateCreated":"2018-05-15","modifiedBy":"ROBINSONJ","dateModified":"2018-07-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6333517","version":"1","preferredName":"Patient Chemically-Induced Menopause Status Yes No Indicator","preferredDefinition":"The yes/no response to a question that asks if a female patient's menopause is chemically induced.","longName":"PT_CHEM_IND_MENO_STAT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E134ED3-4792-1A87-E053-F662850ACC4B","latestVersionIndicator":"Yes","beginDate":"2018-06-07","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2018-06-07","modifiedBy":"TIFFANIS","dateModified":"2018-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6335166","version":"1","preferredName":"Staging Surgical Procedure Excision Performed Yes No Not Applicable Indicator","preferredDefinition":"The Yes/No/NA indicator as to whether or not a work-up or staging was done prior to an anticipated surgical procedure/resection.","longName":"STAGING_SURG_PROC_Y_N_NA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E8B0A55-CFCF-7EA4-E053-F662850AA808","latestVersionIndicator":"Yes","beginDate":"2018-06-13","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-06-13","modifiedBy":"KRYSTKIA","dateModified":"2018-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6341850","version":"1","preferredName":"Patient Blood Pressure Measurement Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no criteria stating whether a patient is willing and able to record daily blood pressure measurements","longName":"PT_BP_MEASUREMENT_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F7D162C-756B-6AA6-E053-F662850A87EC","latestVersionIndicator":"Yes","beginDate":"2018-06-25","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-06-25","modifiedBy":"SARAHB","dateModified":"2018-06-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6342965","version":"1","preferredName":"Imaging Technique Reason Cardiac Disease Type","preferredDefinition":"Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy._An explanation of the cause of some phenomenon or action._the type of cardiac event experienced.","longName":"CARDIAC_REASON_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F8C4C3E-98CF-0F09-E053-F662850A3DC4","latestVersionIndicator":"Yes","beginDate":"2018-06-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-06-26","modifiedBy":"SARAHB","dateModified":"2018-06-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6343166","version":"1","preferredName":"Patient Heart Function Echocardiogram Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"information related to an assessment of cardiac function by echocardiogram or nuclear study as an element of the personal medical history which is necessary to allow an individual to participate in a specific clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4828153v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F8CF7AC-5618-3510-E053-F662850AC68D","latestVersionIndicator":"Yes","beginDate":"2018-06-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-06-26","modifiedBy":"BOWSERC","dateModified":"2021-05-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6343188","version":"1","preferredName":"Patient Prior Randomization Electrocardiography Eligibility Determination Yes No Indicator","preferredDefinition":"information related to patient's criteria to determine eligibility based on an ECG prior to randomization/treatment assignment._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"PT_QTC_ELIGIBILITY_CRIT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F8C4C3E-9926-0F09-E053-F662850A3DC4","latestVersionIndicator":"Yes","beginDate":"2018-06-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-06-26","modifiedBy":"BOWSERC","dateModified":"2021-05-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6343368","version":"1","preferredName":"ALK Inhibitor Most Recent Brigatinib Administered Yes No Indicator","preferredDefinition":"The yes/no indicator as to whether the ALK inhibitor, brigatinib, was the most recent drug administered.","longName":"BRIG_MOST_RECENT_ALK_INHIB_ADM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FA03D8F-7EEF-5EC4-E053-F662850A0661","latestVersionIndicator":"Yes","beginDate":"2018-06-27","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-06-27","modifiedBy":"KRYSTKIA","dateModified":"2018-06-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6374406","version":"1","preferredName":"Neoadjuvant Therapy Chemotherapy Pembrolizumab Administered Medication Dose","preferredDefinition":"Information related to the dose of pembrolizumab administered","longName":"6374405v1.0:5418211v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71E89E3D-3A8C-584E-E053-F662850AD30C","latestVersionIndicator":"Yes","beginDate":"2018-07-26","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-07-26","modifiedBy":"SARAHB","dateModified":"2018-07-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430421","version":"1","preferredName":"Fistula Present  Assessment Yes No Indicator","preferredDefinition":"Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body. Being or existing in a specified place or at the specified time. The final result of a determination of the value, significance, or extent of._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3116539v1.0:3108967v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"761234A2-BCD9-6422-E053-F662850ABFF4","latestVersionIndicator":"Yes","beginDate":"2018-09-17","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-17","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430428","version":"1","preferredName":"Metastatic Neoplasm Lymph Node Confirmed Diagnosis Indicator","preferredDefinition":"A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology._A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found through out the body. It is composed predominantly of lymphocytes and its main function is immune protection._Confirmed; having been established or verified._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Indicator of Yes, No, Unknown, Not Done, or Not Applicable to a question.[manually curated]","longName":"2969624v1.0:2784450v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"761249B2-8D31-6410-E053-F662850A34D5","latestVersionIndicator":"Yes","beginDate":"2018-09-17","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-17","modifiedBy":"VUJANOVA","dateModified":"2020-01-07","changeNote":"4/27/11: changed the workflow status from CMTE SUBMTD  to DRAFT NEW per RA.wz","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430434","version":"1","preferredName":"Person Endometrial Metastatic Malignant Neoplasm Paraaortic Lymph Node Eligibility Determination Ind-3b","preferredDefinition":"the yes/no/not applicable indicator whether there is an  atypical neoplastic relating to or composed of endometrium having spread to any lymph node located adjacent to the lumbar region of the spine as part of the eligibility criteria for participation on a clinical trial.","longName":"3245189v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"761249B2-8DB2-6410-E053-F662850A34D5","latestVersionIndicator":"Yes","beginDate":"2018-09-17","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-17","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeNote":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430675","version":"1","preferredName":"Lymph Node Confirmed Yes No Not Applicable Indicator","preferredDefinition":"information related to confirmed lymph node._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2185946v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7617C6C8-DF1B-6709-E053-F662850AFDD7","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-18","modifiedBy":"KENNISHM","dateModified":"2021-08-11","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6433378","version":"1","preferredName":"Surgical Procedure Performed Status","preferredDefinition":"Surgical procedure performed in relation to radiation therapy administration.","longName":"SURG_PROC_PERFORMED_STATUS","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"763C0EF5-F1FF-4ACB-E053-F662850ABB69","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2018-09-19","modifiedBy":"TIFFANIS","dateModified":"2018-11-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6433405","version":"1","preferredName":"Patient Therapy Completion Status Indicator","preferredDefinition":"The yes/no indicator that asks whether patient has completed treatment.","longName":"PT_THER_COMP_STATUS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"763E3805-16A8-11F4-E053-F662850A07F0","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2018-09-19","modifiedBy":"TSESU","dateModified":"2023-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6436434","version":"1","preferredName":"Cancer Survivorship Research Document Submission Type","preferredDefinition":"The method used to submit the survivorship care plan.","longName":"CAN_SUR_RES_DOC_SUB_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"763E3805-16C8-11F4-E053-F662850A07F0","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2018-09-19","modifiedBy":"TIFFANIS","dateModified":"2018-11-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6450646","version":"1","preferredName":"Person Malignant Neoplasm Pathology Clinical Trial Eligibility Criteria Malignant Neoplasm Pathology Type","preferredDefinition":"information related to the cellular classification or pathology of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial._the type of cellular classification of a malignant neoplasm.","longName":"3178319v1.0:6450618v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76F1BBFD-4BC7-0AF0-E053-F662850A73C3","latestVersionIndicator":"Yes","beginDate":"2018-09-28","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-09-28","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454109","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"the yes/no indicator related to patient eligibility criteria and immunosuppressive therapy as elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3536195v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7730367D-A343-46B3-E053-F662850A1AD8","latestVersionIndicator":"Yes","beginDate":"2018-10-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-10-01","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6454130","version":"1","preferredName":"Neoplasm Measurable Type Indicator","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Capable of being measured._Something distinguishable as an identifiable class based on common qualities._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"4749017v1.0:6450733v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77306674-4B75-7956-E053-F662850A4C8B","latestVersionIndicator":"Yes","beginDate":"2018-10-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-10-01","modifiedBy":"ZHWENDY","dateModified":"2022-08-02","changeNote":null,"administrativeNotes":"8/2/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6471130","version":"1","preferredName":"Mismatch Repair Gene Mutation Status Gene Mutation Status","preferredDefinition":"A change in the nucleotide sequence of a gene involved in DNA mismatch repair._A condition or state at a particular time._change occurring in one gene._A condition or state at a particular time.","longName":"6002179v1.0:3086324v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77B9D5D7-05E0-3C28-E053-F662850A0BF3","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-10-08","modifiedBy":"BOWSERC","dateModified":"2022-02-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6477505","version":"1","preferredName":"Patient Current Cytochrome P450 3A4 Inducer CYP3A5 Inducer Therapeutic Procedure Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether the patient is currently taking a CYP3A4/5 inducer.","longName":"PT_CURRENT_CYP3A4/5_INDUCER_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77E0E35C-C21D-1057-E053-F662850AF024","latestVersionIndicator":"Yes","beginDate":"2018-10-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-10-10","modifiedBy":"KRYSTKIA","dateModified":"2018-10-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6477516","version":"1","preferredName":"Patient Current Cytochrome P450 3A4 Inhibitor CYP3A5 Inhibitor Therapeutic Procedure Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether the patient is currently taking a CYP3A4/5 Inhibitor.","longName":"PT_CURRENT_CYP3A4/5_INHIB_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77E12379-BC4C-07E2-E053-F662850A9029","latestVersionIndicator":"Yes","beginDate":"2018-10-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-10-10","modifiedBy":"KRYSTKIA","dateModified":"2018-10-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6477517","version":"2","preferredName":"Patient Current CYP3A4 Or CYP3A5 Substrate Therapeutic Procedure With Narrow Therapeutic Index Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether the patient is currently taking a CYP3A4/5 substrate with narrow therapeutic indices.","longName":"PT_CRNT_CYP3A4_5_SBSTRT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FFEB0D9E-5E92-62EE-E053-731AD00ADCA8","latestVersionIndicator":"Yes","beginDate":"2023-07-07","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-07","modifiedBy":"TSESU","dateModified":"2023-07-07","changeNote":null,"administrativeNotes":"7/7/23_Created new version due to improper short name_smt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6477525","version":"1","preferredName":"Patient Current CYP2C9 Substrate Therapeutic Procedure With Narrow Therapeutic Index Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether the patient is currently taking a CYP2C9 substrate with narrow therapeutic indices.","longName":"PT_CURRENT_CYP2C9_SUBSTRATE_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77E1822C-E7EB-2A9E-E053-F662850AF8A0","latestVersionIndicator":"Yes","beginDate":"2018-10-10","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-10-10","modifiedBy":"KRYSTKIA","dateModified":"2018-10-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6517207","version":"1","preferredName":"Radiation Therapy Technique Text","preferredDefinition":"information related to the practiced series of actions completed for therapeutic radiation using visible, laser, or ultraviolet light._Something distinguishable as an identifiable class based on common qualities.","longName":"RT_TECHNIQUE_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7894FDD4-EB9D-1682-E053-F662850AC7C1","latestVersionIndicator":"Yes","beginDate":"2018-10-19","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-10-19","modifiedBy":"VUJANOVA","dateModified":"2019-01-08","changeNote":"Alternate Question Text (CRF Text 2) added for use in CALGB-30610 OPEN Registration Worksheet","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6547024","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having strength, power, or intensity greater than average or expected._Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids._This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics._The act of bringing about something._The interference with or prevention of an action or response even though the stimulus for that action or response is present._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"STR_P450_IND_COD_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"799E1EDE-3A01-5671-E053-F662850AAB6A","latestVersionIndicator":"Yes","beginDate":"2018-11-01","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2018-11-01","modifiedBy":"SOKKERL","dateModified":"2019-06-06","changeNote":"9343_Theradex_ghd_09.03.14 - Changed Theradex Text 32 from \"Application Standard Question Text\" to \"Alternate Question Text\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596648","version":"1","preferredName":"Prior Chemotherapy Trastuzumab Administered Neoadjuvant Therapy Trastuzumab Type","preferredDefinition":"information related to earlier in time or order administration of treatment with anticancer drug Trastuzumab (a humanized recombinant monoclonal antibody directed against the HER2- receptor protein)._The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)_Something distinguishable as an identifiable class based on common qualities.","longName":"P_CTX_TRAST_ADMIN_6596645v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D63AA81-AE72-301A-E053-F662850AA536","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"SARAHB","dateModified":"2019-01-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596702","version":"1","preferredName":"Laboratory Procedure Blood Cell Count with Differential Specimen Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes no indicator related to a patient having a manual differential with no abnormalities upon complete blood count (CBC) testing","longName":"6577873v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D651E12-FD91-65B7-E053-F662850A15D8","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"VUJANOVA","dateModified":"2019-10-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596740","version":"1","preferredName":"Magnetic Resonance Imaging Computed Tomography Brain Medical Imaging Prior Therapy Assessment Yes No Indicator","preferredDefinition":"information related to the medical imaging assessment of the brain, that part of the central nervous system contained within the cranium, comprising the prosencephalon, mesencephalon, and rhombencephalon, using magnetic resonance imaging, a procedure in which a magnet linked to a computer is used to create detailed pictures of areas inside the body, or computed tomograhpy, series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine prior to the start or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2555175v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D6677AA-BC03-2351-E053-F662850AB30D","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2018-12-19","modifiedBy":"SARAHB","dateModified":"2019-01-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6601797","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Yes No Unknown Indicator","preferredDefinition":"The Yes No Unknown indicator that indicates whether the patient is requiring systemic treatment with corticosteroid or other immunosuppressive medications.","longName":"PT_CST_IMMUNO_TX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E948F6F-8997-727A-E053-F662850AB879","latestVersionIndicator":"Yes","beginDate":"2019-01-03","endDate":null,"createdBy":"PATELV","dateCreated":"2019-01-03","modifiedBy":"WISEM","dateModified":"2021-02-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6608428","version":"1","preferredName":"Prostate Gland Cryosurgery Performed Yes No Indicator","preferredDefinition":"The yes/no indicator related to prior treatment performed with an instrument that freezes and destroys tumor for the prostate.","longName":"PROS_GL_CRYO_PERFORMED","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F34FC5C-9192-1C04-E053-F662850AF726","latestVersionIndicator":"Yes","beginDate":"2019-01-11","endDate":null,"createdBy":"WISEM","dateCreated":"2019-01-11","modifiedBy":"WISEM","dateModified":"2019-02-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685649","version":"1","preferredName":"Anticoagulant Agent Administration Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4473461v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A0F4E6-0F9B-1DA8-E053-F662850A2128","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-04-03","modifiedBy":"BOWSERC","dateModified":"2021-10-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685745","version":"1","preferredName":"Diversion Surgery Type Surgical Procedure Surgery","preferredDefinition":"No value exists._The branch of medical science that treats disease or injury by operative procedures._Something distinguishable as an identifiable class based on common qualities._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._The branch of medical science that treats disease or injury by operative procedures.","longName":"5808367v1.0:6685741v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A1A78F-8FBA-41DE-E053-F662850A9BE2","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-04-03","modifiedBy":"VUJANOVA","dateModified":"2019-05-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685838","version":"1","preferredName":"Specimen Surgical Procedure Technique Surgery Method Type","preferredDefinition":"information related to the method of surgical procedure by manual and/or instrumental means, often involving an incision and the removal of a bit of tissue or blood or urine that is taken or used for research purposes._information about the method of extraction of a tissue specimen.","longName":"SPEC_SX_TECH_TP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A1D839-B07F-70D6-E053-F662850A92B8","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-04-03","modifiedBy":"VUJANOVA","dateModified":"2019-05-14","changeNote":"** ISO COMPLIANCE **","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6738678","version":"1","preferredName":"Patient Presumed Diagnosis Glioblastoma MRI Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes No indicator for whether or not the patient has a presumed diagnosis of Glioblastoma based on MRI","longName":"PRESUME_DIAG_GBM_MRI_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C144E5-58B5-54CB-E053-F662850AF5B3","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"WISEM","dateCreated":"2019-04-30","modifiedBy":"WISEM","dateModified":"2019-05-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6738831","version":"2","preferredName":"Neoplasm Unifocal Description Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes No indicator as to whether or not the tumor is unifocal","longName":"NEOPLASM_UNIFOCAL_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B26568C-76CD-5947-E053-F662850AC8A3","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"PATELV","dateCreated":"2019-06-12","modifiedBy":"PATELV","dateModified":"2019-06-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6740601","version":"1","preferredName":"Gross Tumor Residual Remaining Pathology Residual Disease Type","preferredDefinition":"Information relating to gross tumor residual remaining._The type of residual disease that remains","longName":"2200386v1.0:6740599v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FFA4D6-3A4E-26A8-E053-F662850ADBB8","latestVersionIndicator":"Yes","beginDate":"2019-05-03","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-05-03","modifiedBy":"TAYLORT","dateModified":"2019-08-05","changeNote":"8-5-19 tt associated CDE with released version of DEC.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6755425","version":"1","preferredName":"Treating Site Study Site Location","preferredDefinition":"Any healthcare facility where care is provided as part of a cooperative group._A facility in which study/protocol activities are conducted._a point or extent in space.","longName":"6755424v1.0:6755338v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"888DC4C8-BCE5-1672-E053-F662850A21C8","latestVersionIndicator":"Yes","beginDate":"2019-05-10","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-05-10","modifiedBy":"PATELV","dateModified":"2020-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6782169","version":"1","preferredName":"Magnetic Resonance Imaging Diagnostic Imaging Post Surgery Assessment Yes No Indicator","preferredDefinition":"The yes no indicator related to whether the patient will undergo an MRI post surgery.","longName":"MRI_DIAG_POST_SURG_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B47C040-C41A-2379-E053-F662850ABCC1","latestVersionIndicator":"Yes","beginDate":"2019-06-14","endDate":null,"createdBy":"WISEM","dateCreated":"2019-06-14","modifiedBy":"RODELAA","dateModified":"2021-01-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6819098","version":"1","preferredName":"Malignant Neoplasm Systematized Nomenclature of Medicine Clinical Terms Primary Anatomic Site Systematized Nomenclature of Medicine CDISC SDTM Anatomical Location Terminology Code","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004_Published by the College of American Pathologists, the Systematized Nomenclature of Medicine Clinical Terms is a combination of content of SNOMED Reference Terminology and READ codes._Occurring first in time or sequence; original; of greatest rank or importance or value._Named locations of or within the body._A multiaxial, hierarchical classification system for diseases in man developed by the College of American Pathologists._Terminology codelist used with Anatomical Locations within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"PRTUDG","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DCD791E-D246-6AF9-E053-F662850A9C95","latestVersionIndicator":"Yes","beginDate":"2019-07-16","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-07-16","modifiedBy":"VUJANOVA","dateModified":"2019-08-05","changeNote":"8/22/17 tt transferred context, added registration status per Round 5 finalization task. Curated for NCI CRF Initiative Diagnosis CRF","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6819888","version":"1","preferredName":"Patient Protocol Specified Prior Systemic Therapy Exclusion Eligibility Determination Yes No Not Applicable Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data._Specified; clearly and explicitly stated._Earlier in time or order._(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._The deliberate act of omission._Criteria to determine eligibility of patients for medical care programs and services._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"Pati_Prot_Spec_Prio_Syst_Excl_","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0D9463-59CD-6330-E053-F662850AA8E7","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-07-19","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6819892","version":"1","preferredName":"Therapy Malignant Neoplasm Central Nervous System Recurrence Administered Yes No Not Applicable Indicator","preferredDefinition":"information related to administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process of the recurrence or return of a tumor composed of atypical neoplastic cells within the nervous system that consists of the brain, spinal cord, and meninges._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"TX_MALIG_CNS_REC_ADM_YES_NO_NA","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0D9463-59EC-6330-E053-F662850AA8E7","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-07-19","modifiedBy":"PATELV","dateModified":"2020-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6819893","version":"1","preferredName":"Person Radiation Therapy Discontinued Prior Registration Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"information related to a person having discontinued any treatment of a disease by means of exposure of the target or the whole body to radiation prior to registration as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2236731v1.0:3178391v1.0_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0D33C2-6665-32D1-E053-F662850A7270","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-07-19","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6819894","version":"1","preferredName":"Measurable Disease Present Yes No Not Applicable Indicator","preferredDefinition":"information related to measurable disease being present._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"MSRBL_DZ_PRES_YES_NO_NA_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E0D412F-154E-48EA-E053-F662850A83AB","latestVersionIndicator":"Yes","beginDate":"2019-07-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-07-19","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6885521","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication Administration Yes No Not Applicable Indicator","preferredDefinition":"information related to the administration of a medication that either inhibits or induces CYP3A4 (induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), whose activity seems a key predictor of drug responsiveness and toxicity._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"CYP3A4_MEDS_ADM_IND2","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91ABC583-BCFC-10C9-E053-F662850A34C0","latestVersionIndicator":"Yes","beginDate":"2019-09-03","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-09-03","modifiedBy":"VUJANOVA","dateModified":"2020-12-02","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6921635","version":"1","preferredName":"Patient Prior Poly (ADP-Ribose) Polymerase Inhibitor Received Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Earlier in time or order._Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death._To take, accept, or get something offered._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"PARP_REC_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91F5157E-6AFC-46B2-E053-F662850AC2C5","latestVersionIndicator":"Yes","beginDate":"2019-09-07","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-09-07","modifiedBy":"CLOHNES","dateModified":"2022-05-19","changeNote":"9149_Theradex_02.20.15_ghd","administrativeNotes":"added AQT for NRG cjl 5/19/22","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6942955","version":"1","preferredName":"Administration Schedule Yes No Indicator","preferredDefinition":"Ordered list of times for an event or measure to be delivered._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"ADMIN_SCHED_YES_NO_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9302420C-B9F9-7FD9-E053-F662850A3864","latestVersionIndicator":"Yes","beginDate":"2019-09-20","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-09-20","modifiedBy":"PATELV","dateModified":"2020-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6942960","version":"1","preferredName":"Sufficient Access Vein Yes No Indicator","preferredDefinition":"The yes/no indicator related to the accessibility of a patient's vein","longName":"6942959v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93014B03-2D3A-7FE1-E053-F662850A6B37","latestVersionIndicator":"Yes","beginDate":"2019-09-20","endDate":null,"createdBy":"SARAHB","dateCreated":"2019-09-20","modifiedBy":"PATELV","dateModified":"2020-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7038296","version":"1","preferredName":"Patient Salpingo-Oophorectomy Refuse Defer Status Yes No Indicator","preferredDefinition":"The yes/no response to a question that asks if a female patient has declined or elected to defer salpingo-oophorectomy.","longName":"PT_SO_REFUSE_DEFER_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9649D412-EA97-2F15-E053-F662850A8A8E","latestVersionIndicator":"Yes","beginDate":"2019-11-01","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2019-11-01","modifiedBy":"TIFFANIS","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7038300","version":"1","preferredName":"Patient Abnormal Screening Test Yes No Indicator","preferredDefinition":"The yes/no response to a question that asks if the patient had an abnormal screening test.","longName":"PT_ABN_SCREEN_TEST_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"964C1F3C-D4A6-4865-E053-F662850A7C80","latestVersionIndicator":"Yes","beginDate":"2019-11-01","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2019-11-01","modifiedBy":"TIFFANIS","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7039077","version":"1","preferredName":"Risk Factor Type","preferredDefinition":"Any aspect of an individual's life, behavior, an environmental exposure, or an inborn or inherited characteristic that increases the likelihood of a disease, condition or injury._A written or verbal account, representation, statement, or explanation of something._Something that increases the chance of developing a disease. Some examples of risk factors for cancer are age, a family history of certain cancers, use of tobacco products, being exposed to radiation or certain chemicals, infection with certain viruses or bacteria, and certain genetic changes._Something distinguishable as an identifiable class based on common qualities.","longName":"Risk_Factor_Type","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"GDC:NCI Genomic Data Commons","workflowStatus":"RELEASED","registrationStatus":"Application","id":"96886070-1070-05E3-E053-F662850A6140","latestVersionIndicator":"Yes","beginDate":"2019-11-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2019-11-04","modifiedBy":"VUJANOVA","dateModified":"2020-02-06","changeNote":"Created for caDSR Requests Q12018 Dictionary Updates for Review (supplement) 3.15.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7067822","version":"1","preferredName":"Patient IDH Mutation Abnormality Status Yes No Indicator","preferredDefinition":"Indicator for whether or not the patient has an IDH mutation.","longName":"PT_IDH_MUT_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"984387CC-FDDB-04A0-E053-F662850AD1E0","latestVersionIndicator":"Yes","beginDate":"2019-11-26","endDate":null,"createdBy":"WISEM","dateCreated":"2019-11-26","modifiedBy":"WISEM","dateModified":"2019-11-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7159125","version":"1","preferredName":"Hysterectomy Performed Yes No Not Applicable Indicator","preferredDefinition":"information related to a hysterectomy being performed._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2820695v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DD82BF4-4253-6BBA-E053-F662850A42AD","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2020-02-05","modifiedBy":"ZHANGWE","dateModified":"2022-03-14","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164340","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Hot Flashes Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by hot flashes, using a 5 point Likert scale.","longName":"CHKLST_HOTFLASH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEA0646-178E-3355-E053-F662850A4808","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164341","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Night Sweats Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by night sweats, using a 5 point Likert scale.","longName":"CHKLST_NGHT_SWT_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEDF512-54F6-576B-E053-F662850A27D5","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164357","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Cold Sweats Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by cold sweats, using a 5 point Likert scale.","longName":"CHKLST_COLD_SWT_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE0127-3372-02AA-E053-F662850A40C7","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164367","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Constipation Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by constipation, using a 5 point Likert scale.","longName":"CHKLST_CONSTPNTN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE20A8-F97C-0400-E053-F662850AF9E8","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164368","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Vaginal Discharge Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by vaginal discharge, using a 5 point Likert scale.","longName":"CHKLST_VAGDISCH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE2B33-FE22-0F95-E053-F662850AA8E9","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164369","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Vaginal Bleeding Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by vaginal bleeding, using a 5 point Likert scale.","longName":"CHKLST_VAGBLEED_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE32C9-861A-0634-E053-F662850AD7B7","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164370","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Genital Itching and/or Irritation Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by genital itching and/or irritation, using a 5 point Likert scale.","longName":"CHKLST_GENITCH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE3BAA-CCB2-725D-E053-F662850A79FD","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164371","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Vaginal Dryness Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by vaginal dryness, using a 5 point Likert scale.","longName":"CHKLST_VAGDRY_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE41CB-85BD-29AE-E053-F662850A33D4","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164396","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Pain with Intercourse Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by pain with intercourse, using a 5 point Likert scale.","longName":"CHKLST_INTRPAIN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE4DD4-80A7-38B5-E053-F662850A663F","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164398","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Dry Mouth Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by dry mouth, using a 5 point Likert scale.","longName":"CHKLST_DRYMOUTH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE5405-3171-411F-E053-F662850A1B35","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164399","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Weight Loss Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by weight loss, using a 5 point Likert scale.","longName":"CHKLST_WGHTLSS_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE5A42-CC28-482C-E053-F662850A849C","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164410","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Decreased Appetite Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by decreased appetite, using a 5 point Likert scale.","longName":"CHKLST_DCRSAPP_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE6399-41F5-4F44-E053-F662850A6827","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164411","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Abdominal Cramp Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by abdominal cramps, using a 5 point Likert scale.","longName":"CHKLST_ABCRMP_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE711C-BA14-4D88-E053-F662850A13EA","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164412","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Leg Cramp Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by leg cramps, using a 5 point Likert scale.","longName":"CHKLST_LEGCRMP_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE783A-1DF7-7093-E053-F662850A8140","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164413","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Difficulty with Bladder Control when Laughing or Crying Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by difficulty with bladder control when laughing or crying, using a 5 point Likert scale.","longName":"CHKLST_BLDRCNTRL_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE80B2-B79E-7B61-E053-F662850AB7EA","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164414","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Difficulty with Bladder Control at Other Times Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by difficulty with bladder control at other times, using a 5 point Likert scale.","longName":"CHKLST_BLDDR_OTH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE893B-3CEE-0562-E053-F662850A4A5C","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164415","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Weight Gain Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by weight gain, using a 5 point Likert scale.","longName":"CHKLST_WGHTGAIN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEE9A90-83C1-1902-E053-F662850A5C75","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164439","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Forgetfulness Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by forgetfulness, using a 5 point Likert scale.","longName":"CHKLST_FORGETFUL_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEFBD83-B76A-784F-E053-F662850AC0BA","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164440","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Chest Pain Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by chest pain, using a 5 point Likert scale.","longName":"CHKLST_CHESTPAIN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEFC406-F043-7DC6-E053-F662850A0755","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164441","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Fever Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by fever, using a 5 point Likert scale.","longName":"CHKLST_FEVER_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DEFCA7B-50E8-06E3-E053-F662850AEA5F","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164451","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Nausea Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by nausea, using a 5 point Likert scale.","longName":"CHKLST_NAUSEA_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF17677-0065-7456-E053-F662850A1F0F","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164452","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Upset Stomach Bother You and/or Indigestion Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by upset stomach or indigestion, using a 5 point Likert scale.","longName":"CHKLST_UPST_STOM_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF1821F-87B7-745A-E053-F662850A606C","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164453","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Vomiting Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by vomiting, using a 5 point Likert scale.","longName":"CHKLST_VOMTNG_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF18868-43F8-5DDF-E053-F662850AD92A","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164454","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Flatulence Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by flatulence, using a 5 point Likert scale.","longName":"CHKLST_FLATULNCE_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF16474-247A-5DCD-E053-F662850ACED4","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164455","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Sinus Problems Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by sinus problems, using a 5 point Likert scale.","longName":"CHKLST_SINUSPROB_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF19A11-B82F-5D6F-E053-F662850A1F89","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164456","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Coughing Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by coughing, using a 5 point Likert scale.","longName":"CHKLST_COUGHING_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF16474-249B-5DCD-E053-F662850ACED4","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164457","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Skin Rash Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by skin rash, using a 5 point Likert scale.","longName":"CHKLST_SKIN_RASH_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF1821F-87D8-745A-E053-F662850A606C","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164458","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Insomnia Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by insomnia, using a 5 point Likert scale.","longName":"CHKLST_INSOMNIA_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF1AF18-13A8-5DD9-E053-F662850AC043","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164459","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Depression Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by depression, using a 5 point Likert scale.","longName":"CHKLST_DEPRESSN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF17677-0086-7456-E053-F662850A1F0F","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164460","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Headache Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by headaches, using a 5 point Likert scale.","longName":"CHKLST_HDACHES_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF1AF18-13C9-5DD9-E053-F662850AC043","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164461","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Breast Sensitivity or Tenderness Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by breast sensitivity or tenderness, using a 5 point Likert scale.","longName":"CHKLST_BRST_SNS_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DF1C1A2-3F6B-426E-E053-F662850A0DC7","latestVersionIndicator":"Yes","beginDate":"2020-02-06","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-06","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164510","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Aches and Pains Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by general aches and pains, using a 5 point Likert scale.","longName":"CHKLST_ACHEPAIN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEA51E-E414-2EB8-E053-F662850AE376","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-07","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164511","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Joint Pains Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by joint pains, using a 5 point Likert scale.","longName":"CHKLST_JOINTPAIN_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEA51E-E43C-2EB8-E053-F662850AE376","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-07","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164512","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Swelling of Hands or Feet Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by swelling of hands or feet, using a 5 point Likert scale.","longName":"CHKLST_SWLLHNDFT_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEED8F-9AC3-26F4-E053-F662850A6DEE","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-07","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164513","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Muscle Stiffness Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by muscle stiffness, using a 5 point Likert scale.","longName":"CHKLST_MSCLSTFF_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFEF363-3230-26EA-E053-F662850AA92E","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-07","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7164514","version":"1","preferredName":"Symptom Checklist Past 4 Weeks How Much Does Early Awakening Bother You Score 5 Point Scale","preferredDefinition":"A person's stated observation to the extent, in the past 4 weeks, that they were bothered by early awakening, using a 5 point Likert scale.","longName":"CHKLST_ERLYWAKE_SCL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DFF4A79-7FA0-26E6-E053-F662850ADA99","latestVersionIndicator":"Yes","beginDate":"2020-02-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-07","modifiedBy":"TSESU","dateModified":"2020-03-05","changeNote":"2/6/2020 smt created for NRG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7297624","version":"1","preferredName":"Regional Disease or Disorder Present Yes No Indicator","preferredDefinition":"The yes/no indicator whether the patient has regional disease at study entry.","longName":"REGIONAL_DISEASE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A691347B-9D69-5366-E053-4EBD850A44AC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"PATELV","dateCreated":"2020-05-26","modifiedBy":"PATELV","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339379","version":"1","preferredName":"Incomplete Outcome Colonoscopy Yes No Indicator","preferredDefinition":"Not whole; lacking some necessary part or detail; unfinished._The result of an action._Endoscopic examination of the luminal surface of the colon._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"INCOMPL_COLONOSCOPY_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8614F30-A0CD-5A54-E053-4EBD850A4215","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-06-18","modifiedBy":"SARAHB","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339383","version":"1","preferredName":"Partial Colectomy Yes No Indicator","preferredDefinition":"Being or affecting only a part of something._Surgical removal of part or all of the colon._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"PARTIAL_COLECTOMY_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8614F30-A0EC-5A54-E053-4EBD850A4215","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-06-18","modifiedBy":"SARAHB","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339397","version":"1","preferredName":"Incomplete Polyp Excision Yes No Indicator","preferredDefinition":"Not whole; lacking some necessary part or detail; unfinished._A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk.  Polyps can be neoplastic or non-neoplastic.  Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract.  Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas.  Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations._The act of cutting out; the surgical removal of part or all of a structure or organ._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"POLYP_EXCISION_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A860789B-629F-667F-E053-4EBD850AC589","latestVersionIndicator":"Yes","beginDate":"2020-06-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-06-18","modifiedBy":"SARAHB","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7339744","version":"1","preferredName":"Abnormal Investigation Finding Colonoscopy Yes No Indicator","preferredDefinition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm._The result of an examination or inquiry._Endoscopic examination of the luminal surface of the colon._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"ABN_COLONOSCOPY_FINDING_YN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A870A72E-CCEC-4B53-E053-4EBD850A6646","latestVersionIndicator":"Yes","beginDate":"2020-06-19","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-06-19","modifiedBy":"SARAHB","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351643","version":"1","preferredName":"Decipher Prostate Cancer Test High Score Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the decipher prostate cancer test score is within specified range.","longName":"DEC_PRO_TST_SCR_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA66D934-6CBB-645A-E053-4EBD850A43D0","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KENNISHM","dateCreated":"2020-07-14","modifiedBy":"WELSHE","dateModified":"2021-04-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7351737","version":"1","preferredName":"Decipher Prostate Cancer Test Low Intermediate Score Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether or not the decipher prostate cancer test score is within specified range.","longName":"DEC_PRO_LOW_INT_SCR_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA67AF56-BB61-37FD-E053-4EBD850ADCED","latestVersionIndicator":"Yes","beginDate":"2020-07-14","endDate":null,"createdBy":"KENNISHM","dateCreated":"2020-07-14","modifiedBy":"WELSHE","dateModified":"2021-04-02","changeNote":" ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7431171","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Brain First Or Second Distant Recurrence Yes No Indicator","preferredDefinition":"Yes No indicator whether a first or second recurrence of a metastatic brain tumor has been diagnosed","longName":"METS_BRA_DIST_RECUR","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFFD97F8-D65A-0F02-E053-4EBD850A159B","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"WISEM","dateCreated":"2020-09-23","modifiedBy":"TSESU","dateModified":"2023-05-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7433906","version":"1","preferredName":"Local Recurrent Neoplasm Post Previous Therapeutic Procedure present Yes No Unknown Indicator","preferredDefinition":"Yes/No/Unknown indicator whether a local recurrence post previous treatment is present.","longName":"LOC_REC_POS_PREV_TRE_YNU","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B010F4D8-5230-1EA5-E053-4EBD850A9ACB","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"WISEM","dateCreated":"2020-09-24","modifiedBy":"WISEM","dateModified":"2020-12-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7516169","version":"1","preferredName":"Disease-specific Graded Prognostic Assessment Median Overall Survival Score","preferredDefinition":"Numeric representation of the score for the Disease-specific Graded Prognostic Assessment","longName":"DS_GPA_SCORE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4E0F6EA-5800-3E9E-E053-4EBD850A45CB","latestVersionIndicator":"Yes","beginDate":"2020-11-24","endDate":null,"createdBy":"TIFFANIS","dateCreated":"2020-11-24","modifiedBy":"PATELV","dateModified":"2021-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7518877","version":"1","preferredName":"Patient Proteinuria Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The presence of abnormal amounts of protein in the urine._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"6032321v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56858F7-F0BE-0C6C-E053-4EBD850ADEA0","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7518882","version":"1","preferredName":"Patient Sufficient Control Hypertension Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Meeting a quantitative or qualitative measure necessary for a requirement; enough to meet the needs of a situation._The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another._Blood pressure that is abnormally high._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5143733v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56A1CE1-34AD-4C4E-E053-4EBD850A8DA7","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7519041","version":"1","preferredName":"Patient Platinum Refractory Disease or Disorder Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A metal that is an important component of some anticancer drugs, such as cisplatin and carboplatin._Not responding to treatment._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5343233v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56C7035-FB83-3DE2-E053-4EBD850A0F21","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7519052","version":"1","preferredName":"Person Adverse Event Assessment Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A human being._Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._The final result of a determination of the value, significance, or extent of._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5480127v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56CC681-D714-4001-E053-4EBD850A091A","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7519053","version":"1","preferredName":"Patient IV Fluid Or Total Parenteral Nutrition Requirement Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A sterile liquid preparation infused into a vein.  IV fluid is prescribed as a replacement of fluid, electrolytes, calories, vitamins, and other nutritional substances.  In addition, IV fluids are used to administer blood products and medications such as chemotherapy.  Examples of IV fluids include Normal Saline, Ringers Solution, and Lactated Ringers Solution. (NCI)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Total parenteral nutrition formulated for intravenous administration in patients who cannot eat or cannot get enough nutrients from the foods they eat.  It is a liquid mixture of proteins, carbohydrates, fats, vitamins, minerals and other nutrients._Something that is a necessary condition; something that is obligatory._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4901077v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56C80CE-94B2-2F8C-E053-4EBD850ADD11","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2022-03-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7519054","version":"1","preferredName":"Cardiac Condition Left Ventricular Ejection Fraction (LVEF) Less Than 50 Percent Yes No Not Applicable Indicator","preferredDefinition":"Having to do with the heart._A state of being, such as a state of health._The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume._A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status._A number with no fractional part, including the negative and positive numbers as well as zero.::50_A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred)._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"4363961v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56A5329-457C-4B4A-E053-4EBD850A0AF2","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7519055","version":"1","preferredName":"CAM Use Yes No Not Applicable Indicator","preferredDefinition":"the use of any complementary or alternative medications or treatments for cancer or other medical conditions. _The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2179982v1.0:3506036v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B56C7407-7E95-3DE4-E053-4EBD850A0F08","latestVersionIndicator":"Yes","beginDate":"2020-12-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2020-12-01","modifiedBy":"SARAHB","dateModified":"2020-12-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7572752","version":"1","preferredName":"Patient Contact Method Specify","preferredDefinition":"information relating to the method of contacting a patient._a channel for communication between groups_A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Be specific about something; define clearly.","longName":"2416396v1.0:7572748v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA49CBDE-C433-0ED9-E053-4EBD850AC9D5","latestVersionIndicator":"Yes","beginDate":"2021-02-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-01","modifiedBy":"SARAHB","dateModified":"2021-02-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7572759","version":"1","preferredName":"Patient Absent Visit Not Done Reason","preferredDefinition":"information relating to a patient absent visit._A visit by a patient or study participant to a medical professional._Indicates a task, process or examination that has either not been initiated or not been completed._An explanation of the cause of some phenomenon or action.","longName":"2201054v1.0:7572754v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA49DA5C-83D7-4AAF-E053-4EBD850AEF11","latestVersionIndicator":"Yes","beginDate":"2021-02-01","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-01","modifiedBy":"SARAHB","dateModified":"2021-02-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574307","version":"1","preferredName":"Patient Contact Method Yes No Indicator","preferredDefinition":"information relating to the method of contacting a patient._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2416396v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA5E60DF-F57A-43AF-E053-4EBD850AA755","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-02","modifiedBy":"SARAHB","dateModified":"2021-02-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574308","version":"1","preferredName":"Contact Telephone Yes No Indicator","preferredDefinition":"A person acting as a channel for communication between groups._A telephone number is a sequence of decimal digits (0-9) that is used for identifying a destination telephone line or other device in a telephone network.  In the US this is a ten digit number resembling \"123-456-7890\"._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2237868v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA5F7022-326B-3A9F-E053-4EBD850A4DDD","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-02","modifiedBy":"SARAHB","dateModified":"2021-02-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574309","version":"1","preferredName":"Participant Medical Record Yes No Indicator","preferredDefinition":"Someone who takes part in an activity._A chronological written account of a patient's examination and treatment that includes the patient's medical history and complaints, the physician's physical findings, the results of diagnostic tests and procedures, and medications and therapeutic procedures. (dictionary.com)_Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2613751v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA5DE2EC-44E0-3041-E053-4EBD850A0C7C","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-02","modifiedBy":"SARAHB","dateModified":"2021-02-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7574310","version":"1","preferredName":"Video Yes No Indicator","preferredDefinition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a videotape._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"2014332v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA5EAADC-41A8-2E37-E053-4EBD850AF81D","latestVersionIndicator":"Yes","beginDate":"2021-02-02","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-02","modifiedBy":"SARAHB","dateModified":"2021-02-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7575858","version":"1","preferredName":"Patient Fractionated Stereotactic Radiation Therapy Target Lesion Location Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the location of the target lesion for FSRT.","longName":"FSRT_TARGET_LESION_LOC_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA897202-29D4-257C-E053-4EBD850A5812","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"CARTERS","dateCreated":"2021-02-04","modifiedBy":"CARTERS","dateModified":"2021-03-02","changeNote":"CDE workflow status was released in error.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7575951","version":"1","preferredName":"Hormone Therapy Continue Yes No Unknown Not Applicable Indicator","preferredDefinition":"related to the unaltered keeping or maintaining of agents used to produce therapeutic effects by means of change in hormone levels._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"2010205v3.0:3506035v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA89AC46-F29D-721F-E053-4EBD850ABA0B","latestVersionIndicator":"Yes","beginDate":"2021-02-04","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2021-02-04","modifiedBy":"TSESU","dateModified":"2022-11-28","changeNote":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7576069","version":"1","preferredName":"Patient Prior Radiation Therapy Treatment Plan Availability Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the availability of the prior radiotherapy treatment plan.","longName":"PR_RT_TP_AVAIL_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA9A9DA3-7B35-27A9-E053-4EBD850A1419","latestVersionIndicator":"Yes","beginDate":"2021-02-05","endDate":null,"createdBy":"CARTERS","dateCreated":"2021-02-05","modifiedBy":"CARTERS","dateModified":"2021-03-02","changeNote":"CDE was released in error.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7576820","version":"1","preferredName":"Patient Quality of Life Consent Participation Type","preferredDefinition":"information related to a person who receives medical attention, care, or treatment, giving permission for questions concerning Quality of Life._The act of taking part in an activity._Something distinguishable as an identifiable class based on common qualities.","longName":"2654102v1.0:7576818v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB12E462-694A-5DFB-E053-4EBD850A7D54","latestVersionIndicator":"Yes","beginDate":"2021-02-11","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-02-11","modifiedBy":"SARAHB","dateModified":"2021-02-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7592050","version":"1","preferredName":"Patient Credential Physician Review Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to records that qualify a physician to review something.","longName":"PT_CRED_PHY_REV_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD343A24-6F4E-755D-E053-4EBD850AD457","latestVersionIndicator":"Yes","beginDate":"2021-03-10","endDate":null,"createdBy":"WISEM","dateCreated":"2021-03-10","modifiedBy":"WISEM","dateModified":"2021-03-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7592079","version":"1","preferredName":"Patient Brain Metastasis Velocity Clinical Trial Eligibility Criteria 2 Digit Value","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the recurrence rate of new brain metastases after initial treatment with radiosurgery.","longName":"BMV_ELIG_VALUE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD34C4FD-A890-543B-E053-4EBD850A43F5","latestVersionIndicator":"Yes","beginDate":"2021-03-10","endDate":null,"createdBy":"WISEM","dateCreated":"2021-03-10","modifiedBy":"WISEM","dateModified":"2021-03-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7592175","version":"1","preferredName":"Patient Bladder Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Bladder.","longName":"BLADDER_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD489268-5426-702B-E053-4EBD850AB349","latestVersionIndicator":"Yes","beginDate":"2021-03-11","endDate":null,"createdBy":"PATELV","dateCreated":"2021-03-11","modifiedBy":"PATELV","dateModified":"2021-05-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595535","version":"1","preferredName":"Patient Colon Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Colon.","longName":"COLON_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5B43E3-6DAF-182C-E053-4EBD850AA0BE","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"ABATEL","dateModified":"2021-05-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595610","version":"1","preferredName":"Patient Stomach Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Stomach.","longName":"STOMACH_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5CD369-CECD-457F-E053-4EBD850A2BB3","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595616","version":"1","preferredName":"Patient Skin Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Skin.","longName":"SKIN_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5D18F9-1783-7E27-E053-4EBD850AAAF2","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595620","version":"1","preferredName":"Patient Rectum Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Rectum.","longName":"RECTUM_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5C3D20-C2FC-158A-E053-4EBD850A1C85","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"ABATEL","dateModified":"2021-05-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595651","version":"1","preferredName":"Patient Kidney Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Kidney.","longName":"KIDNEY_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5DB35C-9B9D-6E9A-E053-4EBD850AF282","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7595656","version":"1","preferredName":"Patient Esophagus Metastatic Site Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to the metastatic site specified as Esophagus.","longName":"ESOPHAG_MET_SITE_YN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5DD160-27E0-077B-E053-4EBD850A2439","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"ABATEL","dateCreated":"2021-03-12","modifiedBy":"ABATEL","dateModified":"2021-05-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7604514","version":"1","preferredName":"Patient Personal Medical History Bevacizumab Risk Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient's medical background with regards to the potential future harm that may arise from bevacizumab meets the eligibility requirements for participation in a clinical trial.","longName":"7604510v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDBCEAB3-C99E-3FBC-E053-4EBD850AFCE9","latestVersionIndicator":"Yes","beginDate":"2021-03-17","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-03-17","modifiedBy":"TSESU","dateModified":"2023-03-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7604515","version":"1","preferredName":"Patient Polymerase Chain Reaction Laboratory Procedure Outcome Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"An indication as to whether the patient meets the eligibility requirements for participation in a clinical trial with regards to PCR lab results.","longName":"7604513v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDBB9E7D-50A0-3C3E-E053-4EBD850A43F2","latestVersionIndicator":"Yes","beginDate":"2021-03-17","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-03-17","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7620906","version":"1","preferredName":"Radiation Therapy Planned Occurrence Type","preferredDefinition":"The kind of radiation therapy that is intended to take place.","longName":"RT_PLAN_TYPE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED5F5AB-CFF4-7F09-E053-4EBD850A7E97","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"PATELV","dateCreated":"2021-03-31","modifiedBy":"PATELV","dateModified":"2021-04-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7680787","version":"1","preferredName":"PSA Doubling Time Month Duration","preferredDefinition":"Time in months required for PSA (prostate specific antigen) to double in value.","longName":"PSA_DOUBLE_TIME_MONTH_DUR","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4434742-80EB-7C17-E053-4EBD850A5AED","latestVersionIndicator":"Yes","beginDate":"2021-06-08","endDate":null,"createdBy":"KENNISHM","dateCreated":"2021-06-08","modifiedBy":"KENNISHM","dateModified":"2021-09-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7715661","version":"1","preferredName":"Measurable Disease Baseline Present Tumor Present Ind","preferredDefinition":"information related to measurable disease being present a starting point to which things may be compared._the indicator regarding a tumor being present.","longName":"MEASURABLE_DISEASE_PRESENT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5E86C52-9405-3CD8-E053-4EBD850AF1B6","latestVersionIndicator":"Yes","beginDate":"2021-06-29","endDate":null,"createdBy":"WELSHE","dateCreated":"2021-06-29","modifiedBy":"PATELV","dateModified":"2021-10-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7743440","version":"1","preferredName":"Participating Study Site Sentinel Lymph Node Procedure Experience Documentation Submission Indicator","preferredDefinition":"An indication as to whether or not the participating facility in which study/protocol activities are conducted submitted documentation of their experience with sentinel lymph node procedures that produce an effect, or are intended to alter the course of a disease in a patient or population.","longName":"7743439v1.0:3977769v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C790AD70-BFF7-792F-E053-4EBD850A30CE","latestVersionIndicator":"Yes","beginDate":"2021-07-20","endDate":null,"createdBy":"VUJANOVA","dateCreated":"2021-07-20","modifiedBy":"TYRRELLM","dateModified":"2023-10-17","changeNote":null,"administrativeNotes":"10.17.23 Added AQT per request ticket CADSR0002968_mt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799632","version":"1","preferredName":"Colorectal Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for colon and rectal carcinoma, using AJCC Ed. 8 criteria to include Stage II.","longName":"2769361v1.0:7799631v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF4A696-E598-77B4-E053-4EBD850AE3B8","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-10-22","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeNote":"TL and CB created for GI008.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799716","version":"1","preferredName":"Patient Circulating Tumor-Derived DNA Positive Finding Laboratory Test Result Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The detection of cell-free, neoplasm-derived DNA in patient serum or plasma._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._The outcome of a laboratory test._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"7799599v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF67086-76DF-319E-E053-4EBD850AB933","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-22","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799717","version":"1","preferredName":"Patient Randomization Participation Status Confirmation Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The allocation of individuals to groups by chance, especially in order to control the variables in an experiment._The status of a person in relationship to his participation in a given activity._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"7799602v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF67C90-72D8-6B56-E053-4EBD850A1C5D","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-22","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7799718","version":"1","preferredName":"Patient Negation Candidate Systemic Chemotherapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An operation in which a term denies or inverts the meaning of another term or construction._Someone or something considered as suitable or likely for something._Chemotherapy where the agent travels throughout the body by blood circulation._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"7799605v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF683F6-5815-0CC2-E053-4EBD850A0D20","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-22","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801253","version":"1","preferredName":"Patient Circulating Tumor-Derived DNA Laboratory Test Result Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The detection of cell-free, neoplasm-derived DNA in patient serum or plasma._The outcome of a laboratory test._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The detection of cell-free, neoplasm-derived DNA in patient serum or plasma._The result of an action.","longName":"7799614v1.0:7801248v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF812140-0E96-09ED-E053-4EBD850A2116","latestVersionIndicator":"Yes","beginDate":"2021-10-29","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-29","modifiedBy":"ZHWENDY","dateModified":"2023-03-28","changeNote":null,"administrativeNotes":"3/28/2023: Added AQT per CADSR0002213.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7843552","version":"1","preferredName":"Patient Vaginal Brachytherapy Occurrence Stratification Factors Yes No Indicator","preferredDefinition":"Indication as to whether or not the patient will have vaginal brachytherapy as part of the randomization process","longName":"7843551v1.0:3506068v1.0","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D190EA22-54A3-65CE-E053-4EBD850A53E4","latestVersionIndicator":"Yes","beginDate":"2021-11-24","endDate":null,"createdBy":"SARAHB","dateCreated":"2021-11-24","modifiedBy":"SARAHB","dateModified":"2022-02-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8038136","version":"1","preferredName":"Laboratory Procedure ERBB2 Gene Amplification Next Generation Sequencing Outcome Value","preferredDefinition":"HER2 result based on the assessment done using next generation sequencing.","longName":"HER2_NGS_LAB_VALUE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7C0502F-77E4-7DC7-E053-4EBD850A160B","latestVersionIndicator":"Yes","beginDate":"2022-02-11","endDate":null,"createdBy":"PATELV","dateCreated":"2022-02-11","modifiedBy":"TSESU","dateModified":"2022-07-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8070695","version":"1","preferredName":"Mismatch Repair Laboratory Test Result Source","preferredDefinition":"The source of the laboratory finding for mismatch repair (MMR).","longName":"MMR_RESULT_SOURCE","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9A445BF-1C0A-026B-E053-4EBD850AC525","latestVersionIndicator":"Yes","beginDate":"2022-03-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-07","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"TL curated for GY018 OPEN form. Unable to reuse CDE 3809152 because OPEN required exact matches for PVs/PVMs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8173338","version":"1","preferredName":"Person No Prior Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"A human being._No prior treatment for the study disorder._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"NO_PRIOR_THERAPY_YES_NO","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD1BE817-1C3D-71A8-E053-4EBD850AB222","latestVersionIndicator":"Yes","beginDate":"2022-04-20","endDate":null,"createdBy":"SARAHB","dateCreated":"2022-04-20","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10376454","version":"1","preferredName":"Assessment Result Positive Negative Not Done Category","preferredDefinition":"the result of a patient assessment.:Involving advantage or good._Negative; not indicating the presence of microorganisms or disease or a specific condition._Category; used informally to mean a class of things.","longName":"2014620v1.00:3911843v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-21EB-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-05-26","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-05-26","modifiedBy":"MMADDINENI","dateModified":"2023-06-02","changeNote":"ISO 11179 compliance. Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10497292","version":"1","preferredName":"Smoking History Years Smoked Number","preferredDefinition":"the history of use of tobacco products by a person.:A numeral or string of numerals expressing value, quantity, or identification.","longName":"SMOK_HIS_YR_AMT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E17E3623-93DC-491A-E053-731AD00A0CC1","latestVersionIndicator":"Yes","beginDate":"2022-06-22","endDate":null,"createdBy":"TSESU","dateCreated":"2022-06-22","modifiedBy":"TSESU","dateModified":"2022-06-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10558664","version":"1","preferredName":"Surgeon Organizational Affiliation Type","preferredDefinition":"The surgeon's affiliation type.","longName":"SURGEON_AFFIL_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-389E-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2022-07-05","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10558665","version":"1","preferredName":"Surgeon Site Site Location Type","preferredDefinition":"A physician who treats disease, injury, and deformity by operation or manipulation that involves gaining access to the patient's body by incisional access.:A position in relation to its surroundings.:Something distinguishable as an identifiable class based on common qualities.","longName":"SURGEON_LOC_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-38A0-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2022-07-05","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10558668","version":"1","preferredName":"Non-NCORP Site Name Text","preferredDefinition":"Text field to indicate the name of the non-NCORP site.","longName":"NON_NCORP_STE_TXT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-38A4-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2022-07-05","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10560066","version":"1","preferredName":"Tumor Histology Type","preferredDefinition":"Response indicating the tumor histology type.","longName":"TUMOR_HST_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26FF5FD-9E4A-66FB-E053-731AD00AB816","latestVersionIndicator":"Yes","beginDate":"2022-07-06","endDate":null,"createdBy":"TSESU","dateCreated":"2022-07-06","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10567613","version":"1","preferredName":"Histologic Stratification Factors Type Category","preferredDefinition":"The response indicating the category used for stratification of patients enrolled on a clinical trial based upon histologic grade and type.","longName":"HIST_STRAT_FACT_CAT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E350B199-B88D-32C8-E053-731AD00A87E3","latestVersionIndicator":"Yes","beginDate":"2022-07-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-08","modifiedBy":"GDEEN","dateModified":"2023-01-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10574256","version":"1","preferredName":"Laboratory Procedure HER2/neu Chromosome 17 Probe Fluorescence In Situ Hybridization Performed Numerical Value","preferredDefinition":"The numerical value to represent the ratio of gene amplification by FISH (HER2/CEP17 ratio).","longName":"HER2NEU_NUM_VAL","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3B4D4AA-0716-01DC-E053-731AD00ADCDE","latestVersionIndicator":"Yes","beginDate":"2022-07-13","endDate":null,"createdBy":"TSESU","dateCreated":"2022-07-13","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11018435","version":"1","preferredName":"Patient Medical History Amenable Consolidation Immunotherapy Indicator","preferredDefinition":"Indicator of whether patient has medial history amenable for treatment with consolidation immunotherapy.","longName":"AMNBL_CNSLIMMTX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D2DB8C-6F85-50A4-E053-731AD00AA539","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-09","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11018436","version":"1","preferredName":"Patient History Investigational Treatment Regimen Interference Indicator","preferredDefinition":"Indicator of whether patient's history may interfere with the investigational regimen.","longName":"INTF_INVTX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D2FF4F-CB82-54D8-E053-731AD00ABC0F","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-09","modifiedBy":"FINCHAMB","dateModified":"2023-04-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11018437","version":"1","preferredName":"Patient Without Neoplasm Pathologic Enlargement Lymph Node Indicator","preferredDefinition":"Indicator of whether patient is without identifiable primary tumor and has at least one pathologically enlarged lymph node.","longName":"PATH_ENLRG_LN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D30A95-1649-55F2-E053-731AD00A290A","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-09","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11018438","version":"1","preferredName":"Primary Stereotactic Body Radiation Therapy Significant Overlap Nodal Radiation Field Indicator","preferredDefinition":"Indicator of whether primary tumor centrally located less than 2 cm from involved nodal disease which would result in significant overlap of primary SBRT and nodal radiation fields.","longName":"OVRLP_SBRT_NDL_RDFLD_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5D319C7-8377-57C5-E053-731AD00A8A43","latestVersionIndicator":"Yes","beginDate":"2022-08-09","endDate":null,"createdBy":"TSESU","dateCreated":"2022-08-09","modifiedBy":"TSESU","dateModified":"2022-09-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12117079","version":"1","preferredName":"Mastectomy Planned Or Performed Indicator","preferredDefinition":"Indicator of whether mastectomy was or is planned to be performed.","longName":"MAST_PLN_PRF_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA27151-E315-2E52-E053-731AD00A11B7","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"TSESU","dateCreated":"2022-11-29","modifiedBy":"TSESU","dateModified":"2023-06-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12117094","version":"1","preferredName":"Paget Disease Diagnosis Indicator","preferredDefinition":"Indicator of whether patient has Paget's Disease.","longName":"12117093v1.00:3506068v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA2977F-49FE-3323-E053-731AD00AB1F9","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"TSESU","dateCreated":"2022-11-29","modifiedBy":"TSESU","dateModified":"2022-11-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12117098","version":"1","preferredName":"ypT0N0 Surgery Diagnosis Indicator","preferredDefinition":"Indicator of whether tumor was ypT0N0 at time of surgery.","longName":"12117097v1.00:3506068v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA2BA39-3B87-36D9-E053-731AD00AAB6C","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"TSESU","dateCreated":"2022-11-29","modifiedBy":"TSESU","dateModified":"2022-11-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12137348","version":"1","preferredName":"Prior Whole-Brain Radiotherapy Stable Disease Indicator","preferredDefinition":"Indicator of whether patient had prior whole-brain radiotherapy and has stable disease.","longName":"PR_RAD_STABDIS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EFB95E18-17A8-171F-E053-731AD00A45B5","latestVersionIndicator":"Yes","beginDate":"2022-12-13","endDate":null,"createdBy":"TSESU","dateCreated":"2022-12-13","modifiedBy":"TSESU","dateModified":"2022-12-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12213770","version":"1","preferredName":"Stop Nutritional Supplementation Agreement Indicator","preferredDefinition":"The indicator to whether there was an agreement to stop taking nutritional supplementation.","longName":"12213776v1.00:3506035v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F06D4DE0-CE84-539E-E053-731AD00AF2D7","latestVersionIndicator":"Yes","beginDate":"2022-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-12","changeNote":null,"administrativeNotes":"2023.9.12 Released per metrics report. ak 2/15/23 added AQT for URMC ticket request CADSR0002058 cjl; 2022.12022 Created per ticket request CADSR0001812. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12284215","version":"1","preferredName":"Metastatic Disease Imaging Or Tissue Diagnosis Confirmation Indicator","preferredDefinition":"Response indicating whether metastatic disease was confirmed by imaging or tissue diagnosis.","longName":"MET_DIS_IMG_TISS_DX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F17250D5-572E-6053-E053-731AD00AF6DE","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"SOKKERL","dateModified":"2023-02-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12284262","version":"1","preferredName":"Patient NF1 Gene Mutation Present  Indicator","preferredDefinition":"Response indicating whether patient has NF1 gene mutation.","longName":"NF1GENE_MUT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F1737032-A99C-11E2-E053-731AD00A07BA","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12285181","version":"1","preferredName":"Estrogen Receptor or Progesterone Receptor Positive per ASCO/CAP Guideline Indicator","preferredDefinition":"Response indicating whether tumor is Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) positive per American Society of Clinical Oncology (ASCO) or College of American Pathologists (CAP) guideline.","longName":"ER_PGR_POSITIVE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1744792-A9C0-362A-E053-731AD00A3391","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-06-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12285187","version":"1","preferredName":"Breast Carcinoma HER2/Neu Negative Indicator","preferredDefinition":"Response indicating whether tumor is HER2-negative.","longName":"BR_HER2_NEG_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F174C84E-FAC8-4F84-E053-731AD00AE072","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-06-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12285243","version":"1","preferredName":"Left Ventricular Ejection Fraction Measurement Eligibility Criteria Met By Subject Indicator","preferredDefinition":"Response indicating whether Left Ventricular Ejection Fraction (LVEF) measured greater than or equal to 50%.","longName":"LVEF_ELIG_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F175C016-7DC7-708D-E053-731AD00AF910","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12291500","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Response indicating whether patient is receiving immunosuppressive therapy.","longName":"IMMUNO_TX_RECVD_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F177A133-7289-49CF-E053-731AD00AE4F3","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12291814","version":"1","preferredName":"Patient CDK4/6 Inhibitor Use Indicator","preferredDefinition":"Response indicating whether patient used CDK4 or 6 inhibitor.","longName":"CDK4_6_USE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F17B0310-F083-51D1-E053-731AD00A21D6","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TYRRELLM","dateModified":"2023-10-23","changeNote":null,"administrativeNotes":"10.23.23_Added AQT per request ticket CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12291818","version":"1","preferredName":"Patient Fulvestrant Use Indicator","preferredDefinition":"Response indicating whether patient used fulvestrant.","longName":"FULVESTRANT_USE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F17B2089-B5E8-57D3-E053-731AD00A33FD","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12291821","version":"1","preferredName":"Addictive Or Psychiatric Disorder Present Indicator","preferredDefinition":"Response indicating whether patient has psychiatric or addictive disorders.","longName":"ADDC_PSYCH_DIS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F17B4995-1628-5C84-E053-731AD00A202F","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-04","modifiedBy":"TSESU","dateModified":"2024-02-01","changeNote":null,"administrativeNotes":"9.29.2023 Added AQT per request CADSR0002901_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12303912","version":"1","preferredName":"Patient Cohort Study Transition Consent Indicator","preferredDefinition":"Response indicating whether patient has consented to transition to cohort study.","longName":"COHORT_2_CNSNT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18C1EAF-5EC7-7AE0-E053-731AD00A4096","latestVersionIndicator":"Yes","beginDate":"2023-01-05","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-05","modifiedBy":"TSESU","dateModified":"2024-02-01","changeNote":null,"administrativeNotes":"11.16.2023 Added AQT per request ticket CADSR0003089_mmt\r\n10.23.2023 added AQT per request ticket CADSR0002989_mmt\r\n9.29.2023 Added AQT per request CADSR0002902 _mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12303915","version":"1","preferredName":"Patient Binimetinib Candidate Indicator","preferredDefinition":"Response indicating whether patient is a candidate for binimetinib.","longName":"BINIMETNIB_CAND_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F18C8190-1417-0AF5-E053-731AD00A95B1","latestVersionIndicator":"Yes","beginDate":"2023-01-05","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-05","modifiedBy":"TSESU","dateModified":"2023-01-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12357621","version":"1","preferredName":"Patient Neuropathy Present Indicator","preferredDefinition":"Response indicating whether neuropathy was present in the patient.","longName":"NRPTHY_PRSNT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2026CCD-C380-0AF9-E053-731AD00AF3F2","latestVersionIndicator":"Yes","beginDate":"2023-01-11","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-11","modifiedBy":"TYRRELLM","dateModified":"2023-09-29","changeNote":null,"administrativeNotes":"9.29.2023 Added AQT per request CADSR0002901_mmt\r\n2023.3.30 Released per Sung. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12451370","version":"1","preferredName":"Patient Severe Liver Dysfunction Present Indicator","preferredDefinition":"The Yes/No response indicating whether patient has severe (Child-Pugh C) liver dysfunction.","longName":"SVR_LIVDYS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F31CF2F1-A6FB-2654-E053-731AD00A585D","latestVersionIndicator":"Yes","beginDate":"2023-01-25","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-25","modifiedBy":"TSESU","dateModified":"2023-01-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12460865","version":"1","preferredName":"Immediate Treatment Not Required Determined Indicator","preferredDefinition":"Response indicating whether physician determined that no immediate treatment is required.","longName":"IMM_TX_NOTREQ_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F3306299-F9C8-7AFC-E053-731AD00AE223","latestVersionIndicator":"Yes","beginDate":"2023-01-26","endDate":null,"createdBy":"TSESU","dateCreated":"2023-01-26","modifiedBy":"TSESU","dateModified":"2023-01-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13252356","version":"1","preferredName":"Patient Fulfill Criterion New Maintenance Therapy Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient fulfilled criteria for new maintenance therapy.","longName":"MET_CRIT_NEW_MNTNENCTX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F7E38860-F708-5A08-E053-731AD00A7FB7","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13252373","version":"1","preferredName":"Nivolumab During Induction Therapy Permanent Discontinue Yes No Indicator","preferredDefinition":"Yes/No Indicator of whether nivolumab was permanently discontinued during induction therapy.","longName":"13252371v1.00:2015869v3.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F7E3CF44-D8B2-639F-E053-731AD00A7B26","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13252384","version":"1","preferredName":"Patient Discontinue Induction Therapy Yes No Indicator","preferredDefinition":"Yes/No Indicator of whether patient discontinued induction therapy.","longName":"DISCON_INDCTN_TX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F7E44027-6E97-7E60-E053-731AD00AEDF5","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"TSESU","dateModified":"2023-03-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13255910","version":"1","preferredName":"Patient Age Identifier","preferredDefinition":"Range of patient's age.","longName":"PATIENT_AGE_ID","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7E753F4-DAC6-1452-E053-731AD00AD22F","latestVersionIndicator":"Yes","beginDate":"2023-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-03-27","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13552917","version":"1","preferredName":"Distant Metastatic Malignant Neoplasm in the Brain Recurrence Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient developed distant brain relapse(s).","longName":"MET_DIST_BRN_RLPS_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FB480E42-A48C-0910-E053-731AD00A8DE1","latestVersionIndicator":"Yes","beginDate":"2023-05-09","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-09","modifiedBy":"TSESU","dateModified":"2023-05-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13583433","version":"1","preferredName":"Disease Type","preferredDefinition":"The type of disease.","longName":"DIS_TYP","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBD2A004-2F26-7DD2-E053-731AD00A16D7","latestVersionIndicator":"Yes","beginDate":"2023-05-16","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-16","modifiedBy":"TSESU","dateModified":"2023-05-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13707057","version":"1","preferredName":"Patient Agree Medication Discontinue Yes No Indicator","preferredDefinition":"Indicator of whether patient has agreed to discontinue medication use.","longName":"DSCNTNU_DRUGUSE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC923666-8A1F-5A8C-E053-731AD00A1263","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-26","modifiedBy":"TSESU","dateModified":"2023-08-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13751054","version":"1","preferredName":"Patient Receive CYP3A4  Inhibitor or Inducer Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient is receiving medications or substances that are strong inhibitors or inducers of CYP3A4.","longName":"CYP3A4_INDC_INH_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FCEBE841-7710-5806-E053-731AD00A4E6D","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-30","modifiedBy":"TSESU","dateModified":"2023-05-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13767266","version":"1","preferredName":"Patient Pathologic Disease Confirmation Category","preferredDefinition":"The category of the patient's pathologically confirmed disease.","longName":"PATH_CNFRM_CAT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD051D25-FBC9-643E-E053-731AD00A5AA2","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-10-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13768080","version":"1","preferredName":"Patient Taking Multidrug and Toxin Extrusion Protein 1 Or SLC47A2 wt Allele Substrate Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient is taking drugs that use Multidrug and Toxin Extrusion Protein 1 (hMATE1) or Multidrug and Toxin Extrusion Protein 2 (hMATE2) substrate","longName":"hMATE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FD057E58-24CA-70D6-E053-731AD00AEAFE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"TSESU","dateCreated":"2023-05-31","modifiedBy":"TSESU","dateModified":"2023-06-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13809387","version":"1","preferredName":"Neoplasm Stage Met Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether neoplasm stage has met clinical trial eligibility criteria.","longName":"TUM_STG_ELIG_MET_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FD786D43-F8D4-5827-E053-731AD00AC5D3","latestVersionIndicator":"Yes","beginDate":"2023-06-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-06","modifiedBy":"CLOHNES","dateModified":"2023-09-29","changeNote":null,"administrativeNotes":"9/29/23 Added AQT and alt OID, CCTG for ticket number CADSR0002884 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13809412","version":"1","preferredName":"Post Surgical Procedure Primary Neoplasm AJCC v8 Pathologic Examination Breast Cancer pT1 Or pT2 Or pT3 AJCC v8 Yes No Indicator","preferredDefinition":"Yes/No indicator of whether post-surgical primary tumor is pT1 - pT3 according to AJCC 8th edition.","longName":"PR_TMR_PT1_PT3_AJCCV8_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD790095-61E3-762D-E053-731AD00A2DF3","latestVersionIndicator":"Yes","beginDate":"2023-06-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-06","modifiedBy":"TSESU","dateModified":"2023-07-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13809413","version":"1","preferredName":"Patient Multicentric Or Multifocal Breast Carcinoma Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient has multicentric or multifocal breast cancer.","longName":"MLTCEN_MLTFOC_BRCNCR_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FD790A90-005E-7768-E053-731AD00ACACE","latestVersionIndicator":"Yes","beginDate":"2023-06-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-06","modifiedBy":"TSESU","dateModified":"2023-06-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13809428","version":"1","preferredName":"Post Surgical Procedure Ipsilateral Node AJCC v8 Pathologic Category","preferredDefinition":"Post-operative, per AJCC 8th edition, pathologic ipsilateral nodes category.","longName":"IPSNDS_AJCCV8_CAT","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD7A16AE-CAF6-22CE-E053-731AD00A636D","latestVersionIndicator":"Yes","beginDate":"2023-06-06","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-06","modifiedBy":"TSESU","dateModified":"2023-07-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13812824","version":"1","preferredName":"Hormonal Contraception End Use Yes No Not Applicable Indicator","preferredDefinition":"Yes/No/Not Applicable indicator of whether patient has discontinued hormonal contraception.","longName":"HRMN_CNTRC_END_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD9108CA-5BEA-3772-E053-731AD00A4978","latestVersionIndicator":"Yes","beginDate":"2023-06-07","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-07","modifiedBy":"TSESU","dateModified":"2023-06-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13920373","version":"1","preferredName":"Patient Most Recent ANC Known Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known ANC meets clinical trial eligibility criteria.","longName":"RCNT_ANC_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE03A19C-39D7-5AA6-E053-731AD00A3AB6","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13920374","version":"1","preferredName":"Patient Most Recent Platelet Count Known Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known platelet count meets clinical trial eligibility criteria.","longName":"RCNT_PLTLT_CNT_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE03B4B9-CAC2-5D25-E053-731AD00ABA43","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13920375","version":"1","preferredName":"Patient Most Recent Hemoglobin Known Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known hemoglobin meets clinical trial eligibility criteria.","longName":"RCNT_HEMGLBN_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE03C149-FFE2-5EBE-E053-731AD00AD1B7","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13920377","version":"1","preferredName":"Patient Most Recent Total Bilirubin Known Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known total bilirubin meets clinical trial eligibility criteria.","longName":"RCNT_TTL_BLRBN_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE03EC07-6AA3-677E-E053-731AD00AD7A0","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13920379","version":"1","preferredName":"Patient Most Recent Known AST or ALT Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known AST or ALT meets clinical trial eligibility criteria.","longName":"RCNT AST_ALT_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE041620-440B-6C61-E053-731AD00A318C","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13924700","version":"1","preferredName":"Patient Most Recent Glomerular Filtration Rate Known Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Yes/No indicator of whether the patient's most recently known GFR meets clinical trial eligibility criteria.","longName":"RCNT_GFR_KNWN_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE044DCC-246E-73D8-E053-731AD00AD119","latestVersionIndicator":"Yes","beginDate":"2023-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-13","modifiedBy":"TSESU","dateModified":"2023-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13950168","version":"1","preferredName":"Patient Synchronous Ipsilateral Breast Carcinoma Synchronous Bilateral Breast Carcinoma Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient has ipsilateral or contralateral synchronous breast cancer.","longName":"SYNC_IPS_CONTRLTRAL_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"FE2C5093-8C80-0DFC-E053-731AD00A256E","latestVersionIndicator":"Yes","beginDate":"2023-06-15","endDate":null,"createdBy":"TSESU","dateCreated":"2023-06-15","modifiedBy":"TSESU","dateModified":"2023-06-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14182562","version":"1","preferredName":"Central Nervous System Prior Therapy Yes No Indicator","preferredDefinition":"Yes/No indicator of whether participant had prior CNS therapy.","longName":"14182561v1.00:3506068v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"016914CB-F3BA-63A1-E063-731AD00AE376","latestVersionIndicator":"Yes","beginDate":"2023-07-26","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-26","modifiedBy":"TSESU","dateModified":"2023-07-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14183358","version":"1","preferredName":"PHQ-2 Less Than 3 Score Yes No NA Indicator","preferredDefinition":"Indicator of whether the score is less than three (3) on the Patient Health Questionnaire-2 (PHQ-2).","longName":"14183353v1.00:3506036v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0169CA9A-39EF-7F11-E063-731AD00AD37B","latestVersionIndicator":"Yes","beginDate":"2023-07-26","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-26","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14193742","version":"1","preferredName":"Breast Cancer Diagnosis Age Identifier","preferredDefinition":"Age when participant was diagnosed with breast cancer.","longName":"BRST_CNCR_DXAGE_ID","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"017DAB76-796A-1F73-E063-731AD00AAE43","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14194088","version":"1","preferredName":"PROMIS Item Bank v2.0 Cognitive Function Short Form 4a Less Than 12 Score Indicator","preferredDefinition":"Indicator of whether participant scored less than 12 on the PROMIS Item Bank v2.0 - Cognitive Function - Short Form 4a.","longName":"PROM_COGFUNC_SCR_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"017F2DCF-7C9F-5EC8-E063-731AD00A01E0","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14194095","version":"1","preferredName":"PROMIS Item Bank v2.0 Cognitive Function Short Form 4a Total Score Number","preferredDefinition":"PROMIS Adult v2.0 Cognitive Function 4a total score number.","longName":"PROM_COGFUNC_TTSCRE_NUM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"017F5420-8C03-6407-E063-731AD00A9530","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14194463","version":"1","preferredName":"Six-Item Cognitive Impairment Test Score Greater Than 3 Indicator","preferredDefinition":"Indicator of whether the Six-Item Cognitive Impairment Test (6CIT) score is greater than 3.","longName":"6CIT_GRTR_3SCRE_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"017F7642-1A2E-6DD3-E063-731AD00AF70D","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14194466","version":"1","preferredName":"Six-Item Cognitive Impairment Test Total Score 3 Digit Number","preferredDefinition":"Numerical value representing the total score of the Six-Item Cognitive Impairment Test (6CIT).","longName":"6CIT_TT_SCORE_NUM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"017F9AE1-A484-7B82-E063-731AD00A88DD","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14195574","version":"1","preferredName":"Patient Health Questionnaire-2 Total Score 3 Digit Number","preferredDefinition":"Numerical value representing the Patient Health Questionnaire-2 (PHQ-2) total score.","longName":"14195573v1.00:2635618v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"01802C53-78D3-127F-E063-731AD00A09E6","latestVersionIndicator":"Yes","beginDate":"2023-07-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-07-27","modifiedBy":"TSESU","dateModified":"2023-07-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14245083","version":"1","preferredName":"Study Enrollment Yes or No Indicator","preferredDefinition":"Yes/No indicator of whether patient has enrolled on study.","longName":"STDY_ENROLL_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"01F46A44-CAAD-5F77-E063-731AD00ADD1B","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"TSESU","dateCreated":"2023-08-02","modifiedBy":"TSESU","dateModified":"2023-08-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14245705","version":"1","preferredName":"Clinical Trial Participation Patient Declined Reason","preferredDefinition":"The reason patient declined to participate on study.","longName":"STDY_PART_DECLN_RSN","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"01F4D05F-64B7-7010-E063-731AD00A2149","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"TSESU","dateCreated":"2023-08-02","modifiedBy":"TSESU","dateModified":"2023-08-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14265792","version":"1","preferredName":"Patient Benign Ethnic Neutropenia Diagnosis Yes No Indicator","preferredDefinition":"Yes/No indicator of whether patient has been diagnosed with benign ethnic neutropenia (BEN).","longName":"BEN_DX_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"020954CA-3C92-3C52-E063-731AD00A2CEB","latestVersionIndicator":"Yes","beginDate":"2023-08-03","endDate":null,"createdBy":"TSESU","dateCreated":"2023-08-03","modifiedBy":"TSESU","dateModified":"2023-08-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14367447","version":"1","preferredName":"Clinical Trial Randomization Notification Received Yes No Indicator","preferredDefinition":"Indicator of whether notification was received for randomization on clinical trial.","longName":"RNDM_NOTIFY_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"02A9815A-C660-291D-E063-731AD00A121B","latestVersionIndicator":"Yes","beginDate":"2023-08-11","endDate":null,"createdBy":"TSESU","dateCreated":"2023-08-11","modifiedBy":"TSESU","dateModified":"2023-08-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14378646","version":"1","preferredName":"Staff Member Perform On Study Patient Care Yes No Indicator","preferredDefinition":"Yes/No indicator of whether staff member will provide care for patient on study.","longName":"STFF_CARE_PATIENT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"02E7AAEF-208E-6597-E063-731AD00AF3E1","latestVersionIndicator":"Yes","beginDate":"2023-08-14","endDate":null,"createdBy":"TSESU","dateCreated":"2023-08-14","modifiedBy":"TSESU","dateModified":"2023-08-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14461394","version":"1","preferredName":"Recurrent Adult Granulosa Cell Tumor Histologic Confirmation Yes No Indicator","preferredDefinition":"Yes/No indicator of whether recurrent adult granulosa cell tumor was histologically confirmed.","longName":"REC_AD_GRAN_CNF_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"04A12A4F-4E39-1A79-E063-731AD00A6B71","latestVersionIndicator":"Yes","beginDate":"2023-09-05","endDate":null,"createdBy":"TSESU","dateCreated":"2023-09-05","modifiedBy":"TSESU","dateModified":"2023-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14473385","version":"1","preferredName":"Neoplasm Histologic Grade Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The indication that the neoplasm histologic grade meets the criteria for patient participation in a clinical trial.","longName":"14473384v1.00:3506068v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05209B84-E835-7E7C-E063-731AD00ACB15","latestVersionIndicator":"Yes","beginDate":"2023-09-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-11","modifiedBy":"GDEEN","dateModified":"2023-09-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14483822","version":"1","preferredName":"Clinical Study Document Submitted and Randomized Yes No Indicator","preferredDefinition":"Yes/No indicator of whether clinical trial documentation for the site has been submitted and randomized.","longName":"DOC_SUB_RANDMIZ_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"05CDE2AD-286D-6138-E063-731AD00A9137","latestVersionIndicator":"Yes","beginDate":"2023-09-20","endDate":null,"createdBy":"TSESU","dateCreated":"2023-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeNote":null,"administrativeNotes":"2023.9.24 AQT added per ticket request CADSR0002886. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14509798","version":"1","preferredName":"Direct Bilirubin Measurement Normal Range Yes No Indicator","preferredDefinition":"Yes/No indicator of whether direct bilirubin measurement was within normal range.","longName":"DIR_BIL_NRM_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"065D85D1-D7B4-7F94-E063-731AD00A0BE8","latestVersionIndicator":"Yes","beginDate":"2023-09-27","endDate":null,"createdBy":"TSESU","dateCreated":"2023-09-27","modifiedBy":"TSESU","dateModified":"2023-09-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14572331","version":"1","preferredName":"RB1 Gene Deletion Present Yes No Unknown Not Applicable Indicator","preferredDefinition":"The indicator of whether or not the RB1 gene deletion was present.","longName":"RB1_GENE_DELET_PRESNT_IND","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"088AA7BD-03E6-5D64-E063-731AD00A8B7C","latestVersionIndicator":"Yes","beginDate":"2023-10-25","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-10-25","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":"11.2.2023 Added AQT per request ticket CADSR0003026 and edited PQT_mmt\r\n10.25.2023 Added new CDE per request ticket CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14596197","version":"1","preferredName":"Disease Description Name","preferredDefinition":"A description of the disease.","longName":"DS_DSCRPT_NM","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":"NRG CRF:NRG Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"092EE515-B806-6442-E063-731AD00A6BDA","latestVersionIndicator":"Yes","beginDate":"2023-11-02","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-11-02","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":"2023.11.15 AQT added per ticket request CADSR0003071. ak 11.02.2023 Added new CDE per request ticket CADSR0003022_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14599414","version":"1","preferredName":"Testing Use Test Name","preferredDefinition":"A description of the test used.","longName":"14599380v1.00:14599384v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A0B4D9D-5BD1-6EDD-E063-731AD00A50F2","latestVersionIndicator":"Yes","beginDate":"2023-11-13","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14599617","version":"1","preferredName":"Test Method Canadian Provincial Medical Plan Negation Reimbursement","preferredDefinition":"The indicator of whether or not a test is covered by the Canadian Provincial Medical Plan.","longName":"14599550v1.00:3506035v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A1F6B1E-50A4-1671-E063-731AD00A9B97","latestVersionIndicator":"Yes","beginDate":"2023-11-14","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-11-14","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14644138","version":"1","preferredName":"Person's Board Certification Yes No Unknown Not Applicable Indicator","preferredDefinition":"The indicator of whether or not a person has board certification to practice medicine.","longName":"2199700v2.00:3506035v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BC82A62-3AAB-4AE2-E063-731AD00ABD65","latestVersionIndicator":"Yes","beginDate":"2023-12-05","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-12-05","modifiedBy":"TYRRELLM","dateModified":"2024-01-17","changeNote":null,"administrativeNotes":"01.17.2024 Added Alt short name per request ticket CADSR0003291_mmt\r\n12.05.2023 created new CDE to accommodate request ticket CADSR0003154 and added AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14666991","version":"1","preferredName":"Therapeutic Procedure Contraindication Ind","preferredDefinition":"The indicator of whether or not there was a therapeutic procedure contraindication.","longName":"14666990v1.00:3506035v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D814D83-0D52-0BA6-E063-731AD00AD11D","latestVersionIndicator":"Yes","beginDate":"2023-12-27","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2023-12-27","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeNote":null,"administrativeNotes":"12.28.2023 added alt short name per Sherrill_mmt\r\n12.27.2023 added AQT per request ticket CADSR0003219_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14673511","version":"1","preferredName":"Confirmation Pathological Diagnosis Type","preferredDefinition":"A description of the confirmed pathological diagnosis.","longName":"14673508v1.00:14673510v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E87B678-7109-1BEB-E063-731AD00A09A3","latestVersionIndicator":"Yes","beginDate":"2024-01-09","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2024-01-09","modifiedBy":"TYRRELLM","dateModified":"2024-01-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14758841","version":"1","preferredName":"Detectable Viral Load Disease or Disorder Present Laboratory Procedure Outcome","preferredDefinition":"Text term to describe the results of the viral load.","longName":"14596470v1.00:7848671v1.00","contextName":"NRG","contextVersion":"1","dataElementConceptPublicId":"2014620","dataElementConceptVersion":"1","valueDomainPublicId":"2018842","valueDomainVersion":"2.1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"116D9E73-3204-67F1-E063-731AD00A003C","latestVersionIndicator":"Yes","beginDate":"2024-02-15","endDate":null,"createdBy":"TYRRELLM","dateCreated":"2024-02-15","modifiedBy":"TYRRELLM","dateModified":"2024-02-15","changeNote":null,"administrativeNotes":"dded and alt short name per request add on ticket #CADSR0003402_mmt","unresolvedIssues":null,"deletedIndicator":"No"}]}